

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, A61K 31/70, 35/12, 38/13, C07K 16/18, G01N 33/574, C12Q 1/68	A2	(11) International Publication Number: WO 00/20587 (43) International Publication Date: 13 April 2000 (13.04.00)
(21) International Application Number: PCT/US99/22873 (22) International Filing Date: 4 October 1999 (04.10.99) (30) Priority Data: 09/166,300 5 October 1998 (05.10.98) US 09/166,350 5 October 1998 (05.10.98) US (71) Applicant: LUDWIG INSTITUTE FOR CANCER RE- SEARCH [CH/US]; 605 Third Avenue, New York, NY 10158 (US). (72) Inventors: OBATA, Yuichi; Chikusa-Ku, Nagoya 464 (JP). GOUT, Ivan; 91 Riding House Street, London W1P 8BT (GB). TURECI, Ozlem; Innere Medizin 1, D-66421 Hom- burg/Saar (DE). SAHIN, Ugar; Innere Medizin 1, D-66421 Homburg/Saar (DE). PFREUNDSCHUH, Michael; Innere Medizin 1, D-66421 Homburg/Saar (DE). SCANLAN, Matthew, J.; 1275 York Avenue, New York, NY 10021 (US). STOCKERT, Elisabeth; 1275 York Avenue, New York, NY 10021 (US). CHEN, Yao-Tseng; 525 East 68th Street, New York, NY 10021 (US). OLD, Lloyd, J.; 605 Third Avenue, New York, NY 10158 (US). JAGER, Elke; Hohl 2-28, D-60488 Frankfurt am Main (DE). KNUTH, Alex; Hohl 2-28, D-60488 Frankfurt am Main (DE).	(74) Agent: VAN AMSTERDAM, John, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US). (81) Designated States: AU, CA, CN, JP, KR, NZ, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: CANCER ASSOCIATED ANTIGENS AND USES THEREFOR		
(57) Abstract <p>Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in renal cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with renal cancer. The invention provides, <i>inter alia</i>, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Summary of the Invention

Autologous antibody screening has now been applied to renal cancer using antisera from cancer patients. Numerous cancer associated antigens have been identified. The invention provides, *inter alia*, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and CTLs which recognize the proteins and peptides. Fragments including functional fragments and variants of the foregoing also are provided. Kits containing the foregoing molecules additionally are provided. The foregoing can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.

Prior to the present invention, only a handful of cancer associated genes had been identified in the past 20 years. The invention involves the surprising discovery of several genes, some previously known and some previously unknown, which are expressed in individuals who have cancer. These individuals all have serum antibodies against the proteins (or fragments thereof) encoded by these genes. Thus, abnormally expressed genes are recognized by the host's immune system and therefore can form a basis for diagnosis, monitoring and therapy.

The invention involves the use of a single material, a plurality of different materials and even large panels and combinations of materials. For example, a single gene, a single protein encoded by a gene, a single functional fragment thereof, a single antibody thereto, etc. can be used in methods and products of the invention. Likewise, pairs, groups and even panels of these materials and optionally other cancer associated antigen genes and/or gene products can be used for diagnosis, monitoring and therapy. The pairs, groups or panels can involve 2, 3, 4, 5 or more genes, gene products, fragments thereof or agents that recognize such materials. A plurality of such materials are not only useful in monitoring, typing, characterizing and diagnosing cells abnormally expressing such genes, but a plurality of such materials can be used therapeutically. An example of the use of a plurality of such materials for the prevention, delay of onset, amelioration, etc. of cancer cells, which express or will express such genes prophylactically or acutely. Any and all combinations of the genes, gene products, and materials which recognize the genes and gene products can be tested and identified for use according to the invention. It would be far too lengthy to recite all such combinations; those skilled in the art, particularly in view of the teaching contained herein,

CANCER ASSOCIATED ANTIGENS AND USES THEREFOR

Field of the Invention

The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with a variety of cancers. The invention also relates to agents which bind the nucleic acids or polypeptides. The nucleic acid molecules, polypeptides coded for by such molecules and peptides derived therefrom, as well as related antibodies and cytolytic T lymphocytes, are useful, *inter alia*, in diagnostic and therapeutic contexts.

Background of the Invention

The mechanism by which T cells recognize foreign materials has been implicated in cancer. A number of cytolytic T lymphocyte (CTL) clones directed against autologous melanoma antigens, testicular antigens, and melanocyte differentiation antigens have been described. In many instances, the antigens recognized by these clones have been characterized.

The use of autologous CTLs for identifying tumor antigens requires that the target cells which express the antigens can be cultured *in vitro* and that stable lines of autologous CTL clones which recognize the antigen-expressing cells can be isolated and propagated. While this approach has worked well for melanoma antigens, other tumor types, such as epithelial cancers including breast and colon cancer, have proved refractory to the approach.

More recently another approach to the problem has been described by Sahin et al. (*Proc. Natl. Acad. Sci. USA* 92:11810-11813, 1995). According to this approach, autologous antisera are used to identify immunogenic protein antigens expressed in cancer cells by screening expression libraries constructed from tumor cell cDNA. Antigen-encoding clones so identified have been found to have elicited a high-titer humoral immune response in the patients from which the antisera were obtained. Such a high-titer IgG response implies helper T cell recognition of the detected antigen. These tumor antigens can then be screened for the presence of MHC/HLA class I and class II motifs and reactivity with CTLs

Presently there is a need for additional cancer antigens for development of therapeutics and diagnosis applicable to a greater number of cancer patients having various cancers.

will readily be able to determine which combinations are most appropriate for which circumstances.

As will be clear from the following discussion, the invention has *in vivo* and *in vitro* uses, including for therapeutic, diagnostic, monitoring and research purposes. One aspect of the invention is the ability to fingerprint a cell expressing a number of the genes identified according to the invention by, for example, quantifying the expression of such gene products.

Such fingerprints will be characteristic, for example, of the stage of the cancer, the type of the cancer, or even the effect in animal models of a therapy on a cancer. Cells also can be screened to determine whether such cells abnormally express the genes identified according to the invention.

The invention, in one aspect, is a method of diagnosing a disorder characterized by expression of a cancer associated antigen precursor coded for by a nucleic acid molecule. The method involves the steps of contacting a biological sample isolated from a subject with an agent that specifically binds to the nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof complexed with an MHC, preferably an HLA, molecule, wherein the nucleic acid molecule is a NA Group 1 nucleic acid molecule, and determining the interaction between the agent and the nucleic acid molecule, the expression product or fragment of the expression product as a determination of the disorder.

In one embodiment the agent is selected from the group consisting of (a) a nucleic acid molecule comprising NA Group 1 nucleic acid molecules or a fragment thereof, (b) a nucleic acid molecule comprising NA Group 3 nucleic acid molecules or a fragment thereof, (c) a nucleic acid molecule comprising NA Group 5 nucleic acid molecules or a fragment thereof, (d) an antibody that binds to an expression product, or a fragment thereof, of NA group 1 nucleic acids, (e) an antibody that binds to an expression product, or a fragment thereof, of NA group 3 nucleic acids, (f) an antibody that binds to an expression product, or a fragment thereof, of NA group 5 nucleic acids, (g) an agent that binds to a complex of an MHC, preferably HLA, molecule and a fragment of an expression product of a NA Group 1 nucleic acid, (h) an agent that binds to a complex of an MHC, preferably HLA, molecule and a fragment of an expression product of a NA group 3 nucleic acid, and (i) an agent that binds to a complex of an MHC, preferably HLA, molecule and a fragment of an expression product of a NA Group 5 nucleic acid.

The disorder may be characterized by expression of a plurality of cancer associated

antigen precursors. Thus the methods of diagnosis may include use of a plurality of agents, each of which is specific for a different human cancer associated antigen precursor (including at least one of the cancer associated antigen precursors disclosed herein), and wherein said plurality of agents is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9 or at least 10 such agents.

In each of the above embodiments the agent may be specific for a human cancer associated antigen precursor that is selected from the group consisting of breast, gastric, lung, prostate, renal, colon, thyroid, Hodgkin's disease, and hepatocarcinoma cancer associated antigen precursors.

In another aspect the invention is a method for determining regression, progression or onset of a condition characterized by expression of abnormal levels of a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule. The method involves the steps of monitoring a sample, from a subject who has or is suspected of having the condition, for a parameter selected from the group consisting of (i) the protein, (ii) a peptide derived from the protein, (iii) an antibody which selectively binds the protein or peptide, and (iv) cytolytic T cells specific for a complex of the peptide derived from the protein and an MHC molecule, as a determination of regression, progression or onset of said condition. In one embodiment the sample is a body fluid, a body effusion or a tissue.

In another embodiment the step of monitoring comprises contacting the sample with a detectable agent selected from the group consisting of (a) an antibody which selectively binds the protein of (i), or the peptide of (ii), (b) a protein or peptide which binds the antibody of (iii), and (c) a cell which presents the complex of the peptide and MHC molecule of (iv). In a preferred embodiment the antibody, the protein, the peptide or the cell is labeled with a radioactive label or an enzyme. The sample in a preferred embodiment is assayed for the peptide.

According to another embodiment the nucleic acid molecule is one of the following: a NA Group 3 molecule or a NA Group 5 molecule. In yet another embodiment the protein is a plurality of proteins, the parameter is a plurality of parameters, each of the plurality of parameters being specific for a different of the plurality of proteins. In certain embodiments the protein is a plurality of proteins, at least one of which is kinectin, the remainder of which are non-kinectin cancer associated proteins, and wherein the parameter is a plurality of parameters, each of the plurality of parameters being specific for a different of the plurality of

proteins.

The invention in another aspect is a pharmaceutical preparation for a human subject. The pharmaceutical preparation includes an agent which when administered to the subject enriches selectively the presence of complexes of an HLA molecule and a human cancer associated antigen, and a pharmaceutically acceptable carrier, wherein the human cancer associated antigen is a fragment of a human cancer associated antigen precursor encoded by a nucleic acid molecule which comprises a NA Group 1 molecule. In one embodiment the nucleic acid molecule is a NA Group 3 nucleic acid molecule.

The agent in one embodiment comprises a plurality of agents, each of which enriches selectively in the subject complexes of an HLA molecule and a different human cancer associated antigen. Preferably the plurality is at least two, at least three, at least four or at least 5 different such agents.

In certain embodiments, the agent comprises a plurality of agents, at least one of which is kinectin, the remainder of which are non-kinectin cancer associated proteins, and each of which enriches selectively in the subject complexes of an HLA molecule and a different human cancer associated antigen.

In another embodiment the agent is selected from the group consisting of (1) an isolated polypeptide comprising the human cancer associated antigen, or a functional variant thereof, (2) an isolated nucleic acid operably linked to a promoter for expressing the isolated polypeptide, or functional variant thereof, (3) a host cell expressing the isolated polypeptide, or functional variant thereof, and (4) isolated complexes of the polypeptide, or functional variants thereof, and an HLA molecule.

The agent may be a cell expressing an isolated polypeptide. In one embodiment the agent is a cell expressing an isolated polypeptide comprising the human cancer associated antigen or a functional variant thereof. In another embodiment the agent is a cell expressing an isolated polypeptide comprising the human cancer associated antigen or a functional variant thereof, and wherein the cell expresses an HLA molecule that binds the polypeptide. The cell can express one or both of the polypeptide and HLA molecule recombinantly. In preferred embodiments the cell is nonproliferative. In other preferred embodiments, the isolated polypeptide is or includes a kinectin polypeptide. In yet another embodiment the agent is at least two, at least three, at least four or at least five different polypeptides, each representing a different human cancer associated antigen or functional variant thereof.

The agent in one embodiment is a PP Group 2 polypeptide. In other embodiments the agent is a PP Group 3 polypeptide or a PP Group 4 polypeptide.

In an embodiment each of the pharmaceutical preparations described herein also includes an adjuvant.

According to another aspect the invention, a composition is provided which includes an isolated agent that binds selectively a PP Group 1 polypeptide. In separate embodiments the agent binds selectively to a polypeptide selected from the following: a PP Group 2 polypeptide, a PP Group 3 polypeptide, a PP Group 4 polypeptide, and a PP Group 5 polypeptide. In other embodiments, the agent is a plurality of different agents that bind selectively at least two, at least three, at least four, or at least five different such polypeptides. In each of the above described embodiments the agent may be an antibody. In a preferred embodiment, at least one of polypeptides is kinectin or a fragment thereof.

In another aspect the invention is a composition of matter composed of a conjugate of the agent of the above-described compositions of the invention and a therapeutic or diagnostic agent. Preferably the conjugate is of the agent and a therapeutic or diagnostic that is an antineoplastic.

The invention in another aspect is a pharmaceutical composition which includes an isolated nucleic acid molecule selected from the group consisting of: (1) NA Group 1 molecules, and (2) NA Group 2 molecules, and a pharmaceutically acceptable carrier. In one embodiment the isolated nucleic acid molecule comprises a NA Group 3 or NA Group 4 molecule. In another embodiment the isolated nucleic acid molecule comprises at least two isolated nucleic acid molecules coding for two different polypeptides, each polypeptide comprising a different cancer associated antigen. In preferred embodiments, at least one of the polypeptides is a kinectin polypeptide.

Preferably the pharmaceutical composition also includes an expression vector with a promoter operably linked to the isolated nucleic acid molecule. In another embodiment the pharmaceutical composition also includes a host cell recombinantly expressing the isolated nucleic acid molecule.

According to another aspect of the invention a pharmaceutical composition is provided. The pharmaceutical composition includes an isolated polypeptide comprising a PP Group 1 or a PP Group 2 polypeptide, and a pharmaceutically acceptable carrier. In one embodiment the isolated polypeptide comprises a PP Group 3 or a PP Group 4 polypeptide.

In another embodiment the isolated polypeptide comprises at least two different polypeptides, each comprising a different cancer associated antigen at least one of which is encoded by a NA group 1 molecule as disclosed herein. In separate embodiments the isolated polypeptides are selected from the following: PP Group 3 polypeptides or HLA binding fragments thereof and PP Group 5 polypeptides or HLA binding fragments thereof.

In an embodiment each of the pharmaceutical compositions described herein also includes an adjuvant.

Another aspect the invention is an isolated nucleic acid molecule comprising a NA Group 3 molecule. Another aspect the invention is an isolated nucleic acid molecule comprising a NA Group 4 molecule.

The invention in another aspect is an isolated nucleic acid molecule selected from the group consisting of (a) a fragment of a nucleic acid selected from the group of nucleic acid molecules consisting of SEQ ID Nos numbered below and comprising all nucleic acid sequences among SEQ ID NOs 1-11 and 22-46, of sufficient length to represent a sequence unique within the human genome, and identifying a nucleic acid encoding a human cancer associated antigen precursor, (b) complements of (a), provided that the fragment includes a sequence of contiguous nucleotides which is not identical to any sequence selected from the sequence group consisting of (1) sequences having the GenBank accession numbers of Table 1, (2) complements of (1), and (3) fragments of (1) and (2).

In one embodiment the sequence of contiguous nucleotides is selected from the group consisting of: (1) at least two contiguous nucleotides nonidentical to the sequences in Table 1, (2) at least three contiguous nucleotides nonidentical to the sequences in Table 1, (3) at least four contiguous nucleotides nonidentical to the sequences in Table 1, (4) at least five contiguous nucleotides nonidentical to the sequences in Table 1, (5) at least six contiguous nucleotides nonidentical to the sequences in Table 1, or (6) at least seven contiguous nucleotides nonidentical to the sequences in Table 1.

In another embodiment the fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20, nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, 200 nucleotides, 1000 nucleotides and every integer length therebetween.

In yet another embodiment the molecule encodes a polypeptide which, or a fragment

of which, binds a human HLA receptor or a human antibody.

Another aspect of the invention is an expression vector comprising an isolated nucleic acid molecule of the invention described above operably linked to a promoter.

According to one aspect the invention is an expression vector comprising a nucleic acid operably linked to a promoter, wherein the nucleic acid is a NA Group 1 or Group 2 molecule. In another aspect the invention is an expression vector comprising a NA Group 1 or Group 2 molecule and a nucleic acid encoding an MHC, preferably HLA, molecule.

In yet another aspect the invention is a host cell transformed or transfected with an expression vector of the invention described above.

In another aspect the invention is a host cell transformed or transfected with an expression vector comprising an isolated nucleic acid molecule of the invention described above operably linked to a promoter, or an expression vector comprising a nucleic acid operably linked to a promoter, wherein the nucleic acid is a NA Group 1 or 2 molecule and further comprising a nucleic acid encoding HLA.

According to another aspect of the invention an isolated polypeptide encoded by the isolated nucleic acid molecules the invention, described above, is provided. These include PP Group 1-5 polypeptides. The invention also includes a fragment of the polypeptide which is immunogenic. In one embodiment the fragment, or a portion of the fragment, binds HLA or a human antibody. In still another aspect the invention provides as isolated polypeptide comprising a fragment of a kinectin polypeptide which is immunogenic.

The invention includes in another aspect an isolated fragment of a human cancer associated antigen precursor which, or portion of which, binds HLA or a human antibody, wherein the precursor is encoded by a nucleic acid molecule that is a NA Group 1 molecule. In one embodiment the fragment is part of a complex with HLA. In another embodiment the fragment is between 8 and 12 amino acids in length. In another embodiment the invention includes an isolated polypeptide comprising a fragment of the polypeptide of sufficient length to represent a sequence unique within the human genome and identifying a polypeptide that is a human cancer associated antigen precursor.

According to another aspect of the invention a kit for detecting the presence of the expression of a cancer associated antigen precursor is provided. The kit includes a pair of isolated nucleic acid molecules each of which consists essentially of a molecule selected from the group consisting of (a) a 12-32 nucleotide contiguous segment of the nucleotide sequence

of any of the NA Group 1 molecules and (b) complements of ("a"), wherein the contiguous segments are nonoverlapping. In one embodiment the pair of isolated nucleic acid molecules is constructed and arranged to selectively amplify an isolated nucleic acid molecule that is a NA Group 3 molecule. Preferably, the pair amplifies a human NA Group 3 molecule.

According to another aspect of the invention a method for treating a subject with a disorder characterized by expression of a human cancer associated antigen precursor is provided. The method includes the step of administering to the subject an amount of an agent, which enriches selectively in the subject the presence of complexes of an HLA molecule and a human cancer associated antigen, effective to ameliorate the disorder, wherein the human cancer associated antigen is a fragment of a human cancer associated antigen precursor encoded by a nucleic acid molecule selected from the group consisting of (a) a nucleic acid molecule comprising NA group 1 nucleic acid molecules, (b) a nucleic acid molecule comprising NA group 3 nucleic acid molecules, (c) a nucleic acid molecule comprising NA group 5 nucleic acid molecules.

In one embodiment the disorder is characterized by expression of a plurality of human cancer associated antigen precursors and wherein the agent is a plurality of agents, each of which enriches selectively in the subject the presence of complexes of an HLA molecule and a different human cancer associated antigen. Preferably the plurality is at least 2, at least 3, at least 4, or at least 5 such agents. In a preferred embodiment, at least one of the human cancer associated antigens is kinectin or a fragment thereof.

In another embodiment the agent is an isolated polypeptide selected from the group consisting of PP Group 1, PP Group 2, PP Group 3, PP Group 4, and PP group 5 polypeptides.

In yet another embodiment the disorder is cancer.

According to another aspect the invention is a method for treating a subject having a condition characterized by expression of a cancer associated antigen precursor in cells of the subject. The method includes the steps of (i) removing an immunoreactive cell containing sample from the subject, (ii) contacting the immunoreactive cell containing sample to the host cell under conditions favoring production of cytolytic T cells against a human cancer associated antigen which is a fragment of the precursor, (iii) introducing the cytolytic T cells to the subject in an amount effective to lyse cells which express the human cancer associated antigen, wherein the host cell is transformed or transfected with an expression vector comprising an isolated nucleic acid molecule operably linked to a promoter, the isolated

nucleic acid molecule being selected from the group of nucleic acid molecules consisting of NA Group 1, NA Group 2, NA Group 3, NA Group 4, NA Group 5.

In one embodiment the host cell recombinantly expresses an HLA molecule which binds the human cancer associated antigen. In another embodiment the host cell endogenously expresses an HLA molecule which binds the human cancer associated antigen.

The invention includes in another aspect a method for treating a subject having a condition characterized by expression of a cancer associated antigen precursor in cells of the subject. The method includes the steps of (i) identifying a nucleic acid molecule expressed by the cells associated with said condition, wherein said nucleic acid molecule is a NA Group 1 molecule (ii) transfecting a host cell with a nucleic acid selected from the group consisting of (a) the nucleic acid molecule identified, (b) a fragment of the nucleic acid identified which includes a segment coding for a cancer associated antigen, (c) deletions, substitutions or additions to (a) or (b), and (d) degenerates of (a), (b), or (c); (iii) culturing said transfected host cells to express the transfected nucleic acid molecule, and; (iv) introducing an amount of said host cells or an extract thereof to the subject effective to increase an immune response against the cells of the subject associated with the condition. Preferably, the antigen is a human antigen and the subject is a human. In certain preferred embodiments the nucleic acid molecule is a kinectin nucleic acid molecule.

In one embodiment the method also includes the step of (a) identifying an MHC molecule which presents a portion of an expression product of the nucleic acid molecule, wherein the host cell expresses the same MHC molecule as identified in (a) and wherein the host cell presents an MHC binding portion of the expression product of the nucleic acid molecule.

In another embodiment the method also includes the step of treating the host cells to render them non-proliferative.

In yet another embodiment the immune response comprises a B-cell response or a T cell response. Preferably the response is a T-cell response which comprises generation of cytolytic T-cells specific for the host cells presenting the portion of the expression product of the nucleic acid molecule or cells of the subject expressing the human cancer associated antigen.

In another embodiment the nucleic acid molecule is a NA Group 3 molecule.

Another aspect of the invention is a method for treating or diagnosing or monitoring a

subject having a condition characterized by expression of an abnormal amount of a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule. The method includes the step of administering to the subject an antibody which specifically binds to the protein or a peptide derived therefrom, the antibody being coupled to a therapeutically useful agent, in an amount effective to treat the condition.

In one embodiment the antibody is a monoclonal antibody. Preferably the monoclonal antibody is a chimeric antibody or a humanized antibody.

In another aspect the invention is a method for treating a condition characterized by expression in a subject of abnormal amounts of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule. The method involves the step of administering to a subject at least one of the pharmaceutical compositions of the invention described above in an amount effective to prevent, delay the onset of, or inhibit the condition in the subject. In one embodiment the condition is cancer. In another embodiment the method includes the step of first identifying that the subject expresses in a tissue abnormal amounts of the protein.

The invention in another aspect is a method for treating a subject having a condition characterized by expression of abnormal amounts of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule. The method includes the steps of (i) identifying cells from the subject which express abnormal amounts of the protein; (ii) isolating a sample of the cells; (iii) cultivating the cells, and (iv) introducing the cells to the subject in an amount effective to provoke an immune response against the cells.

In one embodiment the method includes the step of rendering the cells non-proliferative, prior to introducing them to the subject.

In another aspect the invention is a method for treating a pathological cell condition characterized by abnormal expression of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule. The method includes the step of administering to a subject in need thereof an effective amount of an agent which inhibits the expression or activity of the protein.

In one embodiment the agent is an inhibiting antibody which selectively binds to the protein and wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody or a fragment thereof. In another embodiment the agent is an antisense nucleic acid molecule which selectively binds to the nucleic acid molecule which encodes the protein. In yet another important embodiment the nucleic acid molecule is a NA Group 3 nucleic acid

molecule. In other preferred embodiments, the nucleic acid molecule is a kinectin nucleic acid molecule.

The invention includes in another aspect a composition of matter useful in stimulating an immune response to a plurality of proteins encoded by nucleic acid molecules that are NA Group 1 molecules. The composition is a plurality of peptides derived from the amino acid sequences of the proteins, wherein the peptides bind to one or more MHC molecules presented on the surface of the cells which express an abnormal amount of the protein. In preferred embodiments, at least one of the proteins is kinectin.

In one embodiment at least a portion of the plurality of peptides bind to MHC molecules and elicit a cytolytic response thereto. In another embodiment the composition of matter includes an adjuvant. In another embodiment the adjuvant is a saponin, GM-CSF, or an interleukin. In still another embodiment, the compositions also includes at least one peptide useful in stimulating an immune response to at least one protein which is not encoded by nucleic acid molecules that are NA Group 1 molecules, wherein the at least one peptide binds to one or more MHC molecules.

According to another aspect the invention is an isolated antibody which selectively binds to a complex of: (i) a peptide derived from a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule and (ii) and an MHC molecule to which binds the peptide to form the complex, wherein the isolated antibody does not bind to (i) or (ii) alone.

In one embodiment the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody or a fragment thereof.

The invention also involves the use of the genes, gene products, fragments thereof, agents which bind thereto, and so on in the preparation of medicaments. A particular medicament is for treating cancer and a more particular medicament is for treating breast cancer, lung cancer, renal cancer, colon cancer, prostate cancer or gastric cancer.

Detailed Description of the Invention

In the above summary and in the ensuing description, lists of sequences are provided. The lists are meant to embrace each single sequence separately, two or more sequences together where they form a part of the same gene, any combination of two or more sequences which relate to different genes, including and up to the total number on the list, as if each and every combination were separately and specifically enumerated. Likewise, when mentioning

fragment size, it is intended that a range embrace the smallest fragment mentioned to the full-length of the sequence (less one nucleotide or amino acid so that it is a fragment), each and every fragment length intended as if specifically enumerated. Thus, if a fragment could be between 10 and 15 in length, it is explicitly meant to mean 10, 11, 12, 13, 14, or 15 in length.

The summary and the claims mention antigen precursors and antigens. As used in the summary and in the claims, a precursor is substantially the full-length protein encoded by the coding region of the isolated DNA and the antigen is a peptide which complexes with MHC, preferably HLA, and which participates in the immune response as part of that complex. Such antigens are typically 9 amino acids long, although this may vary slightly.

As used herein, a subject is a human, non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent. In all embodiments human cancer antigens and human subjects are preferred.

The present invention in one aspect involves the cloning of cDNAs encoding human cancer associated antigen precursors using autologous antisera of subjects having renal cancer. The sequences of the clones representing genes identified according to the methods described herein are presented in the attached Sequence Listing. Of the foregoing, it can be seen that some of the clones are considered completely novel as no nucleotide or amino acid homologies to coding regions were found in the databases searched. Other clones are novel but have some homology to sequences deposited in databases (mainly EST sequences). Nevertheless, the entire gene sequence was not previously known. In some cases no function was suspected and in other cases, even if a function was suspected, it was not known that the gene was associated with cancer. In all cases, it was not known or suspected that the gene encoded a cancer antigen which reacted with antibody from autologous sera. Analysis of the clone sequences by comparison to nucleic acid and protein databases determined that still other of the clones surprisingly are closely related to other previously-cloned genes. The sequences of these related genes is also presented in the Sequence Listing. The nature of the foregoing genes as encoding antigens recognized by the immune systems of cancer patients is, of course, unexpected.

The invention thus involves in one aspect cancer associated antigen polypeptides, genes encoding those polypeptides, functional modifications and variants of the foregoing, useful fragments of the foregoing, as well as diagnostics and therapeutics relating thereto.

Homologs and alleles of the cancer associated antigen nucleic acids of the invention

can be identified by conventional techniques. Thus, an aspect of the invention is those nucleic acid sequences which code for cancer associated antigen precursors. Because this application contains so many sequences, the following chart is provided to identify the various groups of sequences discussed in the claims and in the summary:

Nucleic Acid Sequences

NA Group 1. (a) nucleic acid molecules which hybridize under stringent conditions to a molecule consisting of a nucleic acid sequence selected from the group consisting of nucleic acid sequences among SEQ ID NOs: 1-11 and 22-46 and which code for a cancer associated antigen precursor,

(b) deletions, additions and substitutions which code for a respective cancer associated antigen precursor,

(c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and

(d) complements of (a), (b) or (c).

NA Group 2. Fragments of NA Group 1, which codes for a polypeptide which, or a portion of which, binds an MHC molecule to form a complex recognized by a an autologous antibody or lymphocyte.

NA Group 3. The subset of NA Group 1 where the nucleotide sequence is selected from the group consisting of:

(a) previously unknown human nucleic acids coding for a human cancer associated antigen precursor (i.e. nucleic acid sequences among SEQ ID NOs: 1-11),

(b) deletions, additions and substitutions which code for a respective human cancer associated antigen precursor,

(c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and

(d) complements of (a), (b) or (c).

NA Group 4. Fragments of NA Group 3, which code for a polypeptide which, or a portion of which, binds to an MHC molecule to form a complex recognized by an autologous antibody or lymphocyte.

NA Group 5. A subset of NA Group 1, comprising human cancer associated antigens that react with allogeneic cancer antisera.

Polypeptide Sequences

- PP Group 1. Polypeptides encoded by NA Group 1.
- PP Group 2. Polypeptides encoded by NA Group 2
- PP Group 3. Polypeptides encoded by NA Group 3.
- PP Group 4. Polypeptides encoded by NA Group 4.
- PP Group 5. Polypeptides encoded by NA Group 5.

The term "stringent conditions" as used herein refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. More specifically, stringent conditions, as used herein, refers, for example, to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH₂PO₄(pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetracetic acid. After hybridization, the membrane upon which the DNA is transferred is washed, for example, in 2 x SSC at room temperature and then at 0.1 - 0.5 x SSC/0.1 x SDS at temperatures up to 68°C.

There are other conditions, reagents, and so forth which can be used, which result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of homologs and alleles of cancer associated antigen nucleic acids of the invention (e.g., by using lower stringency conditions). The skilled artisan also is familiar with the methodology for screening

cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

In general homologs and alleles typically will share at least 75% nucleotide identity and/or at least 90% amino acid identity to the sequences of cancer associated antigen nucleic acid and polypeptides, respectively, in some instances will share at least 90% nucleotide identity and/or at least 95% amino acid identity and in still other instances will share at least 95% nucleotide identity and/or at least 99% amino acid identity. The homology can be calculated using various, publicly available software tools developed by NCBI (Bethesda, Maryland) that can be obtained through the internet (<ftp://ncbi.nlm.nih.gov/pub/>). Exemplary tools include the BLAST system available at <http://www.ncbi.nlm.nih.gov>, using default settings. Pairwise and ClustalW alignments (BLOSUM30 matrix setting) as well as Kyte-Doolittle hydropathic analysis can be obtained using the MacVector sequence analysis software (Oxford Molecular Group). Watson-Crick complements of the foregoing nucleic acids also are embraced by the invention.

In screening for cancer associated antigen genes, a Southern blot may be performed using the foregoing conditions, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film to detect the radioactive signal. In screening for the expression of cancer associated antigen nucleic acids, Northern blot hybridizations using the foregoing conditions (see also the Examples) can be performed on samples taken from breast cancer patients or subjects suspected of having a condition characterized by expression of breast cancer associated antigen genes. Amplification protocols such as polymerase chain reaction using primers which hybridize to the sequences presented also can be used for detection of the cancer associated antigen genes or expression thereof.

The renal cancer associated genes correspond to SEQ ID NOs. 1-11 and 22-35. Kinectin cancer associated sequences correspond to SEQ ID Nos:36-46. The preferred cancer associated antigens for the methods of diagnosis disclosed herein are those which were found to react with allogeneic cancer antisera (i.e. NA Group 5). Encoded polypeptides (e.g., proteins), peptides and antisera thereto are also preferred for diagnosis.

The invention also includes degenerate nucleic acids which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT and AGC. Each of the six codons is equivalent for the

purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue into an elongating breast cancer associated antigen polypeptide. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to: CCA, CCC, CCG and CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code.

The invention also provides modified nucleic acid molecules which include additions, substitutions and deletions of one or more nucleotides. In preferred embodiments, these modified nucleic acid molecules and/or the polypeptides they encode retain at least one activity or function of the unmodified nucleic acid molecule and/or the polypeptides, such as antigenicity, enzymatic activity, receptor binding, formation of complexes by binding of peptides by MHC class I and class II molecules, etc. In certain embodiments, the modified nucleic acid molecules encode modified polypeptides, preferably polypeptides having conservative amino acid substitutions as are described elsewhere herein. The modified nucleic acid molecules are structurally related to the unmodified nucleic acid molecules and in preferred embodiments are sufficiently structurally related to the unmodified nucleic acid molecules so that the modified and unmodified nucleic acid molecules hybridize under stringent conditions known to one of skill in the art.

For example, modified nucleic acid molecules which encode polypeptides having single amino acid changes can be prepared. Each of these nucleic acid molecules can have one, two or three nucleotide substitutions exclusive of nucleotide changes corresponding to the degeneracy of the genetic code as described herein. Likewise, modified nucleic acid molecules which encode polypeptides having two amino acid changes can be prepared which have, e.g., 2-6 nucleotide changes. Numerous modified nucleic acid molecules like these will be readily envisioned by one of skill in the art, including for example, substitutions of nucleotides in codons encoding amino acids 2 and 3, 2 and 4, 2 and 5, 2 and 6, and so on. In the foregoing example, each combination of two amino acids is included in the set of

modified nucleic acid molecules, as well as all nucleotide substitutions which code for the amino acid substitutions. Additional nucleic acid molecules that encode polypeptides having additional substitutions (i.e., 3 or more), additions or deletions (e.g., by introduction of a stop codon or a splice site(s)) also can be prepared and are embraced by the invention as readily envisioned by one of ordinary skill in the art. Any of the foregoing nucleic acids or polypeptides can be tested by routine experimentation for retention of structural relation or activity to the nucleic acids and/or polypeptides disclosed herein.

The invention also provides isolated unique fragments of cancer associated antigen nucleic acid sequences or complements thereof. A unique fragment is one that is a 'signature' for the larger nucleic acid. It, for example, is long enough to assure that its precise sequence is not found in molecules within the human genome outside of the cancer associated antigen nucleic acids defined above (and human alleles). Those of ordinary skill in the art may apply no more than routine procedures to determine if a fragment is unique within the human genome. Unique fragments, however, exclude fragments completely composed of the nucleotide sequences of any of GenBank accession numbers listed in Table 1 or other previously published sequences as of the filing date of the priority documents for sequences listed in a respective priority document or the filing date of this application for sequences listed for the first time in this application which overlap the sequences of the invention.

A fragment which is completely composed of the sequence described in the foregoing GenBank deposits is one which does not include any of the nucleotides unique to the sequences of the invention. Thus, a unique fragment must contain a nucleotide sequence other than the exact sequence of those in GenBank or fragments thereof. The difference may be an addition, deletion or substitution with respect to the GenBank sequence or it may be a sequence wholly separate from the GenBank sequence.

Unique fragments can be used as probes in Southern and Northern blot assays to identify such nucleic acids, or can be used in amplification assays such as those employing PCR. As known to those skilled in the art, large probes such as 200, 250, 300 or more nucleotides are preferred for certain uses such as Southern and Northern blots, while smaller fragments will be preferred for uses such as PCR. Unique fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments, or for generating immunoassay components. Likewise, unique fragments can be employed to produce nonfused fragments of the cancer associated antigen polypeptides,

useful, for example, in the preparation of antibodies, and in immunoassays. Unique fragments further can be used as antisense molecules to inhibit the expression of cancer associated antigen nucleic acids and polypeptides, particularly for therapeutic purposes as described in greater detail below.

As will be recognized by those skilled in the art, the size of the unique fragment will depend upon its conservancy in the genetic code. Thus, some regions of cancer associated antigen sequences and complements thereof will require longer segments to be unique while others will require only short segments, typically between 12 and 32 nucleotides (e.g. 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 32 or more bases long, up to the entire length of the disclosed sequence. As mentioned above, this disclosure intends to embrace each and every fragment of each sequence, beginning at the first nucleotide, the second nucleotide and so on, up to 8 nucleotides short of the end, and ending anywhere from nucleotide number 8, 9, 10 and so on for each sequence, up to the very last nucleotide (provided the sequence is unique as described above).

Virtually any segment of the polypeptide coding region of novel cancer associated antigen nucleic acids, or complements thereof, that is 18 or more nucleotides in length will be unique. Those skilled in the art are well versed in methods for selecting such sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from other sequences in the human genome of the fragment to those on known databases typically is all that is necessary, although *in vitro* confirmatory hybridization and sequencing analysis may be performed.

Especially preferred include nucleic acids encoding a series of epitopes, known as "polytopes". The epitopes can be arranged in sequential or overlapping fashion (*see, e.g.,* Thomson et al., *Proc. Natl. Acad. Sci. USA* 92:5845-5849, 1995; Gilbert et al., *Nature Biotechnol.* 15:1280-1284, 1997), with or without the natural flanking sequences, and can be separated by unrelated linker sequences if desired. The polytope is processed to generate individual epitopes which are recognized by the immune system for generation of immune responses.

Thus, for example, peptides derived from a polypeptide having an amino acid sequence encoded by one of the nucleic acid disclosed herein, and which are presented by MHC molecules and recognized by CTL or T helper lymphocytes, can be combined with peptides from one or more other cancer associated antigens (e.g. by preparation of hybrid

nucleic acids or polypeptides) to form "polytopes". The two or more peptides (or nucleic acids encoding the peptides) can be selected from those described herein, or they can include one or more peptides of previously known cancer associated antigens. Exemplary cancer associated peptide antigens that can be administered to induce or enhance an immune response are derived from tumor associated genes and encoded proteins including MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A11, MAGE-A12, MAGE-13, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7, GAGE-8, BAGE-1, RAGE-1, LB33/MUM-1, PRAME, NAG, MAGE-B2, MAGE-B3, MAGE-B4, tyrosinase, brain glycogen phosphorylase, Melan-A, MAGE-C1, MAGE-C2, NY-ESO-1, LAGE-1, SSX-1, SSX-2 (HOM-MEL-40) SSX-4, SSX-5, SCP-1 and CT-7. See, for example, PCT application publication no. WO96/10577. Other examples will be known to one of ordinary skill in the art (for example, see Coulie, *Stem Cells* 13:393-403, 1995), and can be used in the invention in a like manner as those disclosed herein. One of ordinary skill in the art can prepare polypeptides comprising one or more peptides and one or more of the foregoing cancer associated peptides, or nucleic acids encoding such polypeptides, according to standard procedures of molecular biology.

Thus polytopes are groups of two or more potentially immunogenic or immune response stimulating peptides which can be joined together in various arrangements (e.g. concatenated, overlapping). The polytope (or nucleic acid encoding the polytope) can be administered in a standard immunization protocol, e.g. to animals, to test the effectiveness of the polytope in stimulating, enhancing and/or provoking an immune response.

The peptides can be joined together directly or via the use of flanking sequences to form polytopes, and the use of polytopes as vaccines is well known in the art (see, e.g., Thomson et al., *Proc. Acad. Natl. Acad. Sci USA* 92(13):5845-5849, 1995; Gilbert et al., *Nature Biotechnol.* 15(12):1280-1284, 1997; Thomson et al., *J. Immunol.* 157(2):822-826, 1996; Tam et al., *J. Exp. Med.* 171(1):299-306, 1990). For example, Tam showed that polytopes consisting of both MHC class I and class II binding epitopes successfully generated antibody and protective immunity in a mouse model. Tam also demonstrated that polytopes comprising "strings" of epitopes are processed to yield individual epitopes which are presented by MHC molecules and recognized by CTLs. Thus polytopes containing various numbers and combinations of epitopes can be prepared and tested for recognition by CTLs

and for efficacy in increasing an immune response.

It is known that tumors express a set of tumor antigens, of which only certain subsets may be expressed in the tumor of any given patient. Polytopes can be prepared which correspond to the different combination of epitopes representing the subset of tumor rejection antigens expressed in a particular patient. Polytopes also can be prepared to reflect a broader spectrum of tumor rejection antigens known to be expressed by a tumor type. Polytopes can be introduced to a patient in need of such treatment as polypeptide structures, or via the use of nucleic acid delivery systems known in the art (see, e.g., Allsopp et al., *Eur. J. Immunol.* 26(8):1951-1959, 1996). Adenovirus, pox virus, Ty-virus like particles, adeno-associated virus, plasmids, bacteria, etc. can be used in such delivery. One can test the polytope delivery systems in mouse models to determine efficacy of the delivery system. The systems also can be tested in human clinical trials.

In instances in which a human HLA class I molecule presents tumor rejection antigens derived from cancer associated nucleic acids, the expression vector may also include a nucleic acid sequence coding for the HLA molecule that presents any particular tumor rejection antigen derived from these nucleic acids and polypeptides. Alternatively, the nucleic acid sequence coding for such a HLA molecule can be contained within a separate expression vector. In a situation where the vector contains both coding sequences, the single vector can be used to transfect a cell which does not normally express either one. Where the coding sequences for a cancer associated antigen precursor and the HLA molecule which presents it are contained on separate expression vectors, the expression vectors can be cotransfected. The cancer associated antigen precursor coding sequence may be used alone, when, e.g. the host cell already expresses a HLA molecule which presents a cancer associated antigen derived from precursor molecules. Of course, there is no limit on the particular host cell which can be used. As the vectors which contain the two coding sequences may be used in any antigen-presenting cells if desired, and the gene for cancer associated antigen precursor can be used in host cells which do not express a HLA molecule which presents a cancer associated antigen. Further, cell-free transcription systems may be used in lieu of cells.

As mentioned above, the invention embraces antisense oligonucleotides that selectively bind to a nucleic acid molecule encoding a cancer associated antigen polypeptide, to reduce the expression of cancer associated antigens. This is desirable in virtually any medical condition wherein a reduction of expression of cancer associated antigens is

desirable, e.g., in the treatment of cancer. This is also useful for *in vitro* or *in vivo* testing of the effects of a reduction of expression of one or more cancer associated antigens.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon the sequences of nucleic acids encoding breast cancer associated antigen, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides (Wagner et al., *Nature Biotechnol.* 14:840-844, 1996). Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.* 14(5):439-457, 1994) and at which proteins are not expected to bind. Finally, although the

listed sequences are cDNA sequences, one of ordinary skill in the art may easily derive the genomic DNA corresponding to the cDNA of a cancer associated antigen. Thus, the present invention also provides for antisense oligonucleotides which are complementary to the genomic DNA corresponding to nucleic acids encoding cancer associated antigens. Similarly, antisense to allelic or homologous cDNAs and genomic DNAs are enabled without undue experimentation.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamides, carboxymethyl esters and peptides.

The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as

arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding breast cancer associated antigen polypeptides, together with pharmaceutically acceptable carriers.

Antisense oligonucleotides may be administered as part of a pharmaceutical composition. Such a pharmaceutical composition may include the antisense oligonucleotides in combination with any standard physiologically and/or pharmaceutically acceptable carriers which are known in the art. The compositions should be sterile and contain a therapeutically effective amount of the antisense oligonucleotides in a unit of weight or volume suitable for administration to a patient. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The term "physiologically acceptable" refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art, as further described below.

As used herein, a "vector" may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to, plasmids, phagemids and virus genomes. A cloning vector is one which is able to replicate autonomously or integrated in the genome in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not

been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g., β -galactosidase, luciferase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.

As used herein, a coding sequence and regulatory sequences are said to be "operably" joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al.,

Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding a breast cancer associated antigen polypeptide or fragment or variant thereof. That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen), which contains an Epstein Barr Virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 α , which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (*Nuc. Acids Res.* 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (*Mol. Cell. Biol.* 16:4710-4716, 1996). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (*J. Clin. Invest.* 90:626-630, 1992). The use of the adenovirus as an Adeno.P1A recombinant for the expression of an antigen is disclosed by Warnier et al., in intradermal injection in mice for immunization against P1A (*Int. J. Cancer*, 67:303-310, 1996). Additional vectors for delivery of nucleic acid are provided below.

The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of a vector and one or more of the previously discussed cancer associated antigen nucleic acid molecules. Other components may be added, as desired, as long as the previously mentioned nucleic acid molecules, which are required, are included. The invention also includes kits for amplification of a cancer associated antigen nucleic acid, including at least one pair of amplification primers which hybridize to a cancer associated antigen nucleic acid. The primers preferably are 12-32 nucleotides in length and are non-overlapping to prevent formation of "primer-dimers". One of the primers will hybridize to one strand of the cancer associated antigen nucleic acid and the second primer will hybridize to the complementary strand of the cancer associated antigen nucleic acid, in an arrangement which permits

amplification of the cancer associated antigen nucleic acid. Selection of appropriate primer pairs is standard in the art. For example, the selection can be made with assistance of a computer program designed for such a purpose, optionally followed by testing the primers for amplification specificity and efficiency.

The invention also permits the construction of cancer associated antigen gene "knock-outs" in cells and in animals, providing materials for studying certain aspects of cancer and immune system responses to cancer.

The invention also provides isolated polypeptides (including whole proteins and partial proteins) encoded by the foregoing cancer associated antigen nucleic acids. Such polypeptides are useful, for example, alone or as fusion proteins to generate antibodies, as components of an immunoassay or diagnostic assay or as therapeutics. Cancer associated antigen polypeptides can be isolated from biological samples including tissue or cell homogenates, and can also be expressed recombinantly in a variety of prokaryotic and eukaryotic expression systems by constructing an expression vector appropriate to the expression system, introducing the expression vector into the expression system, and isolating the recombinantly expressed protein. Short polypeptides, including antigenic peptides (such as are presented by MHC molecules on the surface of a cell for immune recognition) also can be synthesized chemically using well-established methods of peptide synthesis.

A unique fragment of a cancer associated antigen polypeptide, in general, has the features and characteristics of unique fragments as discussed above in connection with nucleic acids. As will be recognized by those skilled in the art, the size of the unique fragment will depend upon factors such as whether the fragment constitutes a portion of a conserved protein domain. Thus, some regions of cancer associated antigens will require longer segments to be unique while others will require only short segments, typically between 5 and 12 amino acids (e.g. 5, 6, 7, 8, 9, 10, 11 or 12 or more amino acids including each integer up to the full length).

Unique fragments of a polypeptide preferably are those fragments which retain a distinct functional capability of the polypeptide. Functional capabilities which can be retained in a unique fragment of a polypeptide include interaction with antibodies, interaction with other polypeptides or fragments thereof, selective binding of nucleic acids or proteins, and enzymatic activity. One important activity is the ability to act as a signature for identifying the polypeptide. Another is the ability to complex with HLA and to provoke in a human an

immune response. Those skilled in the art are well versed in methods for selecting unique amino acid sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from non-family members. A comparison of the sequence of the fragment to those on known databases typically is all that is necessary.

The invention embraces variants of the cancer associated antigen polypeptides described above. As used herein, a "variant" of a cancer associated antigen polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a cancer associated antigen polypeptide. Modifications which create a cancer associated antigen variant can be made to a cancer associated antigen polypeptide 1) to reduce or eliminate an activity of a cancer associated antigen polypeptide; 2) to enhance a property of a cancer associated antigen polypeptide, such as protein stability in an expression system or the stability of protein-protein binding; 3) to provide a novel activity or property to a cancer associated antigen polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety; or 4) to provide equivalent or better binding to an HLA molecule. Modifications to a cancer associated antigen polypeptide are typically made to the nucleic acid which encodes the cancer associated antigen polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids or non-amino acid moieties. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the cancer associated antigen amino acid sequence. One of skill in the art will be familiar with methods for predicting the effect on protein conformation of a change in protein sequence, and can thus "design" a variant cancer associated antigen polypeptide according to known methods. One example of such a method is described by Dahiyat and Mayo in *Science* 278:82-87, 1997, whereby proteins can be designed *de novo*. The method can be applied to a known protein to vary only a portion of the polypeptide sequence. By applying the computational methods of Dahiyat and Mayo, specific variants of a cancer associated antigen polypeptide can be proposed and tested to determine whether the variant retains a desired conformation.

In general, variants include cancer associated antigen polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its desired physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide

linkages. Similarly, certain amino acids can be changed to enhance expression of a breast cancer associated antigen polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

Mutations of a nucleic acid which encode a cancer associated antigen polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such as hairpins or loops, which can be deleterious to expression of the variant polypeptide.

Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with the desired properties. Further mutations can be made to variants (or to non-variant cancer associated antigen polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *E. coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a cancer associated antigen gene or cDNA clone to enhance expression of the polypeptide. The activity of variants of cancer associated antigen polypeptides can be tested by cloning the gene encoding the variant cancer associated antigen polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the variant cancer associated antigen polypeptide, and testing for a functional capability of the cancer associated antigen polypeptides as disclosed herein. For example, the variant cancer associated antigen polypeptide can be tested for reaction with autologous or allogeneic sera as disclosed in the Examples. Preparation of other variant polypeptides may favor testing of other activities, as will be known to one of ordinary skill in the art.

The skilled artisan will also realize that conservative amino acid substitutions may be made in cancer associated antigen polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e., the variants retain the functional capabilities of the cancer associated antigen polypeptides. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size

characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Exemplary functionally equivalent variants of the cancer associated antigen polypeptides include conservative amino acid substitutions of in the amino acid sequences of proteins disclosed herein. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

For example, upon determining that a peptide derived from a cancer associated antigen polypeptide is presented by an MHC molecule and recognized by CTLs (e.g., as described in the Examples), one can make conservative amino acid substitutions to the amino acid sequence of the peptide, particularly at residues which are thought not to be direct contact points with the MHC molecule. For example, methods for identifying functional variants of HLA class II binding peptides are provided in a published PCT application of Strominger and Wucherpfennig (PCT/US96/03182). Peptides bearing one or more amino acid substitutions also can be tested for concordance with known HLA/MHC motifs prior to synthesis using, e.g. the computer program described by D'Amaro and Drijfhout (D'Amaro et al., *Human Immunol.* 43:13-18, 1995; Drijfhout et al., *Human Immunol.* 43:1-12, 1995). The substituted peptides can then be tested for binding to the MHC molecule and recognition by CTLs when bound to MHC. These variants can be tested for improved stability and are useful, *inter alia*, in vaccine compositions.

Conservative amino-acid substitutions in the amino acid sequence of cancer associated antigen polypeptides to produce functionally equivalent variants of cancer associated antigen polypeptides typically are made by alteration of a nucleic acid encoding a cancer associated antigen polypeptide. Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis according to the method of Kunkel (Kunkel, *Proc. Nat. Acad. Sci. U.S.A.* 82: 488-492, 1985), or by chemical synthesis of a gene encoding a cancer associated antigen polypeptide. Where amino acid substitutions are made to a small unique

fragment of a cancer associated antigen polypeptide, such as an antigenic epitope recognized by autologous or allogeneic sera or cytolytic T lymphocytes, the substitutions can be made by directly synthesizing the peptide. The activity of functionally equivalent fragments of cancer associated antigen polypeptides can be tested by cloning the gene encoding the altered cancer associated antigen polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered cancer associated antigen polypeptide, and testing for a functional capability of the cancer associated antigen polypeptides as disclosed herein. Peptides which are chemically synthesized can be tested directly for function, e.g., for binding to antisera recognizing associated antigens.

The invention as described herein has a number of uses, some of which are described elsewhere herein. First, the invention permits isolation of the cancer associated antigen protein molecules. A variety of methodologies well-known to the skilled practitioner can be utilized to obtain isolated cancer associated antigen molecules. The polypeptide may be purified from cells which naturally produce the polypeptide by chromatographic means or immunological recognition. Alternatively, an expression vector may be introduced into cells to cause production of the polypeptide. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause production of the encoded polypeptide. Translation of mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce polypeptide. Those skilled in the art also can readily follow known methods for isolating cancer associated antigen polypeptides. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.

The isolation and identification of cancer associated antigen genes also makes it possible for the artisan to diagnose a disorder characterized by expression of cancer associated antigens. These methods involve determining expression of one or more cancer associated antigen nucleic acids, and/or encoded cancer associated antigen polypeptides and/or peptides derived therefrom. In the former situation, such determinations can be carried out via any standard nucleic acid determination assay, including the polymerase chain reaction, or assaying with labeled hybridization probes. In the latter situation, such determinations can be carried out by screening patient antisera for recognition of the polypeptide.

The invention also makes it possible isolate proteins which bind to cancer associated antigens as disclosed herein, including antibodies and cellular binding partners of the cancer

associated antigens. Additional uses are described further herein.

The invention also provides, in certain embodiments, "dominant negative" polypeptides derived from cancer associated antigen polypeptides. A dominant negative polypeptide is an inactive variant of a protein, which, by interacting with the cellular machinery, displaces an active protein from its interaction with the cellular machinery or competes with the active protein, thereby reducing the effect of the active protein. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the ligand. Likewise, a dominant negative catalytically-inactive kinase which interacts normally with target proteins but does not phosphorylate the target proteins can reduce phosphorylation of the target proteins in response to a cellular signal. Similarly, a dominant negative transcription factor which binds to a promoter site in the control region of a gene but does not increase gene transcription can reduce the effect of a normal transcription factor by occupying promoter binding sites without increasing transcription.

The end result of the expression of a dominant negative polypeptide in a cell is a reduction in function of active proteins. One of ordinary skill in the art can assess the potential for a dominant negative variant of a protein, and using standard mutagenesis techniques to create one or more dominant negative variant polypeptides. For example, given the teachings contained herein of renal cancer associated antigens, especially those which are similar to known proteins which have known activities, one of ordinary skill in the art can modify the sequence of the cancer associated antigens by site-specific mutagenesis, scanning mutagenesis, partial gene deletion or truncation, and the like. See, e.g., U.S. Patent No. 5,580,723 and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. The skilled artisan then can test the population of mutagenized polypeptides for diminution in a selected and/or for retention of such an activity. Other similar methods for creating and testing dominant negative variants of a protein will be apparent to one of ordinary skill in the art.

The invention also involves agents such as polypeptides which bind to cancer associated antigen polypeptides. Such binding agents can be used, for example, in screening assays to detect the presence or absence of cancer associated antigen polypeptides and complexes of cancer associated antigen polypeptides and their binding partners and in purification protocols to isolated cancer associated antigen polypeptides and complexes of

cancer associated antigen polypeptides and their binding partners. Such agents also can be used to inhibit the native activity of the cancer associated antigen polypeptides, for example, by binding to such polypeptides.

The invention, therefore, embraces peptide binding agents which, for example, can be antibodies or fragments of antibodies having the ability to selectively bind to cancer associated antigen polypeptides. Antibodies include polyclonal and monoclonal antibodies, prepared according to conventional methodology.

Significantly, as is well-known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W.R. (1986) The Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')₂ fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3).

The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

It is now well-established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of conspecific or heterospecific antibodies

while retaining the epitopic specificity of the original antibody. This is most clearly manifested in the development and use of "humanized" antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. See, e.g., U.S. patents 4,816,567, 5,225,539, 5,585,089, 5,693,762 and 5,859,205.

Thus, for example, PCT International Publication Number WO 92/04381 teaches the production and use of humanized murine RSV antibodies in which at least a portion of the murine FR regions have been replaced by FR regions of human origin. Such antibodies, including fragments of intact antibodies with antigen-binding ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab')₂, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric F(ab')₂ fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies.

Thus, the invention involves polypeptides of numerous size and type that bind specifically to cancer associated antigen polypeptides, and complexes of both cancer associated antigen polypeptides and their binding partners. These polypeptides may be derived also from sources other than antibody technology. For example, such polypeptide binding agents can be provided by degenerate peptide libraries which can be readily prepared in solution, in immobilized form or as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. m13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent, for example, a completely degenerate or biased array. One then can select phage-bearing inserts which bind to the cancer associated antigen

polypeptide. This process can be repeated through several cycles of reselection of phage that bind to the cancer associated antigen polypeptide. Repeated rounds lead to enrichment of phage bearing particular sequences. DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear portion of the sequence that binds to the cancer associated antigen polypeptide can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Yeast two-hybrid screening methods also may be used to identify polypeptides that bind to the cancer associated antigen polypeptides. Thus, the cancer associated antigen polypeptides of the invention, or a fragment thereof, can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding partners of the cancer associated antigen polypeptides of the invention. Such molecules can be used, as described, for screening assays, for purification protocols, for interfering directly with the functioning of cancer associated antigen and for other purposes that will be apparent to those of ordinary skill in the art.

As detailed herein, the foregoing antibodies and other binding molecules may be used for example to identify tissues expressing protein or to purify protein. Antibodies also may be coupled to specific diagnostic labeling agents for imaging of cells and tissues that express cancer associated antigens or to therapeutically useful agents according to standard coupling procedures. Diagnostic agents include, but are not limited to, barium sulfate, iocetamic acid, iopanoic acid, ipodate calcium, diatrizoate sodium, diatrizoate meglumine, metrizamide, tyropanoate sodium and radiodiagnostics including positron emitters such as fluorine-18 and carbon-11, gamma emitters such as iodine-123, technitium-99m, iodine-131 and indium-111, nuclides for nuclear magnetic resonance such as fluorine and gadolinium. Other diagnostic agents useful in the invention will be apparent to one of ordinary skill in the art. As used herein, "therapeutically useful agents" include any therapeutic molecule which desirably is targeted selectively to a cell expressing one of the cancer antigens disclosed herein, including antineoplastic agents, radioiodinated compounds, toxins, other cytostatic or cytolytic drugs, and so forth. Antineoplastic therapeutics are well known and include: aminoglutethimide, azathioprine, bleomycin sulfate, busulfan, carmustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporine, cytarabidine, dacarbazine, dactinomycin, daunorubicin, doxorubicin, taxol, etoposide, fluorouracil, interferon- α , lomustine, mercaptopurine,

methotrexate, mitotane, procarbazine HCl, thioguanine, vinblastine sulfate and vincristine sulfate. Additional antineoplastic agents include those disclosed in Chapter 52, Antineoplastic Agents (Paul Calabresi and Bruce A. Chabner), and the introduction thereto, 1202-1263, of Goodman and Gilman's "The Pharmacological Basis of Therapeutics", Eighth Edition, 1990, McGraw-Hill, Inc. (Health Professions Division). Toxins can be proteins such as, for example, pokeweed anti-viral protein, cholera toxin, pertussis toxin, ricin, gelonin, abrin, diphtheria exotoxin, or *Pseudomonas* exotoxin. Toxin moieties can also be high energy-emitting radionuclides such as cobalt-60.

In the foregoing methods, antibodies prepared according to the invention also preferably are specific for the renal cancer associated antigen/MHC complexes described herein.

When "disorder" is used herein, it refers to any pathological condition where the cancer associated antigens are expressed. An example of such a disorder is cancer, breast, colon, gastric, renal, prostate and lung cancers as particular examples.

Samples of tissue and/or cells for use in the various methods described herein can be obtained through standard methods such as tissue biopsy, including punch biopsy and cell scraping, and collection of blood or other bodily fluids by aspiration or other methods.

In certain embodiments of the invention, an immunoreactive cell sample is removed from a subject. By "immunoreactive cell" is meant a cell which can mature into an immune cell (such as a B cell, a helper T cell, or a cytolytic T cell) upon appropriate stimulation. Thus immunoreactive cells include CD34⁺ hematopoietic stem cells, immature T cells and immature B cells. When it is desired to produce cytolytic T cells which recognize a cancer associated antigen, the immunoreactive cell is contacted with a cell which expresses a cancer associated antigen under conditions favoring production, differentiation and/or selection of cytolytic T cells; the differentiation of the T cell precursor into a cytolytic T cell upon exposure to antigen is similar to clonal selection of the immune system.

Some therapeutic approaches based upon the disclosure are premised on a response by a subject's immune system, leading to lysis of antigen presenting cells, such as breast cancer cells which present one or more cancer associated antigens. One such approach is the administration of autologous CTLs specific to a cancer associated antigen/MHC complex to a subject with abnormal cells of the phenotype at issue. It is within the ability of one of ordinary skill in the art to develop such CTLs *in vitro*. An example of a method for T cell

differentiation is presented in International Application number PCT/US96/05607. Generally, a sample of cells taken from a subject, such as blood cells, are contacted with a cell presenting the complex and capable of provoking CTLs to proliferate. The target cell can be a transfectant, such as a COS cell. These transfectants present the desired complex of their surface and, when combined with a CTL of interest, stimulate its proliferation. COS cells are widely available, as are other suitable host cells. Specific production of CTL clones is well known in the art. The clonally expanded autologous CTLs then are administered to the subject.

Another method for selecting antigen-specific CTL clones has recently been described (Altman et al., *Science* 274:94-96, 1996; Dunbar et al., *Curr. Biol.* 8:413-416, 1998), in which fluorogenic tetramers of MHC class I molecule/peptide complexes are used to detect specific CTL clones. Briefly, soluble MHC class I molecules are folded *in vitro* in the presence of β_2 -microglobulin and a peptide antigen which binds the class I molecule. After purification, the MHC/peptide complex is purified and labeled with biotin. Tetramers are formed by mixing the biotinylated peptide-MHC complex with labeled avidin (e.g. phycoerythrin) at a molar ratio of 4:1. Tetramers are then contacted with a source of CTLs such as peripheral blood or lymph node. The tetramers bind CTLs which recognize the peptide antigen/MHC class I complex. Cells bound by the tetramers can be sorted by fluorescence activated cell sorting to isolate the reactive CTLs. The isolated CTLs then can be expanded *in vitro* for use as described herein.

To detail a therapeutic methodology, referred to as adoptive transfer (Greenberg, *J. Immunol.* 136(5): 1917, 1986; Riddel et al., *Science* 257: 238, 1992; Lynch et al, *Eur. J. Immunol.* 21: 1403-1410, 1991; Kast et al., *Cell* 59: 603-614, 1989), cells presenting the desired complex (e.g., dendritic cells) are combined with CTLs leading to proliferation of the CTLs specific thereto. The proliferated CTLs are then administered to a subject with a cellular abnormality which is characterized by certain of the abnormal cells presenting the particular complex. The CTLs then lyse the abnormal cells, thereby achieving the desired therapeutic goal.

The foregoing therapy assumes that at least some of the subject's abnormal cells present the relevant HLA/cancer associated antigen complex. This can be determined very easily, as the art is very familiar with methods for identifying cells which present a particular HLA molecule, as well as how to identify cells expressing DNA of the pertinent sequences, in

this case a cancer associated antigen sequence. Once cells presenting the relevant complex are identified via the foregoing screening methodology, they can be combined with a sample from a patient, where the sample contains CTLs. If the complex presenting cells are lysed by the mixed CTL sample, then it can be assumed that a cancer associated antigen is being presented, and the subject is an appropriate candidate for the therapeutic approaches set forth *supra*.

Adoptive transfer is not the only form of therapy that is available in accordance with the invention. CTLs can also be provoked *in vivo*, using a number of approaches. One approach is the use of non-proliferative cells expressing the complex. The cells used in this approach may be those that normally express the complex, such as irradiated tumor cells or cells transfected with one or both of the genes necessary for presentation of the complex (i.e. the antigenic peptide and the presenting HLA molecule). Chen et al. (*Proc. Natl. Acad. Sci. USA* 88: 1110-1114, 1991) exemplifies this approach, showing the use of transfected cells expressing HPVE7 peptides in a therapeutic regime. Various cell types may be used. Similarly, vectors carrying one or both of the genes of interest may be used. Viral or bacterial vectors are especially preferred. For example, nucleic acids which encode a cancer associated antigen polypeptide or peptide may be operably linked to promoter and enhancer sequences which direct expression of the cancer associated antigen polypeptide or peptide in certain tissues or cell types. The nucleic acid may be incorporated into an expression vector. Expression vectors may be unmodified extrachromosomal nucleic acids, plasmids or viral genomes constructed or modified to enable insertion of exogenous nucleic acids, such as those encoding cancer associated antigen, as described elsewhere herein. Nucleic acids encoding a cancer associated antigen also may be inserted into a retroviral genome, thereby facilitating integration of the nucleic acid into the genome of the target tissue or cell type. In these systems, the gene of interest is carried by a microorganism, e.g., a Vaccinia virus, pox virus, herpes simplex virus, retrovirus or adenovirus, and the materials de facto "infect" host cells. The cells which result present the complex of interest, and are recognized by autologous CTLs, which then proliferate.

A similar effect can be achieved by combining the cancer associated antigen or a stimulatory fragment thereof with an adjuvant to facilitate incorporation into antigen presenting cells *in vivo*. The cancer associated antigen polypeptide is processed to yield the peptide partner of the HLA molecule while a cancer associated antigen peptide may be presented without the need for further processing. Generally, subjects can receive an

intradermal injection of an effective amount of the cancer associated antigen. Initial doses can be followed by booster doses, following immunization protocols standard in the art. Preferred cancer associated antigens include those found to react with allogeneic cancer antisera, shown in the examples below.

The invention involves the use of various materials disclosed herein to "immunize" subjects or as "vaccines". As used herein, "immunization" or "vaccination" means increasing or activating an immune response against an antigen. It does not require elimination or eradication of a condition but rather contemplates the clinically favorable enhancement of an immune response toward an antigen. Generally accepted animal models can be used for testing of immunization against cancer using a cancer associated antigen nucleic acid. For example, human cancer cells can be introduced into a mouse to create a tumor, and one or more cancer associated antigen nucleic acids can be delivered by the methods described herein. The effect on the cancer cells (e.g., reduction of tumor size) can be assessed as a measure of the effectiveness of the cancer associated antigen nucleic acid immunization. Of course, testing of the foregoing animal model using more conventional methods for immunization include the administration of one or more cancer associated antigen polypeptides or peptides derived therefrom, optionally combined with one or more adjuvants and/or cytokines to boost the immune response. Methods for immunization, including formulation of a vaccine composition and selection of doses, route of administration and the schedule of administration (e.g. primary and one or more booster doses), are well known in the art. The tests also can be performed in humans, where the end point is to test for the presence of enhanced levels of circulating CTLs against cells bearing the antigen, to test for levels of circulating antibodies against the antigen, to test for the presence of cells expressing the antigen and so forth.

As part of the immunization compositions, one or more cancer associated antigens or stimulatory fragments thereof are administered with one or more adjuvants to induce an immune response or to increase an immune response. An adjuvant is a substance incorporated into or administered with antigen which potentiates the immune response. Adjuvants may enhance the immunological response by providing a reservoir of antigen (extracellularly or within macrophages), activating macrophages and stimulating specific sets of lymphocytes. Adjuvants of many kinds are well known in the art. Specific examples of adjuvants include monophosphoryl lipid A (MPL, SmithKline Beecham), a congener obtained after purification

and acid hydrolysis of *Salmonella minnesota* Re 595 lipopolysaccharide; saponins including QS21 (SmithKline Beecham), a pure QA-21 saponin purified from *Quillja saponaria* extract; DQS21, described in PCT application WO96/33739 (SmithKline Beecham); QS-7, QS-17, QS-18, and QS-L1 (So et al., *Mol. Cells* 7:178-186, 1997); incomplete Freund's adjuvant; complete Freund's adjuvant; montanide; and various water-in-oil emulsions prepared from biodegradable oils such as squalene and/or tocopherol. Preferably, the peptides are administered mixed with a combination of DQS21/MPL. The ratio of DQS21 to MPL typically will be about 1:10 to 10:1, preferably about 1:5 to 5:1 and more preferably about 1:1. Typically for human administration, DQS21 and MPL will be present in a vaccine formulation in the range of about 1 μ g to about 100 μ g. Other adjuvants are known in the art and can be used in the invention (*see, e.g. Goding, Monoclonal Antibodies: Principles and Practice*, 2nd Ed., 1986). Methods for the preparation of mixtures or emulsions of peptide and adjuvant are well known to those of skill in the art of vaccination.

Other agents which stimulate the immune response of the subject can also be administered to the subject. For example, other cytokines are also useful in vaccination protocols as a result of their lymphocyte regulatory properties. Many other cytokines useful for such purposes will be known to one of ordinary skill in the art, including interleukin-12 (IL-12) which has been shown to enhance the protective effects of vaccines (*see, e.g., Science* 268: 1432-1434, 1995), GM-CSF and IL-18. Thus cytokines can be administered in conjunction with antigens and adjuvants to increase the immune response to the antigens.

There are a number of immune response potentiating compounds that can be used in vaccination protocols. These include costimulatory molecules provided in either protein or nucleic acid form. Such costimulatory molecules include the B7-1 and B7-2 (CD80 and CD86 respectively) molecules which are expressed on dendritic cells (DC) and interact with the CD28 molecule expressed on the T cell. This interaction provides costimulation (signal 2) to an antigen/MHC/TCR stimulated (signal 1) T cell, increasing T cell proliferation and effector function. B7 also interacts with CTLA4 (CD152) on T cells and studies involving CTLA4 and B7 ligands indicate that the B7-CTLA4 interaction can enhance antitumor immunity and CTL proliferation (Zheng P., et al. *Proc. Natl. Acad. Sci. USA* 95 (11):6284-6289 (1998)).

B7 typically is not expressed on tumor cells so they are not efficient antigen presenting cells (APCs) for T cells. Induction of B7 expression would enable the tumor cells to stimulate more efficiently CTL proliferation and effector function. A combination of B7/IL-6/IL-12

costimulation has been shown to induce IFN-gamma and a Th1 cytokine profile in the T cell population leading to further enhanced T cell activity (Gajewski et al., *J. Immunol.*, 154:5637-5648 (1995)). Tumor cell transfection with B7 has been discussed in relation to *in vitro* CTL expansion for adoptive transfer immunotherapy by Wang et al., (*J. Immunol.*, 19:1-8 (1986)). Other delivery mechanisms for the B7 molecule would include nucleic acid (naked DNA) immunization (Kim J., et al. *Nat Biotechnol.*, 15:7:641-646 (1997)) and recombinant viruses such as adeno and pox (Wendtner et al., *Gene Ther.*, 4:7:726-735 (1997)). These systems are all amenable to the construction and use of expression cassettes for the coexpression of B7 with other molecules of choice such as the antigens or fragment(s) of antigens discussed herein (including polytopes) or cytokines. These delivery systems can be used for induction of the appropriate molecules *in vitro* and for *in vivo* vaccination situations. The use of anti-CD28 antibodies to directly stimulate T cells *in vitro* and *in vivo* could also be considered. Similarly, the inducible co-stimulatory molecule ICOS which induces T cell responses to foreign antigen could be modulated, for example, by use of anti-ICOS antibodies (Hutloff et al., *Nature* 397:263-266, 1999).

Lymphocyte function associated antigen-3 (LFA-3) is expressed on APCs and some tumor cells and interacts with CD2 expressed on T cells. This interaction induces T cell IL-2 and IFN-gamma production and can thus complement but not substitute, the B7/CD28 costimulatory interaction (Parra et al., *J. Immunol.*, 158:637-642 (1997), Fenton et al., *J. Immunother.*, 21:2:95-108 (1998)).

Lymphocyte function associated antigen-1 (LFA-1) is expressed on leukocytes and interacts with ICAM-1 expressed on APCs and some tumor cells. This interaction induces T cell IL-2 and IFN-gamma production and can thus complement but not substitute, the B7/CD28 costimulatory interaction (Fenton et al., *J. Immunother.*, 21:2:95-108 (1998)). LFA-1 is thus a further example of a costimulatory molecule that could be provided in a vaccination protocol in the various ways discussed above for B7.

Complete CTL activation and effector function requires Th cell help through the interaction between the Th cell CD40L (CD40 ligand) molecule and the CD40 molecule expressed by DCs (Ridge et al., *Nature*, 393:474 (1998), Bennett et al., *Nature*, 393:478 (1998), Schoenberger et al., *Nature*, 393:480 (1998)). This mechanism of this costimulatory signal is likely to involve upregulation of B7 and associated IL-6/IL-12 production by the DC (APC). The CD40-CD40L interaction thus complements the signal 1 (antigen/MHC-TCR)

and signal 2 (B7-CD28) interactions.

The use of anti-CD40 antibodies to stimulate DC cells directly, would be expected to enhance a response to tumor antigens which are normally encountered outside of a inflammatory context or are presented by non-professional APCs (tumor cells). In these situations Th help and B7 costimulation signals are not provided. This mechanism might be used in the context of antigen pulsed DC based therapies or in situations where Th epitopes have not been defined within known TRA precursors.

A cancer associated antigen polypeptide, or a fragment thereof, also can be used to isolate their native binding partners. Isolation of such binding partners may be performed according to well-known methods. For example, isolated cancer associated antigen polypeptides can be attached to a substrate (e.g., chromatographic media, such as polystyrene beads, or a filter), and then a solution suspected of containing the binding partner may be applied to the substrate. If a binding partner which can interact with cancer associated antigen polypeptides is present in the solution, then it will bind to the substrate-bound cancer associated antigen polypeptide. The binding partner then may be isolated.

It will also be recognized that the invention embraces the use of the cancer associated antigen cDNA sequences in expression vectors, as well as to transfect host cells and cell lines, be these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., dendritic cells, B cells, CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as human, mouse, hamster, pig, goat, primate, etc. They may be of a wide variety of tissue types, and include primary cells and cell lines. Specific examples include keratinocytes, peripheral blood leukocytes, bone marrow stem cells and embryonic stem cells. The expression vectors require that the pertinent sequence, i.e., those nucleic acids described *supra*, be operably linked to a promoter.

The invention also contemplates delivery of nucleic acids, polypeptides or peptides for vaccination. Delivery of polypeptides and peptides can be accomplished according to standard vaccination protocols which are well known in the art. In another embodiment, the delivery of nucleic acid is accomplished by *ex vivo* methods, i.e. by removing a cell from a subject, genetically engineering the cell to include a breast cancer associated antigen, and reintroducing the engineered cell into the subject. One example of such a procedure is outlined in U.S. Patent 5,399,346 and in exhibits submitted in the file history of that patent, all of which are publicly available documents. In general, it involves introduction *in vitro* of a

functional copy of a gene into a cell(s) of a subject, and returning the genetically engineered cell(s) to the subject. The functional copy of the gene is under operable control of regulatory elements which permit expression of the gene in the genetically engineered cell(s). Numerous transfection and transduction techniques as well as appropriate expression vectors are well known to those of ordinary skill in the art, some of which are described in PCT application WO95/00654. *In vivo* nucleic acid delivery using vectors such as viruses and targeted liposomes also is contemplated according to the invention.

In preferred embodiments, a virus vector for delivering a nucleic acid encoding a cancer associated antigen is selected from the group consisting of adenoviruses, adeno-associated viruses, poxviruses including vaccinia viruses and attenuated poxviruses, Semliki Forest virus, Venezuelan equine encephalitis virus, retroviruses, Sindbis virus, and Ty virus-like particle. Examples of viruses and virus-like particles which have been used to deliver exogenous nucleic acids include: replication-defective adenoviruses (e.g., Xiang et al., *Virology* 219:220-227, 1996; Eloit et al., *J. Virol.* 71:5375-5381, 1997; Chengalvala et al., *Vaccine* 15:335-339, 1997), a modified retrovirus (Townsend et al., *J. Virol.* 71:3365-3374, 1997), a nonreplicating retrovirus (Irwin et al., *J. Virol.* 68:5036-5044, 1994), a replication defective Semliki Forest virus (Zhao et al., *Proc. Natl. Acad. Sci. USA* 92:3009-3013, 1995), canarypox virus and highly attenuated vaccinia virus derivative (Paoletti, *Proc. Natl. Acad. Sci. USA* 93:11349-11353, 1996), non-replicative vaccinia virus (Moss, *Proc. Natl. Acad. Sci. USA* 93:11341-11348, 1996), replicative vaccinia virus (Moss, *Dev. Biol. Stand.* 82:55-63, 1994), Venezuelan equine encephalitis virus (Davis et al., *J. Virol.* 70:3781-3787, 1996), Sindbis virus (Pugachev et al., *Virology* 212:587-594, 1995), and Ty virus-like particle (Allsopp et al., *Eur. J. Immunol* 26:1951-1959, 1996). In preferred embodiments, the virus vector is an adenovirus.

Another preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus is capable of infecting a wide range of cell types and species and can be engineered to be replication-deficient. It further has advantages, such as heat and lipid solvent stability, high transduction frequencies in cells of diverse lineages, including hematopoietic cells, and lack of superinfection inhibition thus allowing multiple series of transductions. The adeno-associated virus can integrate into human cellular DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression. In addition, wild-type adeno-associated virus

infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

In general, other preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA.

Adenoviruses and retroviruses have been approved for human gene therapy trials. In general, the retroviruses are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell lined with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M., "Gene Transfer and Expression, A Laboratory Manual," W.H. Freeman Co., New York (1990) and Murry, E.J. Ed. "Methods in Molecular Biology," vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

Preferably the foregoing nucleic acid delivery vectors: (1) contain exogenous genetic material that can be transcribed and translated in a mammalian cell and that can induce an immune response in a host, and (2) contain on a surface a ligand that selectively binds to a receptor on the surface of a target cell, such as a mammalian cell, and thereby gains entry to the target cell.

Various techniques may be employed for introducing nucleic acids of the invention into cells, depending on whether the nucleic acids are introduced *in vitro* or *in vivo* in a host. Such techniques include transfection of nucleic acid- CaPO_4 precipitates, transfection of nucleic acids associated with DEAE, transfection or infection with the foregoing viruses including the nucleic acid of interest, liposome mediated transfection, and the like. For certain uses, it is preferred to target the nucleic acid to particular cells. In such instances, a vehicle used for delivering a nucleic acid of the invention into a cell (e.g., a retrovirus, or other virus; a liposome) can have a targeting molecule attached thereto. For example, a molecule such as an antibody specific for a surface membrane protein on the target cell or a

ligand for a receptor on the target cell can be bound to or incorporated within the nucleic acid delivery vehicle. Preferred antibodies include antibodies which selectively bind a cancer associated antigen, alone or as a complex with a MHC molecule. Especially preferred are monoclonal antibodies. Where liposomes are employed to deliver the nucleic acids of the invention, proteins which bind to a surface membrane protein associated with endocytosis may be incorporated into the liposome formulation for targeting and/or to facilitate uptake. Such proteins include capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half life, and the like. Polymeric delivery systems also have been used successfully to deliver nucleic acids into cells, as is known by those skilled in the art. Such systems even permit oral delivery of nucleic acids.

When administered, the therapeutic compositions of the present invention can be administered in pharmaceutically acceptable preparations. Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, supplementary immune potentiating agents such as adjuvants and cytokines and optionally other therapeutic agents.

The therapeutics of the invention can be administered by any conventional route, including injection or by gradual infusion over time. The administration may, for example, be oral, intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, or transdermal. When antibodies are used therapeutically, a preferred route of administration is by pulmonary aerosol. Techniques for preparing aerosol delivery systems containing antibodies are well known to those of skill in the art. Generally, such systems should utilize components which will not significantly impair the biological properties of the antibodies, such as the paratope binding capacity (see, for example, Sciarra and Cutie, "Aerosols," in Remington's Pharmaceutical Sciences, 18th edition, 1990, pp 1694-1712; incorporated by reference). Those of skill in the art can readily determine the various parameters and conditions for producing antibody aerosols without resort to undue experimentation. When using antisense preparations of the invention, slow intravenous administration is preferred.

The compositions of the invention are administered in effective amounts. An "effective amount" is that amount of a cancer associated antigen composition that alone, or together with further doses, produces the desired response, e.g. increases an immune response to the cancer associated antigen. In the case of treating a particular disease or condition

characterized by expression of one or more cancer associated antigens, such as renal cancer, the desired response is inhibiting the progression of the disease. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently. This can be monitored by routine methods or can be monitored according to diagnostic methods of the invention discussed herein. The desired response to treatment of the disease or condition also can be delaying the onset or even preventing the onset of the disease or condition.

Such amounts will depend, of course, on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is generally preferred that a maximum dose of the individual components or combinations thereof be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.

The pharmaceutical compositions used in the foregoing methods preferably are sterile and contain an effective amount of cancer associated antigen or nucleic acid encoding cancer associated antigen for producing the desired response in a unit of weight or volume suitable for administration to a patient. The response can, for example, be measured by determining the immune response following administration of the cancer associated antigen composition via a reporter system by measuring downstream effects such as gene expression, or by measuring the physiological effects of the cancer associated antigen composition, such as regression of a tumor or decrease of disease symptoms. Other assays will be known to one of ordinary skill in the art and can be employed for measuring the level of the response.

The doses of cancer associated antigen compositions (e.g., polypeptide, peptide, antibody, cell or nucleic acid) administered to a subject can be chosen in accordance with different parameters, in particular in accordance with the mode of administration used and the state of the subject. Other factors include the desired period of treatment. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that

patient tolerance permits.

In general, for treatments for eliciting or increasing an immune response, doses of cancer associated antigen are formulated and administered in doses between 1 ng and 1 mg, and preferably between 10 ng and 100 μ g, according to any standard procedure in the art. Where nucleic acids encoding cancer associated antigen of variants thereof are employed, doses of between 1 ng and 0.1 mg generally will be formulated and administered according to standard procedures. Other protocols for the administration of cancer associated antigen compositions will be known to one of ordinary skill in the art, in which the dose amount, schedule of injections, sites of injections, mode of administration (e.g., intra-tumoral) and the like vary from the foregoing. Administration of cancer associated antigen compositions to mammals other than humans, e.g. for testing purposes or veterinary therapeutic purposes, is carried out under substantially the same conditions as described above.

Where cancer associated antigen peptides are used for vaccination, modes of administration which effectively deliver the cancer associated antigen and adjuvant, such that an immune response to the antigen is increased, can be used. For administration of a cancer associated antigen peptide in adjuvant, preferred methods include intradermal, intravenous, intramuscular and subcutaneous administration. Although these are preferred embodiments, the invention is not limited by the particular modes of administration disclosed herein. Standard references in the art (e.g., *Remington's Pharmaceutical Sciences*, 18th edition, 1990) provide modes of administration and formulations for delivery of immunogens with adjuvant or in a non-adjuvant carrier.

When administered, the pharmaceutical preparations of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptable compositions. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like.

Also, pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.

A renal cancer associated antigen composition may be combined, if desired, with a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.

The pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt.

The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.

The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

Compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound. Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as a syrup, elixir or an emulsion.

Compositions suitable for parenteral administration conveniently comprise a sterile aqueous or non-aqueous preparation of breast cancer associated antigen polypeptides or nucleic acids, which is preferably isotonic with the blood of the recipient. This preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be

employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono-or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier formulation suitable for oral, subcutaneous, intravenous, intramuscular, etc. administrations can be found in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA.

As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art. An isolated nucleic acid as used herein is not a naturally occurring chromosome.

As used herein with respect to polypeptides, "isolated" means separated from its native environment and present in sufficient quantity to permit its identification or use. Isolated, when referring to a protein or polypeptide, means, for example: (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated proteins or polypeptides may, but need not be, substantially pure. The term "substantially pure" means that the proteins or polypeptides are essentially free of other substances with which they may be found in nature or *in vivo* systems to an extent practical and appropriate for their intended use. Substantially pure polypeptides may be produced by techniques well known in the art. Because an isolated protein may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the protein may comprise only a small percentage by weight of the preparation. The protein is nonetheless isolated in that it has been separated from the substances with which it may be associated in living systems, i.e. isolated from other proteins.

Examples

Example 1: SEREX screening of renal cancer cell line 1973/10.4

A standard cDNA library was prepared using 5 µg of poly A⁺ RNA derived from the cell line 1973/10.4. A primary (unamplified) cDNA library was immunoscreened (5 x 10⁵ clones per library) by standard SEREX methodology, with absorbed autologous patient serum at 1:200 dilution [Sahin, U. et al., *Proc Natl Acad Sci USA* 92:11810-3 (1995); Chen, Y.T. et al. *Proc Natl Acad Sci USA*. 94:1914-8 (1997)]. Excluding false-positive clones encoding immunoglobulin gene fragments, clones were purified and sequence analyzed. Comparisons of the sequences showed that these clones represented cDNAs from 22 distinct genes, designated NY-REN-45 through NY-LU-66 (Table A and Sequence Listing (SEQ ID NOs:1-21)). A homology search through the GenBank/EMBO databases revealed that 14 of the 22 genes corresponded to previously known molecules, and 8 others were unknown genes, with sequence identity limited only to short segments of known genes or to expressed sequence tags (ESTs).

Analysis of isolated clones:

I. NY-REN clones which are known gene products

Designation	Gene/Sequence Identity	Accession Number	SEQ ID NO
NY-REN-46	lactate dehydrogenase B	Y00711	22
NY-REN-47	ERK tyrosine kinase	D31661	23
NY-REN-48	PINCH protein	U09284	24
NY-REN-51	BBP/53BP2	U58334	25
NY-REN-52	steroid receptor coactivator	U59302	26
NY-REN-53	KIAA0336 mRNA tag	AB002334	27
NY-REN-54	E6 oncogenic protein-associated protein	X98033	28
NY-REN-55	murine NEK1 protein kinase homologue	S45828	29

NY-REN-56	6-phospho-fructokinase	D49817	30
NY-REN-59	lactate dehydrogenase A	X02152	31
NY-REN-61	KIAA0081 mRNA tag	D42039	32
NY-REN-63	DDB p127-associated protein	AF035950	33
NY-REN-65	HREV107 protein	X92814	34
NY-REN-66	acidic ribosomal phosphoprotein 2	M17887	35

II. Novel gene products

<u>Clone</u>	<u>SEQ ID NO:</u>	<u>Size</u>	<u>Tissue mRNA expression</u>	<u>Protein SEQ ID NO:</u>
NY-REN-45	1	4.0kb	Ubiquitous	12
NY-REN-49	2	1.1kb	Ubiquitous	13
NY-REN-50	3	1.8kb	Ubiquitous	14
NY-REN-57	4,5	2.9kb	Ubiquitous	15, 16
NY-REN-58	6	1.9kb	Ubiquitous	17
NY-REN-60	7	4.0kb	Ubiquitous	18
NY-REN-62	8,9	2.7kb	Ubiquitous	19, 20
NY-REN-64	10,11	3.0kb	Ubiquitous	21

III. Clones which react with autologous sera only:

NY-REN-47

NY-REN-49

NY-REN-50

IV. Clones which react with sera from normal control donors

Frequency of sera reactivity

<u>Clone</u>	<u>normal</u>	<u>cancer patient</u>
NY-REN-46	4/4	6/14
NY-REN-48	14/14	17/17
NY-REN-51	1/12	3/17

- 52 -

NY-REN-52	4/12	7/17
NY-REN-53	4/19	10/31
NY-REN-54	5/8	7/7
NY-REN-55	3/19	6/31
NY-REN-56	3/19	7/31
NY-REN-57	1/19	3/31
NY-REN-58	1/12	2/17
NY-REN-59	1/19	4/31
NY-REN-61	3/19	5/31
NY-REN-62	1/19	4/31
NY-REN-63	2/19	12/31
NY-REN-64	3/19	6/31
NY-REN-65	2/19	2/31

V. Clones which react with sera from cancer patients only (failed to react with 19 normal patient serum samples). These clones are preferred for therapeutic and diagnostic applications.

	<u>Frequency of reactivity</u>
NY-REN-32	3/31
NY-REN-45	3/31
NY-REN-57	2/31
NY-REN-60	5/31
NY-REN-66	2/31

VI. Additional allogeneic screening of NY-REN renal SEREX clones

Renal SEREX clones were tested for reactivity with sera from the normal and various cancer patients listed below.

Sera

<u>Clone</u>	<u>normal</u>	<u>colon</u>	<u>renal</u>	<u>lung</u>	<u>breast</u>
NY-REN-3	0/26	7/37	8/32	0/23	1/26
NY-REN-12	0/19	0/16	3/32	0/15	0/16
NY-REN-19	0/19	0/16	2/32	0/15	0/16
NY-REN-21	0/16	3/16	3/32	1/15	0/16
NY-REN-25	0/15	0/16	5/32	0/15	0/16
NY-REN-31	0/14	0/16	5/32	0/15	0/16
NY-REN-32	0/14	2/16	3/32	0/15	0/16
NY-REN-37	0/15	0/16	2/32	0/15	0/16
NY-REN-45	0/14	0/16	3/32	1/15	0/16
NY-REN-57	0/19	0/16	2/32	0/15	0/16
NY-REN-60	0/19	0/16	7/32	0/15	0/16
NY-REN-66	0/19	0/16	2/32	0/15	0/16

Example 2: SEREX screening of tumor cells and testis libraries

Standard cDNA libraries were prepared using poly A⁺ RNA derived from the various cancer sources, as well as testis. The cDNA libraries were immunoscreened by standard SEREX methodology, with absorbed autologous patient serum [Sahin, U. et al., *Proc Natl Acad Sci USA* 92:11810-3 (1995); Chen, Y.T. et al. *Proc Natl Acad Sci USA* 94:1914-8 (1997)]. Excluding false-positive clones encoding immunoglobulin gene fragments, clones were purified and sequence analyzed. Comparisons of the sequences showed that these clones all were substantially identical to the kinectin cDNA (GenBank Accession number L25616).

Table A: Kinectin clones isolated by SEREX

<u>Clone designation</u>	<u>SEQ ID NO</u>	<u>Library</u>	<u>Patient sera for screen</u>
NGO-St-47	36	Gastric tumor	autologous
TS-64-5'	37	Testis	seminoma
HOM-TSOv3-41 (5')	38	Testis	seminoma
HOM-TSOv3-41 (3')	39	Testis	seminoma
HOM-HD2-2(3')	40	Hodgkin's disease	autologous
HOM-HD2-232(3')	41	Hodgkin's disease	autologous
Thy4 (3')	42	Thyroid tumor	autologous

Thy4 (3')	42	Thyroid tumor	autologous
Thy5 (3')	43	Thyroid tumor	autologous
Thy8 (3')	44	Thyroid tumor	autologous
Thy10 (3')	45	Thyroid tumor	autologous
NGO-Br-1	46	Breast cancer	autologous

In addition, a hepatocarcinoma library screened with autologous sera also identified several clones which were sequenced and found to be substantially identical to kinectin.

Allotyping (gastric cancer)

12/12 gastric cancer patient sera recognized kinectin

0/27 normal individual sera recognized kinectin

Therefore it was determined that recognition of kinectin was diagnostic for cancer patients.

Example 3: Preparation of recombinant cancer associated antigens

To facilitate screening of patients' sera for antibodies reactive with cancer associated antigens, for example by ELISA, recombinant proteins are prepared according to standard procedures. In one method, the clones encoding cancer associated antigens are subcloned into a baculovirus expression vector, and the recombinant expression vectors are introduced into appropriate insect cells. Baculovirus/insect cloning systems are preferred because post-translational modifications are carried out in the insect cells. Another preferred eukaryotic system is the *Drosophila* Expression System from Invitrogen. Clones which express high amounts of the recombinant protein are selected and used to produce the recombinant proteins. The recombinant proteins are tested for antibody recognition using serum from the patient which was used to isolated the particular clone, or in the case of cancer associated antigens recognized by allogeneic sera, by the sera from any of the patients used to isolate the clones or sera which recognize the clones' gene products.

Alternatively, the cancer associated antigen clones are inserted into a prokaryotic expression vector for production of recombinant proteins in bacteria. Other systems, including yeast expression systems and mammalian cell culture systems also can be used.

Example 4: Preparation of antibodies to cancer associated antigens

The recombinant cancer associated antigens produced as in Example 4 above are used to generate polyclonal antisera and monoclonal antibodies according to standard procedures. The antisera and antibodies so produced are tested for correct recognition of the cancer associated antigens by using the antisera/antibodies in assays of cell extracts of patients known to express the particular cancer associated antigen (e.g. an ELISA assay). These antibodies can be used for experimental purposes (e.g. localization of the cancer associated antigens, immunoprecipitations, Western blots, etc.) as well as diagnostic purposes (e.g., testing extracts of tissue biopsies, testing for the presence of cancer associated antigens).

Example 5: Expression of cancer associated antigens in cancers of similar and different origin.

The expression of one or more of the cancer associated antigens is tested in a range of tumor samples to determine which, if any, other malignancies should be diagnosed and/or treated by the methods described herein. Tumor cell lines and tumor samples are tested for cancer associated antigen expression, preferably by RT-PCR according to standard procedures. Northern blots also are used to test the expression of the cancer associated antigens. Antibody based assays, such as ELISA and western blot, also can be used to determine protein expression. A preferred method of testing expression of cancer associated antigens (in other cancers and in additional same type cancer patients) is allogeneic serotyping using a modified SEREX protocol (as described above).

In all of the foregoing, extracts from the tumors of patients who provided sera for the initial isolation of the cancer associated antigens are used as positive controls. The cells containing recombinant expression vectors described in the Examples above also can be used as positive controls.

The results generated from the foregoing experiments provide panels of multiple cancer associated nucleic acids and/or polypeptides for use in diagnostic (e.g. determining the existence of cancer, determining the prognosis of a patient undergoing therapy, etc.) and therapeutic methods (e.g., vaccine composition, etc.).

Example 6: HLA typing of patients positive for cancer associated antigens

To determine which HLA molecules present peptides derived from the cancer associated antigens of the invention, cells of the patients which express the cancer associated

antigens are HLA typed. Peripheral blood lymphocytes are taken from the patient and typed for HLA class I or class II, as well as for the particular subtype of class I or class II. Tumor biopsy samples also can be used for typing. HLA typing can be carried out by any of the standard methods in the art of clinical immunology, such as by recognition by specific monoclonal antibodies, or by HLA allele-specific PCR (e.g. as described in WO97/31126).

Example 7: Characterization of cancer associated antigen peptides presented by MHC class I and class II molecules.

Antigens which provoke an antibody response in a subject may also provoke a cell-mediated immune response. Cells process proteins into peptides for presentation on MHC class I or class II molecules on the cell surface for immune surveillance. Peptides presented by certain MHC/HLA molecules generally conform to motifs. These motifs are known in some cases, and can be used to screen the renal cancer associated antigens for the presence of potential class I and/or class II peptides. Summaries of class I and class II motifs have been published (e.g., Rammensee et al., *Immunogenetics* 41:178-228, 1995). Based on the results of experiments such as those described above, the HLA types which present the individual breast cancer associated antigens are known. Motifs of peptides presented by these HLA molecules thus are preferentially searched.

One also can search for class I and class II motifs using computer algorithms. For example, computer programs for predicting potential CTL epitopes based on known class I motifs has been described (*see, e.g.*, Parker et al, *J. Immunol.* 152:163, 1994; D'Amato et al., *Human Immunol.* 43:13-18, 1995; Drijfhout et al., *Human Immunol.* 43:1-12, 1995).

Computer programs for predicting potential T cell epitopes based on known class II motifs has also been described (*see, e.g.* Sturniolo et al., *Nat Biotechnol* 17(6):555-61, 1999). HLA binding predictions can conveniently be made using an algorithm available via the Internet on the National Institutes of Health World Wide Web site at URL <http://bimas.dcrt.nih.gov> . See also the website of: SYFPEITHI: An Internet Database for MHC Ligands and Peptide Motifs (access via <http://www.uni-tuebingen.de/uni/kxi/> or <http://134.2.96.221/scripts/hlaserver.dll/EpPredict.htm>). Methods for determining HLA class II peptides and making substitutions thereto are also known (e.g. Strominger and Wucherpfennig (PCT/US96/03182)).

Example 8: Identification of the portion of a cancer associated polypeptide encoding an antigen

To determine if the cancer associated antigens isolated as described above can provoke a cytolytic T lymphocyte response, the following method is performed. CTL clones are generated by stimulating the peripheral blood lymphocytes (PBLs) of a patient with autologous normal cells transfected with one of the clones encoding a cancer associated antigen polypeptide or with irradiated PBLs loaded with synthetic peptides corresponding to the putative protein and matching the consensus for the appropriate HLA class I molecule (as described above) to localize an antigenic peptide within the cancer associated antigen clone (see, e.g., Knuth et al., *Proc. Natl. Acad. Sci. USA* 81:3511-3515, 1984; van der Bruggen et al., *Eur. J. Immunol.* 24:3038-3043, 1994). These CTL clones are screened for specificity against COS cells transfected with the cancer associated antigen clone and autologous HLA alleles as described by Brichard et al. (*Eur. J. Immunol.* 26:224-230, 1996). CTL recognition of a cancer associated antigen is determined by measuring release of TNF from the cytolytic T lymphocyte or by ^{51}Cr release assay (Herin et al., *Int. J. Cancer* 39:390-396, 1987). If a CTL clone specifically recognizes a transfected COS cell, then shorter fragments of the cancer associated antigen clone transfected in that COS cell are tested to identify the region of the gene that encodes the peptide. Fragments of the cancer associated antigen clone are prepared by exonuclease III digestion or other standard molecular biology methods. Synthetic peptides are prepared to confirm the exact sequence of the antigen.

Optionally, shorter fragments of cancer associated antigen cDNAs are generated by PCR. Shorter fragments are used to provoke TNF release or ^{51}Cr release as above.

Synthetic peptides corresponding to portions of the shortest fragment of the cancer associated antigen clone which provokes TNF release are prepared. Progressively shorter peptides are synthesized to determine the optimal cancer associated antigen tumor rejection antigen peptides for a given HLA molecule.

A similar method is performed to determine if the cancer associated antigen contains one or more HLA class II peptides recognized by T cells. One can search the sequence of the cancer associated antigen polypeptides for HLA class II motifs as described above. In contrast to class I peptides, class II peptides are presented by a limited number of cell types. Thus for these experiments, dendritic cells or B cell clones which express HLA class II molecules preferably are used.

Table 1: Sequence homologies

SEQ ID NO.: 1

AB002794, U46118RNU46118U19482AF026216AB002739, AB002730, AB002728, AF058796, AB002777, AF020187, AF009411, AB015609, AF006627, M95076, U43527, AB002741, U25846, AF006628, AF019043, D83352, U10355, M99575, U48288, AF090440, AB007504, U82480, Y15794, AJ005572, AF029349, L10111, S80963, U38894, L41731, AF022733, AJ225108, Y11879, AF001688, U33214, Z97178, AF009413, AF019907, AF016371, X71980, AF001522, M77169, AF023132, D83476, AJ009675, U90554, AF069324, AF048691, Z34799, AF004947, U60149, AF022732, AF019887, L02937, U55848, AF011331, AF045770, AF043533, X69524, M32882, U08214, U50847, AF017364, U35364, Y14339, AJ005969, U90555, U44430, U74296, AF001501, AJ223316, D78609, U41060, Z54362, AF034387, U62398, AB005545, AB002533, Y13865, AF009959, L02938, U10555, AL010246, AC003041, U37699, S75970, AF071010, Z81311, AB003681, X16353, AB002731, X53081, D63450, D10911, D90115, X97065, Z82275, AB016891, Y09455, X77990, , W58357, W07820, AA188593, W81046, AA858164, AI018124, AI139112, AA769634, W00437, D80849, AA448160, N98650, T31293, H15307, H51146, N29314, AA770301, AA187822, AA978299, T31823, AA936410, AA993194, N41386, W45601, W81099, C05691, D60153, AA780119, AA929004, R68608, Z43271, N37024, AA974718, AA928663, T30120, AA936583, H51109, N20251, W92917, T36035, AA480197, Z24908, N79450, AA872019, AA902275, N59810, R13443, AA740162, AA937759, N72168, AA970708, T36257, AA433833, H15700, D51185, AA249138, R37356, W93028, Z28641, AA371494, N72757, AA719126, N56164, T31790, D57384, Z41959, N58984, AA847848, AA587009, Z39343, AA654834, AA505490, Z38243, D20344, AA252395, AA025593, H70133, R09101, AA159862, AI032981, Z28355, C75020, AI139642, D82421, AI126922, C75170, AI016032, C18748, C75478, AI129334, C75472, AA310765, D63057, C05952, AA357303, C16591, D82132, L48852, D82799, C75176, AI124552, AA669404, U30155, C75118, AA374918, C75108, C05853, U30151, D57346, AI127548, AA918527, AA317816, AA573490, R21699, AA917928, R36311, AA361522, AA701252, AI085492, H44387, AA156256, AA587935, AA976510, AA515269, W73374, T27986, N34493, AA737770, N32609, N32612, H64420, , AA415243, AA113717, AA117350, AA242502, AA117343, AA545256, AA795651, AA106372, U31322, AA681967, AA221922, AA600546, AA050610, AU018628, C80932, AA920654, AA863834, AI099036, AA183239, AI115182, AA590910, W65628, AA162291, , AA109440, AI052952, AA999324, AI105714, AI026280, AI072678, AA964820, AA754198, AA944557, AI045710, C94989, AA471630, AA933231, AA509077, AA257557, AA509328, AA109365, AA963207, AA435473, AA999306, AA406684, AI105662, AA509174, AI108597, AA109374, AA925182, AA471671, AA088161, AA752812, AA626989, AA406924, AA840999, AA509033, C94899, AA406875, AA842672, AA123619, AA072471, AA509339, AA933108, AI110259, AA842135, N99262, AA661430, AA842512, AA180648, AI066048, AA559515, AA406761, AA109423, AF074736, AA257676, D87312, AA257488, AA114390, AI087701, W06665, W32852, AA123649, AA842505, AA509330, AA908025, AA257279, AI105717, AA406673, AA627018, AA406850, AA161668, AA114453, AA109372, AA257572, AA803997, AA406943, AA257495, AA842019, AA661368, AI082949, AA842888, W06539, AA118223, AA406986, AA471717, AI096212, AA257707, AA257649, AI053126, AA508950, AA713366, W69049, AA965381, AA208680, AI057997, AA161707, AI058071, AA675858, AA257513, AI083337, AA406908, AI083256, AA659956, AA842532, AA754036, AA753165, W18199, AI109620, AI058022, AI064026, AA471431, AA032116, AA754544, AI108146, C42045, AA843025, AI109103, AA509237, AA161620, AA257665, AA471605, W84932, AA841358, AA843040, AA471695, AA003471, AA840977, AA509267, AA841711, AA471488, AA257699, N98079, AA454318, W04102, AA842874, N99754, AA509307, AA751845, AA661358, AA508954, AA406746, AA842720, W23363, AA508951, AI068913, AA417420, AI108220, AA508946, AA471497, AA842911, AA842501, AA123614, AA509218, AA547812, AA752986, AA752003, AA406839, AA508993, AA161747, AA509008, AA180623, AA508986, AA842627, AA753129, AA509214, AA406733, AI105737, N74818, AA753300, AA430818, AA417415, AA114426, R46936, AA979824, AA246112, AA753138, AI058077, AA842464, AA966639, AA842265, AA509025, AA601853, W15128, AA660039, AA842275, AA454424, AA180651,

AA842423, AA257507, AI063375, AA180692, AA051990, W15094, AA180620, W00308, AA406729, AA257712, AA257445, AA433148, C48534, AA495533, C08939, AA406845, AA933362, AA509242, AA842023, W29144, AI087490, AA842237, AA601823, W06538, AI087739, AI087524, AA842164, AA842642, AA471553, AA842419, AI113700, AA675813, AI083003, AI021727, AI083274, AI083309, W32823, AA253962, AA114520, AA430792, C47230, AA842674, AI053141, D75937, AA843034, W68979, AI105681, W91819, AA756971, AA509104, AA111828, AI109720, AI110161, AA933311, AA180602, AA842093, R86419, AI058057, AA186285, AA406891, AI105725, AA406888, AA649397, N94700, W51718, AA547916, AA840646, U74116, AA257756, AI082996, W91818, N74830, AA123585, AA118224, AA454446, AA841367, AA509109, AA842387, AI052833, AA751998, AA123634, AA257327, AA803962, AA842493, AA471448, AA406716, AA841361, AA840661, AA713447, AA406754, AA257695, AA841403, AA751834, AA406947, AI096182, AI105734, W15132, W59918, AA089352, AA180566, AA257427, AA406980, AA471469, AA509264, AA509032, AA749469, AA752028, AA754167, AA754646, AA842335, AA842574, AI065957, AI065970, AI096289, AA109379, AA109472, AA114484, AA161689, AA430830, AA406948, AA433246, AA454371, AA471492, AA471703, AA752086, AA842624, AI096185, R47079, R86415, AA161711, AA161655, AA180549, AA257424, AA257437, AA257749, AA433393, AA471419, AA471602, AA430922, AA661401, AA752034, AA752066, AA842384, AI082936, AI083329, AI105677, Z33912, AA109362, AA109417, AA051807, AA430797, AA406799, AA430806, AA495548, AA661116, AI082951, AI105685, AI114069, R47062, W59884, AA109292, AA751829, AA754172, AA842257, AI082934, AI082958, AA180706, AA471516, AA508962, AA751563, AA751816, AA753137, AA753167, AA840972, AA842079, AA874756, AI105522, AI108824, AA180588, AA406676, AA471392, AA509142, AA840909, AA842175, AI066854, R47172, AA161565, AA257643, AA753161, AA471447, AA680450, AA752897, AA753237, AA842230, AA842544, AA161635, AA454428, AA508933, AA509309, C41215, AA842585, D73786, D75990, D75808, AA627049, N74809, AA257682, AA257517, AA257668, AA471470, AA509251, AA509051, AA990913, C39627, C41200, C42101, C46071, C48450, AA840970, AA842156, AA430902, AA842216, AA007706, AA406765, AA180574, AA842310, AI067585, AI077003, AA756933, AA114501, AA406690, AA454440, AA661371, AA056797, AA114372, AA180676, AI082955, AA406735, AA675746, AA752005, W29142, AA109261, AA842401, AA842602, AA246079, AI043420, AA626993, AA123655, AA257716, AA406931, AA791379, AI105668, AA842538, R47669, AA088150, AA109308, AA738555, AA123638, AA180582, AA123597, AA471535, AA180728, AA161741, AA186201, AA430817, AA433170, AA454407, AA471686, AA161596, AA509110, AA675874, AA471540, Z26577, AA753093, AI066829, D37716, AA627017, N99292, AA508936, AA257656, AA406768, AA471587, H39287, AA842431, AA161715, AA509204, AA979935

SEQ ID NO.: 2, AF086243, AE001154, X62889, , W67765, W67764, AA947751, AI141491, W76469, AA906091, AA872676, AA349825, H77545, H91001, W72232, AA948309, AA361403, R57582, AA337188, AA215714, AA481093, T75310, AA976452, , AI120744, AA462558, AI158491, AA014020, AA285990, AA051044, AA473453, AA896862, W56907, AA218305, AA020167, W85164, AA017810, W30604, AA541978, W20894, AA023164, AA760425, AA024084, AA840044, , AA231755, T20644, C45833, T24185, C68940, D37618, AA964657, AI011924

SEQ ID NO.: 3, L08501, Z97205, Z48950, AF010400, AC005162, L08502, D50608, , AA707653, AA861639, AA292496, AA702524, AI097367, AI138504, AI147933, AI141836, AI075247, N63868, W88668, AA703146, AA625621, AA292247, AI032848, AA005331, AA699781, AA427941, D31111, D31113, N92013, AA884207, AA044752, R70900, R16693, AA906542, R35112, AA481286, D80100, AA235512, AA960995, AA867982, D59403, W88874, AA558590, R10048, AA719917, H43573, R49500, AA744780, AA047136, AA789101, AA906332, AA747301, AA830606, AA434559, AA236698, AA328889, N98469, W17299, W46605, AA258082, AI078045, R11930, W74577, AA703312, AI082727, R45189, N76461, AA010500, W63646, W38891, AA490651, AA558805, W87891, AA160849, AA618177, AA776126, AA161281, , AA822308, AA499768, AA028780, AA183100, AA276783, AA120227, AA200285, AA212541, AA116265, AA821616, AA265629, AA108594, W61565, AA030311, W42275, AA419903, AA268027, AA028211, AA518504, AA125394, , C92235, C92002, C29917, AI145662, C65317, AA901847, AI137443, Z14719, D35515, R90625, H76970,

SEQ ID NO.: 4, AL031178, Y11905, AF031904, M34309, M29366, L33953, L33952,

- 60 -

L33956, L33954, L33957, U41289, X13369, AL022072, AJ223074, AF078695, AC004683, X17267, AF025526, AF071798, AC005274, AB004537, X68248, AF035537, AF056116, AB009052, AL023286, AF058701, L20725, AF001308, U22438, , AA211485, AA579574, AI078750, AA568661, AA604128, H49462, AA767424, H97012, AA565823, H49463, AA827171, T87152, F22114, AA748475, T31504, Z42997, T89930, R02581, H75949, T87057, AA322268, R02700, AA005034, AA576177, AI014302, AA348159, T83607, AA322497, AA211532, AA019517, R27657, AA026869, N67589, T83782, AA129383, Z39829, AA814308, AA425564, H67997, AA004420, AA644513, AA007691, T62593, AA333601, H75334, AI057250, T62521, N73865, AA004558, AA004484, AA007690, AA910241, AA456251, AA004568, AA341266, T28757, AA132360, AA781316, AA456942, AA782765, AA662593, AA461351, AA885220, N33840, AA843737, T62232, AA608559, AA643270, R44662, AI074863, AI051088, N63305, W24955, AA085886, W31918, AA047466, AA178965, AA369890, AA515015, N79466, AA768162, AA864694, AA811390, AA834531, AA293263, AA768335, AA749083, T57520, AA292001, AI085512, AA969032, AI027062, AA595663, AA827242, AA744475, , AA472485, AA097011, AA959170, AA647546, AA986669, AI006628, W12604, AI122356, AA571721, AA433697, AA880171, AA015463, AA116290, C87721, AA437983, AA990395, AA265925, W14785, W89262, AA059703, AA413613, AI020231, AA667024, AA407526, AA221491, AA222523, C76436, AA409700, W35766, , AA859485, H33704, T46512, C25899, T41882, C26586, C92302, AA660448, C94493, C25527, D35045, D33727, F14543, D37473, T45969, AA040979, D68274, T38420, AA228607, AA660541, T38283, AA842575, C71889, T38745, D68465, T46732, AA598393, C23775, C64798, AA042714, F19972, C65873, N97974, AA114425, AA900456

SEQ ID NO.: 5, U29344, S80437, M76767, X62889, M84761, J03514, X62888, X13415, X13135, U05714, AC004013, U58675, S47635, Z81533, AC005250, AC003661, AB008567, Y13444, X96401, AF026487, AF026488, , AA781445, AI037943, AI129371, C15883, AI073336, AA904077, AA569042, AI039428, AA568701, AA058907, AA911112, AA234022, N95359, AA565390, AA082427, AA588430, D60358, AA045488, AA084417, N72089, AI143390, R51974, AA081439, AA635907, T47621, AA579930, AA995057, AA827039, AA872490, AA588319, AA069032, AA062768, AA534011, W96404, H06082, AA938900, AA971262, AA836547, AA251544, AA250742, AA830405, AA906492, AA102653, R38286, AA258075, H83302, H38522, R61787, R33742, R24094, AI052406, AA931452, R23634, R39640, AA974568, AI028383, AA312451, AA148800, AI138982, R36172, AA926921, , AA472563, AA914598, AA423256, AA476186, AA041992, W84938, AA797706, AA709956, AA544361, AI006075, AA717202, AA008602, AA033399, AA472306, AI037430, AI152943, AA475582, AA471742, AA530292, AA277496, AA718588, AA823112, AA822771, AA710973, AA981780, AA718846, AA797557, AA510746, AI036049, AA543891, AA606513, AA981758, AA822268, AA413161, AA472201, AA646527, AA213036, AA168254, AA718549, AA458342, AA119418, AA879925, AA050917, AA718814, AA793638, AA177849, AA575627, AA537367, AI121788, AA203946, AA413157, AA517432, AA867736, AI037420, W30436, , Z71851, AA957415, AI112847, AA955881, AA963915, AI043663, C95061, AI009894, AA957229, AI044678

SEQ ID NO.: 6, AC002426, AC004674, AC004675, AC004006, L12157, U20839, U46028, U20835, AC004058, X67115, X76266, M25485, U59759, AC005172, U70848, AF042274, X14724, L31840, L41679, , W52480, AA863014, W56770, AA286755, AA164604, W52777, AA814246, AA765427, AA873647, AA360577, AI139274, AA770312, AA732557, AA568651, AA164603, W56724, AA194905, AA865009, R16884, R08110, F07672, AA577790, T11467, AA502489, AA366688, AA480628, AA516318, AA090005, AA081908, F01265, AA780686, , AA466811, AA465808, AA197646, AI157174, AA153086, AA197667, AA066612, AA058086, AA024186, AA110104, AA880419, AA870161, AA153880, AA072995, , AI031052, AI043934, AA849320, D15181, U95093, AI096188, T09655, C62926, AA996434, AA925202, AA817271, AA901051, R03660, AA948980, AA658709, AA899446, AA957150, AA800160, T76196, AA891787

SEQ ID NO.: 7, X63547, X63546, AF017306, U44839, U20657, AF017305, AJ001589, L21998, D21270, Z48245, U63834, Z68006, L04573, D63819, AC005266, AF025468, M94131, , AI056961, C15588, AA373847, AA887911, N87070, R39133, AA226825, AA353972, AA325352, R88378, AA490675, AA456219, AA701415, AA046611, AA456224, , AA065652, AA221447, AA710221, AA717401, AA254049,

AA041745, AA510261, AA170745, AA656404, AA572506, AA174539, AA217630, ,
AI134284, C58457, C11202, AA413362, AA728532

SEQ ID NO.: 8, AB016886, Z92811, AL021481, U52078, L46702, U23515, AC005555,
Z84814, Z93016, D21138, X57513, L07144, D83711, M28488, U15974, U52513,
AF026939, L19120, J05258, Z13985, Z70691, U59227, , AA190526, AA764854,
AI014655, H88220, AA622877, N32046, H89609, AA682362, AA464420, AA375477,
AA284905, AA257109, N80276, H89373, N92393, AA884334, AA778708, AA766209,
AA535677, W46414, AA770266, AA983635, AA721113, H88219, R87349, AA628091, ,
AI116513, AA183589, AI035517, AA209952, AA184622, AI097904, AA016440,
AA162370, AA939521, AA162376, AA718152, AA048154, AA253815, AA795350, ,
AA996981, C44448, C41783, C44695, C44039, C62421, C47063, C45014, D36613,
C60872, C50136, C69177, AI055708, D27648, C65648, AI114022, AI064663,
AI107213, AA395461, AA800126, AA891487, T01611, C27943, AI113482, C83830

SEQ ID NO.: 9, L43510, U71249, L11275, X73541, Z28317, AB008270, X75652,
U05987, U85262, U24189, Z46676, X70823, AC004981, D11079, X56121, M58053,
U33636, Z92773, U23168, D31662, , R15557, F01629, N71722, AA252548,
AA806751, T59557, AA612671, AA329585, AA295675, AA166990, AA128100, H46363,
AA125810, , AA396888, AA408999, AA270873, AA144722, AA863954, W10303, ,
C38016, N96746, Z37622, AA395862, C38756, F15295, N99294, W68877, C44749,
C24349, F15569, AA113611, AA689147, N96676, C73598, F15564, L46559, W06235,
T09718, H77154, T14151, AI082914, AA650815, AA728021, AA072559, C92112,
T46743, C61743, AA550223, C12798, AA275531, AA681003, T75878, AI100047,
T75882, AA848187, T44109, AA542686, H21339

SEQ ID NO.: 10, Z81595, U41372, U01317, AE000696, AC002057, X66250, L11665,
D13438, U29377, Z50028, U40953, AA114228, AI025080, R80188, W28745,
AA381819, AA381991, Z44165, H75915, AI124743, H08139, AA375957, AA381750,
AA166751, R42511, T26985, , AA471592, AA661387, AA606231, D35147

SEQ ID NO.: 11, X76498, Z97632, AC004232, AC005184, AC002545, AC003991.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

All references disclosed herein are incorporated by reference in their entirety.

We claim:

Claims

1. A method of diagnosing a disorder characterized by expression of a human cancer associated antigen precursor coded for by a nucleic acid molecule, comprising:
contacting a biological sample isolated from a subject with an agent that specifically binds to the nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof complexed with an HLA molecule, wherein the nucleic acid molecule is a NA Group 1 nucleic acid molecule, and
determining the interaction between the agent and the nucleic acid molecule or the expression product as a determination of the disorder.
2. The method of claim 1, wherein the agent is selected from the group consisting of
 - (a) a nucleic acid molecule comprising NA group 1 nucleic acid molecules or a fragment thereof,
 - (b) a nucleic acid molecule comprising NA group 3 nucleic acid molecules or a fragment thereof,
 - (c) a nucleic acid molecule comprising NA group 5 nucleic acid molecules or a fragment thereof,
 - (d) an antibody that binds to an expression product of NA group 1 nucleic acids,
 - (e) an antibody that binds to an expression product of NA group 3 nucleic acids,
 - (f) an antibody that binds to an expression product of NA group 5 nucleic acids,
 - (g) an agent that binds to a complex of an HLA molecule and a fragment of an expression product of a NA group 1 nucleic acid,
 - (h) an agent that binds to a complex of an HLA molecule and a fragment of an expression product of a NA group 3 nucleic acid, and
 - (i) an agent that binds to a complex of an HLA molecule and a fragment of an expression product of a NA group 5 nucleic acid.
3. The method of claim 1, wherein the disorder is characterized by expression of a plurality of human cancer associated antigen precursors and wherein the agent is a plurality of agents, each of which is specific for a different human cancer associated antigen precursor, and wherein said plurality of agents is at least 2, at least 3, at least 4, at least 4, at least 6, at least 7, or at least 8, at least 9 or at least 10 such agents.

4. The method of claims 1-3, wherein the agent is specific for a human cancer associated antigen precursor that is selected from the group consisting of breast, gastric, lung, prostate, renal, colon, thyroid, Hodgkin's disease, and hepatocarcinoma cancer associated antigen precursors.
5. A method for determining regression, progression or onset of a condition characterized by expression of abnormal levels of a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule, comprising
monitoring a sample, from a patient who has or is suspected of having the condition, for a parameter selected from the group consisting of
 - (i) the protein,
 - (ii) a peptide derived from the protein,
 - (iii) an antibody which selectively binds the protein or peptide, and
 - (iv) cytolytic T cells specific for a complex of the peptide derived from the protein and an MHC molecule,as a determination of regression, progression or onset of said condition.
6. The method of claim 5, wherein the sample is a body fluid, a body effusion or a tissue.
7. The method of claim 5, wherein the step of monitoring comprises contacting the sample with a detectable agent selected from the group consisting of
 - (a) an antibody which selectively binds the protein of (i), or the peptide of (ii),
 - (b) a protein or peptide which binds the antibody of (iii), and
 - (c) a cell which presents the complex of the peptide and MHC molecule of (iv).
8. The method of claim 7, wherein the antibody, the protein, the peptide or the cell is labeled with a radioactive label or an enzyme.
9. The method of claim 5, comprising assaying the sample for the peptide.
10. The method of claim 5, wherein the nucleic acid molecule is a NA Group 3 molecule.

11. The method of claim 5, wherein the nucleic acid molecule is a NA Group 5 molecule.
12. The method of claim 5, wherein the protein is a plurality of proteins, the parameter is a plurality of parameters, each of the plurality of parameters being specific for a different of the plurality of proteins, at least one of which is a cancer associated protein encoded by a NA Group 1 molecule.
13. The method of claim 5, wherein the protein is a plurality of proteins, at least one of which is kinectin, the remainder of which are non-kinectin cancer associated proteins, and wherein the parameter is a plurality of parameters, each of the plurality of parameters being specific for a different of the plurality of proteins.
14. A pharmaceutical preparation for a human subject comprising
an agent which when administered to the subject enriches selectively the presence of complexes of an HLA molecule and a human cancer associated antigen, and
a pharmaceutically acceptable carrier, wherein the human cancer associated antigen is a fragment of a human cancer associated antigen precursor encoded by a nucleic acid molecule comprises a NA Group 1 molecule.
15. The pharmaceutical preparation of claim 14, wherein the agent comprises a plurality of agents, each of which enriches selectively in the subject complexes of an HLA molecule and a different human cancer associated antigen, wherein at least one of the human cancer associated antigens is encoded by a NA Group 1 molecule.
16. The pharmaceutical preparation of claim 15, wherein the plurality is at least two, at least three, at least four or at least 5 different such agents.
17. The pharmaceutical preparation of claim 14, wherein the nucleic acid molecule is a NA Group 3 nucleic acid molecule.
18. The pharmaceutical preparation of claim 14, wherein the agent comprises a plurality of

agents, at least one of which is kinectin, the remainder of which are non-kinectin cancer associated proteins, and each of which enriches selectively in the subject complexes of an HLA molecule and a different human cancer associated antigen.

19. The pharmaceutical preparation of claim 14, wherein the agent is selected from the group consisting of
 - (1) an isolated polypeptide comprising the human cancer associated antigen, or a functional variant thereof,
 - (2) an isolated nucleic acid operably linked to a promoter for expressing the isolated polypeptide, or functional variant thereof,
 - (3) a host cell expressing the isolated polypeptide, or functional variant thereof, and
 - (4) isolated complexes of the polypeptide, or functional variant thereof, and an HLA molecule.
20. The pharmaceutical preparation of claims 14-19, further comprising an adjuvant.
21. The pharmaceutical preparation of claim 14, wherein the agent is a cell expressing an isolated polypeptide comprising the human cancer associated antigen or a functional variant thereof, and wherein the cell is nonproliferative.
22. The pharmaceutical preparation of claim 14, wherein the agent is a cell expressing an isolated polypeptide comprising the human cancer associated antigen or a functional variant thereof, and wherein the cell expresses an HLA molecule that binds the polypeptide.
23. The pharmaceutical preparation of claim 21 or 22, wherein the isolated polypeptide comprises a kinectin polypeptide.
24. The pharmaceutical preparation of claim 14, wherein the agent is at least two, at least three, at least four or at least five different polypeptides, each coding for a different human cancer associated antigen or functional variant thereof, wherein at least one of the human cancer associated antigens is encoded by a NA Group 1 molecule.

25. The pharmaceutical preparation of claim 24, wherein the at least one of the human cancer associated antigens is kinectin or a fragment thereof.
26. The pharmaceutical preparation of claim 14, wherein the agent is a PP Group 2 polypeptide.
27. The pharmaceutical preparation of claim 14, wherein the agent is a PP Group 3 polypeptide or a PP Group 4 polypeptide.
28. The pharmaceutical preparation of claim 22, wherein the cell expresses one or both of the polypeptide and HLA molecule recombinantly.
29. The pharmaceutical preparation of claim 22, wherein the cell is nonproliferative.
30. A composition comprising
an isolated agent that binds selectively a PP Group 1 polypeptide.
31. The composition of matter of claim 30, wherein the agent binds selectively a PP Group 2 polypeptide.
32. The composition of matter of claim 30, wherein the agent binds selectively a PP Group 3 polypeptide.
33. The composition of matter of claim 30, wherein the agent binds selectively a PP Group 4 polypeptide.
34. The composition of matter of claim 30, wherein the agent binds selectively a PP Group 5 polypeptide.
35. The composition of claims 30-34, wherein the agent is a plurality of different agents that bind selectively at least two, at least three, at least four, or at least five different such polypeptides.

36. The composition of claim 35, wherein the at least one of polypeptides is kinectin or a fragment thereof.
37. The composition of claims 30-34, wherein the agent is an antibody.
38. The composition of claim 315 wherein the agent is an antibody.
39. A composition of matter comprising
a conjugate of the agent of claims 30-34 and a therapeutic or diagnostic agent.
40. A composition of matter comprising
a conjugate of the agent of claim 35 and a therapeutic or diagnostic agent.
41. The composition of matter of claim 39, wherein the conjugate is of the agent and a therapeutic or diagnostic that is a toxin.
42. A pharmaceutical composition comprising an isolated nucleic acid molecule selected from the group consisting of NA Group 1 molecules and NA Group 2 molecules, and a pharmaceutically acceptable carrier.
43. The pharmaceutical composition of claim 42, wherein the isolated nucleic acid molecule comprises a NA Group 3 or NA Group 4 molecule.
44. The pharmaceutical composition of claim 42, wherein the isolated nucleic acid molecule comprises at least two isolated nucleic acid molecules coding for two different polypeptides, each polypeptide comprising a different human cancer associated antigen.
45. The pharmaceutical composition of claim 44, wherein at least one of the polypeptides is a kinectin polypeptide.
46. The pharmaceutical composition of claims 42-45 further comprising an expression

vector with a promoter operably linked to the isolated nucleic acid molecule.

47. The pharmaceutical composition of claims 42-45 further comprising a host cell recombinantly expressing the isolated nucleic acid molecule.
48. A pharmaceutical composition comprising
an isolated polypeptide comprising a PP Group 1 or a PP Group 2 polypeptide, and
a pharmaceutically acceptable carrier.
49. The pharmaceutical composition of claim 48, wherein the isolated polypeptide comprises a PP Group 3 or a PP Group 4 polypeptide.
50. The pharmaceutical composition of claim 48, wherein the isolated polypeptide comprises at least two different polypeptides, each comprising a different human cancer associated antigen.
51. The pharmaceutical composition of claim 50, wherein at least one human cancer associated antigen is kinectin.
52. The pharmaceutical composition of claim 48, wherein the isolated polypeptides are PP Group 11 polypeptides or HLA binding fragments thereof.
53. The pharmaceutical composition of claim 48, wherein the isolated polypeptides are PP Group 12 polypeptides or HLA binding fragments thereof.
54. The pharmaceutical composition of claims 48-53, further comprising an adjuvant.
55. An isolated nucleic acid molecule comprising a NA Group 3 molecule.
56. An isolated nucleic acid molecule comprising a NA Group 4 molecule.
57. An isolated nucleic acid molecule selected from the group consisting of

(a) a fragment of a nucleic acid molecule having a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs. 1-11 and 22-46, of sufficient length to represent a sequence unique within the human genome, and identifying a nucleic acid encoding a human cancer associated antigen precursor,

(b) complements of (a),

provided that the fragment includes a sequence of contiguous nucleotides which is not identical to any sequence selected from the sequence group consisting of

- (1) sequences having the GenBank accession numbers of Table 1,
- (2) complements of (1), and
- (3) fragments of (1) and (2).

58. The isolated nucleic acid molecule of claim 50, wherein the sequence of contiguous nucleotides is selected from the group consisting of:

- (1) at least two contiguous nucleotides nonidentical to the sequence group,
- (2) at least three contiguous nucleotides nonidentical to the sequence group,
- (3) at least four contiguous nucleotides nonidentical to the sequence group,
- (4) at least five contiguous nucleotides nonidentical to the sequence group,
- (5) at least six contiguous nucleotides nonidentical to the sequence group,
- (6) at least seven contiguous nucleotides nonidentical to the sequence group.

59. The isolated nucleic acid molecule of claim 57, wherein the fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20, nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, and 200 nucleotides.

60. The isolated nucleic acid molecule of claim 57, wherein the molecule encodes a polypeptide which, or a fragment of which, binds a human HLA receptor or a human antibody.

61. An expression vector comprising an isolated nucleic acid molecule of any of claims 55-60 operably linked to a promoter.

62. An expression vector comprising a nucleic acid operably linked to a promoter, wherein the nucleic acid is a NA Group 2 molecule.
63. An expression vector comprising a NA Group 1 or Group 2 molecule and a nucleic acid encoding an HLA molecule.
64. A host cell transformed or transfected with an expression vector of claim 61.
65. A host cell transformed or transfected with an expression vector of claims 62 or 63.
66. A host cell transformed or transfected with an expression vector of claim 61 and further comprising a nucleic acid encoding HLA.
67. A host cell transformed or transfected with an expression vector of claim 62 and further comprising a nucleic acid encoding HLA.
68. An isolated polypeptide encoded by the isolated nucleic acid molecule of claim 55 or claim 56.
69. A fragment of the polypeptide of claim 68 which is immunogenic.
70. An isolated polypeptide comprising a fragment of a kinectin polypeptide which is immunogenic.
71. The fragment of claims 69 or 70, wherein the fragment, or a portion of the fragment, binds HLA or a human antibody.
72. An isolated fragment of a human cancer associated antigen precursor which, or portion of which, binds HLA or a human antibody, wherein the precursor is encoded by a nucleic acid molecule that is a NA Group 1 molecule.

73. The fragment of claim 72, wherein the fragment is part of a complex with HLA.
74. The fragment of claim 73, wherein the fragment is between 8 and 12 amino acids in length.
75. An isolated polypeptide comprising a fragment of the polypeptide of claim 68 of sufficient length to represent a sequence unique within the human genome and identifying a polypeptide that is a human cancer associated antigen precursor.
76. A kit for detecting the presence of the expression of a human cancer associated antigen precursor comprising
a pair of isolated nucleic acid molecules each of which consists essentially of a molecule selected from the group consisting of (a) a 12-32 nucleotide contiguous segment of the nucleotide sequence of any of the NA Group 1 molecules and (b) complements of ("a"), wherein the contiguous segments are nonoverlapping.
77. The kit of claim 76, wherein the pair of isolated nucleic acid molecules is constructed and arranged to selectively amplify an isolated nucleic acid molecule that is a NA Group 3 molecule.
78. A method for treating a subject with a disorder characterized by expression of a human cancer associated antigen precursor, comprising
administering to the subject an amount of an agent, which enriches selectively in the subject the presence of complexes of an HLA molecule and a human cancer associated antigen, effective to ameliorate the disorder, wherein the human cancer associated antigen is a fragment of a human cancer associated antigen precursor encoded by a nucleic acid molecule selected from the group consisting of
- (a) a nucleic acid molecule comprising NA group 1 nucleic acid molecules,
 - (b) a nucleic acid molecule comprising NA group 3 nucleic acid molecules,
 - (c) a nucleic acid molecule comprising NA group 5 nucleic acid molecules.
79. The method of claim 78, wherein the disorder is characterized by expression of a

plurality of human cancer associated antigen precursors and wherein the agent is a plurality of agents, each of which enriches selectively in the subject the presence of complexes of an HLA molecule and a different human cancer associated antigen, wherein at least one of the human cancer associated antigens is encoded by a NA Group 1 molecule.

80. The method of claim 79, wherein at least one of the human cancer associated antigens is kinectin or a fragment thereof.

81. The method of claim 79, wherein the plurality is at least 2, at least 3, at least 4, or at least 5 such agents.

82. The method of claims 78-81, wherein the agent is an isolated polypeptide selected from the group consisting of PP Group 1, PP Group 2, PP Group 3, PP Group 4, and PP Group 5.

83. The method of claims 78-81, wherein the disorder is cancer.

84. The method of claims 82, wherein the disorder is cancer.

85. A method for treating a subject having a condition characterized by expression of a human cancer associated antigen precursor in cells of the subject, comprising:

- (i) removing an immunoreactive cell containing sample from the subject,
- (ii) contacting the immunoreactive cell containing sample to the host cell under conditions favoring production of cytolytic T cells against a human cancer associated antigen which is a fragment of the precursor,
- (iii) introducing the cytolytic T cells to the subject in an amount effective to lyse cells which express the human cancer associated antigen, wherein the host cell is transformed or transfected with an expression vector comprising an isolated nucleic acid molecule operably linked to a promoter, the isolated nucleic acid molecule being selected from the group of nucleic acid molecules consisting of NA Group 1, NA Group 2, NA Group 3, NA Group 4, and NA Group 5.

86. The method of claim 85, wherein the host cell recombinantly expresses an HLA molecule which binds the human cancer associated antigen.
87. The method of claim 85, wherein the host cell endogenously expresses an HLA molecule which binds the human cancer associated antigen.
88. A method for treating a subject having a condition characterized by expression of a human cancer associated antigen precursor in cells of the subject, comprising:
- (i) identifying a nucleic acid molecule expressed by the cells associated with said condition, wherein said nucleic acid molecule is a NA Group 1 molecule;
 - (ii) transfecting a host cell with a nucleic acid selected from the group consisting of (a) the nucleic acid molecule identified, (b) a fragment of the nucleic acid identified which includes a segment coding for a human cancer associated antigen, (c) deletions, substitutions or additions to (a) or (b), and (d) degenerates of (a), (b), or (c);
 - (iii) culturing said transfected host cells to express the transfected nucleic acid molecule, and;
 - (iv) introducing an amount of said host cells or an extract thereof to the subject effective to increase an immune response against the cells of the subject associated with the condition.
89. The method of claim 88, wherein the nucleic acid molecule is a kinectin nucleic acid molecule.
90. The method of claim 88, further comprising identifying an MHC molecule which presents a portion of an expression product of the nucleic acid molecule, wherein the host cell expresses the same MHC molecule as identified and wherein the host cell presents an MHC binding portion of the expression product of the nucleic acid molecule.
91. The method of claim 88, wherein the immune response comprises a B-cell response or a T cell response.
92. The method of claim 91, wherein the response is a T-cell response which comprises

generation of cytolytic T-cells specific for the host cells presenting the portion of the expression product of the nucleic acid molecule or cells of the subject expressing the human cancer associated antigen.

93. The method of claim 88, wherein the nucleic acid molecule is a NA Group 3 molecule.
94. The method of claims 88 or 90, further comprising treating the host cells to render them non-proliferative.
95. A method for treating or diagnosing or monitoring a subject having a condition characterized by expression of an abnormal amount of a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule, comprising
administering to the subject an antibody which specifically binds to the protein or a peptide derived therefrom, the antibody being coupled to a therapeutically useful agent, in an amount effective to treat the condition.
96. The method of claim 95, wherein the antibody is a monoclonal antibody.
97. The method of claim 96, wherein the monoclonal antibody is a chimeric antibody or a humanized antibody.
98. A method for treating a condition characterized by expression in a subject of abnormal amounts of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule, comprising
administering to a subject a pharmaceutical composition of any one of claims 14-29 and 42-547 in an amount effective to prevent, delay the onset of, or inhibit the condition in the subject.
99. The method of claim 98, wherein the condition is cancer.
100. The method of claim 98, further comprising first identifying that the subject expresses

in a tissue abnormal amounts of the protein.

101. The method of claim 99, further comprising first identifying that the subject expresses in a tissue abnormal amounts of the protein.

102. A method for treating a subject having a condition characterized by expression of abnormal amounts of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule, comprising

- (i) identifying cells from the subject which express abnormal amounts of the protein;
- (ii) isolating a sample of the cells;
- (iii) cultivating the cells, and
- (iv) introducing the cells to the subject in an amount effective to provoke an immune response against the cells.

103. The method of claim 102, further comprising rendering the cells non-proliferative, prior to introducing them to the subject.

104. A method for treating a pathological cell condition characterized by aberrant expression of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule, comprising

administering to a subject in need thereof an effective amount of an agent which inhibits the expression or activity of the protein.

105. The method of claim 104, wherein the agent is an inhibiting antibody which selectively binds to the protein and wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody or an antibody fragment.

106. The method of claim 104, wherein the agent is an antisense nucleic acid molecule which selectively binds to the nucleic acid molecule which encodes the protein.

107. The method of claim 104, wherein the nucleic acid molecule is a NA Group 3 nucleic acid molecule.

108. The method of claim 104, wherein the nucleic acid molecule is a kinectin nucleic acid molecule.

109. A composition of matter useful in stimulating an immune response to a plurality of a proteins encoded by nucleic acid molecules that are NA Group 1 molecules, comprising
a plurality of peptides derived from the amino acid sequences of the proteins, wherein the peptides bind to one or more MHC molecules presented on the surface of the cells which express an abnormal amount of the protein.

110. The composition of matter of claim 109, wherein at least a portion of the plurality of peptides bind to MHC molecules and elicit a cytolytic response thereto.

111. The composition of matter of claim 109, wherein at least one of the proteins is kinectin.

112. The composition of matter of claim 110, further comprising an adjuvant.

113. The composition of matter of claim 112, wherein said adjuvant is a saponin, GM-CSF, or an interleukin.

114. The composition of matter of claim 109, further comprising at least one peptide useful in stimulating an immune response to at least one protein which is not encoded by nucleic acid molecules that are NA Group 1 molecules, wherein the at least one peptide binds to one or more MHC molecules.

115. An isolated antibody which selectively binds to a complex of:

- (i) a peptide derived from a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule and
 - (ii) and an MHC molecule to which binds the peptide to form the complex,
- wherein the isolated antibody does not bind to (i) or (ii) alone.

116. The antibody of claim 115, wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, or a fragment thereof.

SEQUENCE LISTING

<110> Ludwig Institute for Cancer Research

5 <120> Cancer Associated Antigens
and Uses Therefor

<130> L0461/7050WO

10 <140> US 09/166,300
<141> 1997-10-05<140> US 09/166,350
<141> 1997-10-05

15 <160> 45

<170> FastSEQ for Windows Version 3.0

20 <210> 1
<211> 4422
<212> DNA
<213> Homo sapiens

25 <400> 1

gattattctg	gaggaagatg	accttcattt	tatggttatg	tgtgtgtgtc	tgtgtgtctt	60
tggaataata	tatataattt	tttcaaatag	gaagccaaca	tatcaagtga	tgaattaaag	120
tatgctgcag	aatatatatt	ctaaaactac	aaaaaagtca	ctgaatatca	aaatgataca	180
gcttatacat	atagttactg	tgacaagtga	cagactgcta	gttcagaatt	caaaaatcct	240
ttcctagttt	gtgagataat	gggctaaaatt	ccttctgcct	gccactgggg	caaagcaaat	300
tgcttttagtt	tttgatgaga	gttcttagaa	gtttgttggg	attccttcat	ccacagcatc	360
cattgttgaa	ataaccattt	tcagttgtga	tgcccttaact	aagaagccaa	ttgttagcct	420
gaaatgcaat	cttggtagcc	agtttcaatg	aagctagaga	ttagtcagaa	aaagttagct	480
gttgggcttt	agaaagggat	tttgagtcct	gncattttcta	cttggggagca	ttttggagca	540
gattaagctt	tcagtataaa	aacaagtggc	tacctgatgg	aaacttttct	taccttata	600
gggaaactga	gcacaagctg	aatgatattg	tctgctgcaa	aaaaaaaaca	acaaaaaaa	660
aaacaaaaca	aaaacaaaaa	aaaaaaaaaa	aaaacctcgt	gccgaattcg	gcacgagggg	720
aagccccgtg	cacccccccg	cctccggccg	ccgcccgcgc	gctggccctg	cagccgtcgc	780
cgctgctcgc	ggctacagcc	ccgggctcgc	cggtcccggc	tggggaagga	gggcggcgag	840
40 cgcgctccgga	gccgcccggg	atggcgggag	ggcactgcgg	cagcttcccc	gcggcggcgg	900
ccggcagcgg	cgagatcgtc	caactgaacg	taggggggac	cagatttagt	acctcaagac	960
aaactcttat	gtggattcca	gattcttttt	tttccagttt	gctgagtggg	agaatttcaa	1020
cacttcgaga	tgaactgggt	gctatatatta	ttgatagaga	tccagcagca	tttgcaccca	1080
ttttaaattt	tcttcggaca	aaagaactag	acttaagggg	agtgagtatt	aatgtttctca	1140
45 ggcatgaagc	agaattttac	gggatcactc	cattagtaag	aaggcttctc	ttatgtgaag	1200
aattggagcg	ttcctcttgt	ggcagtgctc	tttttcatgg	ttacttgccc	ccaccaggta	1260
ttcctagtcg	taaaataaac	aacacagtca	gatctgctga	ttctaggaat	ggtctaaatt	1320
ctacagaagg	tgaagcccgg	ggaaatggta	cacagcctgt	tctctctgga	acgggagaga	1380
aaactgttag	gctaggattt	cctgtggatc	cacgaaaagg	gctaatagta	gctggccatc	1440
50 acaactggat	tgtagctgca	tatgccattt	ttgctgngtg	gtacagaatc	aaagaatctt	1500
caggatggca	gcaagtgttt	acgagcccat	atlttgattg	gactatcgaa	cgagtagcct	1560
taaatgcaaa	ggtggttggg	gggccacatg	gagacaaaga	caaaatggtt	gctgttgctt	1620
cagagagtag	catcatcttg	tggagtgttc	aggatggggg	aagtgggaagt	gaaattggag	1680
tgttcagcct	gggtgttcc	gtagatgctc	tcttctttat	tggttaaccag	ttggtggcca	1740
55 cgagtcatac	agggaaaagt	ggagtgtgga	atgctgtcac	tcagcactgg	caggttcaag	1800
atgttgttcc	tataactagt	tatgacactg	ctggatcatt	ccttctgctt	ggatgtaaca	1860
atggatcaat	atattacata	gatatgcaga	agttcccctt	gcgaatgaaa	gataatgatc	1920
ttcttgtaac	tgaactgtat	catgatcctt	caaatgatgc	tattactgct	ctgagtgttt	1980
acctcacacc	caaaacaagt	gtcagtggtg	actggatcga	gatcgccctat	ggtacgagct	2040
60 ctggagcagt	acgagtgatt	gtacaacacc	cagagacagt	tgggtcaggt	cctcagcttt	2100
ttcagacttt	cacagttcac	cgaagtccc	taacaaaaat	catgctatca	gagaagcatc	2160
ttgtatcagt	ctgtgcagat	aataatcatg	tccggacgtg	gacagtaaca	cgattcnag	2220
gaatgatctc	tactcagcca	ggttctactc	cttttagcgtc	attcaagata	ctatccctgg	2280
aggagacaga	aagtcatggg	agctattcct	ctggaaatga	cataggacct	tttgagagac	2340
65 gagacgatca	acaggtgttt	atccagaaa	ttgttcccat	caccaacaaa	ctatttgtaa	2400
gactctcatc	gactggaaaa	agaatatgtg	agatccaggc	tggttgactgt	actacaatat	2460
cctcattttac	agtgagggaa	tgtgagggat	ccagtaggat	gggctcaaga	ccaaggcgct	2520

	acttggtcac	aggccataca	aatggcagta	ttcaaagtgt	ggatctgacc	actgctatgg	2580
	atatggttaa	caaaagtga	gataaggatg	taggtggtcc	aaccgaagaa	gagctactca	2640
	aattactcga	tcaatgtgat	ttgagcacat	ctcgctgtgc	tactcctaac	atcagttccag	2700
	caacttccgt	agttcagcat	agccacttac	gagaatcaaa	ttctagcctt	cagcttcagc	2760
5	accatgatac	cacccatgaa	gcagctactt	acggttccat	gaggccttac	agagaaagtc	2820
	ctttattagc	aagggcaaga	aggactgaga	gctttcacag	ttatagggac	ttccagacta	2880
	ttaatttgaa	cagaaatgta	gaaagagctg	tccctgaaaa	tggttaacttg	ggtccaatac	2940
	aagctgaagt	gaaaggggca	acaggggaat	gtaatatatc	tgagagaaaag	tctcctggag	3000
	tagaaataaa	aagtttgaga	gaattggata	gtggattgga	agtgcataaa	atagctgaag	3060
10	gtttttcaga	atccaagaaa	aggtcatcag	aagatgaaaa	tgaaaaataaa	atagagttta	3120
	ggaagaaaag	aggatttgaa	gggggaggat	tccttggaaag	aaagaaaagt	ccctatctgg	3180
	catcatcacc	aagtacttcc	gatggaggaa	ctgactcacc	tggtactgcg	tccccatctc	3240
	ctacaaagac	tactccatct	cctcggcata	aaaaaagtga	ttcttcagggt	caggagtaca	3300
	gcttgtgaaa	actcaccaaa	atgaatagtt	gtttcgggta	catttagatg	aaagttaaac	3360
15	tttactgaat	ttcagtagat	tagtttttac	actaaaactt	tacaagataa	aattggactt	3420
	catttagtat	ctttttaaca	gaattacttg	gaataatgag	atacaataat	catatctctt	3480
	ttgacatttt	ggaaattttt	ttaattttac	aagtacattt	aacagatcat	ttataaagca	3540
	ggagtccatt	ttaacactta	ccgacttttt	ttggtttgga	aacatattac	cacgtcttaa	3600
	taggatgggtg	cccatatagg	tgagcatccc	tttagatcat	gggaaccagc	agactgcatt	3660
20	cctaattcttc	attatgcctg	agacttgtct	tacaatgtta	cctttaagtg	aatcacataa	3720
	ttgtcttttg	aacttggtct	cccaacactt	attgtgattg	caaagtgttt	accagatatt	3780
	tgatgaggtg	ctatgtttgt	gaaaaacata	tcatgttaatt	caaaaacact	attgatattg	3840
	aataccagat	accactatgt	agtaagtctt	ttaggatgat	tttaatttag	tcgtgcgtca	3900
	ttttctgatt	ctcatcattg	ggagatctta	aatcttagca	agcattagca	atattaaatg	3960
25	ccaaaattcc	attgaaactt	tcaagttgga	gcaattgtct	gtgtttgaaa	agatgaaata	4020
	aaaataataa	tcaagggcaa	agctttgagt	gcccagaagg	gaaagctgta	ccagttgcta	4080
	acctgtcttg	tttcaggagc	caccatgttt	ttttttcagt	gttancaaca	atcatgataa	4140
	ttaaattaaa	acnctagttt	gttcacttgt	aggactgcag	ttctgaattt	tgggttaaag	4200
	gttttggtcg	ctgtaagaat	gtgaatttga	atgtattttg	aattgtaaga	gcaaaagaac	4260
30	gtttttgtac	aatttttttt	catttaattg	gaatgatctt	cagggtttcta	caaatagggt	4320
	aattgtaaat	ttaaagcatt	agcattttatt	ggtgaataat	gtatatatcc	ccattccaag	4380
	aaatataagt	gagtgaagtt	gaaataaaat	ctttaaaatt	ta		4422

<210> 2

<211> 502

<212> DNA

<213> Homo sapiens

<400> 2

40	gctagcttctg	gcgcggatcc	ctgggcgtcc	gtacgtcgga	gtccttcgtc	ctccagggtc	60
	cctgttctttt	gcgcagcgg	gaaccactat	ctctgcactc	ctgggggttt	gttacatggc	120
	tgctttcctc	aaaatgagtg	ttagtgtcaa	ttcttccaga	cctttcacca	ggtttttggt	180
	gccattttacc	cttcatagga	agagaaataa	cttaacaatt	ttgcagagat	acatgtcttc	240
	caaaaatacca	gctgttactt	atcctaataa	tgagagtaca	cgcccttctg	aagagctaga	300
45	gttggtgataag	tggaaaacta	ccatgaaatc	tagtgtgcaa	gaagaatgtg	tttcaacaat	360
	ctcaagcagt	aaggatgaag	atcctctagc	tgccacaga	gagttcattg	agatgtggag	420
	attgctttggc	agagaagtag	cagaacacat	cactgaagaa	gagctcaaaa	cccttatgga	480
	atgtgtttct	aacacagcaa	aa				502

<210> 3

<211> 1948

<212> DNA

<213> Homo sapiens

<400> 3

55	ccatgtgagg	gaggggccc	ctcctgcttg	gtgacagagt	cagcacgcgg	tggcctgcag	60
	ttcctccagc	agtgtgaccg	ggaggatctg	gtggaattgg	ctctgcctca	gctggctcag	120
	gttgtgaccg	tgtatgagtt	tcttctgatg	aaggttgaaa	aagatcatct	agcaaagcct	180
	tttttcccag	ctatatataa	ggaatttgaa	gagttgcata	aaatggttaa	gaaaatgtgc	240
60	caagattacc	tcagtagttc	tggtctgtgt	tcccaggaga	ccctggaaat	aaacaatgat	300
	aaggttgtcg	agtcattagg	aatcacagaa	ttcctacgga	agaaagaaat	acaccagac	360
	aaccttgagc	ccaagcacct	cagccgagac	atggatgggg	agcagctaga	gggagctagc	420
	agcgagaaga	gggaacgtga	ggctgcggag	gagggactgg	cctcagtga	aaggcccaga	480
	agagaagccc	tgtccaacga	taccactgaa	tctcttgctg	ccaacagcag	aggccgggag	540
65	aagcccaggc	ccttgcatgc	tttgcccgcg	ggtttttccc	ctccagtaaa	tgtgactgtc	600
	tctcccgtt	ctgaagaaag	ccatacaacg	acggtttctg	gtggcaatgg	gagcgtgttc	660
	caggcgggcc	cgcagcttca	ggcactggct	aacttagaag	ccaggagggg	gtctataggt	720

	gctgctctct	catccccgga	tgtcagtggg	ctgcctgttt	atgctcagtc	aggagagcct	780
	aggaggctga	cccaggcaca	ggtggcagcg	tttcttgagg	agaatgcttt	ggaacactct	840
	tcagaccagg	acacctggga	cagcctgagg	agcccgggtt	tctgcagccc	tttgtcatct	900
	ggtgggtggag	cagagtccct	gccgcctggg	gggcctggac	atgcagaggc	aggacacctc	960
5	ggcaaggttt	gtgacttcca	cctgaaccac	cagcagccca	gccccaccag	cgtcctgcct	1020
	acagagggtg	cagccccctc	gcttgagaaa	attttgtctg	tggatagcgt	ggcagtggac	1080
	tgtgcctaca	ggactgtgcc	caagccaggg	cctcagcctg	gcccacatgg	atcactattg	1140
	actgaagggt	gtctcagaag	cctttcgggg	gacttgaacc	ggttcccctg	tgggatggag	1200
	gtgcactctg	gccagagaga	actggagagc	gtggttgcgt	tcggcggaagc	catggctttg	1260
10	aaatttccaa	tgggagccat	gagttactgt	ctcagggaca	gaagcagatt	tttattcaga	1320
	cttccgatgg	gcttatcttg	tccccctccag	gtacaatagt	gtctcaggag	gaggacattg	1380
	tcacagtgc	tgatgcagag	gggcgtgcct	gcggatgggc	ccgctagaag	gagttcctct	1440
	agaagctgtg	gagtcgggtc	tcaccgcgag	agccctcaca	gtgaagtgga	gtcagatcct	1500
	agattcgtct	gatttttatcc	agagaagggtc	tatggcaagc	aatgtatat	tttctaagt	1560
15	gaatattgca	cagatgaacc	ttttatttat	aaagaataat	gtctttctgc	cctgctgtct	1620
	acatttttct	atggagcttg	tcataataat	agcagatatt	acctgatcag	gaatccctgt	1680
	ggcgcgtctg	acgctcatga	gtttttcatg	atggtgatga	gtagcactgc	actgtcacct	1740
	gatgattggc	cctgtcccg	ttcccttctc	tcctgggaga	tatgctgctt	ttccaccaga	1800
	cttgctccat	actagaagct	tcttttgggt	tcaattaaaa	agaaaataag	ctagtcattc	1860
20	tgggcagcat	tttattgata	gaagggggaa	aaagtcattt	ctacttgc	gattttttta	1920
	attaaattaa	attaaattaa	tttaaaaa				1948

<210> 4

<211> 1486

25 <212> DNA

<213> Homo sapiens

<400> 4

	ccgcggcggc	gtccgggggtc	tccagtaggg	ctgaogctcc	ggtgctcgca	caatcccccg	60
30	cctcggctgg	caacggggcgt	ccctccactc	cccagagccc	cggcagccgc	cgccacccca	120
	gcgcgccccg	atctggcccc	ctgcccccg	aagatggctg	ccgtacgccg	ggcccgcagt	180
	tattgcogct	gctcgggtgc	cttctccgac	cgagaactct	gctaagctcc	gctgcagaga	240
	caggcaggag	tagacacccg	gacacccagc	acccctcctc	cggggggcgg	tgcagagggg	300
	gcacggagag	cccctcgagc	gcagcaggcc	gccccgccag	catggcagaa	gctgaggaag	360
35	attgtcattc	tgatactgtc	agagcagatg	atgatgaaga	aaatgaaagt	cctgctgaaa	420
	cagatctgca	ggcacaactc	cagatgttcc	gagctcagtg	gatgtttgaa	cttgctccag	480
	gtgtaagctc	tagcaattta	gaaaatcgac	cttgccagag	agcaagaggc	tctctccaga	540
	aaacatcggc	agataccaaa	ggaaaacaa	aacaggcaaa	agaagaaaag	gctcgagaac	600
	tcttcctaaa	agcagtagaa	gaagaacaaa	atggagctct	ctatgaagcc	atcaagtttt	660
40	atcgtagggc	tatgcaactt	gtacctgata	tagagttcaa	gattacttat	acccggtctc	720
	cagatggtga	tggcgtttga	aacagctaca	ttgaagataa	tgatgatgac	agcaaaatgg	780
	cagatctctt	gtcctacttc	cagcagcaac	tcacatttca	ggagtctgtg	cttaaactgt	840
	gtcagcctga	gcttgagagc	agtcagattc	acatatcagt	gctgccaatg	gaggtcctga	900
	tgtacatctt	ccgatgggtg	gtgtctagtg	acttggacct	cagatcattg	gagcagttgt	960
45	cgctgggtgtg	cagaggattc	tacatctgtg	ccagagaccc	tgaatatatg	cgtctggcct	1020
	gcttgaaggt	ttggggcaga	agctgtatta	aacttgttcc	gtacacgtcc	tggagagaga	1080
	tgtttttaga	acggcctcgt	gttcggtttg	atggcgtgta	tatcagtaaa	accacatata	1140
	ttcgtcaagg	ggaacagtct	cttgatgggt	tctatagagc	ctggcaccaa	gtggaatatt	1200
	acaggtacat	aagattcttt	cctgatggcc	atgtgatgat	gttgacaacc	cctgaagagc	1260
50	ctcagtcctat	tgttccacgt	ttaagaacta	gggaatacca	ggactgatgc	caattctact	1320
	gggtcactat	cgcttggcac	aagacacaga	ccatcagacc	caaagtattt	tgctgtaata	1380
	actaagaaaa	aaagggaagaa	aaaccacttg	gactataaat	acccgatatt	ttcgtcgggg	1440
	tccctgtacc	aaagaagccg	aatcagaagt	tttcatgnng	gggctn		1486

55 <210> 5

<211> 774

<212> DNA

<213> Homo sapiens

60 <400> 5

	tgcgccaccc	cacccccacc	cacccccgcc	atgcaacggg	attgaagggt	cctgccgggtg	60
	ggaccctgtc	cggcccagtg	ccactgcccc	ccgaggctgc	tagacgtagg	tgttaggc	120
	gtcccaccca	ccgcgcgcct	cccacggcac	ctcggggaca	ccagagctgc	cgacttggag	180
	actcctgggtc	tgtgaagagc	cggtgggtgcc	cgtgcccgca	ggaactgggc	tgggcctcgt	240
65	gcgcccgtgg	ggtctgcgct	tgggtctttct	gtgcttggat	ttgcatattt	attgcattgc	300
	tggtagagac	ccccaggcct	gtccaccctg	ccaagactcc	tcaggcagcg	tgtgggtccc	360
	gcactctgcc	cccatttccc	cgatgtcccc	tgcggggcgcg	ggcagccacc	caagcctgct	420

	ggctgcgggcc	ccctctcggc	caggcattgg	ctcagcccg	tgagtggggg	gtcgtggggc	480
	agtccccgag	gagctggggc	cctgcacag	cacacagggc	ccggccacac	ccagcggccc	540
	cccgacagc	caccctggg	gtgctgcct	tatgcccggc	gccgggcacc	aactccatgt	600
	ttgggtgtttg	tctgtgtttg	tttttcaaga	aatgattcaa	attgctgctt	ggatttttgaa	660
5	atttactgtg	actgtcagtg	tacacgtctg	gaccccgttt	cattttttaca	ccaatttggt	720
	aaaaatgctg	ctctcagcct	cccacaatta	aaccgcatgt	gatctccaaa	aaaa	774
	<210> 6						
	<211> 2936						
10	<212> DNA						
	<213> Homo sapiens						
	<400> 6						
	cgtaaccctt	agtcccaatg	cctccgtaag	cggagttgag	tgggtgcctg	tggttggagc	60
15	tgtggaggtg	tccccggtg	cgagcgcggc	cagaactgcg	gtcacttaag	ttttccgtgt	120
	gcggtgtgca	aggagcgtgc	gtgctgctgg	tatagggagg	acacctctgg	attgaggatc	180
	ttatgacctg	cttttagagga	aggtataatt	tggcttcctg	agattctgcc	ttagcaagaa	240
	aggagtggga	aatacccttg	gaaagaaaa	taaaacagta	agaaagccaa	aacttatttt	300
	tacatgggtg	tcagcacatt	taccgatatg	gacacttttc	ccaataattt	tcctcctggt	360
20	ggagacagtg	gattgacagg	ttctcagtcg	gagttccaga	aaatgttaat	tgatgaaagg	420
	ttacgatgtg	agcatcataa	agctaattat	cagacactga	aggctgaaca	cacaaggttg	480
	cagaatgaac	atgtaaaagt	acaaaaatg	ctcaagcacc	tggttaatga	aaagcaaat	540
	cagcagggaa	aacttcagct	cctgcttgaa	gaactaagag	gagaattagt	agagaaaaat	600
	aaagatttag	aagaaatgaa	actgcagata	ttactccca	aaaattggaa	ttgctaagag	660
25	cccaaataca	acaagaatta	gaaactccaa	tgagagaacg	ttttaggaat	ctagatgaag	720
	aggtagaaaa	gtatagagct	gtatataata	agcttcgcta	tgaacataca	tttctcaagt	780
	cagaatttga	acaccagaag	gaagagtatg	cacgtatttt	agatgaagga	aaaataaaat	840
	atgaatcaga	gattgcaaga	ctggaggaag	ataaagaaga	actacgtaac	cagctgctta	900
	atgttgatct	cacaaaagac	agcaaacgag	tggaacaact	tgctcgagaa	aaagtctatt	960
30	tgtgtcaaaa	attaaaaggt	ttagaggctg	aagtagcgga	attaaaggct	gaaaaggaga	1020
	attctgaggg	tcaggtggaa	aatgcccmaa	gaatacaggt	gcggcagttg	gctgagatgc	1080
	aggctacagt	cagatccctg	ggggtgaaa	aacaatcagc	taatttacgg	gcagaaacgt	1140
	tggaaaaaga	gctacaatca	agcagtgaac	aaaatacctt	tttaattaat	aaattgcata	1200
	aagctgaacg	agaaataaat	acattgtcca	gtaaagtaaa	agaacttaaa	cattcaaaca	1260
35	aactggaat	aacagacatc	aaactggaga	cagcaagagc	taagagttag	ctagaaagag	1320
	aaaggaataa	gcttcaaagt	gaactggatg	gattacagtc	agacaatgaa	attctcaaag	1380
	cagctgttga	acatcacaaa	gtgctcttag	tagaaaagga	tcgtgaatta	atacgtaaa	1440
	tacaagctgc	caaagaagaa	ggttatcaaa	aacttgtggt	attacaagat	gaaaagttag	1500
	aactcgagaa	cagattagca	gatttgagga	aaatgaaagt	ggaacatgat	gtctggaggc	1560
40	aatctgaaaa	ggatcagtat	gaagagaaat	tgccggcttc	acagatggca	gaagagatca	1620
	ccaggaagga	gcttcagagt	gttaggttaa	aacttcagca	acaaaattgtg	actattgaaa	1680
	atgcagagaa	ggaaaaaaat	gaaaattctg	acctaaaaca	gcaaatcagt	agtttgcaga	1740
	tccaagtgc	ttcacttgca	cagtcagaga	atgacttgct	gaattcaaac	caaatgctga	1800
	aggaaatggt	ggagagatta	aaacaagaat	gccgaaat	tagaagccaa	gctgaaaaag	1860
45	cgcaactaga	agctgaaaag	acattggaag	agaaacagat	acagtgggtg	gaagaaaagc	1920
	ataagcttca	tgaccgtatc	acagacagag	aagaaaagta	caatcaagct	aaggagaaac	1980
	tgccagcagc	tgcaattggc	cagaaaaaga	gaaaatctct	tcatgaaaac	aaattgaaaa	2040
	gactacaaga	gaaagtagaa	gtcttgagg	caaagaaaga	agaattggaa	acagaaatca	2100
	ggtcttaaat	agacaaaatg	ttcctttgaa	gactatacaa	ggcttcaaaa	aagactaaaa	2160
50	gatatacaga	gaagacataa	tgaatttcga	agtctaattt	tggttcctaa	catgcctcca	2220
	acagcatcta	tcaatcctgt	tagcttttcag	tcacagccca	tggttccaag	catggaacta	2280
	ccatttcctc	ctcatatgca	ggaggaacaa	catcaaagg	aactctctct	acttcgcaaa	2340
	agactagaag	aactggaaac	aacacaaaga	aaacaactag	aggaacttgg	atcttccgga	2400
	gaatgatgtt	cttgagagac	aggcagatca	aaagaggtga	agttggtgac	tcagtaaaac	2460
55	ttgacatttt	aacctgtggc	atttagatac	tttttactgt	ttgccaaaac	acttgaatgt	2520
	gcctcaagaa	aaggtaccta	ctacatgctg	tattgtatga	ctgtcaggat	tttaagatta	2580
	tacaagtga	agaaaattc	agaaattctc	agagatat	agaatatttg	acaatggttt	2640
	gagaatgtaa	aacaaaaagg	aactagttag	agtcaagttt	taaaaatttt	actttgttga	2700
	atTTTTTTTT	ttggcatttt	gagtgaaata	taactatcat	taattctctc	ttcatctttg	2760
60	agatgcttgg	ccataacagg	gtccatacac	atcttctggt	ttactatata	caaaaactgt	2820
	agttgaaaaa	agatgacaat	ttaaaagtca	gcctaaagaa	tgtaaaggtg	tctatatata	2880
	aaaggctacc	ttttctaaaa	tctgtgtgca	cataattaaa	gagcttaatt	tttaaa	2936
	<210> 7						
	<211> 1387						
65	<212> DNA						
	<213> Homo sapiens						

<400> 7

	aaaggtctaca	tcattaacac	tagaaggagg	acgattaaaa	cgaactccac	agctgattca	60
	tggaagagac	tatgaaatgg	tcccagaacc	tgtgtggaga	gcactttatc	actgggatgg	120
5	agcaaaccctg	gccttaccta	gaccagttat	caagaacagc	aagacagaca	ccccagagct	180
	ggaattatctt	ccccgctatc	ttctcttctt	gagacagcag	cctgccactc	ggacacagca	240
	gtctaacatc	tgggtgaata	tgggaaatgt	accttctctc	aatgcacctt	taaagcgggt	300
	attagcctat	acaggctgtt	ttagtccaat	gcagaccatc	aaggaaattc	acgaatatct	360
	atctcaaagg	ctgcgcatta	aagaggaaga	tatgcgcctg	tggctataca	acagtggaga	420
10	ctaccttact	cttctggatg	atgaggatca	taaattggaa	tatttgaaaa	tccaggatga	480
	acaacacctg	gtaattgaag	ttcgcaacaa	agatatgagt	tggcctgagg	agatgtcttt	540
	tatagcaaat	agtagtaaaa	tagatagaca	caaggttccc	acagaaaagg	gagccacagg	600
	tctaagcaat	ctgggaaaca	catgttctat	gaactcaagc	atccagtgtg	ttagtaacac	660
	acagccactg	acacagtatt	ttatctcagg	gagacatctt	tatgaactca	acaggacaaa	720
15	tcccattgggt	atgaaggggc	atatggctaa	atgctatggt	gatttagtgc	aggaactttg	780
	gagtggaaact	cagaagaatg	ttgccccatt	aaagcttcgg	tggaccatag	caaaatatgc	840
	tcccagggttt	aatgggtttc	agcaacagga	ctcccaagaa	cttctggctt	ttctcttgga	900
	tgggtcttcac	gaagatctta	atcgagtcca	tgaaaagcca	tatgtggaac	tgaaggacag	960
	tgatgggcga	ccagactggg	aagttagctgc	agaggcctgg	gacaaccatc	taagaagaaa	1020
20	tagatcaatt	gttgtggatt	tgttccatgg	gcagctaaga	tctcaagtaa	aatgcaagac	1080
	atgtgggcat	ataagtgtcc	gatttgaccc	tttcaatttt	ttgtctttgc	cactaccaat	1140
	ggacagttat	atgcacttag	aaataacagt	gattaagtta	gatggtagta	ccccgttacg	1200
	gtatggacta	agactgaata	tggatgaaaa	gtacacaggt	ttaaaaaaac	agctgagtga	1260
	tctctgtgga	cttaattcag	aacaaatcct	tctagcagaa	gtacatgggt	ccaacataaa	1320
25	gaacttttct	caggacaacc	caaaaagtac	cgaacttctc	agtgaagtgg	gatttttttg	1380
	tgtgccca						1387

<210> 8

<211> 749

<212> DNA

<213> Homo sapiens

<400> 8

	gccccacatg	gctggagcgc	ggcggagggtg	agccggccgc	ccgcccgcag	acgccccagc	60
35	ctactgcgcc	cgagtcccg	ggccccagtg	gcgcctcagc	tctgcggtgc	cgaggcccaa	120
	cggctcgatc	gctgcccgc	gccagcatgt	tgggcgcccc	ggacgagagc	tccgtgcggg	180
	tggctgtcag	aataagacca	cagcttgcca	aagagaagat	tgaaggatgc	catatttgta	240
	catctgtcac	accaggagag	cctcaggtct	tcctagggaa	agataaggct	tttacttttg	300
	actatgtatt	tgacattgac	tcccagcaag	agcagatcta	cattcaatgt	atagaaaaac	360
40	taattgaagg	ttgctttgaa	ggataacaatg	ctacagtttt	tgcttatgga	caaactggag	420
	ctggtaaaac	atacacaatg	ggaacaggat	ttgatgttaa	cattgttgag	gaagaactgg	480
	gtattatttc	tcgagctgtt	aaacaccttt	ttaagagtat	tgaagaaaaa	aaacacatag	540
	caattaaaaa	tgggttctct	gctccagatt	ttaaagtga	tgcccaattc	ttagagctct	600
	ataatgaaga	ggtccttgac	ttatttgata	ccactcgtga	tattgatgca	aaaagttaaa	660
45	aatcaaatat	aagaattcat	gaagattcaa	ctggagggaa	tttatactgt	gggcgtttcc	720
	aacacgtact	gtgaatacac	aatcnagag				749

<210> 9

<211> 686

<212> DNA

<213> Homo sapiens

<400> 9

	tggaaattat	agacctagca	aaaaaagatt	tagagaaggt	tgnaaagaaa	agaaaagagg	60
55	aagnaaaaaa	gtgtggctgg	taaagaggat	aatacagaca	ctgaccaaga	gaagaaagaa	120
	gaaaagggtg	tttcggaaag	agaaacccaa	tgaattagaa	gtggaagaaa	gtcaagaagt	180
	gagtgatcat	gaggatgaag	aagaggagga	ggaggaggag	gaagatgaca	ttgatggggg	240
	tgaaagtctt	gatgaatcag	attctgaatc	agatgaaaaa	gccnattatc	aagcagactt	300
	ggcaaacatt	acttgtgaaa	ttgcaattaa	gcaaaaagctg	attgatgaac	tagaaaaacag	360
60	ccagaaaaga	ctgcagactc	tgaaaaagca	gtatgaagag	aagntaatga	tgctgcaaca	420
	taaaattcgg	gatactcagc	ttgaaagaga	ccagggtgctt	caaaacttag	gctcggtaga	480
	atcttactca	gaagaaaaag	caaaaaaagt	taggtctgaa	tatgaaaaa	aactccaagc	540
	catgaacaaa	gaactgcaga	gacttcaagc	agctcaaaaa	gaacatgcaa	ggttgcttaa	600
	aaatcagttc	cagtatgaaa	agcnattgaa	gaaattgcag	caggatgtga	tggaaatgaa	660
65	aaaaacaaa	gttcgcctaa	tgaaaa				686

<210> 10

<211> 833
 <212> DNA
 <213> Homo sapiens

5 <400> 10
 gttcttctgt cgccggcttc agcagcccgc gcccgggcag gaatagaaga tgaacaaacc 60
 cataacacca tcaacatatg tgcgctgcct caatgtttgga ctaatttagga agctgtcaga 120
 ttttattgat cctcaagaag gatggaagaa gttagctgta gctattaaaa aacctctgg 180
 10 tgatgataga tacaatcagt ttcacataag gagatttgaa gcattacttc aaactggaaa 240
 aagtcccact tctgaattac tgtttgactg gggcaccaca aattgcacag ttggtgatct 300
 tgtggatctt ttgatccaaa atgaattttt tgctcctgcg agtcttttgc tcccagatgc 360
 tgttcccaaa actgctaata cactaccttc taaagaagct ataacagttc agcaaaaaca 420
 gatgcctttc tgtgacaaaag acaggacatt gatgacacct gtgcagaatc ttgaacaaag 480
 ctatatgcca cctgactcct caagtccaga aaataaaagt ttagaagtta gtgatacacg 540
 15 ttttcacagt ttttcatttt atgaattgaa gaatgtcaca aataactttg atgaacgacc 600
 catttctggt ggtggttaata aaatgggaga gggaggattt ggagttgtat ataaagggct 660
 acgtaataaa cacaactgtg gcagtgaag aagcttgcag caatggttga cattactact 720
 gaaggaaactg aaaccagcag tttgatccaa gaaaataaaa gtaatgggca aaagtgggtca 780
 accatggaaa aacttttagta ggaacctact tgggttttct caagtggatg gga 833

<210> 11
 <211> 799
 <212> DNA
 <213> Homo sapiens

25 <400> 11
 taaaaatatt cccttngatg atacctgccaa ataattgatat gtcccattat tagattatgt 60
 tacatgccaa agttttaaagg aatttgggca gatccagtta aggttcctta aacaacntca 120
 30 ctttgagact gttgaaaggg cctgacctaa tccaagtga ccccttgcaa gaagaattct 180
 ccttgtaagc cttgaagaag tatgtgagag ggccacattg gctaaaacct aaaggtggcc 240
 tctaggagat gagacctacc ttccagttgt cagcaagcag gaaaaaaaaa ttgggacctc 300
 agttgcaacc acaaggaaact gaattctgcc aaaaatntga gtcagcttag aagagtactc 360
 caagcttcag atgataacca cagcctgggc tgacacctgg atttagcttt gcatgatcct 420
 35 cagtatgaga atctatctgt tctgtgctgg acttctaata tatagaactg tgagataatg 480
 ggtcacattg gctggatgtg gtggctcata cctgtaaate ccagcacttt gggaggccga 540
 ggcaggcaga tcacctgagg tcaagagttc aagaccggcc tggccaacat ggtgaaaccc 600
 cgtctntact aaaaatacaa aaattagacg agcgtggtgg tggacacctg tagtcccagc 660
 tgcttgggag gctgaggcag gagactagct ggaaccaggg aggtagaggt tgcagtgagc 720
 40 tgagatcgtg ccactgcact ccagcctggg tgacagagtg agactccatc ataaataaat 780
 aaataataaa atgggtcnc 799

<210> 12
 <211> 812
 <212> PRT
 <213> Homo sapiens

45 <400> 12
 Met Ala Gly Gly His Cys Gly Ser Phe Pro Ala Ala Ala Ala Gly Ser
 1 5 10 15
 50 Gly Glu Ile Val Gln Leu Asn Val Gly Gly Thr Arg Phe Ser Thr Ser
 20 25 30
 Arg Gln Thr Leu Met Trp Ile Pro Asp Ser Phe Phe Ser Ser Leu Leu
 35 40 45
 55 Ser Gly Arg Ile Ser Thr Leu Arg Asp Glu Thr Gly Ala Ile Phe Ile
 50 55 60
 Asp Arg Asp Pro Ala Ala Phe Ala Pro Ile Leu Asn Phe Leu Arg Thr
 65 70 75 80
 Lys Glu Leu Asp Leu Arg Gly Val Ser Ile Asn Val Leu Arg His Glu
 85 90 95
 60 Ala Glu Phe Tyr Gly Ile Thr Pro Leu Val Arg Arg Leu Leu Leu Cys
 100 105 110
 Glu Glu Leu Glu Arg Ser Ser Cys Gly Ser Val Leu Phe His Gly Tyr
 115 120 125
 65 Leu Pro Pro Pro Gly Ile Pro Ser Arg Lys Ile Asn Asn Thr Val Arg
 130 135 140
 Ser Ala Asp Ser Arg Asn Gly Leu Asn Ser Thr Glu Gly Glu Ala Arg
 145 150 155 160

Gly Asn Gly Thr Gln Pro Val Leu Ser Gly Thr Gly Glu Glu Thr Val
 165 170 175
 Arg Leu Gly Phe Pro Val Asp Pro Arg Lys Val Leu Ile Val Ala Gly
 180 185 190
 5 His His Asn Trp Ile Val Ala Ala Tyr Ala His Phe Ala Tyr Arg Ile
 195 200 205
 Lys Glu Ser Ser Gly Trp Gln Val Phe Thr Ser Pro Tyr Leu Asp
 210 215 220
 10 Trp Thr Ile Glu Arg Val Ala Leu Asn Ala Lys Val Val Gly Gly Pro
 225 230 235 240
 His Gly Asp Lys Asp Lys Met Val Ala Val Ala Ser Glu Ser Ser Ile
 245 250 255
 Ile Leu Trp Ser Val Gln Asp Gly Gly Ser Gly Ser Glu Ile Gly Val
 260 265 270
 15 Phe Ser Leu Gly Val Pro Val Asp Ala Leu Phe Phe Ile Gly Asn Gln
 275 280 285
 Leu Val Ala Thr Ser His Thr Gly Lys Val Gly Val Trp Asn Ala Val
 290 295 300
 20 Thr Gln His Trp Gln Val Gln Asp Val Val Pro Ile Thr Ser Tyr Asp
 305 310 315 320
 Thr Ala Gly Ser Phe Leu Leu Leu Gly Cys Asn Asn Gly Ser Ile Tyr
 325 330 335
 Tyr Ile Asp Met Gln Lys Phe Pro Leu Arg Met Lys Asp Asn Asp Leu
 340 345 350
 25 Leu Val Thr Glu Leu Tyr His Asp Pro Ser Asn Asp Ala Ile Thr Ala
 355 360 365
 Leu Ser Val Tyr Leu Thr Pro Lys Thr Ser Val Ser Gly Asn Trp Ile
 370 375 380
 30 Glu Ile Ala Tyr Gly Thr Ser Ser Gly Ala Val Arg Val Ile Val Gln
 385 390 395 400
 His Pro Glu Thr Val Gly Ser Gly Pro Gln Leu Phe Gln Thr Phe Thr
 405 410 415
 Val His Arg Ser Pro Val Thr Lys Ile Met Leu Ser Glu Lys His Leu
 420 425 430
 35 Val Ser Val Cys Ala Asp Asn Asn His Val Arg Thr Trp Thr Val Thr
 435 440 445
 Arg Phe Gly Met Ile Ser Thr Gln Pro Gly Ser Thr Pro Leu Ala Ser
 450 455 460
 40 Phe Lys Ile Leu Ser Leu Glu Glu Thr Glu Ser His Gly Ser Tyr Ser
 465 470 475 480
 Ser Gly Asn Asp Ile Gly Pro Phe Gly Glu Arg Asp Asp Gln Gln Val
 485 490 495
 Phe Ile Gln Lys Val Val Pro Ile Thr Asn Lys Leu Phe Val Arg Leu
 500 505 510
 45 Ser Ser Thr Gly Lys Arg Ile Cys Glu Ile Gln Ala Val Asp Cys Thr
 515 520 525
 Thr Ile Ser Ser Phe Thr Val Arg Glu Cys Glu Gly Ser Ser Arg Met
 530 535 540
 50 Gly Ser Arg Pro Arg Arg Tyr Leu Phe Thr Gly His Thr Asn Gly Ser
 545 550 555 560
 Ile Gln Met Trp Asp Leu Thr Thr Ala Met Asp Met Val Asn Lys Ser
 565 570 575
 Glu Asp Lys Asp Val Gly Gly Pro Thr Glu Glu Glu Leu Lys Leu
 580 585 590
 55 Leu Asp Gln Cys Asp Leu Ser Thr Ser Arg Cys Ala Thr Pro Asn Ile
 595 600 605
 Ser Pro Ala Thr Ser Val Val Gln His Ser His Leu Arg Glu Ser Asn
 610 615 620
 60 Ser Ser Leu Gln Leu Gln His His Asp Thr Thr His Glu Ala Ala Thr
 625 630 635 640
 Tyr Gly Ser Met Arg Pro Tyr Arg Glu Ser Pro Leu Leu Ala Arg Ala
 645 650 655
 Arg Arg Thr Glu Ser Phe His Ser Tyr Arg Asp Phe Gln Thr Ile Asn
 660 665 670
 65 Leu Asn Arg Asn Val Glu Arg Ala Val Pro Glu Asn Gly Asn Leu Gly
 675 680 685
 Pro Ile Gln Ala Glu Val Lys Gly Ala Thr Gly Glu Cys Asn Ile Ser

690
 Glu Arg Lys Ser Pro Gly Val Glu Ile Lys Ser Leu Arg Glu Leu Asp
 705 710 715 720
 5 Ser Gly Leu Glu Val His Lys Ile Ala Glu Gly Phe Ser Glu Ser Lys
 725 730 735
 Lys Arg Ser Ser Glu Asp Glu Asn Glu Asn Lys Ile Glu Phe Arg Lys
 740 745 750
 Lys Gly Gly Phe Glu Gly Gly Gly Phe Leu Gly Arg Lys Lys Val Pro
 755 760 765
 10 Tyr Leu Ala Ser Ser Pro Ser Thr Ser Asp Gly Gly Thr Asp Ser Pro
 770 775 780
 Gly Thr Ala Ser Pro Ser Pro Thr Lys Thr Thr Pro Ser Pro Arg His
 785 790 795 800
 15 Lys Lys Ser Asp Ser Ser Gly Gln Glu Tyr Ser Leu
 805 810

<210> 13
 <211> 167
 <212> PRT
 <213> Homo sapiens

20
 <400> 13
 Leu Ala Ser Ala Arg Ile Pro Gly Arg Pro Tyr Val Gly Val Leu Arg
 1 5 10 15
 25 Pro Pro Gly Ser Leu Phe Phe Ala Pro Ala Gly Thr Thr Ile Ser Ala
 20 25 30
 Leu Leu Gly Phe Cys Tyr Met Ala Ala Phe Leu Lys Met Ser Val Ser
 35 40 45
 Val Asn Phe Phe Arg Pro Phe Thr Arg Phe Leu Val Pro Phe Thr Leu
 50 55 60
 30 His Arg Lys Arg Asn Asn Leu Thr Ile Leu Gln Arg Tyr Met Ser Ser
 65 70 75 80
 Lys Ile Pro Ala Val Thr Tyr Pro Lys Asn Glu Ser Thr Arg Pro Ser
 85 90 95
 35 Glu Glu Leu Glu Leu Asp Lys Trp Lys Thr Thr Met Lys Ser Ser Val
 100 105 110
 Gln Glu Glu Cys Val Ser Thr Ile Ser Ser Ser Lys Asp Glu Asp Pro
 115 120 125
 40 Leu Ala Ala Thr Arg Glu Phe Ile Glu Met Trp Arg Leu Leu Gly Arg
 130 135 140
 Glu Val Pro Glu His Ile Thr Glu Glu Glu Leu Lys Thr Leu Met Glu
 145 150 155 160
 Cys Val Ser Asn Thr Ala Lys
 165

<210> 14
 <211> 452
 <212> PRT
 <213> Homo sapiens

50
 <400> 14
 Pro Cys Glu Gly Gly Ala Arg Ser Cys Leu Val Thr Glu Ser Ala Arg
 1 5 10 15
 55 Gly Gly Leu Gln Phe Leu Gln Gln Cys Asp Arg Glu Asp Leu Val Glu
 20 25 30
 Leu Ala Leu Pro Gln Leu Ala Gln Val Val Thr Val Tyr Glu Phe Leu
 35 40 45
 Leu Met Lys Val Glu Lys Asp His Leu Ala Lys Pro Phe Phe Pro Ala
 50 55 60
 60 Ile Tyr Lys Glu Phe Glu Leu His Lys Met Val Lys Lys Met Cys
 65 70 75 80
 Gln Asp Tyr Leu Ser Ser Ser Gly Leu Cys Ser Gln Glu Thr Leu Glu
 85 90 95
 65 Ile Asn Asn Asp Lys Val Ala Glu Ser Leu Gly Ile Thr Glu Phe Leu
 100 105 110
 Arg Lys Lys Glu Ile His Pro Asp Asn Leu Gly Pro Lys His Leu Ser
 115 120 125

Arg Asp Met Asp Gly Glu Gln Leu Glu Gly Ala Ser Ser Glu Lys Arg
 130 135 140
 Glu Arg Glu Ala Ala Glu Glu Gly Leu Ala Ser Val Lys Arg Pro Arg
 145 150 155 160
 5 Arg Glu Ala Leu Ser Asn Asp Thr Thr Glu Ser Leu Ala Ala Asn Ser
 165 170 175
 Arg Gly Arg Glu Lys Pro Arg Pro Leu His Ala Leu Pro Ala Gly Phe
 180 185 190
 10 Ser Pro Pro Val Asn Val Thr Val Ser Pro Arg Ser Glu Glu Ser His
 195 200 205
 Thr Thr Thr Val Ser Gly Gly Asn Gly Ser Val Phe Gln Ala Gly Pro
 210 215 220
 Gln Leu Gln Ala Leu Ala Asn Leu Glu Ala Arg Arg Gly Ser Ile Gly
 225 230 235 240
 15 Ala Ala Leu Ser Ser Arg Asp Val Ser Gly Leu Pro Val Tyr Ala Gln
 245 250 255
 Ser Gly Glu Pro Arg Arg Leu Thr Gln Ala Gln Val Ala Ala Phe Pro
 260 265 270
 20 Gly Glu Asn Ala Leu Glu His Ser Ser Asp Gln Asp Thr Trp Asp Ser
 275 280 285
 Leu Arg Ser Pro Gly Phe Cys Ser Pro Leu Ser Ser Gly Gly Gly Ala
 290 295 300
 Glu Ser Leu Pro Pro Gly Gly Pro Gly His Ala Glu Ala Gly His Leu
 305 310 315 320
 25 Gly Lys Val Cys Asp Phe His Leu Asn His Gln Gln Pro Ser Pro Thr
 325 330 335
 Ser Val Leu Pro Thr Glu Val Ala Ala Pro Pro Leu Glu Lys Ile Leu
 340 345 350
 30 Ser Val Asp Ser Val Ala Val Asp Cys Ala Tyr Arg Thr Val Pro Lys
 355 360 365
 Pro Gly Pro Gln Pro Gly Pro His Gly Ser Leu Leu Thr Glu Gly Cys
 370 375 380
 Leu Arg Ser Leu Ser Gly Asp Leu Asn Arg Phe Pro Cys Gly Met Glu
 385 390 395 400
 35 Val His Ser Gly Gln Arg Glu Leu Glu Ser Val Val Ala Val Gly Glu
 405 410 415
 Ala Met Ala Leu Lys Phe Pro Met Gly Ala Met Ser Tyr Cys Leu Arg
 420 425 430
 40 Asp Arg Ser Arg Phe Leu Phe Arg Leu Pro Met Gly Leu Ser Cys Pro
 435 440 445
 Leu Gln Val Gln
 450
 45 <210> 15
 <211> 321
 <212> PRT
 <213> Homo sapiens
 <400> 15
 50 Met Ala Glu Ala Glu Glu Asp Cys His Ser Asp Thr Val Arg Ala Asp
 1 5 10 15
 Asp Asp Glu Glu Asn Glu Ser Pro Ala Glu Thr Asp Leu Gln Ala Gln
 20 25 30
 55 Leu Gln Met Phe Arg Ala Gln Trp Met Phe Glu Leu Ala Pro Gly Val
 35 40 45
 Ser Ser Ser Asn Leu Glu Asn Arg Pro Cys Arg Ala Ala Arg Gly Ser
 50 55 60
 Leu Gln Lys Thr Ser Ala Asp Thr Lys Gly Lys Gln Glu Gln Ala Lys
 65 70 75 80
 60 Glu Glu Lys Ala Arg Glu Leu Phe Leu Lys Ala Val Glu Glu Glu Gln
 85 90 95
 Asn Gly Ala Leu Tyr Glu Ala Ile Lys Phe Tyr Arg Arg Ala Met Gln
 100 105 110
 65 Leu Val Pro Asp Ile Glu Phe Lys Ile Thr Tyr Thr Arg Ser Pro Asp
 115 120 125
 Gly Asp Gly Val Gly Asn Ser Tyr Ile Glu Asp Asn Asp Asp Asp Ser
 130 135 140

Lys Met Ala Asp Leu Leu Ser Tyr Phe Gln Gln Gln Leu Thr Phe Gln
 145 150 155 160
 Glu Ser Val Leu Lys Leu Cys Gln Pro Glu Leu Glu Ser Ser Gln Ile
 165 170 175
 5 His Ile Ser Val Leu Pro Met Glu Val Leu Met Tyr Ile Phe Arg Trp
 180 185 190
 Val Val Ser Ser Asp Leu Asp Leu Arg Ser Leu Glu Gln Leu Ser Leu
 195 200 205
 10 Val Cys Arg Gly Phe Tyr Ile Cys Ala Arg Asp Pro Glu Ile Trp Arg
 210 215 220
 Leu Ala Cys Leu Lys Val Trp Gly Arg Ser Cys Ile Lys Leu Val Pro
 225 230 235 240
 Tyr Thr Ser Trp Arg Glu Met Phe Leu Glu Arg Pro Arg Val Arg Phe
 245 250 255
 15 Asp Gly Val Tyr Ile Ser Lys Thr Thr Tyr Ile Arg Gln Gly Glu Gln
 260 265 270
 Ser Leu Asp Gly Phe Tyr Arg Ala Trp His Gln Val Glu Tyr Tyr Arg
 275 280 285
 20 Tyr Ile Arg Phe Phe Pro Asp Gly His Val Met Met Leu Thr Thr Pro
 290 295 300
 Glu Glu Pro Gln Ser Ile Val Pro Arg Leu Arg Thr Arg Glu Tyr Gln
 305 310 315 320
 Asp

25
 <210> 16
 <211> 172
 <212> PRT
 <213> Homo sapiens

30
 <400> 16
 Ala Cys Pro Thr His Pro Pro Pro Pro Thr Ala Pro Arg Gly His Gln
 1 5 10 15
 35 Ser Cys Arg Leu Gly Asp Ser Trp Ser Val Lys Ser Arg Trp Cys Pro
 20 25 30
 Cys Pro Gln Glu Leu Gly Trp Ala Ser Cys Ala Arg Gly Val Cys Ala
 35 40 45
 Trp Ser Phe Cys Ala Trp Ile Cys Ile Phe Ile Ala Leu Leu Val Glu
 50 55 60
 40 Thr Pro Arg Pro Val His Pro Ala Lys Thr Pro Gln Ala Ala Cys Gly
 65 70 75 80
 Ser Arg Thr Leu Pro Pro Phe Pro Arg Cys Pro Leu Arg Ala Arg Ala
 85 90 95
 45 Ala Thr Gln Ala Cys Trp Leu Arg Pro Pro Leu Gly Gln Ala Leu Ala
 100 105 110
 Gln Pro Ala Glu Trp Gly Val Val Gly Gln Ser Pro Arg Ser Trp Ala
 115 120 125
 Pro Ala Gln Ala His Arg Ala Arg Pro His Pro Ala Ala Pro Arg Thr
 130 135 140
 50 Ala Thr Arg Gly Val Leu Pro Leu Cys Pro Ala Pro Gly Thr Asn Ser
 145 150 155 160
 Met Phe Gly Val Cys Leu Cys Leu Phe Phe Lys Lys
 165 170

55
 <210> 17
 <211> 472
 <212> PRT
 <213> Homo sapiens

60
 <400> 17
 Met Arg Glu Arg Phe Arg Asn Leu Asp Glu Glu Val Glu Lys Tyr Arg
 1 5 10 15
 Ala Val Tyr Asn Lys Leu Arg Tyr Glu His Thr Phe Leu Lys Ser Glu
 20 25 30
 65 Phe Glu His Gln Lys Glu Glu Tyr Ala Arg Ile Leu Asp Glu Gly Lys
 35 40 45
 Ile Lys Tyr Glu Ser Glu Ile Ala Arg Leu Glu Glu Asp Lys Glu Glu

50 55 60
 Leu Arg Asn Gln Leu Leu Asn Val Asp Leu Thr Lys Asp Ser Lys Arg
 65 70 75 80
 Val Glu Gln Leu Ala Arg Glu Lys Val Tyr Leu Cys Gln Lys Leu Lys
 85 90 95
 Gly Leu Glu Ala Glu Val Ala Glu Leu Lys Ala Glu Lys Glu Asn Ser
 100 105 110
 Glu Ala Gln Val Glu Asn Ala Gln Arg Ile Gln Val Arg Gln Leu Ala
 115 120 125
 10 Glu Met Gln Ala Thr Val Arg Ser Leu Gly Ala Glu Lys Gln Ser Ala
 130 135 140
 Asn Leu Arg Ala Glu Arg Leu Glu Lys Glu Leu Gln Ser Ser Ser Glu
 145 150 155 160
 15 Gln Asn Thr Phe Leu Ile Asn Lys Leu His Lys Ala Glu Arg Glu Ile
 165 170 175
 Asn Thr Leu Ser Ser Lys Val Lys Glu Leu Lys His Ser Asn Lys Leu
 180 185 190
 Glu Ile Thr Asp Ile Lys Leu Glu Thr Ala Arg Ala Lys Ser Glu Leu
 195 200 205
 20 Glu Arg Glu Arg Asn Lys Leu Gln Ser Glu Leu Asp Gly Leu Gln Ser
 210 215 220
 Asp Asn Glu Ile Leu Lys Ala Ala Val Glu His His Lys Val Leu Leu
 225 230 235 240
 25 Val Glu Lys Asp Arg Glu Leu Ile Arg Lys Val Gln Ala Ala Lys Glu
 245 250 255
 Glu Gly Tyr Gln Lys Leu Val Val Leu Gln Asp Glu Lys Leu Glu Leu
 260 265 270
 Glu Asn Arg Leu Ala Asp Leu Glu Lys Met Lys Val Glu His Asp Val
 275 280 285
 30 Trp Arg Gln Ser Glu Lys Asp Gln Tyr Glu Glu Lys Leu Arg Ala Ser
 290 295 300
 Gln Met Ala Glu Glu Ile Thr Arg Lys Glu Leu Gln Ser Val Arg Leu
 305 310 315 320
 35 Lys Leu Gln Gln Gln Ile Val Thr Ile Glu Asn Ala Glu Lys Glu Lys
 325 330 335
 Asn Glu Asn Ser Asp Leu Lys Gln Gln Ile Ser Ser Leu Gln Ile Gln
 340 345 350
 Val Thr Ser Leu Ala Gln Ser Glu Asn Asp Leu Leu Asn Ser Asn Gln
 355 360 365
 40 Met Leu Lys Glu Met Val Glu Arg Leu Lys Gln Glu Cys Arg Asn Phe
 370 375 380
 Arg Ser Gln Ala Glu Lys Ala Gln Leu Glu Ala Glu Lys Thr Leu Glu
 385 390 395 400
 45 Glu Lys Gln Ile Gln Trp Leu Glu Glu Lys His Lys Leu His Asp Arg
 405 410 415
 Ile Thr Asp Arg Glu Glu Lys Tyr Asn Gln Ala Lys Glu Lys Leu Gln
 420 425 430
 Arg Ala Ala Ile Ala Gln Lys Lys Arg Lys Ser Leu His Glu Asn Lys
 435 440 445
 50 Leu Lys Arg Leu Gln Glu Lys Val Glu Val Leu Glu Ala Lys Lys Glu
 450 455 460
 Glu Leu Glu Thr Glu Ile Arg Ser
 465 470

 55 <210> 18
 <211> 462
 <212> PRT
 <213> Homo sapiens

 60 <400> 18
 Lys Ala Thr Ser Leu Thr Leu Glu Gly Gly Arg Leu Lys Arg Thr Pro
 1 5 10 15
 Gln Leu Ile His Gly Arg Asp Tyr Glu Met Val Pro Glu Pro Val Trp
 20 25 30
 65 Arg Ala Leu Tyr His Trp Tyr Gly Ala Asn Leu Ala Leu Pro Arg Pro
 35 40 45
 Val Ile Lys Asn Ser Lys Thr Asp Ile Pro Glu Leu Glu Leu Phe Pro

50 55 60
 Arg Tyr Leu Leu Phe Leu Arg Gln Gln Pro Ala Thr Arg Thr Gln Gln
 65 70 75 80
 Ser Asn Ile Trp Val Asn Met Gly Asn Val Pro Ser Pro Asn Ala Pro
 85 90 95
 Leu Lys Arg Val Leu Ala Tyr Thr Gly Cys Phe Ser Arg Met Gln Thr
 100 105 110
 Ile Lys Glu Ile His Glu Tyr Leu Ser Gln Arg Leu Arg Ile Lys Glu
 115 120 125
 10 Glu Asp Met Arg Leu Trp Leu Tyr Asn Ser Glu Asn Tyr Leu Thr Leu
 130 135 140
 Leu Asp Asp Glu Asp His Lys Leu Glu Tyr Leu Lys Ile Gln Asp Glu
 145 150 155 160
 15 Gln His Leu Val Ile Glu Val Arg Asn Lys Asp Met Ser Trp Pro Glu
 165 170 175
 Glu Met Ser Phe Ile Ala Asn Ser Ser Lys Ile Asp Arg His Lys Val
 180 185 190
 Pro Thr Glu Lys Gly Ala Thr Gly Leu Ser Asn Leu Gly Asn Thr Cys
 195 200 205
 20 Phe Met Asn Ser Ser Ile Gln Cys Val Ser Asn Thr Gln Pro Leu Thr
 210 215 220
 Gln Tyr Phe Ile Ser Gly Arg His Leu Tyr Glu Leu Asn Arg Thr Asn
 225 230 235 240
 25 Pro Ile Gly Met Lys Gly His Met Ala Lys Cys Tyr Gly Asp Leu Val
 245 250 255
 Gln Glu Leu Trp Ser Gly Thr Gln Lys Asn Val Ala Pro Leu Lys Leu
 260 265 270
 Arg Trp Thr Ile Ala Lys Tyr Ala Pro Arg Phe Asn Gly Phe Gln Gln
 275 280 285
 30 Gln Asp Ser Gln Glu Leu Leu Ala Phe Leu Leu Asp Gly Leu His Glu
 290 295 300
 Asp Leu Asn Arg Val His Glu Lys Pro Tyr Val Glu Leu Lys Asp Ser
 305 310 315 320
 35 Asp Gly Arg Pro Asp Trp Glu Val Ala Ala Glu Ala Trp Asp Asn His
 325 330 335
 Leu Arg Arg Asn Arg Ser Ile Val Val Asp Leu Phe His Gly Gln Leu
 340 345 350
 Arg Ser Gln Val Lys Cys Lys Thr Cys Gly His Ile Ser Val Arg Phe
 355 360 365
 40 Asp Pro Phe Asn Phe Leu Ser Leu Pro Leu Pro Met Asp Ser Tyr Met
 370 375 380
 His Leu Glu Ile Thr Val Ile Lys Leu Asp Gly Thr Thr Pro Val Arg
 385 390 395 400
 45 Tyr Gly Leu Arg Leu Asn Met Asp Glu Lys Tyr Thr Gly Leu Lys Lys
 405 410 415
 Gln Leu Ser Asp Leu Cys Gly Leu Asn Ser Glu Gln Ile Leu Leu Ala
 420 425 430
 Glu Val His Gly Ser Asn Ile Lys Asn Phe Pro Gln Asp Asn Pro Lys
 435 440 445
 50 Ser Thr Glu Leu Leu Ser Glu Val Gly Phe Phe Gly Val Pro
 450 455 460

<210> 19

<211> 243

<212> PRT

<213> Homo sapiens

<400> 19

60 Pro Thr Trp Leu Glu Arg Gly Gly Gly Glu Pro Ala Ala Arg Pro Gln
 1 5 10 15
 Thr Pro Gln Pro Thr Ala Pro Glu Ser Arg Gly Pro Ser Gly Ala Ser
 20 25 30
 Ala Leu Arg Cys Arg Gly Pro Thr Ala Arg Ser Leu Pro Ala Ala Ser
 35 40 45
 65 Met Leu Gly Ala Pro Asp Glu Ser Ser Val Arg Val Ala Val Arg Ile
 50 55 60
 Arg Pro Gln Leu Ala Lys Glu Lys Ile Glu Gly Cys His Ile Cys Thr

65 70 75 80
 Ser Val Thr Pro Gly Glu Pro Gln Val Phe Leu Gly Lys Asp Lys Ala
 85 90 95
 5 Phe Thr Phe Asp Tyr Val Phe Asp Ile Asp Ser Gln Gln Glu Gln Ile
 100 105 110
 Tyr Ile Gln Cys Ile Glu Lys Leu Ile Glu Gly Cys Phe Glu Gly Tyr
 115 120 125
 Asn Ala Thr Val Phe Ala Tyr Gly Gln Thr Gly Ala Gly Lys Thr Tyr
 130 135 140
 10 Thr Met Gly Thr Gly Phe Asp Val Asn Ile Val Glu Glu Glu Leu Gly
 145 150 155 160
 Ile Ile Ser Arg Ala Val Lys His Leu Phe Lys Ser Ile Glu Glu Lys
 165 170 175
 15 Lys His Ile Ala Ile Lys Asn Gly Leu Pro Ala Pro Asp Phe Lys Val
 180 185 190
 Asn Ala Gln Phe Leu Glu Leu Tyr Asn Glu Glu Val Leu Asp Leu Phe
 195 200 205
 Asp Thr Thr Arg Asp Ile Asp Ala Lys Ser Lys Lys Ser Asn Ile Arg
 210 215 220
 20 Ile His Glu Asp Ser Thr Gly Gly Asn Leu Tyr Cys Gly Arg Phe Gln
 225 230 235 240
 His Val Leu

25 <210> 20
 <211> 223
 <212> PRT
 <213> Homo sapiens

30 <400> 20
 Gly Asn Tyr Arg Pro Ser Lys Lys Arg Phe Arg Glu Gly Lys Glu Lys
 1 5 10 15
 Lys Arg Gly Lys Lys Val Trp Leu Val Lys Arg Ile Ile Gln Thr Leu
 20 25 30
 35 Thr Lys Arg Arg Lys Lys Lys Arg Val Phe Arg Lys Glu Lys Pro Asn
 35 40 45
 Glu Leu Glu Val Glu Glu Ser Gln Glu Val Ser Asp His Glu Asp Glu
 50 55 60
 40 Glu Glu Glu Glu Glu Glu Glu Glu Asp Asp Ile Asp Gly Gly Glu Ser
 65 70 75 80
 Ser Asp Glu Ser Asp Ser Glu Ser Asp Glu Lys Ala Tyr Gln Ala Asp
 85 90 95
 Leu Ala Asn Ile Thr Cys Glu Ile Ala Ile Lys Gln Lys Leu Ile Asp
 100 105 110
 45 Glu Leu Glu Asn Ser Gln Lys Arg Leu Gln Thr Leu Lys Lys Gln Tyr
 115 120 125
 Glu Glu Lys Met Met Leu Gln His Lys Ile Arg Asp Thr Gln Leu Glu
 130 135 140
 50 Arg Asp Gln Val Leu Gln Asn Leu Gly Ser Val Glu Ser Tyr Ser Glu
 145 150 155 160
 Glu Lys Ala Lys Lys Val Arg Ser Glu Tyr Glu Lys Lys Leu Gln Ala
 165 170 175
 Met Asn Lys Glu Leu Gln Arg Leu Gln Ala Ala Gln Lys Glu His Ala
 180 185 190
 55 Arg Leu Leu Lys Asn Gln Ser Gln Tyr Glu Lys Leu Lys Lys Leu Gln
 195 200 205
 Gln Asp Val Met Glu Met Lys Lys Thr Lys Val Arg Leu Met Lys
 210 215 220

60 <210> 21
 <211> 206
 <212> PRT
 <213> Homo sapiens

65 <400> 21
 Met Asn Lys Pro Ile Thr Pro Ser Thr Tyr Val Arg Cys Leu Asn Val
 1 5 10 15

Gly Leu Ile Arg Lys Leu Ser Asp Phe Ile Asp Pro Gln Glu Gly Trp
 20 25 30
 Lys Lys Leu Ala Val Ala Ile Lys Lys Pro Ser Gly Asp Arg Tyr
 35 40 45
 5 Asn Gln Phe His Ile Arg Arg Phe Glu Ala Leu Leu Gln Thr Gly Lys
 50 55 60
 Ser Pro Thr Ser Glu Leu Phe Asp Trp Gly Thr Thr Asn Cys Thr
 65 70 75 80
 10 Val Gly Asp Leu Val Asp Leu Leu Ile Gln Asn Glu Phe Phe Ala Pro
 85 90 95
 Ala Ser Leu Leu Leu Pro Asp Ala Val Pro Lys Thr Ala Asn Thr Leu
 100 105 110
 Pro Ser Lys Glu Ala Ile Thr Val Gln Gln Lys Gln Met Pro Phe Cys
 115 120 125
 15 Asp Lys Asp Arg Thr Leu Met Thr Pro Val Gln Asn Leu Glu Gln Ser
 130 135 140
 Tyr Met Pro Pro Asp Ser Ser Ser Pro Glu Asn Lys Ser Leu Glu Val
 145 150 155 160
 20 Ser Asp Thr Arg Phe His Ser Phe Ser Phe Tyr Glu Leu Lys Asn Val
 165 170 175
 Thr Asn Asn Phe Asp Glu Arg Pro Ile Ser Val Gly Gly Asn Lys Met
 180 185 190
 Gly Glu Gly Gly Phe Gly Val Val Tyr Lys Gly Leu Arg Lys
 195 200 205

<210> 22
 <211> 1260
 <212> DNA
 <213> Homo sapiens

30 <400> 22
 cttctccgca cgactgttac agaggtctcc agagccttct ctctcctgtg caaaatggca 60
 actcttaagg aaaaactcat tgcaccagtt gcggaagaag aggcaacagt tccaaacaat 120
 aagatcactg tagtggtgtg tggacaagtt ggtatggcgt gtgctatcag cattctggga 180
 35 aagtctcttg ctgatgaact tgctcttctg gatgttttgg aagataagct taaaggagaa 240
 atgatggatc tgcagcatgg gagcttattt cttcagacac ctaaaattgt ggcagataaa 300
 gattattctg tgaccgccaa ttctaagatt gtagtggtaa ctgcaggagt ccgtcagcaa 360
 gaaggggaga gtcggctcaa tctggtgcag agaaatgtta atgtcttcaa attcattatt 420
 cctcagatcg tcaagtacag tcctgattgc atcataattg tggtttccaa cccagtggac 480
 40 attcttacgt atgttacctg gaaactaagt ggattaccca aacaccgcgt gattggaagt 540
 ggatgtaatc tggattctgc tagatttcgc taccttatgg ctgaaaaact tggcattcat 600
 cccagcagct gccatggatg gattttgggg gaacatggcg actcaagtgt ggctgtgtg 660
 agtgggtgta atgtggcagg tgtttctctc caggaattga atccagaaat gggaactgac 720
 aatgatagtg aaaattggaa ggaagtgc ataatggatg ttgaaagtgc ctatgaagtc 780
 45 atcaagctaa aagatatac caactgggct attggattaa gtgtggctga tcttattgaa 840
 tccatgttga aaaatctatc caggattcat cccgtgtcaa caatggtaaa ggggatgtat 900
 ggcattgaga atgaagtctt cctgagcctt ccatgtatcc tcaatgcccg gggattaacc 960
 agcgttatca accagaagct aaaggatgat gaggttgctc agctcaagaa aagtgcagat 1020
 accctgtggg acatccagaa ggacctaata gacctgtgac tagtgagctc taggctgtag 1080
 50 aaatttaaaa actacaatgt gattaactcg agcctttagt tttcatccat gtacatggat 1140
 cacagtttgc tttgatcttc ttcaatatgt gaatttgggc tcacagaatc aaagcctatg 1200
 cttggtttta tgcttgcaat ctgagctctt gaacaaataa aattaactat tgtagtgtga 1260

<210> 23
 <211> 3151
 <212> DNA
 <213> Homo sapiens

60 <400> 23
 taacacagtt gtgaaaagag atggatgtgg gttccagctc tagccctgcc tgtgtgcaact 60
 tatgcagaaa cgctaattga ctccactaca gcgactgctg agctgggctg gatggtgcat 120
 cctccatcag ggtgggaaga ggtgagtggc tacgatgaga acatgaacac gatccgcacg 180
 taccaggtgt gcaacgtggt tgagtcaagc cagaacaact ggctacggac caagtttatt 240
 cggcgccctg gcgcccaccg catccacgtg gagatgaagt ttccggtgcg tgactgcagc 300
 65 agcatcccca gcgtgcctgg ctccctgcaag gagaccttca acctctatta ctatgaggct 360
 gactttgact cggccaccaa gaccttcccc aactggatgg agaatccatg ggtgaagggtg 420
 gataaccattg cagccgacga gagcttctcc cagggtggacc tgggtgaccg cgtcatgaaa 480

	atcaacaccg	aggtgcgag	cttcggacct	gtgtcccgca	gcggcttcta	cctggccttc	540
	caggactatg	gcggctgcat	gtccctcatc	gccgtgctgt	tcttctaccg	caagtgcctc	600
	cgcacatcc	agaatggcgc	catcttccag	gaaaccctgt	cgggggctga	gagcacatcg	660
5	ctgggtggctg	cccggggcag	ctgcatcgcc	aatgcggaag	aggtggatgt	acccatcaag	720
	ctctactgta	acggggacgg	cgagtggctg	gtgcccacat	ggcgctgcat	gtgcaaagca	780
	ggcttcgagg	ccgttgagaa	tggcaccgtc	tgccgaggtt	gtccatctgg	gactttcaag	840
	gccaaccaag	gggatgaggg	ctgtacccac	tgtcccatca	acagccggac	cacttctgaa	900
	ggggccacca	actgtgtctg	ccgcaatggc	tactacagag	cagacctgga	ccccctggac	960
10	atgccctgca	caaccatccc	ctccgcgccc	caggctgtga	ttccagtggt	caatgagacc	1020
	tccctcatgc	tggagtggac	ccctccccgc	gactccggag	gccgagagga	cctcgtctac	1080
	aacatcatct	gcaagagctg	tggctcgggc	cggggtgcct	gcacccgctg	cggggacaaat	1140
	gtacagtacg	caccacgcca	gctaggcctg	accgagccac	gcattttacat	cagtgcctg	1200
	ctggcccaca	cccagttacac	cttcgagatc	caggctgtga	acggcggttac	tgaccagagc	1260
15	cccttctcgc	ctcagttcgc	ctctgtgaac	atcaccacca	accaggcagc	tccatcgcca	1320
	gtgtccatca	tgcacaggt	gagccgcacc	gtggacagca	ttaccctgtc	gtgggtccag	1380
	ccagaccagc	ccaatggcgt	gacccctggc	tatgagctgc	agtactatga	gaagcaggag	1440
	ctcagtgagt	acaacgccac	agccataaaa	agccccacca	acacggtcac	cgtgcagggc	1500
	ctcaaagccg	gcgcccatac	tgtcttccag	gtgcggggcac	gcaccgtggc	aggctacggg	1560
20	cgctacagcg	gcaagatgta	cttcagagcc	atgacagaag	ccgattacca	gacaagcatc	1620
	caggagaagt	tgcactcat	catcggctcc	tcggccgctg	gcctgggtctt	cctcatgtgt	1680
	gtgggtgtca	tgcacatcgt	gtgtaacaga	cgggggtttg	agcgtgctga	ctcggagtac	1740
	acggacaagc	tgcaacacta	caccagtggc	cacatgaccc	caggcatgaa	gatctacatc	1800
	gatcctttca	cctacagagga	ccccaacgag	gcagtgcggg	agtttgccaa	ggaaattgac	1860
25	atctcctgtg	tcaaaattga	gcaggtgata	ggagcagggg	agttttggcg	ggtctgcagt	1920
	ggccacctga	agctgccagg	caagagagag	atctttgtgg	ccatcaagac	gctcaagctg	1980
	ggctacacgg	agaagcagcg	ccgggacttc	ctgagcgaag	cctccatcat	gggccagttc	2040
	gaccatccca	acgtcatcca	cctggagggg	gtcgtgacca	agagcacacc	tgtgatgatc	2100
	atcacccgag	tcattggagaa	tggctccctg	gactccttcc	tccggcaaaa	cgatgggcag	2160
30	ttcacagtca	tccagctggt	gggcatgctt	cggggcatcg	cagctggcat	gaagtacctg	2220
	gcagacatga	actatgttca	ccgtgacctg	gctgcccgcg	acatcctcgt	caacagcaac	2280
	ctgggtctgca	aggtgtcgga	ctttgggctc	tcacgcttcc	tagaggacga	tacctcagac	2340
	cccacatata	ccagtgcctt	ggggcgaaag	atccccatcc	gctggacagc	cccgggaagcc	2400
	atccagttac	ggaagttcac	ctcggccagt	gatgtgtgga	gctacggcat	tgtcatgtgg	2460
35	gaggtgatgt	cctatgggga	gcggccctac	tgggacatga	ccaaccagga	tgtaatcaat	2520
	gccatttgagc	aggactatcg	gctgccaccg	cccatggact	gcccagctgc	cctgcaccaa	2580
	ctcatgctgg	actgttggca	gaaggaccgc	aaccacccgc	ccaagttcgg	ccaaattgtc	2640
	aacacgtag	acaagatgat	ccgcaatccc	aacagcctca	aagccatggc	gccccctctc	2700
	tctggcatca	acctgcccgt	gctggaccgc	acgatccccg	actacaccag	ctttaacacg	2760
40	gtggacgagt	ggctgaaggc	catcaagatg	gggcagtaca	aggagagcct	cgccaatgcc	2820
	ggcttcacct	cctttgacgt	cgtgtctcag	atgatgatgg	aggacattct	ccgggttggg	2880
	gtcacttttg	ctggccacca	gaaaaaaatc	ctgaacagta	tccaggtgat	gcggggcgag	2940
	atgaaccaga	ttcagttctg	ggaggtttga	cattccactg	cctcggtcca	cctcttctct	3000
	caagccccgc	ccctctctgc	ccactgtccg	gccctcctgg	tgtcttatcc	actgcagggc	3060
45	cagccactcg	ccaggaggcc	acgggcacgg	gaagaacca	gcgggtgccag	ccacgagacg	3120
	tcaccaagaa	aacatgcaac	tcaaacgacg	g			3151

<210> 24

<211> 1234

<212> DNA

<213> Homo sapiens

<400> 24

	tagttcaaga	caacagagac	aaagctaaga	tgagggaagtt	ctgtacagtt	taggaaatag	60
55	aggctttcaa	agataattcg	cagtgatgtg	aaactggcct	ccaagccct	gataacaaca	120
	tggccaacgc	cctggccagc	gccacttgcg	agcgtgcaa	ggggcgcttt	gcgcccgtg	180
	agaagatcgt	gaacagtaat	ggggagctgt	accatgagca	gtgtttcgtg	tgcgctcagt	240
	gcttccagca	gattccagaa	ggactcttct	atgagtttga	aggaagaaag	tactgtgaac	300
	atgactttca	gatgctcttt	gcccttctgt	gtcatcagtg	tgggtgaattc	atcattggcc	360
60	gagttatcaa	agccatgaat	aacagctggc	atccggagtg	cttccgctgt	gacctctgcc	420
	aggaagttct	ggcagatata	gggtttgtca	agaatgctgg	gagacacctg	tgtcggccct	480
	gtcataatcg	tgagaaagcc	agaggccttg	ggaaatacat	ctgccagaaa	tgccatgcta	540
	tcacogtag	gcagcctctg	atattcaaga	acgaccctta	ccatccagac	catttcaact	600
	gcgccaactg	cggaaggagg	ctgactgcgc	atgcacggga	gctgaaaggg	gagctatact	660
	gcctcccatg	ccatgataaa	atgggggtcc	ccatctgtgg	tgcttgccga	cggcccatcg	720
65	aagggcgcg	ggtgaacgct	atgggcaagc	agtggcatgt	ggagcatttt	gtttgtgcca	780
	agtgtgagaa	accctttctt	ggacatcgcc	attatgagag	gaaaggcctg	gcatattgtg	840
	aaactcacta	taaccagcta	tttgggtgatg	tttgcttcca	ctgcaatcgt	gttatagaag	900

5	gtgatgtggt	ctctgctctt	aataaggcct	ggtgctgtaa	ctgctttgcc	tgttctacct	960
	gcaacactaa	attaacactc	aagaataagt	ttgtggagtt	tgacatgaag	ccagtctgta	1020
	agaagtgcta	tgagatttcc	attggagctg	aagaaaagac	ttaagaaact	agctgagacc	1080
	ttaggaagga	aataagttcc	tttatttttt	cttttctatg	caagataaga	gattaccaac	1140
	attacttgct	ttgatctacc	catattttaa	gctatatctc	aaagcagttg	agagaagagg	1200
	acctatatga	atggttttat	gtcatttttt	taaa			1234
	<210> 25						
	<211> 4534						
10	<212> DNA						
	<213> Homo sapiens						
	<400> 25						
15	gtcacgagcg	tcgaagagac	aaagccgcgt	cagggggccc	ggccggggcg	ggggagcccc	60
	gggcttggtg	gtgccccagc	ccgcgcggag	ggcccttcgg	acccgcgcgc	cgccgctgcc	120
	gccgccgccc	cctcgcaaca	ggtccgggcg	gcctcgctct	ccgctcccc	ccccgcctc	180
	cgcgaccctc	cggggcacct	cagctcgccc	ggggccgcag	tctggccacc	cgcttccatg	240
	cgttccgggt	ccaagatgat	gccgatgttt	cttaccgtgt	atctcagtaa	caatgagcag	300
20	cacttcacag	aagttccagt	tactccagaa	acaatatgca	gagacgtggg	ggatctgtgc	360
	aaagaacccg	gcgagagtga	ttgccatttg	gctgaagtgt	ggtgtggctc	tgtagagata	420
	gagtttcatc	atgtttggcca	ggatggtctc	gatctcctga	ccttgtgatc	cgctgcctc	480
	ggcctcccaa	agtgtctggat	tacaggtgtg	agccaccacg	atcagcctct	agtgtttaaa	540
	aaagaacgtc	cagttgcgga	taatgagcga	atgtttgatg	ttcttcaacg	atttgggaagt	600
25	cagaggaacg	aagttcgctt	cttccctcgt	catgaacgcc	cccctggcag	ggacattgtg	660
	agtggaccaaa	gatctcagga	tccaagttta	aaaagaaatg	gtgtaaaagt	tcctggtgaa	720
	tatcgaagaa	aggagaacgg	tgttaatatg	cctaggatgg	atctgactct	tgtgaactt	780
	caggaaatgg	catctcgcca	gcagcaacag	attgaagccc	agcaacaatt	gctggcaact	840
	aaggaacacg	gcttaaagtt	tttgaacaaa	caagatcagc	gacaacagca	acaagttgct	900
30	gagcaggaga	aacttaaaag	gctaaaagaa	atagctgaga	atcaggaagc	taagctaaaa	960
	aaagtggagag	cacttaaaag	ccacgtggaa	cagaagagac	taagcaatgg	gaaacttgtg	1020
	gaggaatttg	aacagatgaa	taatttggtc	cagcaaaaac	agagggagct	cgctctggct	1080
	gtgtcaaaag	tagaagaact	gaccaggcag	ctagagatgc	tcaagaacgg	caggatcgac	1140
	agccaccatg	acaatcagtc	tgcatgtggc	gagcttgatc	gcctctataa	ggagctgcag	1200
35	ctaagaaaca	aattgaatca	agagcagaat	gccaaagctac	aacaacagag	ggagtgtttg	1260
	aataagcgta	attcagaagt	ggcagtcatg	gataagcgtg	ttaatgagct	gagggaccgg	1320
	ctgtggaaga	agaaggcagc	tctacagcaa	aaagaaaatc	taccagtttc	atctgatgga	1380
	aatcttcccc	agcaagccgc	gtcagcccca	agccgtgtgg	ctgcagtagg	tccttatatc	1440
	cagtcattcta	ctatgcctcg	gatgccctca	agccctgaat	tgctggtgaa	gccagccctg	1500
40	ccggatgggt	ccttggtcat	tcaggcttca	gaggggcccga	tgaaaataca	gacactcccc	1560
	aacatgagat	ctggggctgc	ttcacaaact	aaaggctcta	aaatccatcc	agttggccct	1620
	gattggagtc	cttcaaattgc	agatcttttc	ccaagccaag	gctctgcttc	tgtacctcaa	1680
	agcactggga	atgctctgga	tcaagttgat	gatggagagg	ttccgctgag	ggagaaagag	1740
	aagaaagtgc	gtccgtttctc	aatgtttgat	gcagtagacc	agtccaatgc	cccacttccc	1800
45	tttggtactc	tgaggaagaa	ccagagcagt	gaagatatct	tgccgggatgc	tcaggttgca	1860
	aataaaaaatg	tggtctaaagt	accacctcct	gttcctacaa	aaccaaaaca	gattaatttg	1920
	ccttattttg	gacaaactaa	tcagccacct	tcagacatta	agccagacgg	aagttctcag	1980
	cagttgttca	cagttgttcc	gtccatggga	actaaaccaa	aaccagcagg	gcagcagccc	2040
	agagtgtctg	tatctcccag	cataccttgc	gttggccaag	accagaccct	ttctccaggt	2100
50	tctaagcaag	aaagtccacc	tgctgctgcc	gtccggccct	ttactcccca	gccttccaaa	2160
	gacaccttac	ttccaccctt	cagaaaaccc	cagaccgtgg	cagcaagttc	aatatatattc	2220
	atgtatacgc	aacagcaggg	gccaggaaaa	aacttccagc	aggctgtgca	gagcgcgttg	2280
	accaagactc	ataccagagg	gccacacttt	tcaagtgtat	atggtaagcc	tgtaattgct	2340
	gctgcccaga	atcaacagca	gcacccagag	aacattttatt	ccaatagcca	gggcaagcct	2400
55	ggcagtcag	aacctgaaac	agagcctgtt	tcttcagttc	aggagaacca	tgaaaacgaa	2460
	agaattcctc	ggccactcag	cccaactaaa	ttactgcctt	tcttatctaa	tccttaccga	2520
	aaccagagtg	atgctgacct	agaagcctta	cgaaagaaac	tgtctaacgc	accaaggcct	2580
	ctaaagaaaac	gtagttctat	tacagagcca	gagggctcta	atggggccaa	tattcagaag	2640
	ctttttatatt	agaggaccac	catagcgccc	atggagacca	tctctgtccc	atcataccca	2700
60	tccaagtcat	cttctgtgac	tgccagctca	gaaagcccag	tagaaatcca	gaatccatat	2760
	ttacatgtgg	agcccgaaaa	ggaggtgggtc	tctctgggtc	ctgaatcatt	gtccccagag	2820
	gatgtgggga	atgccagtac	agagaacagt	gacatgccag	ctccttctcc	aggccttgat	2880
	tatgagcctg	aggagtcctc	agacaacagc	ccaaatctcc	agaataaccc	agaagaacca	2940
	aatccagagg	ctccacatgt	gcttgatgtg	tacctggagg	agtaccctcc	ataccacccc	3000
65	ccaccatacc	catctgggga	gcctgaaggg	cccggagaag	actcggtgag	catgcccgcg	3060
	cctgaaatca	ccgggcaggt	ctctctgcct	cctggtaaaa	ggacaaactt	gcgtaaaact	3120
	ggctcagagc	gtatcgctca	tggaaatgag	gtgaaattca	accccttgc	tttactgcta	3180
	gattcgtctt	tggaggggaga	atttgacctt	gtacagagaa	ttattttatga	ggttgatgac	3240

	ccaagcctgc	ccaatgatga	aggcatcaag	gctcttcaca	atgctgtgtg	tgcaggccac	3300
	acagaaatcg	ttaagttcct	ggtacagttt	ggtgtaaatg	ttaaagctgc	tgatagtgtat	3360
	ggatggactc	cattacattg	tgctgcctca	tgtaacaacg	tccaagtgtg	taagtttttg	3420
5	gtggagtcag	gagccgctgt	gtttgccatg	acctacagtg	acatgcagac	tgctgcagat	3480
	aagtgcgagg	aaatggagga	aggctacact	cagtgtctcc	aattttcttta	tgaggttcag	3540
	gagaagatgg	gcataatgaa	taaaggagtc	atztatgcgc	tttgggatta	tgaacctcag	3600
	aatgatgatg	agctgcccac	gaaagaagga	gactgcatga	caatcatcca	cagggaagac	3660
	gaagatgaaa	tcgaatggtg	gtgggcgcg	cttaatgata	aggagggata	tgttccacgt	3720
10	aacttgctgg	gactgtaccc	aagaattaaa	ccaagacaaa	ggagcttggc	ctgaaacttc	3780
	cacacagaat	tttagtcaat	gaagaattaa	tctctgttaa	gaagaagtaa	tacgattatt	3840
	tttgccaaaa	atttcacaag	acttatttta	atgacaatgt	agcttgaaag	cgatgaagaa	3900
	tgctctctaga	agagaatgaa	ggattgaaga	attcaccatt	agaggacatt	tagcgtgatg	3960
	aaataaagca	tctacgtcag	caggccatac	tggtgtgggg	caaagggtgtc	ccgtgtagca	4020
	ctcagataag	tatacagcga	caatcctgtt	ttctacaaga	atcctgtcta	gtaaatagga	4080
15	tcattttattg	ggcagttggg	aaatcagctc	tctgtcctgt	tgagtgtttt	cagcagctgc	4140
	tcctaaacca	gtcctcctgc	cagaaaggac	cagtgcctgc	acatcgctgt	ctctgattgt	4200
	ccccggcacc	agcaggcctt	ggggctcact	gaaggctcga	aggcactgca	caccttgtat	4260
	attgtcagtg	aagaacgtta	gttgggtgtc	agtgaacaat	aactttatta	tatgagtttt	4320
20	tgtagcatct	taagaattat	acatatgttt	gaaatattga	aactaagcta	cagtaccagt	4380
	aattagatgt	agaatcttgt	ttgtaggctg	aattttaatc	tgtattttatt	gtctttttgta	4440
	tctcagaaat	tagaaacttg	ctacagactt	acccgtaata	tttgtcaaga	tcatagctga	4500
	ctttaaaaaac	agttgtaata	aactttttga	tgct			4534
	<210> 26						
25	<211> 4660						
	<212> DNA						
	<213> Homo sapiens						
	<400> 26						
30	ggggcttaga	aattaacagg	ttgttttatat	aattggcctt	aaatgaggtg	agagtgaaga	60
	gactagagcc	atctctggaa	aacatcatta	tcccattccc	cgggaaagcta	ccctctggaa	120
	ctcaagatttt	gaccatatct	gttttgagga	ttcattatga	acaaagaagt	ctcccagggtg	180
	tgaagttttt	caacatgagt	ggcctcgggg	acagttcatc	cgacctgctc	aaccagact	240
35	cacataagag	gaaaggatcg	ccatgtgaca	cactggcatc	aagcacggaa	aagaggcgca	300
	gggagcaaga	aaataaatat	ttagaagaac	tagctgagtt	actgtctgcc	aacattagtg	360
	acattgacag	cttgagtgtg	aaaccagaca	aatgcaagat	tttgaagaaa	acagtcgac	420
	agatacagct	aatgaagaga	atggaacaag	agaaatcaac	aactgatgac	gatgtacaga	480
	aatcagacat	ctcatcaagt	agtcaaggag	tgatagaaaa	ggaatccttg	ggaccttttc	540
	ttttggaggc	tttggatgga	ttttcttttg	ttgtgaactg	tgaagggaga	attgtatttg	600
40	tgtcagagaa	tgtaaccagc	tacttaggtt	acaatcagga	ggaattaatg	aataccagcg	660
	tctacagcat	actgcacgtg	ggggatcatg	cagaatttgt	gaagaatctg	ctacccaaat	720
	cactagtaaa	tggagtctct	tggcctcaag	aggcaacacg	acgaaatagc	cataccttta	780
	actgcaggat	gctaattcac	cctccagatg	agccagggac	cgagaaccaa	gaagcttgcc	840
	agcgttatga	agtaatgcag	tgtttcaactg	tgtcacagcc	aaaatcaatt	caagaggatg	900
45	gagaagattt	ccagtcattg	ctgattttgta	ttgcacggcg	attacctcgg	cctccagcta	960
	ttacgggtgt	agaatccttt	atgaccaagc	aagatactac	aggtaaaatc	atctctattg	1020
	atactagttc	cctgagagct	gctggcagaa	ctggttgagg	agattttagt	aggaagtgc	1080
	tttatgcttt	tttccaacct	cagggcagag	aacctcttta	tgccagacag	ctgttccaag	1140
	aagtgatgac	tctgtggcact	gcctccagcc	cctcctatag	attcatattg	aatgatggga	1200
50	caatgcttag	cgccacacac	aagtgtaaac	tttgctaccc	tcaaagtcca	gacatgcaac	1260
	ctttcatcat	gggaattcat	atcatcgaca	gggagcacag	tgggctttct	cctcaagatg	1320
	acactaattc	tggaaatgtca	attccccgag	taaatccctc	ggtcaatcct	agtatctctc	1380
	cagctcatgg	tgtggctcgt	tcatccacat	tgccaccatc	caacagcaac	atggatcca	1440
	ccagaataaa	ccgccagcag	agctcagacc	ttcatagcag	cagtcatagt	aattctagca	1500
55	acagccaagg	aagtttcgga	tgctcaccgc	gaagtcagat	tgtagccaat	gttgccctta	1560
	accaaggaca	ggccagttca	cagagcagta	atccctcttt	aaacctcaat	aattctccta	1620
	tggaaaggtac	aggaattatcc	ctagcacagt	tcatgtctcc	aaggagacag	gttactcttg	1680
	gattggcaac	aaggcccgag	atgccaaaca	attcctttcc	tcctaattat	tcgacattaa	1740
60	gctctcccgt	tggcatgaca	agtagtgctt	gtaataataa	taaccgatct	tattcaaaaca	1800
	tcccagtaac	atcttttacag	ggtatgaatg	aaggacccaa	taactccgtt	ggcttctctg	1860
	ccagttctcc	agtcctcagg	cagatgagct	cacagaattc	acctagcaga	ttaaataatc	1920
	aaccagcaaa	agctgagtc	aaagataaca	aagagattgc	ctcaatttta	aatgaataga	1980
	ttcaatctga	caacagctct	agtgatggca	aacctctgga	ttcagggtct	ctgcataaca	2040
65	atgacagact	ttcagatgga	gacagtaaat	actctcaaac	cagtcacaaa	ctagtgcagc	2100
	ttttgacaac	aactgccgaa	cagcagttac	ggcatgctga	tatagacaca	agctgcaaa	2160
	atgtcctgtc	ttgcacaggc	acttccaact	ctgctctctg	taactcttca	ggaggttctt	2220
	gtccctcttc	tcatagctca	ttgacagaac	ggcataaaat	tctacaccgg	ctcttacagg	2280

	agggtagccc	ctcagatatc	accactttgt	ctgtcagagcc	tgataaaaag	gacagtgcac	2340
	ctactttctgt	gtcagtgact	ggacaggtac	aaggaaactc	cagtataaaa	ctagaactgg	2400
	atgcttcaaa	gaaaaaagaa	tcaaaaagacc	atcagctcct	acgctatctt	ttagataaag	2460
5	atgagaaaga	tttaagatca	actccaaacc	tgagcctgga	tgatgtaaag	gtgaaagtgg	2520
	aaaagaaaga	acagatggat	ccatgtaata	caaaccacac	cccaatgacc	aaacccactc	2580
	ctgaggaat	aaaactggag	gcccagagcc	agttttacagc	tgaccttgac	cagtttgatc	2640
	agttactgcc	cacgctggag	aaggcagcac	agttgccagg	cttatgtgag	acagacagga	2700
	tggatggtgc	ggtcaccagt	gtaaccatca	aatcggagat	cctgccagct	tcacttcagt	2760
	ccgccactgc	cagacccact	tccaggctaa	atagattacc	tgagctggaa	ttggaagcaa	2820
10	ttgataacca	at ttggacaa	ccaggaacag	gcgatcagat	tccatggaca	aataatacag	2880
	tgacagctat	aaatcagagt	aaatcagaag	accagtgtat	tagctcacia	ttagatgagc	2940
	ttctctgtcc	accacaaca	gtagaaggga	gaaatgatga	gaaggctctt	cttgaacagc	3000
	tgggtatcctt	ccttagtgcc	aaagatgaaa	ctgagctagc	tgaactagac	agagctctgg	3060
	gaattgacaa	acttggtcag	gggggtggat	tagatgtatt	atcagagaga	tttccaccac	3120
15	aacaagcaac	gccacctttg	atcatggaag	aaagacccaa	cctttatttc	cagccttact	3180
	cttctccttc	tctactgccc	aatctcccta	gccctttcca	aggcatggtc	aggcaaaaac	3240
	cttcactggg	gacgatgcct	gttcaagtaa	cacctccccg	agggtgctttt	tcacctggca	3300
	tgggcatgca	gcccaggcaa	actctaaca	gacctccggc	tgacacctaac	cagcttcgac	3360
	ttcaactaca	gcagcgatta	cagggacaac	agcagttgat	acacaaaaat	cggcaagcta	3420
20	tcttaaacca	gtttgcagca	actgctcctg	ttggcatcaa	tatgagatca	ggcatgcaac	3480
	agcaaattac	acctcagcca	cccctgaatg	ctcaaagtgt	ggcacaacgt	cagcgggaac	3540
	tgtacagttc	acagcaccga	cagaggcagc	taatacagca	gcaaagagcc	atgcttatga	3600
	ggcagcaaaag	ctttgggaac	aacctccctc	cctcatcttg	actaccagtt	caaatgggga	3660
	acccccgtct	tctcagggt	gctccacagc	aattcccccta	tccaccaaac	tatggtacaa	3720
25	atccaggaac	cccacctgct	tctaccagcc	cgttttcaca	actagcagca	aatcctgaag	3780
	catccttgcc	caaccgcaac	agcatggtga	gcagaggcat	gacaggaaac	ataggaggac	3840
	agtttggcac	tggaaatcaat	cctcagatgc	agcagaatgt	cttcagtat	ccaggagcag	3900
	gaatggttcc	ccaaggtgag	gccaactttg	tctcatctct	aagccctggg	agctccatgg	3960
	tgccgatgcc	aatccctcct	cctcagagtt	ctctgctcca	gcaaactcca	cctgcctccg	4020
30	ggtatcagtc	accagacatg	aaggcctggc	agcaaggagc	gataggaaac	aacaatgtgt	4080
	tcagtcaagc	tgtccagaac	cagcccacgc	ctgcacagcc	aggagtatac	aacaacatga	4140
	gcataccgtg	ttccatggca	ggtggaaata	cgaatgttca	gaacatgaac	ccaatgatgg	4200
	cccagatgca	gatgagctct	ttgcagatgc	caggaaatga	cactgtgtgc	cctgagcaga	4260
	taaatgatcc	cgcactgaga	cacacaggcc	tctactgcaa	ccagctctca	tccactgacc	4320
35	ttctcaaaac	agaagcagat	ggaacccagg	tgcaacaggt	tcaggtgttt	gctgacgtcc	4380
	agtgtacagt	gaatctggta	ggcggggacc	cttacctgaa	ccagcctggt	ccactgggaa	4440
	ctcaaaagcc	cacgtcagga	ccacagacc	cccaggccca	gcagaagagc	ctccttcagc	4500
	agctactgac	tgaataacca	cttttaagg	aatgtgaaat	ttaaataata	gacatacaga	4560
40	gatatacaaa	tatattatat	at ttttctga	gatttttgat	atctcaatct	gcagccattc	4620
	ttcaggtcgt	agcatttggg	gcaaaaaaaa	aaaaaaaaaa			4660

<210> 27

<211> 6773

<212> DNA

45 <213> Homo sapiens

<400> 27

	gcggctggtt	gcgggccggc	ggcgggctgg	cggagatgga	ggatcttgtt	caagatgggg	60
50	tggcttcacc	agctaccctt	gggaccggga	aatctaagaa	ttggagaaag	aaattgaaga	120
	actcagatca	aaacctgtta	ctgaagggaac	tggatgatatt	attaaggcat	taactgaacg	180
	tctggatgct	cttcttctgg	aaaaagcaga	gactgagcaa	cagtgtcttt	ctctgaaaaa	240
	ggaaaatata	aaaatgaagc	aagaggttga	ggattctgta	acaaagatgg	gagatgcaca	300
	taaggagttg	gaacaatcac	atataaacta	tgtgaaagaa	attgaaaatt	tgaaaaatga	360
	gttgatggca	gtacgttcca	aatacagtga	agacaaagct	aacttacaaa	agcagctgga	420
55	agaagcaatg	aatacgcaat	tagaactttc	agaacaactt	aaatttcaga	acaactctga	480
	agataatgtt	aaaaaactac	aagaagagat	tgagaaaatt	aggccaggct	ttgaggagca	540
	aattttatat	ctgcaaaagc	aattagagc	taccactgat	gaaaagaagg	aaacagttac	600
	tcaactccaa	aatatcattg	aggctaattc	tcagcattac	caaaaaata	ttaatagtgtt	660
	gcaggaagag	cttttacagt	tgaaagctat	acaccaagaa	gagggtgaaag	agttgatgtg	720
60	ccagattgaa	gcatcagcta	aggaacatga	agcagagata	aataagttga	acgagctaaa	780
	agagaactta	gtaaaacaat	gtgaggcaag	tgaaaagaac	atccagaaga	aatatgaatg	840
	tgagtttaga	aatttaagga	aagccacctc	aaatgcaaac	caagacaatc	agatatgttc	900
	tattctcttg	caagaaaata	cattttgtaga	acaagttaga	aatgaaaaag	tcaaacactt	960
	agaagatacc	ttaaaagaac	ttgaatctca	acacagtatc	ttaaaagatg	aggtaactta	1020
65	tatgaataat	cttaagttaa	aacttgaaat	ggatgctcaa	catataaagg	atgagttttt	1080
	tcatgaacgg	gaagacttag	agtttaaaat	taatgaatta	ttactagcta	aagaagaaca	1140
	gggctgtgta	attgaaaaat	taaaatctga	gctagcaggt	ttaaataaac	agttttgcta	1200

	tactgtagaa	cagcataaca	gagaagtaca	gagtcttaag	gaacaacatc	aaaaagaaat	1260
	atcagaacta	aatgagacat	ttttgtcaga	ttcagaaaaa	gaaaaattaa	cattaatgtt	1320
	tgaatatcacg	ggtctttaagg	aacagtgtga	aaacctacag	caagaaaaagc	aagaagcaat	1380
	tttaaattat	gagagttttac	gagagattat	ggaaatttta	caaacagaaac	tgggggaatc	1440
5	tgctggaaaa	ataagtcaag	agttcgaatc	aatgaagcaa	cagcaagcat	ctgatgttca	1500
	tgaactgcag	cagaagctca	gaactgcttt	tactgaaaaa	gatgcccttc	tcgaaactgt	1560
	gaatcgctc	cagggagaaa	atgaaaagtt	actatctcaa	caagaattgg	taccagaact	1620
	tgaaaaatacc	ataaagaacc	ttcaagaaaa	gaatggagta	tacttactta	gtctcagtca	1680
	aagagatacc	atgttataaag	aattagaagg	aaagataaat	tctcttactg	aggaaaaaga	1740
10	tgattttata	aataaactga	aaaattccca	tgaagaaatg	gataatttcc	ataagaaatg	1800
	tgaaggggaa	gaaagattga	ttcttgaact	tgggaagaaa	gtagagcaaa	caatccagta	1860
	caacagtga	ctagaacaaa	aggtaaatga	attaacagga	ggactagagg	agacttttaa	1920
	agaaaaggat	caaaaatgacc	aaaaactaga	aaaacttatg	gttcaaataga	aagttctctc	1980
	tgaagacaaa	gaagtattgt	cagctgaagt	gaagtctctt	tatgaggaaa	acaataaact	2040
15	cagttcagaa	aaaaaacagt	tgagtaggga	tttggagggt	tttttgtctc	aaaaagaaga	2100
	tgttatcctt	aaagaacata	ttactcaatt	agaaaagaaa	cttcagttaa	tgggtgaaga	2160
	gcaagataat	ttaaataaac	tgcttgaaaa	tgagcaagtt	cagaagttat	ttgttaaaac	2220
	tcagttgtat	ggttttctta	aagaaatggg	atcagaagtt	tcagaagaca	gtgaagagaa	2280
	agatgttgtt	aatgtcctac	aggcagctcg	tgaatccttg	gcaaaaataa	atgaggaaaa	2340
20	atgcaacctg	gcttttcagc	gtgatgaaaa	agtattagag	ttagaaaaag	agattaaagt	2400
	ccttcaagaa	gagagtgtag	ttcagtgatg	agaacttaag	tctttattga	gagactatga	2460
	gcaagagaaa	gttctcttaa	ggaaagagtt	agaagaaata	cagtcagaaa	aagaggccct	2520
	gcagtcctgat	cttctagaaa	tgaagaatgc	taatgaaaaa	acaaggcttg	aaaatcagaa	2580
	tcttttaatt	caagttgaag	aagtatctca	aacatgtagc	aaaagtgaag	tccataatga	2640
25	aaaagaaaaa	tgttttataa	aggaacatga	aaacctaaag	ccactactag	aacaaaaaga	2700
	attacgagat	aggagagcag	agttgatact	attaaaggat	tccttagcaa	aatcaccttc	2760
	tgtaaaaaat	gatcctctgt	cttcagtaaa	agagttggaa	gaaaaaatag	aaaatctgga	2820
	aaaagaatgc	aaagaaaagg	aggagaaaaa	aaataagata	aaattagttg	ccgtaaaggc	2880
	aaagaaagaa	ctagattcca	gcagaaaaaga	gaccagact	gtgaagggaag	aacttgaatc	2940
30	tcttcgatca	gaaaaggacc	agttatctgc	ttccatgaga	gatctcattc	aaggagcaga	3000
	aagctataag	aatcttttat	tagaatatga	aaagcagtc	gagcaactgg	atgtggaaaa	3060
	agaacgtgct	aataattttg	agcatcgtat	tgaagacctt	acaagacaat	taagaaattc	3120
	gactttgcag	tgtgaaacaa	ttaattctga	taatgaagat	ctcctggctc	gtattgagac	3180
	attacagtct	aatgccaaat	tattagaagt	acagatttta	gaagtccaga	gagccaaagc	3240
35	aatggtagac	aaagaattag	aagctgaaaa	acttcagaaa	gaacagaaga	taaaggaaca	3300
	tgccactact	gtaaatgaac	ttgaagaact	tcaggtacaa	cttcaaaaag	aaaagaaaca	3360
	gcttcagaaa	accatgcaag	aattagagct	ggttaaaaaa	gatgcccaac	aaaccacatt	3420
	gtgaattatg	gaaatgactg	attatgaacg	tttgatgaaa	gaactaaatc	aaaagttaac	3480
	taataaaaaac	aacaagatag	aagatttgg	gcaagaaata	aaaattcaaa	aacagaaaca	3540
40	agaaacccta	caagaagaaa	taacttcatt	acagtcttca	gtacaacaat	atgaagaaaa	3600
	aaacacccaa	atcaagcaat	tgcttgtgaa	aaccaaaaag	gaactggcag	attcaaagca	3660
	agcagaaact	gatcacttaa	tacttcaagc	atcttttaaa	ggtgagctgg	aggcaagcca	3720
	gcagcaagta	gaagtctata	aaatacagct	ggctgaaata	acatcagaga	agcacaatat	3780
	ccacgagcac	ctgaaaacct	ctgcggaaca	gcaccagcgt	acgctaagtg	cataccagca	3840
45	gagagtgcac	gcactacagg	aagagtgcg	tgctgccaa	gcagaaaca	ctactgtaac	3900
	ctctgaattc	gagagctaca	aagtcagagt	tcataatgtt	ctaaaacaac	agaaaaataa	3960
	atctatgtct	caggctgaaa	ctgagggcgc	taaacagaag	agggaaacatc	tggaaatgct	4020
	gattgaccag	ctaaaaaatc	aattacaaga	tagccaaaat	aacttacaga	ttaatgtatc	4080
	tgaacttcaa	acattgcagt	ctgaacatga	tacactgcta	gaaaggcaca	acaagatgct	4140
50	gcaggaaaact	gtgtccaaag	aggcggaact	ccgggaaaaa	ttgtgttcaa	tacagtcaga	4200
	gaacatgatg	atgaaatctg	aacatacaca	gactgtgagt	cagctaacat	cccagaacga	4260
	ggtccttcga	aatagcttcc	gagatcaagt	gcgacatttg	caggaagaac	acagaaagac	4320
	agtgagagaca	ttacagcagc	agctctccaa	gatggaaagc	cagctcttcc	agcttaagaa	4380
	tgaaccgacc	acaagaagcc	cagtttcttc	tcaaaactct	ttgaagaacc	ttcgagaaag	4440
55	gagaaacaca	gacctcccg	ttctagacat	gcacactgta	acccgggaag	agggagaagg	4500
	catggagaca	actgatacgg	agtctgtgtc	ttccgccagc	acatacacac	agtctttaga	4560
	cagctgctt	aactctccc	aaactaaact	tgagcctcca	ttatggcatg	ctgaattttac	4620
	caaagaagaa	ttggttcaga	agctcagttc	caccacaaaa	agtgagatc	acttaaacgg	4680
	cctgcttcgg	gaaacagaag	caaccaatgc	aattcttatg	gagcaaatga	agcttctcaa	4740
60	aagtgaataa	agaagattgg	aaaggaatca	agagcgagag	aagtctgcag	ctaacttgga	4800
	atacttgaag	aacgtcttgc	tgcagttcat	tttcttgaaa	ccaggtagtg	aaagagagag	4860
	acttcttctt	gttataaata	cgatgttgca	gctcagcctc	gaagaaaaag	gaaaacttgc	4920
	tgcggttgct	caaggtgagg	aagaaaaatgc	ttcccgctct	tctggatggg	catcctatct	4980
	tcatagttgg	tctggacttc	gataggttga	tggaaaggaat	atttttatta	accaaataga	5040
65	atctattttac	aaaaatggtt	cacgtatatt	accacaattc	ttttgtcaaa	aagtgtgtat	5100
	atatgtttgc	atctacatat	atttgtacat	ctatatgaca	gatgtatttt	aaaagtttca	5160
	tcttgaagta	aaagtacaac	agcttgaagt	ggttagtagca	ggccacagcc	ctctaactca	5220

	tgtgatttcc	catgcatgct	gccagaataa	aaccaccagg	aatgaattca	ctccccactt	5280
	ctctggaacc	tcaggaccgc	cccattttct	ggcagtagct	tgaattttga	agttaaacta	5340
	aattttggta	ccataccaac	tggaaattag	gctttaaaaa	taatgtttca	aggccagggtg	5400
	tgggtgattca	tgcctgaaat	cccactactt	tgggaggctg	aggctggaga	attgcttgag	5460
5	gctagtgage	tgtgactccc	actgcactcc	agctcgggga	acagagcgag	acctgtctc	5520
	taaaaataat	agtaataaaa	taaaaataac	gttttatgac	tatttattgc	aaggtcagag	5580
	ttacagattg	ttataaattg	ttgagaaatt	tttgtgatta	gaatatgaag	gaaaaagctt	5640
	tgttggtaaa	agtgcacatg	taaggggcta	tgaagtaaat	atgctgcagt	taattgtgct	5700
	aagttaaaat	acagtttagt	tatttgcttt	aaaataaact	cttctttttt	tctttaaagt	5760
10	atactatctc	aaaactcatt	atgttgctag	agccctagag	ctggctagtg	taacactgac	5820
	tatgagttag	tgggcccacc	acttgagttg	agggtgattc	atgggtgtct	tccaggctct	5880
	tgatagggtg	tcactgcctg	caagccatga	atctgttttg	agaatcctct	ccattttccc	5940
	aaataaaaaac	ctatcacaac	agtgcactata	tcactcagca	ttggatctaa	atataaaaagt	6000
	ggtgctttca	gtgttttttg	cagatagtgt	tccataagct	ttccatcaga	agggtattta	6060
15	gacaccttag	aggctcgtgc	tacatcgtca	cagttcctcc	gaataacctt	agggtgtagt	6120
	gttacttgcc	tttgacacct	ctgcatatgt	tttaatgact	agatccaaac	tgtgttgttc	6180
	ttaaatcaaaa	aattggataa	tttgtaatat	ttatgtgtta	atcacacagt	atgctctctg	6240
	aagtctctct	aagccttcag	tttatactct	taatttaatt	ttctttctga	gctggagaac	6300
	tggctttgca	ctttggttac	acagaacatt	ggtttccaat	tcagtttaac	tgaattttgc	6360
20	tgctgatatg	ttgagtttgt	tctttaaaaa	atagctcata	tatctcatct	ttcctcctgt	6420
	cttagaagaa	cagacctaac	tagtgaatgt	attaatgaaa	atgcatctat	ttcagagctg	6480
	acatgaagag	tttagttttt	ttactttata	aactgtgaat	atgagtatgc	cagctgcata	6540
	cgatgtaact	aatcatattt	aaatatattt	cactttctct	ttgacttttag	accttttgaa	6600
	gtctgtataa	acttgttttg	aaatatagtc	tctgcttacg	aatgtcataa	caaaataatt	6660
25	ttttgcatga	taaaaaatta	ctttgattac	aaaaggcgta	ttctttcatg	gtttctgcaa	6720
	tgagaggaag	tgtaatgatt	attttaatat	ttctattaaa	tatgtttaac	tgt	6773
30	<210> 28						
	<211> 2619						
	<212> DNA						
	<213> Homo sapiens						
35	<400> 28						
	atggccacag	cttgtaaaaag	atcaggagaa	cctcagttctg	acgacattga	agctagccga	60
	atgaagcgag	cagctgcaaa	gcatctaata	gaacgctact	accaccagtt	aactgagggc	120
	tgtggaaatg	aagcctgcac	gaatgagttt	tgtgcttctt	gtccaaacttt	tcttcgtatg	180
	gataataatg	cagcagctat	taaagccctc	gagctttata	agattaatgc	aaaactctgt	240
40	gatcctcatc	cctccaagaa	aggagcaagc	tcagcttacc	ttgagaactc	gaaaggtgcc	300
	cccaacaact	cctgctctga	gataaaaaatg	aacaagaaag	gcgctagaat	tgatttttaa	360
	gatgtgactt	acttaacaga	agagaaggta	tatgaaattc	ttgaattatg	tagagaaaga	420
	gaggattatt	cccctttaat	ccgtgttatt	ggaagagttt	tttctagtgc	tgaggcattg	480
	gtacagagct	tccggaagt	taacaacac	accaaggaag	aactgaaatc	tcttcaagca	540
45	aaagatgaag	acaaagatga	agatgaaaag	gaaaaagctg	catgtttctg	tgctgctatg	600
	gaagaagact	cagaagcatc	ttcctcaagg	ataggtgata	gtcacagggt	agacaacaat	660
	ttgcaaaaat	taggcctga	tgtatgtgtc	gtggatattg	atgccattag	aagggtctac	720
	accagattgc	tctctaata	aaaaattgaa	actgcctttc	tcaatgcact	tgtatatttg	780
	tcacctaacg	tggaaatgtg	cttgacgtat	cacaatgtat	actctcgaga	tcctaattat	840
50	ctgaattttg	tcattatcgg	aatggagaat	agaaatctcc	acagtcctga	atatctggaa	900
	atggctttgc	cattattttg	caaagcgatg	agcaagctac	cccttgccgc	ccaaggaana	960
	ctgatcagac	tgtggtctaa	atacaatgca	gaccagattc	ggagaatgat	ggagacattt	1020
	cagcaactta	ttactttata	agtcataagc	aatgaattta	acagtcgaaa	tctagtgaat	1080
	gatgatgatg	ccattgttgc	tgtctcgaag	tgtttgaaaa	tggtttacta	tgcaaatgta	1140
55	gtgggagggg	aagtggacac	aaatcacaaat	gaagaagatg	atgaagagcc	catccctgag	1200
	tccagcgagc	tgacactttc	ggaacttttg	ggagaagaaa	gaagaaacaa	gaaaggtcct	1260
	cgagtggacc	ccctggaaac	tgaacttggt	gttaaaaccc	tggattgtcg	aaaaccactt	1320
	atcccttttg	aagagtttat	taatgaacca	ctgaatgagg	ttctagaaat	ggataaagat	1380
	tatacttttt	tcaaagtaga	aacagagaa	aaattctctt	ttatgacatg	tccctttata	1440
60	ttgaatgctg	tcacaaagaa	tttgggatta	tattatgaca	atagaattcg	catgtacagt	1500
	gaacgaagaa	tcactgttct	ctacagctta	gttcaaggac	agcagttgaa	tccatatttg	1560
	agactcaaa	ttagacgtg	ccatatcata	gatgatgcac	ttgtccggct	agagatgatc	1620
	gctatggaaa	atcctgcaga	cttgaagaag	cagttgtatg	tggaaattga	aggagaacaa	1680
	ggagttgatg	agggaggtgt	ttccaaagaa	ttttttcagc	tggttgtgga	ggaaatcttc	1740
65	aatccagata	ttggtatgtt	cacatacgat	gaatctacaa	aattgttttg	gtttaatcca	1800
	tcttcttttg	aaactgaggg	tcagtttact	ctgattggca	tagtactggg	tctggctatt	1860
	tacaataact	gtatactgga	tgtacatttt	cccatggttg	tctacaggaa	gctaattggg	1920

	aaaaaaggaa	cttttcgtga	cttgggagac	tctcaccag	ttctatatca	gagtttaaaa	1980
	gatttattgg	agtatgaagg	gaatgtggaa	gatgacatga	tgatcacttt	ccagatatca	2040
	cagacagatc	tttttggtaa	cccaatgatg	tatgatctaa	aggaaaatgg	tgataaaatt	2100
5	ccaattacaa	atgaaaacag	gaaggaatgt	gtcaatcttt	attctgacta	cattctcaat	2160
	aaatcagtag	aaaaacagtt	caaggctttt	cggagaggtt	ttcatatggt	gaccaatgaa	2220
	tctcccttaa	agtacttatt	cagaccagaa	gaaattgaat	tgcttatatg	tggaagccgg	2280
	aatctagatt	tccaagcact	agaagaaact	acagaatatg	acggtggcta	taccagggac	2340
	tctgttctga	ttaggggagtt	ctgggaaatc	gttcattcat	ttacagatga	acagaaaaga	2400
10	ctcttcttgc	agttttacaac	gggcacagac	agagcacctg	tgggaggact	aggaaaatta	2460
	aagatgatta	tagccaaaaa	tggcccagac	acagaaaggt	tacctacatc	tcatacttgc	2520
	tttaatgtgc	ttttacttcc	ggaatactca	agcaaaagaa	aacttaaaga	gagattgttg	2580
	aaggccatca	cgtatgccaa	aggatttggc	atgctgtaa			2619
	<210> 29						
15	<211> 4263						
	<212> DNA						
	<213> Homo sapiens						
	<400> 29						
20	ggccgttccc	ctctcctcag	cagtagctct	atggtttcag	ggcggcaacg	tgcagcgtcc	60
	ttaccttgag	cctgtgcagt	tgccctcacc	ccggaatcca	tagtcaactgt	gacgagggcg	120
	gaggacttgg	gcgacaggtg	gcctcccagt	cccacacgct	gcgggtccgc	gcctggccaa	180
	gccacctcga	cctgtgaagt	tggggcggtg	accagcaac	tccccctgtg	cagccgccgt	240
25	ttccaagggg	tcaggaaccg	ctgtgtttgt	ttcgctccgc	tagccagggc	gggtccggga	300
	gtactgtgcc	tgacccgacg	gtggcaagtc	tgacgcgtca	gccagagacc	ggtgccgggt	360
	gtaggagtgc	cagcctgggc	tgtgagcggc	tgctgggtag	acagacttgc	tttctcttac	420
	agcatgtcat	ttccaaaatg	catcgtgggt	cttctgcctt	aagtcctata	ggaagacact	480
	gccgccacta	gaccgggtgt	tatggtcgcc	actgttattc	tgactcaggt	cccgtgtcat	540
30	tgagcatatg	tatgaaaatg	ccttagggagg	gaaccatgga	gaagtatgtg	agactgcaga	600
	agattggaga	aggttcattt	ggaaaagctg	ttcttgttaa	atcgacagag	gatggcagac	660
	attatgtcat	caaggaaatt	aacatctcaa	gaatgtctga	taaagaaagg	caagaatcaa	720
	ggagagaagt	tgctgtattg	gcaaaccatga	agcatccaaa	tattgtccaa	tataaagaat	780
	catttgaaga	aaatggctct	ctctacatag	taattggatta	ctgtgaagga	ggtgatttgt	840
35	ttaaacgaat	aaatgctcag	aaaggcgctc	tgtttcaaga	agaccagatt	ttggactggg	900
	ttgtgcagat	atgtttggct	ctgaagcatg	tacatgatag	aaaaattctt	caccgagaca	960
	taaagtcaga	gaacatatat	ctaaccaaaag	atgggacagt	gcagcttggg	gattttggaa	1020
	ttgctcgagt	tcttaatagt	actgtagagc	tggctcgaac	ttgcataggg	actccatact	1080
	acttgtcacc	tgaaatctgt	gaaaacaagc	cttataacaa	taaaagtgc	atttgggctt	1140
40	tgggctgtgt	cctttatgag	ttgtgtacac	ttaaacatgc	atttgaagct	ggaacatga	1200
	aaaacctggt	actgaagata	atctccggat	cctttcctcc	agtgtctcca	cattactcct	1260
	atgatctccg	cagcttgcgt	tctcagttat	ttaaaagaaa	tcctagggat	agaccatcag	1320
	tcaactccat	attggagaaa	ggttttatag	ctaaacgaat	cgaaaagttt	ctctccccctc	1380
	agcttattgc	agaagaattt	tgtctaaaaa	cactttcaaa	gtttggacca	cagcctctcc	1440
45	caggtaaaag	accagcatca	ggacaagggtg	tcagttcttt	tgtccctgct	cagaaaatca	1500
	caaagcctgc	tgctaaatac	ggagtgcctt	taacatataa	gaagtatgga	gataaaaagt	1560
	tacttgagaa	aaaaccaccc	ccaaaacata	aacaggccca	tcaaattccc	gtgaagaaaa	1620
	tgaattctgg	agaagaaaag	aagaaaatgt	ctgaggaagc	agcaaaaaaa	agaaggttgg	1680
	aatttattga	gaaagaaaag	aagcaaaaag	atcagattag	gttcctgaag	gctgagcaga	1740
50	tgaagcggca	agagaagcag	cgggttgaga	ggataaatag	ggccagggga	caaggatgga	1800
	ggaatgtttt	aagggtggtg	ggaagcgggtg	aagtaaaggc	ttcctttttt	ggcattggag	1860
	gggctgtctc	tccatcaccg	tgttctcctc	gaggccagta	tgaacattac	catgccattt	1920
	ttgaccaaatt	gcagcggcta	agagcagaag	ataatgaagc	aagatggaag	gggggaatct	1980
	atggctcgatg	gctcccagaa	aggcaaaaag	gacacttagc	tgtagagaga	gccaaaccaag	2040
55	tggaagaatt	cctacagcgt	aaacgagaag	ctatgcagaa	taaagcccga	gccgaaggac	2100
	acgtgggttta	tttggcaaga	ctgaggcaaaa	taagactaca	aaattttaat	gagcgccaac	2160
	agattaaagc	caaacttcgt	ggtgagaata	aagaagctga	tggtaccaaa	ggacaagaag	2220
	caactgaaga	gactgacatg	aggctcaaaa	agatggagtc	acttaaggcg	caaaaaatg	2280
	cacgtgctgc	tgtactaaaa	gaacagctgg	agcgaaaaag	aaaggaagct	tatgaaagag	2340
60	aaaagaaagt	atgggaagaa	catttggtgg	cgagggtaaa	aagctcagat	gttcctctgc	2400
	ctttggaact	tcttgaaaca	ggtggttctc	catcaaagca	gcaggtgaag	cctgtcattt	2460
	ctgtgacttc	agctttgaaa	gaagtgggcc	tggatggaag	tttaactgat	acccaggaag	2520
	aagaaatgga	aaagagtaac	agtgtatttt	caagtaagcg	agaaatcctg	cgtaggctaa	2580
	atgaaaatct	taaagctcaa	gaggatgaaa	aggaaaaagca	gcatcactca	ggttcttgtg	2640
65	agaccgttgg	tcacaaagat	gagagagagt	atgagacaga	aaatgccatt	tcctctgctc	2700
	gcaagaagtg	ggagatggga	ggtcagcttg	tgattcctct	cgatgcagtg	acactggata	2760
	catccttctc	tgcaaccgaa	aaacatactg	tgggagaggt	tattaaatta	gattctaattg	2820
	gctctccaag	aaaagtctgg	gggaaaaacc	ctacagattc	tgtgctgaag	atacttggag	2880

	aagctgaatt	acagctatag	acagaactac	tagaaaaacac	atctttttaa	agtgaagttt	2940
	atgctgaaga	ggagaactac	aaacccttac	ttactgaaga	agagaatctg	cagtgcattt	3000
	caaaagaaat	aaatccatca	gctactgttg	attctactga	aacgaaaagt	ccaaagttta	3060
5	ctgaggtgtc	tccacaaatg	tcagaaggaa	atgtggaaga	acctgatgat	ttggaacacg	3120
	aagttctaca	agagccaagt	agcacacaca	cagatgggag	tttgccacct	gttcttaatg	3180
	atgtgtggac	tagagagaag	gaagcagcta	aggaaactga	gttggaagat	aaggttgctg	3240
	tgcagcagag	tgaagtttgt	gaagatagaa	ttccagggaa	cgtggaccaa	tcctgtaagg	3300
	atcagagaga	tcctgcagta	gacgattctc	cgcagtctgg	ctgtgatgta	gagaagtcag	3360
10	tacagccaga	atcgattttc	cagaaagtgg	ttcattctaa	ggacttgaac	ttagttcagg	3420
	cagttcattg	ctcaccagaa	gaaccaattc	caattcgatc	tcactctgat	tctccaccaa	3480
	aaactaagag	caagaattcc	ttactgattg	gactttcaac	tggctctgtt	gatgcaaaca	3540
	atccaaagat	gctgaggacc	tgctcacttc	cagatcttcc	caagctgttc	agaaccctaa	3600
	tggacgttcc	cactgtgggg	gacgttcata	aagacagtct	tgaaatcgat	gagctggaag	3660
15	atgaaccaat	taaagaaggg	ccttctgatt	ccgaagacac	tgtatttgaa	gaaactgaca	3720
	cagattttaca	agagcttcag	gcctcaatgg	agcagctgct	tagggagcaa	ccaggtgacg	3780
	aatacagtga	ggaggaagag	tctgttttaa	aaagcagcga	tgtggagcag	acagcaagag	3840
	ggacagatgc	cccagacgag	gaggacaacc	ccagcagcga	aagccccga	acgaggaatg	3900
	gcactcagat	aatagtgcag	ctgagaccac	tagtgaatgt	gaatatgaca	gtgtctttaa	3960
20	ccattttagag	gaactaagac	ttcacttgga	gcaagaaatg	ggctttgaaa	agttctttga	4020
	ggttttatgag	aaagtaaagg	ctattcatga	ggatgaagat	gaaaatattg	aaatttgctc	4080
	aacaatagtt	gagaatattt	tgggcaatga	gcaccagcat	ctctatgcca	agattctgca	4140
	tttagtcctg	gcatcaggag	ctatcaggga	agataatgat	gaataatcct	caggacattc	4200
	tttaatagtc	aactgtaaga	acacatttga	acttggtcca	taatacaagc	ttctctgggaa	4260
25	ata						4263
	<210> 30						
	<211> 1756						
	<212> DNA						
	<213> Homo sapiens						
30	<400> 30						
	tcgggagcag	ccgcgaagat	gccgttgga	ctgacgcaga	gccgagtgca	gaagatctgg	60
	gtgcccgtgg	accacaggcc	ctcgttgccc	agatcctgtg	ggccaaagct	gaccaactcc	120
35	cccaccgtca	tcgtcatggt	gggcctcccc	gcccggggca	agacctacat	ctccaagaag	180
	ctgactcgtc	acctcaactg	gattggcgct	cccacaaaag	tgttcaacgt	cggggagtat	240
	cgccgggag	ctgtgaagca	gtacagctcc	tacaacttct	tccgccccga	caatgaggaa	300
	gccatgaaag	tccggaagca	atgtgcctta	gctgccttga	gagatgtcaa	aagctacctg	360
	gcgaaagaag	ggggacaaat	tgcggttttc	gatgccacca	atactactag	agagaggaga	420
40	cacatgatcc	ttcattttgc	caaagaaaat	gactttaaag	cgtttttcat	cgagtcggtg	480
	tgcgacgacc	ctacagttgt	ggcctccaat	atcatggaag	ttaaaatctc	cagcccggat	540
	tacaaagact	gcaactcggc	agaagccatg	gacgacttca	tgaagaggat	cagtttgctat	600
	gaagccagct	accagccctc	cgaccccgac	aaatgcgaca	gggacttgct	gctgatcaag	660
	gtgattgacg	tgggcccggg	gttcctgggt	aaccgggtgc	aggaccacat	ccagagccgc	720
45	atcgtgtact	acctgatgaa	catccacgtg	cagccgcgta	ccatctacct	gtgccggcac	780
	ggcgagaacg	agcacaacct	ccagggccgc	atcggggggc	actcaggcct	gtccagccgc	840
	ggcaagaagt	ttgccagtgc	tctgagcaag	ttcgtggagg	agcagaacct	gaaggacctg	900
	cgctgttgga	ccagccagct	gaagagcacc	atccagacgg	ccgaggcgct	gcggctgccc	960
	tacgagcagt	ggaaggcgct	caatgagatc	gacgcgggcg	tctgtgagga	gctgacctac	1020
50	gaggagatca	gggacacct	ccctgaggag	tatgcgctgc	gggagcagga	caagtactat	1080
	taccgctacc	ccaccgggga	gtcctaccag	gacctggctc	agcgcttgga	gccagtgatc	1140
	atggagctgg	agcggcagga	gaatgtgctg	gtcatctgcc	accaggccgt	cctgcgctgc	1200
	ctgcttgctc	acttccctga	taagagtgcg	gaggagatgc	cctacctgaa	atgccctctt	1260
	cacaccgtcc	tgaactgac	gcctgtcgct	tatggctgcc	gtgtggaatc	catctacctg	1320
55	aacgtggagt	ccgtctgcac	acaccgggag	aggtcagagg	atgcaaagaa	gggacctaac	1380
	cgctcatga	gacgcaatag	tgtcaccctc	ctagccagcc	ccgaacccac	caaaaagcct	1440
	cgcatcaaca	gctttgagga	gcatgtggcc	tccacctcgg	ccgccctgcc	cagctgcctg	1500
	ccccgggagg	tgcctcagca	gctgocctga	caaaacatga	aaggctcccg	gagcagcgct	1560
	gactcctcca	ggaaacactg	aggcagacgt	gtcggttcca	ttccatttcc	atttctcgag	1620
60	cttagcttgt	gtcctgcctc	ccgcccaggg	caaaacgtat	cctgaggact	tcttccggag	1680
	aggggtgggt	ggagcagcgg	gggagccttg	gccgaagaga	accatgcttg	gcaccgtctg	1740
	tgtccctctg	gocgct					1756
	<210> 31						
	<211> 1661						
65	<212> DNA						
	<213> Homo sapiens						

<400> 31

	tgctgcagcc	gctgccgccc	attccggatc	tcattgccac	gcgcccccca	cgaccgccc	60
	acgtgcattc	ccgattccctt	ttggttccaa	gtccaatatg	gcaactctaa	aggatcagct	120
5	gatttataat	cttctaaagg	aagaacagac	cccccagaat	aagattacag	ttgttgggg	180
	tggtgctgtt	ggcatggcct	gtgccatcag	tatcttaatg	aaggacttgg	cagatgaact	240
	tgctcttggt	gatgtcatcg	aagacaaatt	gaagggagag	atgatggatc	tccaacatgg	300
	cagccttttc	cttagaacac	caaagattgt	ctctggcaaa	gactataatg	taactgcaaa	360
	ctccaagctg	gtcattatca	cggctggggc	acgtcagcaa	gagggagaaa	gccgtcttaa	420
10	tttgggtccag	cgtaacgtga	acatatttaa	attcatcatt	cctaattgtt	taaaatacag	480
	cccgaactgc	aagttgctta	ttgtttcaaa	tccagtggat	atcttgacct	acgtggcttg	540
	gaagataagt	ggttttccca	aaaaccgtgt	tattggaagt	ggttgcaatc	tggattcagc	600
	ccgattccgt	tacctgatgg	gggaaaaggct	gggagttcac	ccattaagct	gtcatgggtg	660
	ggctcttggg	gaacatggag	attccagtgt	gcctgtatgg	agtggaatga	atgttgctgg	720
	tgtctctctg	aagactctgc	accagatttt	agggactgat	aaagataagg	aacagtggaa	780
15	agaggttcac	aagcagggtg	ttgagagtgc	ttatgagggt	atcaaactca	aaggctacac	840
	atcctgggct	attggactct	ctgtagcaga	tttggcagag	agtataatga	agaatcttag	900
	cggggtgcac	ccagtttcca	ccatgattaa	gggtctttac	ggaataaagg	atgatgtctt	960
	ccttagtggt	ccttgcatct	tgggacagaa	tggaaatctc	gaccttggtg	agtgactctt	1020
	gacttctgag	gaagaggccc	gtttgaagaa	gagtgcagat	acactttggg	ggatccaaaa	1080
20	ggagctgcaa	ttttaaaagtc	ttctgatgtc	atatcatttc	actgtctagg	ctacaacagg	1140
	attctaggtg	gaggttggtc	atgttgctct	ttttatctga	tctgtgatta	aagcagtaat	1200
	attttaagat	ggactgggaa	aaacatcaac	tctgaaagt	gaaataaaga	atggtttgta	1260
	aaatccacag	ctatatcctg	atgctggatg	gtattaatct	tgtgtagtct	tcaactggtt	1320
	agtgtgaaat	agtcttgcca	cctctgacgc	accactgcca	atgctgtacg	tactgcattt	1380
25	gccccctgag	ccagggtggat	gtttaccgtg	tgttatataa	cttcctggct	ccttcaactga	1440
	acatgcctag	tccaacattt	tttcccagtg	agtcacatcc	tgggatccag	tgtataaatc	1500
	caatatcatg	tcttgtgcat	aattcttcca	aaggatctta	ttttgtgaac	tatatcagta	1560
	gtgtacatta	ccatataaat	taaaaagatc	tacatacaaa	caatgcaacc	aactatccaa	1620
30	gtgttatacc	aactaaaacc	cccaataaac	cttgaacagt	g		1661

<210> 32

<211> 4169

<212> DNA

<213> Homo sapiens

<400> 32

	ggcggtcttc	aggtggggcg	gcaaggccgt	ggctcctgctt	tgtgcctctg	acctgctgct	60
	gctgctgcta	ctgctaccac	cgcttgggtc	ctgcggggcc	gaaggctcgc	ccgggacgcc	120
40	cgacagagtct	acccacacct	cccggagaa	gaagaaggat	attcgcgatt	acaatgatgc	180
	agacatggcg	cgtcttcttg	agcaatggga	gaaagatgat	gacattgaag	aaggagatct	240
	tccagagcac	aagagacctt	cagcacctgt	cgacttctca	aagatagacc	caagcaagcc	300
	tgaagcata	ttgaaaatga	cgaaaaaagg	gaagactctc	atgatgtttg	tcactgtatc	360
	aggaagccct	actgagaagg	agacagagga	aattacgagc	ctctggcagg	gcagcctttt	420
45	caatgccaac	tatgacgtcc	agagggtcat	tgtgggatca	gaccgtgcta	tcttcatgct	480
	tcgcgatggg	agctacgcct	gggagatcaa	ggactttttg	gtcgggtcaag	acagggtgtg	540
	tgatgtaact	ctggagggcc	aggtgtaccc	cggcaaagga	ggaggaagca	aagagaaaaa	600
	taaaacaaag	caagacaagg	gcaaaaaaaa	gaaggaaagg	gatctgaaat	ctcggctctt	660
	caaggaagaa	aatcgagctg	ggaataaaag	agaagacctg	tgatggggca	gcagtgcgc	720
	gctgtggggg	gacaggtgga	cgtggagagc	tctttgcccc	gctcctgggg	tgggagtgg	780
50	ctcaggcaac	tgcacaccgg	atgacattct	agtgtcttct	agaaagggtc	tgccacatga	840
	ccagtttgtg	gtcaaagaat	tactgcttaa	taggcttcaa	gtaagaagac	agatgttttc	900
	taattaatac	tggacactga	caaattcatg	tttactataa	aatctcctta	catggaaatg	960
	tgactgtgtt	gctttttccc	atttacactt	ggtgagtcat	caactctact	gagattccac	1020
	tcccccccaa	gcaoctgctg	tgattgggtg	gcctgctctg	atcagatagc	aaattctgat	1080
55	caagagaagac	tttaaaactc	ttgacttaat	tgagtaaact	cttcatgcca	tatacatcat	1140
	tttcattatg	ttaaaggtaa	aatatgcttt	gtgaactcag	atgtctgtag	ccaggaagcc	1200
	aggggtgtgta	aatccaaaat	ctatgcagga	aatgcggaga	atagaaaata	tgtcacttga	1260
	aatcctaagt	agttttgaat	ttctttgact	tgaatcttac	tcatcagtaa	gagaactctt	1320
	gggtgtctgtc	aggttttatg	tgggtctgtaa	agttaggggt	tctgttttgt	ttccttattt	1380
60	aggaaagagt	actgctgggtg	tgcagggggt	atatgtttcca	tttaatgtga	cagtttttaa	1440
	ggatttaagt	agggaaatcag	agtcctttgc	agaggtgtgac	agacgactca	ataacctcat	1500
	ttgtttctaa	acatttttct	ttgataaagt	gcctaaatct	gtgctttcgt	atagagtaac	1560
	atgatgtgct	actgttgatg	tctgattttg	ccgttcatgt	tagagcctac	tgtgaataag	1620
	agttagaaca	tttatataca	gatgtcattt	ctaagaacta	aaattctttg	ggaaaaaccc	1680
65	tcaattgtga	ttttaataaa	ttaaaagtga	cacattacat	ggttagaaaa	tgtcagtgtt	1740
	aaagaatggg	acaaagtga	aagtgtatcc	ctctcttgcc	gccgggtgga	gcttgtccca	1800
	gtggaagctg	ctgttaacaa	tttgtgcccc	cacatcccc	tccctgcccc	tccacccaaa	1860

	aaaagtacat	ttactttatgt	aaatgtactt	atggtgatgt	atgtttgttt	tggcctcaca	1920
	gcatctgttt	cccttaatt	tggtagctgc	tcacatttcc	ctcgaaagaa	ccacaccctc	1980
	tgcattctca	gttctttgct	ttggatggga	catttgccct	gcagtcccc	caccctccag	2040
5	gccatgccct	ctccagggtg	aggcctgtgt	gatctaccgt	actagggtac	taggcccctga	2100
	aagaggcttt	tcttgttccct	cctgcacatt	gaacctggag	cgggagctgt	tgtaggcccc	2160
	gcccttggag	aagagaactg	tctgacagtg	gggagagagc	gccacaccct	ggtggcataa	2220
	acgagtcctt	gaatcatgcc	gtggctgaac	caagccctgt	ctgtgggctt	tttctgttgt	2280
	actcaggcca	gtttgatggg	gttactgtcc	tgcatagcc	taatggccca	gtataaagca	2340
10	gctgttttga	tgagataatt	gctttaatta	agcaaaagg	agcaaaagctt	tcactccgcc	2400
	ctgtaccttc	tgtttccact	taggagcctt	cccatgtcag	aatgtgcaga	tctgtctcat	2460
	tgtttccctgt	gcagtgtgcc	cccacttcac	ccagtagttt	ctgtgtgtct	gttatgtact	2520
	aggctactaca	agggtgccagg	acgggtgtaga	tacagcctct	gctatcgtaa	aactcaatga	2580
	ttcgggtggg	gaagacaaat	gtcagtaattg	tacaaagtaa	aatggcagct	gttagaagta	2640
15	tgaaaggggc	agggtagggg	gaggtagaat	cttccctgac	caggttaaga	aaaccagagg	2700
	ccttctctga	gggcaagagg	aggagaggag	aaatagagta	aggcaggcag	aggaaacagt	2760
	ctgagctaag	accctgtggc	tagaagtggc	agagggagag	gcagcaggaa	ggccagcggg	2820
	gaggctgggg	cccagtgagc	gcccagggtg	gaggagcgta	gcacatggag	tttggttagga	2880
	gtttgggacg	ccctgggtga	tcttaattgt	gatgggggtg	gtgtgaaagg	cagtccaggt	2940
20	tgactgggtt	gcacaggaga	agtgatcaga	agaggacccc	agcaggtgtg	agccgtgagc	3000
	tgggaggtgc	ttcagtagtg	caggccatag	ctgaagggtg	cctacatcag	cagggtgatg	3060
	gtgaggtttg	aaccactgtt	tcactgcata	gtccctgctg	atggacactt	gagtgttcag	3120
	attttttgct	ggtatattca	gtgctgcagt	ggacattttc	atacaaaata	tttcgggtaca	3180
	cttttgttta	tatctgaaag	gtaaaattcct	agcagtagaa	ttattagagc	aaacggaatt	3240
25	taacattttg	gtgtgtattg	ccaaattgcc	ctcccaagtg	gtttagtcag	cttacccttg	3300
	ccaacaatag	atctatcctt	gccagccttg	ggcatcacat	ttaccagttt	aatagattgt	3360
	aaaaccatag	cttaattggc	taccctgaag	ccaccatact	ggagaggctg	cgtacagtgt	3420
	ttcacgtaga	gagagggata	cccaggaggc	ccacctgtct	caacccccagc	tgcattgagtc	3480
	ttcccagccc	aggcacagac	atgtggataa	gatttaaaca	tttccagccc	cagccttcaa	3540
30	gcaatcctag	ttgacactga	ggggagccaa	cataagctga	gctgagaaac	agtctgccca	3600
	gtctgcagat	tcatgagcaa	aagaaatgtt	gggctgggta	cagtggctca	cgctgtaat	3660
	cccagtactt	tgggaggccg	agggtgggtg	atcagtttag	gtcaggagtt	tgagaccagc	3720
	ctggccaaca	tgttgaagcc	ctgtctctac	taaaaattag	ccgagtgtgg	tgggtgcgggc	3780
	ctgtaatccc	agctactcag	gtggctgagg	caggagaatg	gcttgaaccc	gggaggcgga	3840
35	ggttgacagt	agccaagatc	aggccactgc	actccagcct	ggatgacggg	atgagactct	3900
	gtctcaaaaa	aacgaaacaa	aaatttttta	agagaaatgt	catttgtttt	tgtttttgag	3960
	acagggtctc	actctgttgc	cctcactaga	gtgcagtagg	gatcacggct	cactgaagtc	4020
	tctacctacc	ggctcaattg	atcttccac	cacagcctcc	caaatagctg	ggagaaatgt	4080
	cctgttttta	atgaatttgt	cttccctttt	gtcttgtttg	ttttaatatc	tagtgatcta	4140
40	ataaatttgg	atgatattct	ttgactatc				4169

<210> 33
 <211> 859
 <212> DNA
 <213> Homo sapiens

45	<400> 33	
	catgccatgc	agcttaccac
	cgactgggtg	caagtaaaac
50	tgccaggaag	agaaaataga
	ctggaatctc	agcgaatcta
	gaggaaatta	acaacatgaa
	gagcacaac	taaatgatct
	ctaaacacaa	aagtggccaa
55	tgtttgcgag	ccaaccaagt
	aaggagacct	gtgacaaaaa
	gtcatgttct	acctggagac
	gaaatccagg	aggacagat
	gggggcagtg	ggaagttgcc
60	gagcaacaga	catccctgag
	agctaaatgt	gagggtgggc
	ccttagagat	ggatgaggc

<210> 34
 <211> 1070
 <212> DNA
 <213> Homo sapiens

<400> 34							
5	gcgattgctg	gggctgcagc	gctgcctccg	agaccgagag	tgggtggagc	gggtcttcct	60
	ggaaggggtgc	gataaggccg	ggcgaggtgc	ctgggatgct	tctccccttc	cgcgaggaaag	120
	agatctaatt	gggtagggcg	ggtgtagact	agcctgccga	gccgcccgt	ggcacctgca	180
	gcctcctggg	cgcccgcggg	cccggcgaga	aagttgttaa	agggagcgag	gtggttggtc	240
	ctgggggtccg	aggcgcgcct	ctcacgccct	gcccacacaga	agccgcagtc	ccgtgggggtc	300
10	tggagacgca	gtttccttgt	taatgacaat	aaatccctgc	tccccctgcc	tcagacatct	360
	acgcagcgaa	atcgagcctg	gccttgaggg	tccacaccgc	gaggaagatg	cgtgcgcccc	420
	ttccagagcc	taagcctgga	gacctgattg	agatttttctg	ccctttctac	agacactggg	480
	ccatctatgt	tggcgatgga	tatgtggttc	atctggcccc	tccaagtgaag	gtcgcaggag	540
	ctgggtgcagc	cagtgtcatg	tccgccttga	ctgacaaggc	catcgtgaag	aaggaattgc	600
15	tgtatgatgt	ggccgggagt	gacaagtacc	aggtcaacaa	caaacatgat	gacaagtact	660
	cgccgctgcc	ctgcacgaaa	atcatccagc	ggcgaggaga	gctgggtggg	caggaggtgc	720
	tctacaagct	gaccagtgaag	aactgcgagc	actttgtgaa	tgagctgcgc	tatggagtgc	780
	cccgcagtga	ccaggtcaga	gatgtcatca	tcgctgcaag	cgttgcaagg	atgggcttgg	840
	cagccatgag	ccttatttga	gtcatgttct	caagaaacaa	gcgacaaaag	caataactga	900
20	aaaagactgt	ctgtcagcga	tgactttata	catcaagggg	gtcttgtttt	gctagagagt	960
	ttgggggtttg	gtttgtggat	ttcattgtga	tttataataa	ggcttatttt	cacagaataa	1020
	aataaagcaa	aacgagggag	gattttattg	ggggagtga	gccccaaaaa		1070
<210> 35							
<211> 460							
<212> DNA							
<213> Homo sapiens							
<400> 35							
30	cttttcctcc	catgtgcgca	ccgaggtgcc	acgcgtgaga	cttctccgcc	gcctccgcgc	60
	cagacgcgcg	cgcgatgcgc	tacgtgcctt	cctacctgct	ggctgcctta	gggggcaact	120
	cctccccccag	cgccaaggac	atcaagaaga	tcttgacag	cgtgggtatc	gaggcggacg	180
	acgaccggct	caacaagggt	atcagtgaag	tgaatggaaa	aaacattgaa	gacgtcattg	240
	cccagggtat	tggcaagctt	gccagtgtac	ctgctgggtg	ggctgtagcc	gtctctgctg	300
35	ccccaggctc	tgcagccctt	gctgctggtt	ctgcccctgc	tgacgcagag	gagaagaaag	360
	atgagaagaa	ggaggagtct	gaagagtcag	atgatgacat	gggatttggc	ctttttgatt	420
	aaattcctgc	tcccctgcaa	ataaagcctt	tttacacatc			460
<210> 36							
<211> 4416							
<212> DNA							
<213> Homo sapiens							
<400> 36							
45	gccgcacagg	gttttatagg	atcacattga	caaaagtacc	atggagtttt	atgagtcagc	60
	atatttttatt	gttcttattc	cttcaatagt	tattacagta	attttcctct	tcttctggct	120
	tttcatgaaa	gaaacattat	atgatgaagt	tcttgcaaaa	cagaaaagag	aacaaaagct	180
	tattcctacc	aaaacagata	aaaagaaaag	agaaaagaaa	aagaataaaa	agaaaagaaat	240
	ccagaatgga	aacctccatg	aatccgactc	tgagagtgtg	cctcgagact	ttaaattatc	300
50	agatgctttg	gcagtagaag	atgatcaagt	tgacactgtt	ccattgaatg	tcgttgaaac	360
	ttcaagtagt	gttagggaaa	gaaaaaagaa	ggaaaagaaa	caaaaagcctg	tgcttgaaga	420
	gcaggtcatc	aaagaaaagt	acgcatacaa	gattcctggc	aaaaaagtag	aacctgtccc	480
	agttactaaa	cagcccaccc	ctccctctga	agcagctgcc	tcgaagaaga	aaccagggca	540
	gaagaagtct	aaaaatggaa	gcgatgacca	ggataaaaag	gtggaaactc	tcattggtacc	600
55	atcaaaaagg	caagaagcat	tgcccctcca	ccaagagact	aaacaagaaa	gtggatcagg	660
	gaagaagaaa	gcttcatcaa	agaaaacaaa	gacagaaaat	gtcttcgtag	atgaacccct	720
	tattcatgca	actacttata	ttcctttgat	ggataatgct	gactcaagtc	ctgtggtaga	780
	taagagagag	gttattgatt	tgcttaaac	tgaccaagta	gaagggatcc	agaaatctgg	840
	gactaaaaaa	ctgaagaccg	aaactgacaa	agaaaatgct	gaagtgaagt	ttaaagattt	900
60	tcttctgtcc	ttgaagacta	tgatgttttc	tgaagatgag	gctctttgtg	ttgtagactt	960
	gctaaaggag	aagtctggtg	taatacaaga	tgctttaaag	aagtcaagta	agggagaatt	1020
	gactacgctt	atacatcagc	ttcaagaaaa	ggacaagtta	ctcgtgctg	tgaaggaga	1080
	tgctgctgct	acaaaggatc	ggtgtaagca	gttaaccag	gaaatgatga	cagagaaaga	1140
	aagaagcaat	gtggttataa	caaggtgaa	agatcgaatt	ggaacattag	aaaaggaaca	1200
65	taatgtattt	caaaacaaaa	tacatgtcag	ttatcaagag	actcaacaga	tcagatgaa	1260
	gtttcagcaa	gttcgtgagc	agatggaggc	agagatagct	cacttgaagc	aggaaaatgg	1320
	tatactgaga	gatgcagtca	gcaacactac	aaatcaactg	gaaagcaagc	agtctgcaga	1380
	actaaataaa	ctacgccagg	attatgctag	gttggtgaat	gagctgactg	agaaaacagg	1440
	aaagctacag	caagaggaag	tccaaaagaa	gaatgctgag	caagcagcta	ctcagttgaa	1500
70	ggttcaacta	caagaagctg	agagaaggtg	ggaagaagtt	cagagctaca	tcaggaagag	1560

	aacagcgga	catgaggcag	cacagcaaga	tttacagagt	aaatttgtgg	ccaaagaaaa	1620
	tgaagtacag	agtctgcata	gtaagcttac	agataccttg	gtatcaaaac	aacagttgga	1680
	gcaaagacta	atgcagttta	tggaatcaga	gcagaaaagg	gtgaacaaag	aagagttctct	1740
5	acaaatgcag	gttcaggata	ttttggagca	gaatgaggct	ttgaaagctc	aaattcagca	1800
	gttccattcc	cagatagcag	cccagacctc	cgcttcagtt	ctagcagaag	aattacataa	1860
	agtgattgca	gaaaaggata	agcagataaa	acagactgaa	gattcttttag	caagtgaacg	1920
	tgatcgttta	acaagtaaa	aagaggaact	taaggatata	cagaatatga	atttcttatt	1980
	aaaagctgaa	gtgcagaaat	tacaggccct	ggcaaataag	caggctgctg	ctgcacatga	2040
10	attggagaag	atgcaacaaa	gtgtttatgt	taaagatgat	aaaataagat	tgctggaaga	2100
	gcaactacaa	catgaaattt	caaacaaaat	ggaagaattt	aagattctaa	atgaccaaaa	2160
	caaagcatta	aaatcagaag	ttcagaagct	acagactcct	gtttctgaac	agcctaataa	2220
	ggatgtttgt	gaacaaatgg	aaaaatgcac	tcaagaaaaa	gatgagaagt	taaagactgt	2280
	ggaagaatta	cttgaaactg	gacttattca	ggaggcaact	aaagaagagg	agctgaatgc	2340
15	aataagaaca	gaaaattcat	ctctgacaaa	agaagttcaa	gacttaaaag	ctaagcaaaa	2400
	tgatcagggt	tcttttgcc	ctctagttga	agaacttaag	aaagtgatcc	atgagaaaga	2460
	tggaaagatc	aagtctgtag	aagagcttct	ggaggcagaa	cttctcaaa	ttgctaacaa	2520
	ggagaaaact	gttcaggatt	tgaacacagga	aataaaggct	ctaaaagaag	aaataggaaa	2580
	gtgccagctt	gaaaaggctc	aacagttatc	tatcacttcc	aaagttcagg	agcttcagaa	2640
20	cttattaaaa	ggaaaagagg	aacagatgaa	taccatgaag	gctgttttgg	aagagaaaga	2700
	gaaagacctt	gccaatacag	ggaagtgggt	acaggatctt	caagaagaaa	atgaatcttt	2760
	aaaagcacat	gttcagggaag	tagcacaaca	taacttgaaa	gaggcctctt	ctgcatcaca	2820
	gtttgaagaa	cttgagattg	tgttgaaaga	aaaggaaaaa	gaattgaaga	ggttagaagc	2880
	catgtctaaa	gagagggaga	gtgacttttc	tagcaaaaac	cagctgttac	aggatgtaca	2940
25	agatgaaaac	aaattgttta	agtcccaaat	tgagcagctt	aaacaacaaa	actaccaaca	3000
	ggcatcttct	tttccccctc	atgaagaatt	attaaaagta	atttcagaaa	gagagaaaga	3060
	aataagtgg	ctctggaatg	agttagattc	tttgaaggat	gcagttgaac	accagaggaa	3120
	gaaaaacaat	gaaaggcagc	aacaggtgga	agctgttgag	ttggaggcta	aagaagttct	3180
	caaaaaatta	tttccaaagg	tgtctgtccc	ttctaatttg	agttatgggt	aatgggttga	3240
30	tggatttgaa	aaaaaggcaa	aagaatgtat	ggctggaact	tcagggtcag	aggaggttaa	3300
	ggttctagag	cacaagttga	aagaagctga	tgaaatgcac	acattgttac	agctagagt	3360
	tgaaaaatac	aaatccgtcc	ttgcagaaac	agaagggaat	ttacagaagc	tacagagaag	3420
	tggttagcaa	gaagaaaata	aatggaaagt	taaggctgat	gaatcacaca	agactattaa	3480
	acagatgcag	tcattcattta	catcttcaga	acaagagcta	gagcgattaa	gaagcgaaaa	3540
35	taaggatatt	gaaaatctga	gaagagaacg	agaacatttg	gaaatggaac	tagaaaaagg	3600
	agagatggaa	cgatctacct	atgttacaga	agtcagagag	ttgaaggcac	agttaaatga	3660
	aacactcaca	aaacttagaa	ctgaacaaaa	tgaaagacag	aaggtagctg	gtgatttgca	3720
	taaggctcaa	gagtcactgg	agcttatcca	gtcaaaaata	gtaaaagctg	ctggagacac	3780
	tactgttatt	gaaaatagtg	atgtttcccc	agaaacggag	tcttctgaga	aggagacaat	3840
40	gtctgtaagt	ctaaatcaga	ctgtaacaca	gttacagcag	ttgcttcagg	cggtaaacca	3900
	acagctcaca	aaggagaaag	agcactacca	ggtgttagag	tgaagtaatt	gggaaactgt	3960
	tcatttgagg	ataaaaaagg	cattgtatta	tattttgcca	aattaaagcc	ttatttatgt	4020
	tttcaccctt	tctactttgt	cagaaacact	gaacagagtt	ttgtcttttc	taatccttgt	4080
	tagactactg	atttaaaaga	ggaaaaaaaa	aagccaactc	tgtagacacc	ttcagagttt	4140
45	agttttataa	taaaaaactgt	ttgaataatt	agacctttac	attcctgaag	ataaacatgt	4200
	aatctttttt	cttattttgc	tcaataaaat	tgttcagaag	atcaaagtgg	ttaaagacaat	4260
	gtaaaattta	acattttta	actgatgttg	tacactgttt	tacttaacat	tttgggaagt	4320
	aactgcctct	gacttcaact	caagaaaaac	cttttttgtt	gctaattgtaa	tcgggtttttg	4380
	taatggcgctc	agcaaaataa	aggatgctta	ttatttc			4416

50 <210> 37
 <211> 628
 <212> DNA
 <213> Homo sapiens

55 <220>
 <221> unsure
 <222> 284..284
 <223> n = a, c, g or t

60 <220>
 <221> unsure
 <222> 594..594
 <223> n = a, c, g or t

65 <220>
 <221> unsure
 <222> 597..597

<223> n = a, c, g or t
 <220>
 <221> unsure
 5 <222> 607..607
 <223> n = a, c, g or t
 <400> 37
 10 ggcacgagaa gaagtctaaa aatggaagcg atgaccaggg ataaaaagggt ggaaactctc 60
 atggtaccat caaaaaggca agaagcattg cccctccacc aagagactaa acaagaaagt 120
 ggatcaggga agaagaaagc ttcattcaag aaacaaaaga cagaaaatgt ctctgtagat 180
 gaacccttta ttcattgcaac tacttatatt cctttgatgg ataattgctga ctcaagtcc 240
 gtggtagata agagagaggt tatttatattg cttaaacctg accnagtaga agggatccag 300
 15 aaatctggga ctaaaaaact gaagacccaa actgacaaaag aaaatgctga agtgaagttt 360
 aaagattttc ttctgtcctt taagactatg atgttttctg aagatgaggc tctttgtgtt 420
 gtagacttgc taaaggagaa gtctcgtgta atacaagatg ctttaaagaa gtcaagtaag 480
 ggagaattga ctacgcttat acatcagctt caagaaaagg accaagttac tcgctgctgt 540
 gaaggaagat gctgctgcta caaaggatcc gtgtaagcag ttaccccagg aatnatncca 600
 20 aagaaanaca gagcaatttg gtatacaa 628
 <210> 38
 <211> 730
 <212> DNA
 25 <213> Homo sapiens
 <220>
 <221> unsure
 <222> 127..127
 30 <223> n = a, c, g or t
 <220>
 <221> unsure
 <222> 260..260
 35 <223> n = a, c, g or t
 <220>
 <221> unsure
 <222> 307..307
 40 <223> n = a, c, g or t
 <220>
 <221> unsure
 <222> 329..329
 45 <223> n = a, c, g or t
 <220>
 <221> unsure
 <222> 336..336
 50 <223> n = a, c, g or t
 <220>
 <221> unsure
 <222> 473..473
 55 <223> n = a, c, g or t
 <220>
 <221> unsure
 <222> 487..487
 60 <223> n = a, c, g or t
 <220>
 <221> unsure
 <222> 494..494
 65 <223> n = a, c, g or t
 <220>
 <221> unsure


```

5      <222> 563..563
      <223> n = a, c, g or t

      <220>
      <221> unsure
      <222> 640..640
      <223> n = a, c, g or t

10     <220>
      <221> unsure
      <222> 681..681
      <223> n = a, c, g or t

15     <220>
      <221> unsure
      <222> 689..689
      <223> n = a, c, g or t

20     <220>
      <221> unsure
      <222> 708..708
      <223> n = a, c, g or t

25     <220>
      <221> unsure
      <222> 714..714
      <223> n = a, c, g or t

30     <220>
      <221> unsure
      <222> 728..728
      <223> n = a, c, g or t

35     <220>
      <221> unsure
      <222> 730..730
      <223> n = a, c, g or t

40     <400> 38
      aaagaattcg gcacgagtgga agaccgaaac tgacaaagaa aatgctgaag tgaagtttaa 60
      agattyyctt ctgtccttga agactatgat gttttctgaa gatgaggctc tttgtgttgt 120
      agactyncta aaggagaagt ctggtgtaat acaagatgct ttaaagaagt caagtaaggg 180
      agaattgact acgcttatac atcagcttca agaaaaggac aagtyactcg ctgctgtgaa 240
      ggaagatgct gctgcyacan aggatcggtg taagcagtta acccaggaaa tgatgacaga 300
      gaaaganaga agcaatgtgg ttataacang gatganagay cgaatyggaa cattagaaaa 360
      ggracataat gtatyycaaaa acaaaaataca tgtcagtyat caagagacyc aacagatgca 420
      gatgaagttt cagcaagttc gtgagcagat acactacaaa tcaactggaa agcaagcagt 480
      aaatggnata ctgngagaat gcagtcagca acactacaaa tcaactggaa agcaagcagt 540
      ctgcagaact aaataaacta cgncaggatt atgctaggtt ggtgaatgag cctgactgag 600
      aaacaggaaa gctacagcaa gaggaagtca aagaagaatn ctgagcaagc agctactcag 660
      ttgaaggttc caactacacg nacgcctgng agaaggtggg ggaggcgntt cagngcctac 720
      atcaggngnng
      730

55     <210> 39
      <211> 571
      <212> DNA
      <213> Homo sapiens

60     <220>
      <221> unsure
      <222> 37..37
      <223> n = a, c, g or t

65     <220>
      <221> unsure
      <222> 42..42
      <223> n = a, c, g or t

```

5 <220>
 <221> unsure
 <222> 64..64
 <223> n = a, c, g or t

10 <220>
 <221> unsure
 <222> 67..67
 <223> n = a, c, g or t

15 <220>
 <221> unsure
 <222> 73..73
 <223> n = a, c, g or t

20 <220>
 <221> unsure
 <222> 86..99
 <223> n = a, c, g or t

25 <220>
 <221> unsure
 <222> 106..107
 <223> n = a, c, g or t

30 <220>
 <221> unsure
 <222> 117..117
 <223> n = a, c, g or t

35 <220>
 <221> unsure
 <222> 139..139
 <223> n = a, c, g or t

40 <220>
 <221> unsure
 <222> 153..153
 <223> n = a, c, g or t

45 <220>
 <221> unsure
 <222> 243..243
 <223> n = a, c, g or t

50 <220>
 <221> unsure
 <222> 257..257
 <223> n = a, c, g or t

55 <220>
 <221> unsure
 <222> 264..264
 <223> n = a, c, g or t

60 <220>
 <221> unsure
 <222> 319..319
 <223> n = a, c, g or t

65 <220>
 <221> unsure
 <222> 337..337
 <223> n = a, c, g or t

 <220>

<221> unsure
<222> 341..341
<223> n = a, c, g or t

5 <220>
 <221> unsure
 <222> 353..353
 <223> n = a, c, g or t

10 <220>
 <221> unsure
 <222> 362..362
 <223> n = a, c, g or t

15 <220>
 <221> unsure
 <222> 373..373
 <223> n = a, c, g or t

20 <220>
 <221> unsure
 <222> 379..379
 <223> n = a, c, g or t

25 <220>
 <221> unsure
 <222> 384..385
 <223> n = a, c, g or t

30 <220>
 <221> unsure
 <222> 419..419
 <223> n = a, c, g or t

35 <220>
 <221> unsure
 <222> 421..421
 <223> n = a, c, g or t

40 <220>
 <221> unsure
 <222> 427..427
 <223> n = a, c, g or t

45 <220>
 <221> unsure
 <222> 433.433
 <223> n = a, c, g or t

50 <220>
 <221> unsure
 <222> 440..442
 <223> n = a, c, g or t

55 <220>
 <221> unsure
 <222> 444..444
 <223> n = a, c, g or t

60 <220>
 <221> unsure
 <222> 448..448
 <223> n = a, c, g or t

65 <220>
 <221> unsure
 <222> 450..450

<223> n = a, c, g or t

<220>
<221> unsure
5 <222> 455..455
<223> n = a, c, g or t

<220>
<221> unsure
10 <222> 486..486
<223> n = a, c, g or t

<220>
<221> unsure
15 <222> 488..489
<223> n = a, c, g or t

<220>
<221> unsure
20 <222> 493..493
<223> n = a, c, g or t

<220>
<221> unsure
25 <222> 496..497
<223> n = a, c, g or t

<220>
<221> unsure
30 <222> 500..500
<223> n = a, c, g or t

<220>
<221> unsure
35 <222> 504..504
<223> n = a, c, g or t

<220>
<221> unsure
40 <222> 506..507
<223> n = a, c, g or t

<220>
<221> unsure
45 <222> 515..515
<223> n = a, c, g or t

<220>
<221> unsure
50 <222> 520..520
<223> n = a, c, g or t

<220>
<221> unsure
55 <222> 523..523
<223> n = a, c, g or t

<220>
<221> unsure
60 <222> 525..526
<223> n = a, c, g or t

<220>
<221> unsure
65 <222> 538..538
<223> n = a, c, g or t

	<div><400> 39</div>	
	<div>aayacaatgc cttttttatc ctcaaataga rcagtttccc anttacttca ctcttacacc</div>	<div>60</div>
	<div>tgggnagngct ctntctcett tgtgrnnnnn nnnnnnnnc ccccyntccg aatggtnctg</div>	<div>120</div>
5	<div>taactgtgtt acagtctgnt ttaggcttac agncattgtc tccttctcag gaggctccgt</div>	<div>180</div>
	<div>ttctggggga acatcacatt tttcaataac agtagtgtct cccgcagctt ttactatttt</div>	<div>240</div>
	<div>tgntcgggata agctccngtg actnttgagc cttatgcaaa tcaccagcta ccttctgtct</div>	<div>300</div>
	<div>ttcattttgt tcagttctna gttttgtggg tgtttcnttt nactgtgccy tcnactctct</div>	<div>360</div>
	<div>gncttctgta acntagggng gtcnntccct ctctgccttt tctagttccc tttcccaang</div>	<div>420</div>
10	<div>ntctcgnctc cncccccagn nngncaanan ccgcnatttt tcgcttctta attcgggtcta</div>	<div>480</div>
	<div>gccccgnnc cgnagnngn aaangnnggc tgcanccggn ttnannaggc ctgtgtgntt</div>	<div>540</div>
	<div>catcggcctt tacctttccc tttattttct t</div>	<div>571</div>
	<div><210> 40</div>	
	<div><211> 644</div>	
15	<div><212> DNA</div>	
	<div><213> Homo sapiens</div>	
	<div><220></div>	
	<div><221> unsure</div>	
20	<div><222> 415..415</div>	
	<div><223> n = a, c, g or t</div>	
	<div><220></div>	
	<div><221> unsure</div>	
25	<div><222> 525..526</div>	
	<div><223> n = a, c, g or t</div>	
	<div><400> 40</div>	
30	<div>atattttgga gcagaatgag gctttgaaag ctcaaattca gcagttccat tcccagatag</div>	<div>60</div>
	<div>cagcccagac ctccgcttca gttctagcag aagaattaca taaagtgatt gcagaaaagg</div>	<div>120</div>
	<div>ataagcagat aaaacagact gaagattctt tagcaagtga acgtgatcgt ttaacaagta</div>	<div>180</div>
	<div>aagaagagga acttaaggat atacagaata tgaatttctt attaaaagct gaagtgcaga</div>	<div>240</div>
	<div>aattacaggc cctggcaaat gagcaggctg ctgctgcaca tgaattggag aagatgcaac</div>	<div>300</div>
35	<div>acagtgttta tgttaaagat gataaaataa gattgctgga agagcaacta caacatgaca</div>	<div>360</div>
	<div>tttcaaacaa aatggaagaa tttaagattc taaatgacca aaacaaagca ttaanatcag</div>	<div>420</div>
	<div>aagttcagaa gctacagact cttgtttctg aacagcctaa taaggatggt gtggaacaca</div>	<div>480</div>
	<div>tggaaaaatg cattcaagaa aagatgagaa gttaaagact gtggnggatt acttgacact</div>	<div>540</div>
	<div>ggacttattc aggtggcaac taaagagagg agctgatgca tagacagaca ttcattctctg</div>	<div>600</div>
40	<div>acaaagagtt caagacttac agctagcaaa tgatcaggtt cttg</div>	<div>644</div>
	<div><210> 41</div>	
	<div><211> 566</div>	
	<div><212> DNA</div>	
45	<div><213> Homo sapiens</div>	
	<div><220></div>	
	<div><221> unsure</div>	
	<div><222> 47.47</div>	
50	<div><223> n = a, c, g or t</div>	
	<div><220></div>	
	<div><221> unsure</div>	
	<div><222> 59..59</div>	
55	<div><223> n = a, c, g or t</div>	
	<div><220></div>	
	<div><221> unsure</div>	
	<div><222> 91..91</div>	
60	<div><223> n = a, c, g or t</div>	
	<div><220></div>	
	<div><221> unsure</div>	
	<div><222> 104..104</div>	
65	<div><223> n = a, c, g or t</div>	
	<div><220></div>	
	<div><221> unsure</div>	

<222> 441..441
 <223> n = a, c, g or t

5
 <220>
 <221> unsure
 <222> 448..448
 <223> n = a, c, g or t

10
 <220>
 <221> unsure
 <222> 457..457
 <223> n = a, c, g or t

15
 <220>
 <221> unsure
 <222> 525..525
 <223> n = a, c, g or t

20
 <220>
 <221> unsure
 <222> 539..539
 <223> n = a, c, g or t

25
 <220>
 <221> unsure
 <222> 564..564
 <223> n = a, c, g or t

30
 <400> 41
 caacacaatc tcaaggtctt caaactggga tgcagaagag gcctctntca agttatgtng 60
 tgctacttcc tgaacaaggg cttgaaaaga ntcaatggct tctngaagag cccgtaacca 120
 cttccccgta ttggctaggg ctttctcttt ctcttccaaa acagccttca tgggattcat 180
 ctgtgcctct tttcctttta ataagttcyg aagctcctga actttggaag tgatagataa 240
 cygttgagcc ttttcaagct ggacatttcc tatttcttct tttagagcct ttatttcccg 300
 35 tttcaaatacc cgaacagttt tctccttggt agcaacattg agaagtgccg cctccagaag 360
 ctcttctaca gacttgatct ttcacctctc tcatggatca ctctcttaag gtcttcaact 420
 agagaggcaa aagaaccga ncatttgnta gttttangct cgaacttctt ttgtcagaga 480
 tgaattttct gttcttattg cattcagctc ctcttcttta ggtgncacca gaataaggnc 540
 40 agtgtcaaga aattcttcca cagnct 566

<210> 42
 <211> 878
 <212> DNA
 <213> Homo sapiens

45
 <220>
 <221> unsure
 <222> 595..595
 <223> n = a, c, g or t

50
 <220>
 <221> unsure
 <222> 756..756
 <223> n = a, c, g or t

55
 <220>
 <221> unsure
 <222> 766..766
 <223> n = a, c, g or t

60
 <220>
 <221> unsure
 <222> 815..815
 <223> n = a, c, g or t

65
 <220>
 <221> unsure

<222> 818..818
 <223> n = a, c, g or t

5
 <220>
 <221> unsure
 <222> 827..827
 <223> n = a, c, g or t

10
 <220>
 <221> unsure
 <222> 831..831
 <223> n = a, c, g or t

15
 <220>
 <221> unsure
 <222> 853..853
 <223> n = a, c, g or t

20
 <220>
 <221> unsure
 <222> 866..866
 <223> n = a, c, g or t

25
 <400> 42
 accttaacct cctctgacct gaagttccag ccatacatte ttttgccttt ttttcaatcc 60
 atgcaaccat tcaccataac tcaaattaga agggacagac acctttggaa ataatttttt 120
 gagaacttct ttagcctcca actcaacagc ttccacctgt tgctgccttt cattgttttt 180
 cttcctctgg tgttcaactg catccttcaa agaattctaac tcattccaga gaccacttat 240
 ttctttctct ctttctgaaa ttacttttaa taattcttca tgagggggaa aagaagatgc 300
 30 ctggttgtag ttttgttggt taagctgctc aatttgggac ttaaacaatt tgttttcatc 360
 ttgtacatcc tgtaacagct gtgttttgct agaaagatca ctctccctct ctttttagcat 420
 ggcttctaac ctcttcaatt cattttcctt ttctttcaac acaatctcaa gttcttcaaa 480
 ctgtgatgca gaagaggcct ctttcaagtt atgttggtgct acttccctgaa catgtgcttt 540
 taaaagattc attttcttct tgaagatcct gtaaccactt ccctgtattg gctangtctt 600
 35 tctctttctc ttccaaaaca gccttcaagg tattcatctg ttccctcttt ccttttaaaa 660
 agttctgaag ctccctgaact ttggaagtga tagataactg ttgagccctt tcaagcctgg 720
 acattcctaa ttccctcttt aaaagcctta attccngttt caaaaanccga aacagttttc 780
 ccccttgtaa gcaactttga gaaattcggc tccanaancc ctectanaga nttgatcttt 840
 40 caacctttcc aanggattac tttccnaaag ttccttaa 878

<210> 43
 <211> 620
 <212> DNA
 <213> Homo sapiens

45
 <220>
 <221> unsure
 <222> 391..391
 <223> n = a, c, g or t

50
 <220>
 <221> unsure
 <222> 400..400
 <223> n = a, c, g or t

55
 <220>
 <221> unsure
 <222> 411..411
 <223> n = a, c, g or t

60
 <220>
 <221> unsure
 <222> 414.. 414
 <223> n = a, c, g or t

65
 <220>
 <221> unsure

<222> 418..418
<223> n = a, c, g or t

5 <220>
 <221> unsure
 <222> 421..421
 <223> n = a, c, g or t

10 <220>
 <221> unsure
 <222> 427..428
 <223> n = a, c, g or t

15 <220>
 <221> unsure
 <222> 435..435
 <223> n = a, c, g or t

20 <220>
 <221> unsure
 <222> 446..446
 <223> n = a, c, g or t

25 <220>
 <221> unsure
 <222> 454..455
 <223> n = a, c, g or t

30 <220>
 <221> unsure
 <222> 463..463
 <223> n = a, c, g or t

35 <220>
 <221> unsure
 <222> 465..465
 <223> n = a, c, g or t

40 <220>
 <221> unsure
 <222> 471..471
 <223> n = a, c, g or t

45 <220>
 <221> unsure
 <222> 480..480
 <223> n = a, c, g or t

50 <220>
 <221> unsure
 <222> 484..484
 <223> n = a, c, g or t

55 <220>
 <221> unsure
 <222> 490..490
 <223> n = a, c, g or t

60 <220>
 <221> unsure
 <222> 493..493
 <223> n = a, c, g or t

65 <220>
 <221> unsure
 <222> 500..500
 <223> n = a, c, g or t

5 <220>
 <221> unsure
 <222> 514..515
 <223> n = a, c, g or t

 10 <220>
 <221> unsure
 <222> 524..524
 <223> n = a, c, g or t

 15 <220>
 <221> unsure
 <222> 539..539
 <223> n = a, c, g or t

 20 <220>
 <221> unsure
 <222> 568..568
 <223> n = a, c, g or t

 25 <220>
 <221> unsure
 <222> 573..574
 <223> n = a, c, g or t

 30 <220>
 <221> unsure
 <222> 581..581
 <223> n = a, c, g or t

 35 <220>
 <221> unsure
 <222> 600..600
 <223> n = a, c, g or t

 40 <220>
 <221> unsure
 <222> 604..604
 <223> n = a, c, g or t

 45 <220>
 <221> unsure
 <222> 608..608
 <223> n = a, c, g or t

 50 <220>
 <221> unsure
 <222> 616..616
 <223> n = a, c, g or t

 55 <220>
 <221> unsure
 <222> 619..619
 <223> n = a, c, g or t

<400> 43
 60 accttaacct cctctgaccc tgaattcca g ccatacatte ttttgccttt ttttcaaate 60
 catgcaacca ttcaccataa ctcaaattag aagggacaga cacctttgga aataattttt 120
 tgagaacttc tttagcctcc aactcaacag cttccacctg ttgctgcctt tcattgtttt 180
 tcttcctctg gtgttcaact gcatccttca aagaatctaa ctcatccag agaccactta 240
 tttctttctc tctttctgaa attactttta ataattcttc atgaggggga aaagaagatg 300
 cctgttggtg gttttgttgt ttaagctgct caatttggga cttaaacaat ttgttttcat 360
 cctgtacatc ctgtaacagc tgtgttttgc naagaaagtn actccccctc nccnttanca 420
 65 nggggttnca acctncttaa atacanttcc tttnncttta aananaatct naggttcctn 480
 caanggtan tgnaaaaaan gcccctttca agtnnggttg tgcnaacttc tgaacatgng 540
 ctttaagatc attttctctg aagatccngt acnnttcccg nattggtagg cttcccttcn 600

ttcnaaanag cttcangng

620

5 <210> 44
 <211> 623
 <212> DNA
 <213> Homo sapiens

10 <220>
 <221> unsure
 <222> 25..25
 <223> n = a, c, g or t

15 <220>
 <221> unsure
 <222> 409..409
 <223> n = a, c, g or t

20 <220>
 <221> unsure
 <222> 412..412
 <223> n = a, c, g or t

25 <220>
 <221> unsure
 <222> 414..414
 <223> n = a, c, g or t

30 <220>
 <221> unsure
 <222> 423..423
 <223> n = a, c, g or t

35 <220>
 <221> unsure
 <222> 426..426
 <223> n = a, c, g or t

40 <220>
 <221> unsure
 <222> 435..435
 <223> n = a, c, g or t

45 <220>
 <221> unsure
 <222> 444..444
 <223> n = a, c, g or t

50 <220>
 <221> unsure
 <222> 450..450
 <223> n = a, c, g or t

55 <220>
 <221> unsure
 <222> 454..454
 <223> n = a, c, g or t

60 <220>
 <221> unsure
 <222> 459..459
 <223> n = a, c, g or t

65 <220>
 <221> unsure
 <222> 490..490
 <223> n = a, c, g or t

5 <220>
 <221> unsure
 <222> 508..508
 <223> n = a, c, g or t

 10 <220>
 <221> unsure
 <222> 511..511
 <223> n = a, c, g or t

 15 <220>
 <221> unsure
 <222> 515..515
 <223> n = a, c, g or t

 20 <220>
 <221> unsure
 <222> 524..524
 <223> n = a, c, g or t

 25 <220>
 <221> unsure
 <222> 545..545
 <223> n = a, c, g or t

 30 <220>
 <221> unsure
 <222> 555..555
 <223> n = a, c, g or t

 35 <220>
 <221> unsure
 <222> 564..564
 <223> n = a, c, g or t

 40 <220>
 <221> unsure
 <222> 600..600
 <223> n = a, c, g or t

 45 <220>
 <221> unsure
 <222> 611..611
 <223> n = a, c, g or t

 50 <400> 44
 accttaacct cctctgaccc tgaantccag ccatacatc ttttgccctt ttttcaaadc 60
 catgcaacca ttcaccataa ctcaaattag aagggacaga cacctttgga aataatTTTT 120
 tgagaacttc tttagcctcc aactcaacag ctccacctg ttgctgcctt tccttggaag 180
 tcttggtcac ttgtcctgc agcatttttt cagttgatgc caatgcttcc attgcttccc 240
 agtttttctc ccgaagggtca ttgtttttct tcctctgggtg ttcaactgca tccttcaaag 300
 aatctaactc attccagaga ccacttattt ctttctctct ttctgaaatt acttttaata 360
 attcttcatg aggggggaaaa gaagatgcct ggtgggaatt tgggtggttna ancnggccaa 420
 ttnggnacct aaaaanatttg gttncactn gtanaccgng taaaaaactgt gttttgctaa 480
 55 aaagataacn cccctctctt ttaagcangg nttcnaacct cttnattcat ttccttttct 540
 tcaanaaatc tcagntctca aacngggatg caaaaagaggc tcttcaagtt aaggtgggcn 600
 acttccggaa natggccctt aaa 623

 60 <210> 45
 <211> 625
 <212> DNA
 <213> Homo sapiens

 65 <220>
 <221> unsure
 <222> 392..392
 <223> n = a, c, g or t

5 <220>
 <221> unsure
 <222> 408..408
 <223> n = a, c, g or t

10 <220>
 <221> unsure
 <222> 417..417
 <223> n = a, c, g or t

15 <220>
 <221> unsure
 <222> 421..421
 <223> n = a, c, g or t

20 <220>
 <221> unsure
 <222> 424..425
 <223> n = a, c, g or t

25 <220>
 <221> unsure
 <222> 437..437
 <223> n = a, c, g or t

30 <220>
 <221> unsure
 <222> 439..439
 <223> n = a, c, g or t

35 <220>
 <221> unsure
 <222> 456..456
 <223> n = a, c, g or t

40 <220>
 <221> unsure
 <222> 467..467
 <223> n = a, c, g or t

45 <220>
 <221> unsure
 <222> 469..469
 <223> n = a, c, g or t

50 <220>
 <221> unsure
 <222> 473..473
 <223> n = a, c, g or t

55 <220>
 <221> unsure
 <222> 475..475
 <223> n = a, c, g or t

60 <220>
 <221> unsure
 <222> 496..496
 <223> n = a, c, g or t

65 <220>
 <221> unsure
 <222> 499..500
 <223> n = a, c, g or t

 <220>

<221> unsure
 <222> 516..516
 <223> n = a, c, g or t

5

<220>
 <221> unsure
 <222> 524..524
 <223> n = a, c, g or t

10

<220>
 <221> unsure
 <222> 535..535
 <223> n = a, c, g or t

15

<220>
 <221> unsure
 <222> 538..538
 <223> n = a, c, g or t

20

<220>
 <221> unsure
 <222> 560..560
 <223> n = a, c, g or t

25

<220>
 <221> unsure
 <222> 582..582
 <223> n = a, c, g or t

30

<220>
 <221> unsure
 <222> 592..592
 <223> n = a, c, g or t

35

<220>
 <221> unsure
 <222> 594..594
 <223> n = a, c, g or t

40

<220>
 <221> unsure
 <222> 604..604
 <223> n = a, c, g or t

45

<400> 45
 accttaacct cctctgaccc tgaagtccag ccatacatte ttttgccctt ttttcaaate 60
 catgcaacca ttcaccataa ctcaaattag aagggaacaga caccttttga aataattttt 120
 tgagaacttc tttagcctcc aactcaacag cttccacctg ttgctgcctt tcattgtttt 180
 ttttcctctg gtgttcaact gcacccctta aagaatctaa ctcatctccag agaccactta 240
 50 tttctttctc tctttctgaa attactttta ataattcttc atgaggggga aaagaagatg 300
 cctggttgga gttttgttgt ttaagctgct caatttgga cttaaacaat ttgttttcat 360
 cttgtacatc ctggtaacag ctgtgttttg cntagaaaag attactcncc ctctctnttt 420
 ncanngggtt caaccnntna aattacattt cocttntctt aaacaanant ctngangttct 480
 tcaaactgtg atgcanaann ggctctttca agttangttg tgcnaacttc tgaanatntg 540
 55 ttttaaagat catttcttctn tgaaatccgt aaccacttcc cngtatgggc angncttccc 600
 ttcncttcaa aaaagcctca aggta 625

<210> 46
 <211> 4416
 <212> DNA
 <213> Homo sapiens

60

<400> 46
 gccgcacagg gttttatagg atcacattga caaaagtacc atggagtttt atgagtcagc 60
 65 atattttatt gttcttattc cttcaatagt tattacagta attttcctct tcttctggct 120
 tttcatgaaa gaaacattat atgatgaagt tcttgcaaaa cagaaaagag aacaaaagct 180
 tattcctacc aaaacagata aaaagaaagc agaaaagaaa aagaataaaa agaaagaaat 240

	ccagaatgga	aacctccatg	aatccgactc	tgagagtgtg	cctcgagact	ttaaattatc	300
	agatgctttg	gcagtagaag	atgatcaagt	tgcacctgtt	ccattgaatg	tcgttgaaac	360
	ttcaagtagt	gttagggaaa	gaaaaaagaa	ggaaaagaaa	caaaagcctg	tgcttgaaaga	420
5	gcaggtcatc	aaagaaagtg	acgcatcaaa	gattcctggc	aaaaaagtag	aacctgtccc	480
	agttactaaa	cagcccaccc	ctccctctga	agcagctgcc	tcgaagaaga	aaccagggca	540
	gaagaagtct	aaaaatggaa	gcgatgacca	ggataaaaaag	gtggaaactc	tcatggtacc	600
	atcaaaaagg	caagaagcat	tgccctccca	ccaagagact	aaacaagaaa	gtggatcagg	660
	gaagaagaaa	gcttcatcaa	agaaacaaaa	gacagaaaat	gtcttcgtag	atgaaccctt	720
10	tattcatgca	actacttata	ttcctttgat	ggataatgct	gactcaagtc	ctgtggtaga	780
	taagagagag	gttattgatt	tgcttaaacc	tgaccaagta	gaagggatcc	agaaatctgg	840
	gactaaaaaa	ctgaagaccg	aaactgacaa	agataatgct	gaagtgaagt	ttaaagattt	900
	tcttctgtcc	ttgaagacta	tgatgttttc	tgaagatgag	gctctttgtg	ttgtagactt	960
	gctaaaggag	aagtctggtg	taatacaaga	tgctttaaag	aagtcaagta	agggagaatt	1020
	gactacgctt	atacatcagc	ttcaagaaaa	ggacaagtta	ctcgctgctg	tgaaggaaaga	1080
15	tgctgctgct	acaaaggatc	ggtgtaagca	gttaaccacg	gaaatgatga	cagagaaaga	1140
	aagaagcaat	gtgggttataa	caaggatgaa	agatcgaatt	ggaacattag	aaaaggaaca	1200
	taatgtattt	caaaacaaaa	tacatgtcag	ttatcaagag	actcaacaga	tgcatatgaa	1260
	gtttcagcaa	gttcgtgagc	agatggaggc	agagatagct	cacttgaagc	aggaaaatgg	1320
20	tatactgaga	gatgcagtca	gcaacactac	aaatcaactg	gaaagcaagc	agtctgcaga	1380
	actaaataaa	ctacgccagg	attatgctag	gttgggtgaat	gagctgactg	agaaaacagg	1440
	aaagctacag	caagaggaag	tccaaaagaa	gaatcgtgag	caagcagcta	ctcagttgaa	1500
	ggttcaacta	caagaagctg	agagaagggtg	ggaagaagtt	cagagctaca	tcaggaaagag	1560
	aacagcggaa	catgaggcag	cacagcaaga	tttacagagt	aaatttgtgg	ccaaagaaaa	1620
	tgaagtacag	agtctgcata	gtaagcttac	agataccttg	gtatcaaaac	aacagttgga	1680
25	gcaaagacta	atgcagttaa	tggaatcaga	gcagaaaagg	gtgaacaaaag	aagagtctct	1740
	acaaatgcag	gttcaggata	ttttggagca	gaatgaggct	ttgaaagctc	aaattcagca	1800
	gttccattcc	cagatagcag	cccagacctc	cgcttcagtt	ctagcagaag	aattacataa	1860
	agtgattgca	gaaaaggata	agcagataaa	acagactgaa	gattcttttag	caagtgaacg	1920
	tgatcgttta	acaagtaaaag	aagaggaact	taaggatata	cagaatatga	atttcttatt	1980
30	aaaagctgaa	gtgcagaat	tacaggccct	ggcaaatgag	caggctgctg	ctgcacatga	2040
	attggagaag	atgcaacaaa	gtgtttatgt	taaaagatga	aaaataagat	tgctggaaga	2100
	gcaactacaa	catgaaattt	caaacaaaat	ggaagaattt	aagattctaa	atgacaaaaa	2160
	caaagcatta	aaatcagaag	ttcagaagct	acagactctt	gtttctgaac	agcctaataa	2220
	ggatgtttgt	gaacaaatgg	aaaaatgcac	tcaagaaaaa	gatgagaagt	taaagactgt	2280
35	ggaagaatta	cttgaaactg	gacttattca	ggtggcaact	aaagaagagg	agctgaatgc	2340
	aataagaaca	gaaaattcat	ctctgacaaa	agaagttcaa	gacttaaaaag	ctaagcaaaa	2400
	tgatcagggt	tcttttgcc	ctctagttga	agaacttaag	aaagtgatcc	atgagaaaga	2460
	tggaaagatc	aagtctgtag	aagagcttct	ggaggcagaa	cttctcaaaag	ttgctaacaa	2520
	ggagaaaact	gttcaggatt	tgaacacagga	aataaaaggct	ctaaaagaag	aaataggaaa	2580
40	gtgccagctt	gaaaaggctc	aacagttatc	tatcaactcc	aaagttcagg	agcttcagaa	2640
	cttatttaaaa	ggaaaagagg	aacagatgaa	taccatgaag	gctgttttgg	aagagaaaga	2700
	gaaagacctt	gccaatacag	ggaagtgggt	acaggatctt	caagaagaaa	atgaatcttt	2760
	aaaagcacat	gttcagggaag	tagcacaaca	taacttgaaa	gaggcctctt	ctgcatcaca	2820
	gtttgaagaa	cttgagattg	tggtgaaaga	aaaggaaaaat	gaattgaaga	ggttagaagc	2880
45	catgtcaaaa	gagagggaga	gtgacttttc	tagcaaaaca	cagctgttac	aggatgtaca	2940
	agatgaaaaa	aaattgttta	agtcctcaat	tgagcagctt	aaacaacaaa	actaccaaca	3000
	ggcatcttct	tttccccctc	atgaagaatt	attaaaagta	atttcagaaa	gagagaaaga	3060
	aataagtggt	ctctggaatg	agttagattc	tttgaaggat	gcagttgaac	accagaggaa	3120
	gaaaaacaat	gaaaggcagc	aacagggtga	agctgttgag	ttggaggcta	aagaagttct	3180
50	caaaaaatta	tttccaaagg	tgtctgtccc	ttctaatttg	agttatggtg	aatgggtgca	3240
	tggattttgaa	aaaaaggcaa	aagaatgtat	ggctggaact	tcagggtcag	aggaggttaa	3300
	ggttctagag	cacaagttga	aagaagctga	tgaatgcac	acattgttac	agctagagtg	3360
	tgaaaaatac	aaatccgtcc	ttgcagaaac	agaagggaat	ttacagaagc	tacagagaag	3420
	tggtgagcaa	gaagaaaaata	aatggaaagt	taaggtcgat	gaatcacaca	agactattaa	3480
55	acagatgcag	tcattcattta	catcttcaga	acaagagcta	gagcgattaa	gaagcgaaaa	3540
	taaggatatt	gaaaatctga	gaagagaacg	agaacatttg	gaaatggaac	tagaaaaagg	3600
	agagatggaa	cgatctacct	atgttacaga	agtcagagag	ttgaaggcac	agttaaatga	3660
	aacactcaca	aaacttagaa	ctgaacaaaa	tgaagacag	aaggtagctg	gtgatttgca	3720
	taaggctcaa	cagtcactgg	agcttatcca	gtcaaaaata	gtaaaagctg	ctggagacac	3780
60	tactgttatt	gaaaatagtg	atgtttcccc	agaaacggag	tcttctgaga	aggagacaat	3840
	gtctgtaagt	ctaaatcaga	ctgtaacaca	gttacagcag	ttgcttcagg	cggtaaaacca	3900
	acagctcaca	aaggagaaag	agcactacca	ggtgttagag	tgaagtaatt	gggaaactgt	3960
	tcatttgagg	ataaaaaagg	cattgtatta	tattttgcc	aattaaaagg	ttattttatgt	4020
	tttcaccctt	tctactttgt	cagaaaacact	gaacagagtt	ttgtcttttc	taatccttgt	4080
65	tagactactg	atttaaagaa	ggaaaaaaaa	aagccaactc	tgtagacacc	ttcagagttt	4140
	agttttataa	taaaaaactgt	ttgaataatt	agacctttac	attcctgaag	ataaacatgt	4200
	aatcttttat	cttatttttgc	tcaataaaat	tgttcagaag	atcaaagtgg	taaagacaat	4260

gtaaaattta	acattttaat	actgatgttg	tacactgttt	tacttaacat	tttgggaagt	4320
aactgcctct	gacttcaact	caagaaaaca	cttttttggt	gctaatagtaa	tcggtttttg	4380
taatggcgtc	agcaaataaa	aggatgctta	ttattc			4416

SEQUENCE LISTING

<110> Ludwig Institute for Cancer Research

<120> Cancer Associated Antigens
and Uses Therefor

<130> L0461/7050WO

<140> US 09/166,300

<141> 1997-10-05

<140> US 09/166,350

<141> 1997-10-05

<160> 45

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 4422

<212> DNA

<213> Homo sapiens

<400> 1

gattattctg	gaggaagatg	accttcattt	tatggttatg	tgtgtgtgtc	tgtgtgtgtc	60
tggaaaaata	tatataattt	ttttttttt	gggggggaca	tatcagtgta	tgaattaaa	120
tatgtgcag	aatatataatt	ctaaaaactac	aaaaaagtcas	ctgaatalca	aatgatata	180
gattatatac	atagttaactg	tggcnaagtg	cagactgcta	gttcagaaatt	caaanntcct	240
l.l.c.k.a.g.l.l.l	gtgagalaal	gggctaaaatt	ccttctgccl	gccaatgygg	caaaagcaat	300
tgccttagtt	ttgatgaga	gttccttagaa	gtttgttgggt	attccttcct	ccacagcctc	360
cattgttgaa	atccccattt	tcagtctgtg	tgccttaact	aaagaagcaa	ttgttaagct	420
gaaalgcac	cttggtagcc	agtttcaatg	aaagctagaga	ttagtcagaa	aaagttagct	480
gttgggcttt	agaaagggat	tttgagtcct	gncatttcta	cttgggagca	ttttggagca	540
gattaaagctt	tcagtataaa	naaaaglggc	laccclgatgg	aaactllllct	taaccllaLa	600
gggaaactga	gcacaagctg	aatgatattg	tctgctgcaa	aaaaaaacaa	acaaaaaaa	660
aaacaaacaa	aaaacaaaaa	aaaaaaana	aaaaactcgt	gccaatctc	gcaagagggg	720
aagctcccg	ccccccccc	cctccggccg	cagccggccc	gctggccctg	cagccgtcgc	780
cgtgcctcg	ggctacagcc	cgggctcctg	cgtcccccgc	tggggaagg	gggcccag	840
cgcgtccgga	gcgcgcggag	ahggggygag	ggcactlgyg	cagcltcccc	gucggcggcg	900
ccggcagcgg	cagatcgtc	caactgaacg	taggggggac	cagatttagt	acctcaagac	960
aaactcttat	gtggattcca	gattcttttt	tttccagttt	gctgaagtcg	agactlllca	1020
cacttcagg	tgaaactgg	gctatattta	ttgatagaga	tccagcagca	tttgcaccca	1080
ttttaaat	tcttcggaca	aaagaactag	acttaagggg	agtgaagtatt	aatgtttctc	1140
ggcatgaagc	agaaattttac	gggactacat	cattaglaay	aaagclllct	llalgtgaag	1200
aattggagcg	llcctctttgt	ggcagtgctc	tttttcatgg	ttacttgccc	ccaccaggt	1260
ttcctagtcg	taaaataaac	aaacacgton	qatctgtcga	ttctaggaat	ggctcaaat	1320
ctacagagag	tgaagcccg	ggaaatgyla	cacagctcgt	lctclcttga	aaaggagag	1380
aaactgttag	gctagggatt	cctgtggatc	cacgaaggt	gctaatagta	gctggccatc	1440
acaaactggat	tgtagctcca	tatgcacatt	ttgcttngtg	gtacagagtc	aaagaaatcl	1500
caggatggca	gcasygttt	acgagcccat	atttggattg	gactatcgaa	caggtagctt	1560
taaatgcaaa	ggtggttga	ggccacacat	gagacaaaga	caaatggtt	gctgttgccl	1620
cagagagtag	cctcatcttg	lggagtgltc	aggatggggg	aaglggaagt	gaatttgag	1680
tgttcagcct	gggtgttctc	gtagatgctc	tcttctttat	tggtaaccag	ttggtggcca	1740
cgagtcatac	agggaaaagt	ggagtgtgga	atgctgtcac	tcagcactg	caggttcay	1800
ahgtgtttc	tataantayl	katgacactg	ctggatcalt	ccttctgctt	ggatgtaaca	1860
atggatcaat	atattacata	gatattgcga	agttccctt	gogaatgaan	gatanctgac	1920
ttcttgtaac	tgaactgtat	cctgactcll	caaatgctgc	lcthactgct	ahggtgttt	1980
actcaaacac	caaaacaayl	gtcagtggt	actggatcga	gatacgcctat	ggtaacagct	2040
ctggagcagt	acaggtgatt	gtacaacacc	cagagacagt	tgggtcaggt	cctcagcttt	2100
ttcagacttt	cacagttcac	cgaagtcccg	taacaaaaat	cattgctatca	gaggaagcctc	2160
ttgtatcctc	ctgtgcagat	ahaaclalc	lccggagclg	gacaglaaca	cgaattcngag	2220
gaatgatclc	laclcagcra	ggttctactc	ctttagcgtc	attcaagata	ctatccctng	2280
aggagacaga	aagtcattggt	agctattcct	ctgggaatga	cataaggaact	tttgagagag	2340
gagacagatca	acaggtgttt	alccagaaag	ttgttcccat	caccaacaaa	ctatttgtaa	2400
gactclcahc	gactggaaaa	agaatatgtg	agatccaggg	tgttgactgt	actacaatat	2460
cctcatttac	agtgaaggaa	tgtgaaggat	caagtagnat	gggclcaay	ccaaagggcl	2520

	acttgttccac	aggccataca	aalgggcaata	ttcaaatgtg	ggatctgacc	actgctatgg	2580
	atattgttta	caaaagtga	gataaggatg	taggtgtgtc	aaccgaagaa	gagctactca	2640
	aatttctcga	tcaattgtat	ttgagcacat	ctcgtctgyc	tcctcctaac	atcagkccay	2700
5	caacttccgt	agttcagcat	agccatttac	gagaatcaaa	tlcclagcett	cagcttcagc	2760
	accatgatac	caccatgaa	gcagctactt	acggttccat	gaggccctac	anagaaggtc	2820
	ctttatttgc	aagggaanng	nggactgaga	gctttcaann	tttataggac	ttccagacta	2880
	tttaatttgaa	cagaaattga	gnanagactg	tccttgaaaa	tggttaacttg	ggtccaatag	2940
	aagctgaagt	gaaaggggca	acagggggaat	glanttatct	tgagagaaaq	tcctcttggg	3000
10	taqaaakaaa	naqtttqgg	qanttgata	gtggattgga	agtgnatcaa	atagctgaag	3060
	gtttttcaga	atccaagaaa	agglcactcag	angatgaaaa	tgaaaataaa	atnagagctta	3120
	ggaanagaaq	anqatttgaa	gggggaggat	tccttggaag	anngannagt	ccctatctgg	3180
	catcatcacc	aaglacctcc	gahgngngaa	ctgnctcacc	tggtactggg	ccccatcttc	3240
	ctacaaagac	tactccatct	cctgggcata	aannngtga	ttcttcaggt	caggagtaca	3300
15	gcttgtgaaa	actcaccaaa	atgaatagtt	gtttcgggta	cahtthngntg	aaagtttaac	3360
	ttlacnlgaa	ttcaglacat	lagctttttac	octannaact	tacaagataa	aal.tggactt	3420
	catttagtat	ctttttaaca	gaattacttg	gaataalyay	atcaatnat	catatctctt	3480
	ttgacattttt	qnaatttttt	ttantttttac	aggtacattt	aacagatcat	tlhlaaagca	3540
	ggagtccatt	ctaanactta	ccgattttttt	llgggtttgga	aacatattac	cagctcttaa	3600
20	taggatggg	cccatatagg	tgagcatccc	tttagatcat	gggagccagc	agantgactt	3660
	actaatcttcc	attatgccc	agactttgtct	tacaatgita	cccttaagtg	aatcacataa	3720
	ttgtcttttg	aacttgggtct	cccaacactt	attgtgally	caanngtgtt	ccccgatatt	3780
	tgatgaggtg	ctatgtttgt	qaaaaacata	tcagttaatt	caaaaaacact	attgatattg	3840
	aataccagat	ccccctatgt	agtaagtctt	ttaggatggt	tttaatttag	tcgtgactca	3900
25	ttttctgatt	ctcatcattg	ggagatctta	natcttagca	agcattagca	alattaaatg	3960
	ccaaenllcc	alltgnaaclt	lcaaglllgya	qimalltctct	gtgtttgaaa	agatgaaata	4020
	aaaataataa	tcaaggggcaa	agctttgagt	gcccagaagg	gaaaggttgh	cccccttga	4080
	acctgtcttg	ttcagggagc	caccatgttt	tttttccagt	gttancaaca	atcatgataa	4140
	ttaaaktaaa	acnccagttt	gttcaacttg	aggactggag	ttctgaattt	tggttcaaan	4200
30	gttttggtcg	ctgtaagaat	gtgaatttga	atgtattttg	aallglaaqa	gcnaaaggaac	4260
	gtttttgtac	antttttttt	cahttaacttg	gactgatctt	caggtttcta	caaatagggt	4320
	aattgtaaat	ttaaagcatt	agcattttatt	ggtgaataal	glahakaton	ccattctaaq	4380
	aatataagt	gagtgaagtt	gnaataaaat	cttlaaaatt	ta		4422
35	<210> 2						
	<211> 502						
	<212> DNA						
	<213> Homo sapiens						
40	<400> 2						
	getagcttgc	ggcggggtac	ntggggggtcc	ghanghngga	ntccttctgtc	ctccaggglc	60
	cctgtttctt	ggccagcggg	gaacacactat	ctctgcactc	ctgggggtttt	gllacattggc	120
	tactttcttc	aaaatgagtg	ttngtgtcaa	ttcttcaga	cccttcaacca	ggttttttgtt	180
	gccattttacc	cttccatagga	agagaaataa	ctlaacaaclt	ttgagagagcl	acnlygtcttc	240
45	caaaataacca	gctgtttact	atcctaaaaa	tgagagtaca	cgcccttctg	aagagctaga	300
	gttggtatay	tngnaaactc	ccatgnaatc	laghgtgcga	gaaqnnatgtg	tttcaacaacl	360
	ctcaagcagc	aaggatgaag	atcctctagc	tgccaccaga	gagttcattg	agatgtggag	420
	attccttggc	agagaagtac	cagaaacacat	cactgaagaa	gagctcaaaa	cccttatggc	480
	atgtgtttct	aacacagcaa	aa				502
50	<210> 3						
	<211> 1948						
	<212> DNA						
	<213> Homo sapiens						
55	<400> 3						
	ccatgkyagg	gagggggccc	ctcclgccll	glganngagt	caggaagggg	tggcctgag	60
	ttcctccagc	agtgtgaccg	ggaggtatct	gtgggaattgg	ctctgcctca	gctggctcag	120
	gttgtgnccg	tgtatgagtt	tcttctctatg	aaqgttgnaa	aagatcatct	agcaagacat	180
	ttttttccag	clataclclaa	ggaaatttgaa	gagtrgcalf	aaahggkkan	gnaaatgtgc	240
60	caagattacc	ttagtagttc	tggtctgtgt	tcacaggaga	ccctggaaat	aaacaatgat	300
	aaggttgctg	agtcattagg	aatcacagaa	ttcctacggg	agaaagaaat	acacccagac	360
	aaactttgac	ccnagcaact	cagccggggc	ahqgtgtgng	agcagctaga	gggagctayc	420
	agcgagagaa	gggaaacgha	ggclgcggag	gagggactuy	ctcagctgaa	aaqyccacga	480
	agagaagccc	tgtccaaagc	taccactgaa	tctcttgctg	ccaaacagcag	aggccgggag	540
65	aaagccaggc	ccttgcatgc	tttgcccgccl	ggtttttccc	ctccagtaaa	tgtgactgtc	600
	tctcccnghl	clghagaaag	ccalacaaacg	acggtttclly	gtngcaatgg	gaagghglto	660
	caggccgggccc	cgcagcttca	ggcactggct	aacttagaag	ccaggagggg	glctataggt	720

	gctgcacatc	actcccgga	tgtcagtcyy	ctgcctgttt	atgcctcagtc	aggagagct	780
	aggagagctga	cccagggca	ggtggcagcg	tttccclggg	ngaagcttll	ggacacactct	840
	lccagaccagg	acacctggga	cagcctgggg	agcccggggtt	tttgcagccc	ttlghcactct	900
5	ggtygtggag	cagcgtccct	gcgccttggy	ggynctnqac	atgcagaggg	aggacacclc	960
	ggcaagggttt	gtgacttccc	cttgaaccac	cagcagccc	gccccaccag	gttcctgctct	1020
	acagaggttg	cagccctccc	gcttgagaaa	attttgtctg	tggatagcgt	ggcagtgga	1080
	tgtgcctaca	ggaactgtgc	caagccaggg	ccctcagcctg	gcccacalgg	atcactattg	1140
	actgaagggg	glttcagagc	cttttcgggg	gacttgacac	gtttccctcg	tgggctggag	1200
	gtgcactctg	gccagagaga	actgggagagc	gtggttgctg	tgggagagag	catggctttg	1260
10	aaatttccan	tggagagccat	gagttactgt	ctcaggggca	gaagcagatt	ttttctcaga	1320
	cttcagatgg	gcllacthcg	tccctccag	gtacaatagt	glttcagagag	gaggacattg	1380
	tcacagtgac	tgatgcagag	ggcgclgagc	gaggtagggc	ccgctagagc	gagttccctct	1440
	agagagctgt	gagtcggctg	tcacccggag	agccclccac	gtgaagtgga	gltcagatct	1500
	agattcgclcl	galttctatc	agagagaggtc	tatggcaagc	ahgtatatt	tttctaattg	1560
15	gaattttgca	cagatgaacc	ttttatttcl	aaagataat	gtttttctgc	ctcagctgtct	1620
	acatttttcl	atggagcttg	tataataat	agcagatatt	acttctcag	gaatccctgt	1680
	ggcgctctg	acgctcagc	gttttclalg	ahgtatagc	gtagcactgc	actgtcact	1740
	galtattggc	ctcgtccgt	ttcccttctc	tcctgggagc	laktgtgtct	ttccaccaga	1800
	cttgcctcat	actagaagct	tcltttgggt	tcaattaaaa	agaaaataag	ctagtcattc	1860
20	tgggcagcat	tttattgata	gaagggggaa	aaagltcttt	ctacttgcac	galttcltla	1920
	ahlaaatttc	actaactaa	tttaaaaa				1980

<210> 4

<211> 1486

<212> DNA

<213> Homo sapiens

<400> 4

	ccgcgggagc	gtccgggagc	tcacgtagag	ctgaagctcc	ggctgctgca	caahctcccg	60
30	ccctcggtcg	caacggggcg	ccctccactc	cccgagltcc	gggagagccg	ggccacccca	120
	gggagcccg	atctggcccg	ctgcctcgag	aagatggctg	ccgtagcccg	ggccagagcl	180
	tattgcctct	gctcgttgcc	cttclccgac	cgagagctct	gcttagctcc	gctgcagaga	240
	caggcaggag	tagacacccg	gacacccagc	acccctctct	ccgggggggg	tccagagggg	300
	gacagggag	ccctccagag	gcagcagggc	gccccccag	catggcagaa	gclgagggag	360
35	attgtcatlc	lgatcttcl	agagcagalg	ahgtatagag	aatgaaggt	ccgtctgaaa	420
	cagatctgca	ggcacaactc	cagatgttcc	gagctcagtg	gatgttclga	attgclccag	480
	gltgaagctc	tgcacattta	gaaactccgc	cttgcagagc	agcaagaggo	tctctccaga	540
	aaacatcggc	agataccaaa	ggaaaacag	aacagycasa	agagaggggg	gttcgaagag	600
	tcttctctaa	agcagtagaa	gaagaaacaa	atggagctct	ctatgaagcc	atcaagtgtt	660
40	atcgtagggc	tatgcacatt	gtacctgata	tagagcltca	gattacttat	acccggtctc	720
	cagatggtag	tggcgttggc	aacagctaca	ttgaagatac	tgatgatgac	agagaaalgg	780
	cagatclclt	gtcctacttc	gagaggggac	hacactttcc	gagctctgtg	cttaactgt	840
	gtcagcctga	gcttgagagc	agtcagatto	acatatcagt	gtgtccaalg	gggclccctg	900
	tgtacatclt	ccgatgggtg	gtgtctatgt	acttggacct	cagatcattg	gagcagttgt	960
45	cgctgggtgt	cagagggatt	tacatctgtg	ccagagagcc	tgaalalgg	cgtctggcct	1020
	gcttgaagct	ttggggcaga	agctgtatta	aaottgttcc	gtacacgtcc	tggagagaga	1080
	tgtttttaga	acggcctcgt	gltcagtttg	atggccltca	tctcagtaaa	accacatata	1140
	ttcgtcaagg	ggaacagctc	cttgatgggt	tctatagagc	ctggcactaa	ghggaaclcl	1200
	acaggtatct	aagattcttt	cttgnitggc	atgtgatgat	gttgacaacc	ccatgaagagc	1260
50	ctcagtcctat	lgtlccacgc	ltaagactca	gggaaalacc	ggactgctgc	caattctact	1320
	gggtcaactat	cgcttggcac	aagacacaga	ccatcagacc	caaggtattt	lgtlgtataa	1380
	actaagaaaa	aaaggaagaa	aaacacttgg	gaatatant	acccgatatt	ttcgtcgggg	1440
	tcctgttacc	aaagaagccg	aatcagaagt	tttcatynny	gggcll		1486

<210> 5

<211> 774

<212> DNA

<213> Homo sapiens

<400> 5

	tggcagagcc	caacccaccc	caaccccgcc	atgaaagggg	attgaagggg	ccctgcgggtg	60
	ggacccctgcl	cgagccagtg	ccacclgcac	ccgagagctg	tagagctagc	tgttcgggct	120
	gtccacccca	cccgccgctc	ccacgggccc	ctcgggggca	ccagagctgc	ngacttggag	180
	actcctgggtc	tgtgaagagc	cggtgggtcc	cgtgcgggca	ggaaactggg	tgggctcgt	240
65	ggcggcggtg	ggtctcggcl	lgtlcttclt	gtgcllgtal	lgtcctctcl	attgcattgc	300
	tggtagagac	cccgaggcct	gtccacccct	ccagactcc	tcaggcagcg	tgtgggtccc	360
	gacactctgac	cccatctccc	cgatgtccac	tgcggggcgc	ggcagccacc	caagcctgtc	420

	yggtgggggc	ccctotoggg	caggcattgg	ctcagggggc	tgagtggggg	glcggggggc	480
	agtcggggg	gggtggggg	ccctggggg	cacacagggg	ggggggggg	ccaggggggc	540
	ccggcaggg	cacgggggg	glggggggg	tatgggggg	ggggggggg	aactccatgt	600
	ttgggtgttg	tctgggtttg	tttttcaaga	aatgallggg	attggtggtt	ggattttgaa	660
5	atttactgla	actgllcagtg	tccacgtctg	ggccgggttt	calttttaca	ccaatttggt	720
	aaaaatgctg	ctctcagcct	cccacaattt	gggggggtgt	gatctccaaa	aaaa	774

<210> 6

<211> 2936

<212> DNA

<213> Homo sapiens

<400> 6

	cgtaacccctt	agtcaccaatg	cttcggtaag	gggagllggg	ttgggtgctg	tggttggaag	60
15	tggtggaggtg	tccccgggtg	cgagcggggc	cagaactgcg	gttgggllggg	ttttccgllg	120
	gggggtttgg	gggggggttg	gtgggtctgg	tatggggggg	acacctctgg	attgagggatc	180
	ttatgaccta	cttttagagg	aggtataatt	tggttccclg	ggtttctgnc	ttagggggaa	240
	aggagtgagg	aatacccttg	gggggggggg	taaaacagta	agaaagccaa	aaatttatttt	300
	laccaggttg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	360
20	ggagacagtg	gattgacagg	ttctcagctg	gagttccagg	gggggggggg	gggggggggg	420
	ttacgatgtg	aggttcctaa	aggtanttat	gggggggggg	gggggggggg	gggggggggg	480
	cagagtgagg	aggttcctaa	aggtanttat	gggggggggg	gggggggggg	gggggggggg	540
	cagagtgagg	aggttcctaa	aggtanttat	gggggggggg	gggggggggg	gggggggggg	600
25	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	660
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	720
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	780
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	840
30	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	900
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	960
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	1020
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	1080
35	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	1140
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	1200
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	1260
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	1320
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	1380
40	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	1440
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	1500
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	1560
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	1620
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	1680
45	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	1740
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	1800
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	1860
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	1920
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	1980
50	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	2040
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	2100
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	2160
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	2220
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	2280
55	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	2340
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	2400
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	2460
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	2520
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	2580
60	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	2640
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	2700
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	2760
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	2820
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	2880
	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	gggggggggg	2936

<210> 7

<211> 1387

<212> DNA

<213> Homo sapiens

<400> 7

	naaggtacaa	tcatttaacac	tangaaggagg	acgalktaaaa	cgaaactcacc	agctgattca	60
5	cyaaagggg	tatgaaatgg	tcccaaggacc	tgtgtggaga	gnaattttatc	actggtatng	120
	agcaaacctg	gntttaccta	gaccagttat	caaaqaaacagc	aagaaagaaac	tccagagagc	180
	ggaattattt	ccccgctatc	ttctcttctc	gagacagaaq	cctgccaccln	qaaacacagca	240
	glttaacatc	tgggtgaata	tgggaaatgt	accttctctc	aatgcacatt	taaaagcggg	300
	attagctat.	acggctqtt	ttagtcgaat	gcagaccatc	aaggaaalhc	acqaatatct	360
	atctcaagg	ctgcgcaltc	aaagaggaaga	tatgcgcclg	tggctatata	acagtaaaac	420
10	clacettact	cttctggatg	atgaggatlc	taatttggaa	talllkyaaa	tccaggatga	480
	acaacacctg	gtaaalkgag	ttcgcaacaa	agatatgag	tqccctgagg	agatgtcttt	540
	tatacaaat	agtagtaaaa	tagalagaaa	caaggttccc	acagaaagaa	gagccacagg	600
	tataagcaal	ctaaagaaac	catgcttcac	gaactcaagg	atccagttyg	llhghaaac	660
	adagccactg	acacaglatl	ttatctcagg	gagacatctt	lctgaactca	acagacaaa	720
15	tccatttgg	atgaaggggc	atatggclac	atqctatgtt	gatlclaghyn	aggaactttg	780
	gagtggaacl	caaaagaaatg	ttgccccatt	aaagcttctg	tggaccatag	caaaalclg	840
	tccaggttt	aatgggttt	agcaaaagga	ctcccaagaa	ctclctggctt	ttctcttggg	900
	lgtttctct	gaagatctta	atcgagtcac	tgaagagaca	tatgtggac	lghaggaacg	960
	tgatgggca	ccagacttgg	aaqtatctgc	agaggcttgg	gacaaacatc	taagagaaa	1020
20	tagatcaatt	gttgtggatt	tgttccalys	gcagctaaqa	tctcaaglan	aatgcaagac	1080
	atgtggqcat	ataagtgtcc	gatttgaccc	ttlcaalclt	ttgtctttgc	cactaccaat	1140
	ggacagttat	algcacltng	aaataacagt	gattaagtta	gahygtacta	ccctgtacg	1200
	gtatgacta	agactgaata	tggatgaaaa	ghacaaaggt	taaaaaaac	agclgagtya	1260
	tctctgltgg	clhacttcaq	aaacaatctc	tctagcagaa	ghaaatgqtt	caaacataaa	1320
25	gaactttct	caggacaacc	caaaaaglan	naaacttctc	agtgaagltgg	yahllhclg	1380
	lgttcca						1387

<210> 8

<211> 749

<212> DNA

<213> Homo sapiens

<400> 8

	gicccacatn	actggagcgc	ggcggaggtg	agccggccgc	atgaaagagaa	acgcctcagc	60
35	ctactgcgcc	cgagtcacag	gaccccaatn	gcgcctcagc	tctggcgtgc	cyagggccaa	120
	cggtctgato	gctgcacgcc	gccagcatgt	tgygcgcgcc	gaaacaaagac	tccgtggcgg	180
	lgyctgtacg	ataaagacca	cagcttgcca	aagagaagat	tgaaggclgc	catatcttga	240
	catctgtcac	accagagag	ctlcaagclt	lclhagggaa	agataagqct	tttacttttg	300
	actatgtatt	tgaacttgac	tccagcaag	agcagatcta	cattcaalgl	atgaaagaa	360
40	taattgaag	tlgclhclgaa	qgatacaaly	atacaatctt	tgttatgga	caaaactggg	420
	ctggtaaaa	atacacaatg	gaaacaggat	ttgatgttaa	calhghthgg	gaagaaactn	480
	gtattalcll	tgaagctgtt	naaaccttt	ttagagtat	tgaagaaaa	aaacacatag	540
	caattaaaa	tgggcttctc	gtccagatt	tlaaalyaaa	hgcacaaatc	ttatagctct	600
	ataalyaaag	ggtccttgac	ctntttgata	ccactcgiga	tattgatgca	aaaaglaaaa	660
45	aatcaaatat	aagaattcat	gaagattcaa	clggagggaa	tttatactct	gggcgtttcc	720
	aaacagtaact	gtgaatacaq	aaconagag				749

<210> 9

<211> 686

<212> DNA

<213> Homo sapiens

<400> 9

	tggaaattat	agacctagca	aaaaaagatt	tagagaaggl	lghaaagggg	agaaatagag	60
55	aaglaaaag	ntgtggctng	taaagaggat	aatcacagaca	ctgaccaaga	gaagaaagaa	120
	gaaaagggtg	tttccggaaay	ayaaaaccaa	lghaattagaa	gtgaaagaaa	gtcaagaggt	180
	gaatgtatcat	agagatgaag	aagaggagga	ggaggaggag	gaagalgaca	hghclggguy	240
	tgaagytctc	natgtaatca	nttctgaatc	agatgaaaaa	gcnaattatc	aagcagactt	300
	ggcaaacatt	acttglygaan	ltgcaalttaa	gcnaaggtctg	attgctgaac	taaaaaaacn	360
60	ccagaaagga	ctgcagactc	tgaaaaagca	gtatgaagag	aagulaalga	lgttgcacaa	420
	taaaattcgg	gatactcagc	ttgaaagaga	ccaggttgctt	caaaacttag	gctcgttaga	480
	atcttactca	gaagaaagag	caaaaaaagc	taggtctgaa	tatgaaaaga	aactcaagc	540
	catgaacaaa	gaactgcaga	gacttcaagc	agctcaaaaa	gaacatgcaa	gatttgcctaa	600
	aaatcagttc	cagtatgaaa	agcnattgaa	gaattgcaag	caagalglya	lggaaatgaa	660
65	aaaaacagag	gttccgctaa	tgaaaa				686

<210> 10

<211> 833
 <212> DNA
 <213> Homo sapiens

5 <400> 10
 gttctttctgt cgcacggttc agcagccccc gcccgggcag caatagaaga lgaacaaacc 60
 cctaacacca tcaacatctg hggcgtgcct caatgttggg ctacttagga agctgkcarq 120
 ttttattggt cctcaagaag gctgggagaa gtttagctgn gctattaaa nccatctctg 180
 tgatgataga kactatcagt ttacacatag nagatttgaq gctattactt aacttggaag 240
 10 aagtcaccact tctgaalac tgtttgactg gggacccaca aatlycaccg ttggtgalch 300
 tgtggatctt ttgatccaaa atgaakttt tgcctcctgc aqtcttttgc lccagatgc 360
 tgttcccaaa actgataata cactaccttc kaaaagatgt ataactgtc agcaaaaaac 420
 gahgcttttc tgtgacaaag acaygacatt gatgacact ctgcagaatc kkgacnaag 480
 ctatatgcca cctgactcct caagtcacag aatataaagt tlaggaqita gtgatacag 540
 15 ttttcacagt ttttcattll atqanttgaa gaatgkccn aataactllg atgaacgacc 600
 caltctctgt ggtggtata aatggggnq gggagggatt cnaqtgtat ataaagggct 660
 aagtaataaa caactctgt gcaqtgaaag aaycttgcaq caatggkkgz cattaactact 720
 aaggaactg aaaccagcag lkhactocaa gaaaataaaa gtaatgggca aaagtgtatc 780
 accatggaaa aactttagta ggaacctact lgggtttttt caagtggatg gga 833

<210> 11
 <211> 799
 <212> DNA
 <213> Homo sapiens

25 <400> 11
 taaaaatctt ccttingatg atacttgcca ctatgatgat gtcccailll tggattatgt 60
 tacatgocaa agctttaaagp aatttgggca gatccagkka aggttccctt aacaaactct 120
 30 otttgagact gttgaaaggg cctgacckaa tocaagtga cccckhgcnn gaagaattct 180
 ccttgtaagc cttgaanag tatgtgagag ggcckatttq gctaaaaacc aaaggtgqcc 240
 totaggagat gagacclacc thraqttrgt cagcaagcag yaaaaaana ttgggacctc 300
 agtgcanaa acaggaact gaattctgca aaaaatntga gtcagcllag aaagtactc 360
 caagcttcag akgtaccca cagcctgggc tgacacclgg atttagcttt gcatgaccl 420
 35 cagtatgaga atctatctgt tctgltctgg aettctata tatayactg tgagataatg 480
 ggtaaccltq qctggatgtg gtggctcata cclghaate ccagcacttt gggnygcga 540
 ggcaggcaga tcaactggcg tozagagttc aagaccggcc kggccanact ggtgaaaccc 600
 cgtctntact aaaaatacaa aaattlagag nyggtgtgtg tggacacclg hgtccacagc 660
 cgttggggag gctyagggag ggaactagct ggaaccaggg aggtagaggt tgcagtgcgc 720
 kgaatctgtg caactgcact ccagccclgg kgcagagtg agactccalc ataatant 780
 40 aataaalaa atgggtctc 799

<210> 12
 <211> 812
 <212> PRT
 <213> Homo sapiens

45 <400> 12
 Met Ala Gly Gly His Cys Gly Ser Phe Pro Ala Ala Ala Ala Gly Ser
 1 5 10 15
 50 Gly Glu Ile Val Cln Leu Asn Val Gly Gly Thr Arg Phe Ser Thr Ser
 20 25 30
 Arg Glu Thr Leu Met Trp Ile Pro Asp Ser Phe Phe Ser Ser Leu Leu
 35 40 45
 55 Ser Gly Arg Ile Ser Thr Leu Arg Asp Glu Thr Gly Ala Ile Phe Ile
 50 55 60
 Asp Arg Asp Pro Ala Ala Phe Ala Pro Ile Leu Asn Phe Leu Arg Thr
 65 70 75 80
 Lys Glu Leu Asp Leu Arg Gly Val Ser Ile Asn Val Leu Arg His Glu
 85 90 95
 60 Ala Glu Phe Tyr Gly Ile Thr Pro Leu Val Arg Arg Leu Leu Leu Cys
 100 105 110
 Glu Glu Leu Glu Arg Ser S r Cys Gly Ser Val Leu Phe His Gly Tyr
 115 120 125
 65 Leu Pro Pro Pro Gly Ile Pro Ser Arg Lys Ile Asn Asn Thr Val Arg
 130 135 140
 Ser Ala Asp Ser Arg Asn Gly Leu Asn Ser Thr Glu Gly Glu Ala Arg
 145 150 155 160

	Gly	Asn	Gly	Thr	Gln	Pro	Val	Leu	Ser	Gly	Thr	Gly	Glu	Glu	Thr	Val
					165					170					175	
	Arg	Leu	Gly	Phe	Pro	Val	Asp	Pro	Arg	Lys	Val	Leu	Ile	Val	Ala	Gly
				180					185					190		
5	His	His	Asn	Trp	Ile	Val	Ala	Ala	Tyr	Ala	His	Phe	Ala	Tyr	Arg	Ile
			195				200						205			
	Lys	Glu	Ser	Ser	Gly	Trp	Gln	Gln	Val	Phe	Thr	Ser	Pro	Tyr	Leu	Asp
		210					215					220				
10	Trp	Thr	Ile	Glu	Arg	Val	Ala	Leu	Asn	Ala	Lys	Val	Val	Gly	Gly	Pro
	225					230					235					240
	His	Gly	Asp	Lys	Asp	Lys	Met	Val	Ala	Val	Ala	Ser	Glu	Ser	Ser	Ile
					245					250					255	
	Ile	Leu	Trp	Ser	Val	Gln	Asp	Gly	Gly	Ser	Gly	Ser	Glu	Ile	Gly	Val
			260					265						270		
15	Phe	Ser	Leu	Gly	Val	Pro	Val	Asp	Ala	Leu	Phe	Phe	Ile	Gly	Asn	Gln
			275					280					285			
	Leu	Val	Ala	Thr	Ser	His	Thr	Gly	Lys	Val	Gly	Val	Trp	Asn	Ala	Val
		290					295					300				
20	Thr	Gln	His	Trp	Gln	Val	Gln	Asp	Val	Val	Pro	Ile	Thr	Ser	Tyr	Asp
	305					310					315					320
	Thr	Ala	Gly	Ser	Phe	Leu	Leu	Leu	Gly	Cys	Asn	Asn	Gly	Ser	Ile	Tyr
					325					330					335	
	Tyr	Ile	Asp	Met	Gln	Lys	Phe	Pro	Leu	Arg	Met	Lys	Asp	Asn	Asp	Leu
			340						345					350		
25	Leu	Val	Thr	Glu	Leu	Tyr	His	Asp	Pro	Ser	Asn	Asp	Ala	Ile	Thr	Ala
			355					360					365			
	Leu	Ser	Val	Tyr	Leu	Thr	Pro	Lys	Thr	Ser	Val	Ser	Gly	Asn	Trp	Ile
			370				375					380				
30	Glu	Ile	Ala	Tyr	Gly	Thr	Ser	Ser	Gly	Ala	Val	Arg	Val	Ile	Val	Gln
	385					390					395					400
	His	Pro	Glu	Thr	Val	Gly	Ser	Gly	Pro	Gln	Leu	Phe	Gln	Thr	Phe	Thr
					405					410					415	
	Val	His	Arg	Ser	Pro	Val	Thr	Lys	Ile	Met	Leu	Ser	Glu	Lys	His	Leu
			420						425					430		
35	Val	Ser	Val	Cys	Ala	Asp	Asn	Asn	His	Val	Arg	Thr	Trp	Thr	Val	Thr
			435					440					445			
	Arg	Phe	Gly	Met	Ile	Ser	Thr	Gln	Pro	Gly	Ser	Thr	Pro	Leu	Ala	Ser
		450					455					460				
40	Phe	Lys	Ile	Leu	Ser	Leu	Glu	Glu	Thr	Glu	Ser	His	Gly	Ser	Tyr	Ser
	465					470					475					480
	Ser	Gly	Asn	Asp	Ile	Gly	Pro	Phe	Gly	Glu	Arg	Asp	Asp	Gln	Gln	Val
					485					490					495	
	Phe	Ile	Gln	Lys	Val	Val	Pro	Ile	Thr	Asn	Lys	Leu	Phe	Val	Arg	Leu
			500						505					510		
45	Ser	Ser	Thr	Gly	Lys	Arg	Ile	Cys	Glu	Ile	Gln	Ala	Val	Asp	Cys	Thr
			515					520					525			
	Thr	Ile	Ser	Ser	Phe	Thr	Val	Arg	Glu	Cys	Glu	Gly	Ser	Ser	Arg	Met
		530					535					540				
50	Gly	Ser	Arg	Pro	Arg	Arg	Tyr	Leu	Phe	Thr	Gly	His	Thr	Asn	Gly	Ser
	545					550					555					560
	Ile	Gln	Met	Trp	Asp	Leu	Thr	Thr	Ala	Met	Asp	Met	Val	Asn	Lys	Ser
					565					570					575	
	Glu	Asp	Lys	Asp	Val	Gly	Gly	Pro	Thr	Glu	Glu	Glu	Leu	Leu	Lys	Leu
			580						585				590			
55	Leu	Asp	Gln	Cys	Asp	Leu	Ser	Thr	Ser	Arg	Cys	Ala	Thr	Pro	Asn	Ile
			595					600					605			
	Ser	Pro	Ala	Thr	Ser	Val	Val	Gln	His	Ser	His	Leu	Arg	Glu	Ser	Asn
		610					615					620				
60	Ser	Ser	Leu	Gln	Leu	Gln	His	His	Asp	Thr	Thr	His	Glu	Ala	Ala	Thr
	625					630					635					640
	Tyr	Gly	Ser	Met	Arg	Pro	Tyr	Arg	Glu	Ser	Pro	Leu	Leu	Ala	Arg	Ala
					645					650					655	
	Arg	Arg	Thr	Glu	Ser	Phe	His	Ser	Tyr	Arg	Asp	Phe	Gln	Thr	Tle	Asn
			660						665					670		
65	Leu	Asn	Arg	Asn	Val	Glu	Arg	Ala	Val	Pro	Glu	Asn	Gly	Asn	Leu	Gly
			675					680					685			
	Pro	Ile	Gln	Ala	Glu	Val	Lys	Gly	Ala	Thr	Gly	Glu	Cys	Asn	Ile	Ser

5 690 695 700
 Glu Arg Lys Ser Pro Gly Val Glu Ile Lys Ser Leu Arg Glu Leu Asp
 705 710 715 720
 Ser Gly Leu Glu Val His Lys Il Ala Glu Gly Phe Ser Glu Ser Lys
 725 730
 Lys Arg Ser Ser Glu Asp Glu Asn Glu Asn Lys Ile Glu Phe Arg Lys
 740 745 750
 Lys Gly Gly Phe Glu Gly Gly Gly Phe Leu Gly Arg Lys Lys Val Pro
 755 760 765
 10 Tyr Leu Ala Ser Ser Pro Ser Thr Ser Asp Gly Gly Thr Asp Ser Pro
 770 775 780
 Gly Thr Ala Ser Pro Ser Phe Thr Lys Thr Thr Pro Ser Pro Arg His
 785 790 795 800
 Lys Lys Ser Asp Ser Ser Gly Glu Glu Tyr Ser Leu
 805 810

20 <210> 13
 <211> 167
 <212> PRT
 <213> Homo sapiens

25 <400> 13
 Leu Ala Ser Ala Arg Ile Pro Gly Arg Pro Tyr Val Gly Val Leu Arg
 1 5 10 15
 Pro Pro Gly Ser Leu Phe Phe Ala Pro Ala Gly Thr Thr Ile Ser Ala
 20 25 30
 Leu Leu Gly Phe Cys Tyr Met Ala Ala Phe Leu Lys Met Ser Val Ser
 35 40 45
 Val Asn Phe Phe Arg Pro Phe Thr Arg Phe Leu Val Pro Phe Thr Leu
 50 55 60
 His Arg Lys Arg Asn Asn Leu Thr Ile Leu Glu Arg Tyr Met Ser Ser
 65 70 75 80
 Lys Ile Pro Ala Val Thr Tyr Pro Lys Asn Glu Ser Thr Arg Pro Ser
 85 90 95
 35 Glu Glu Leu Glu Leu Asp Lys Trp Lys Thr Thr Met Lys Ser Ser Val
 100 105 110
 Glu Glu Glu Cys Val Ser Thr Ile Ser Ser Ser Lys Asp Glu Asp Pro
 115 120 125
 40 Leu Ala Ala Thr Arg Glu Phe Ile Glu Met Trp Arg Leu Leu Gly Arg
 130 135 140
 Glu Val Pro Glu His Ile Thr Glu Glu Glu Leu Lys Thr Leu Met Glu
 145 150 155 160
 Cys Val Ser Asn Thr Ala Lys
 165

45 <210> 14
 <211> 452
 <212> PRT
 <213> Homo sapiens

50 <400> 14
 Pro Cys Glu Gly Gly Ala Arg Ser Cys Leu Val Thr Glu Ser Ala Arg
 1 5 10 15
 Gly Gly Leu Glu Phe Leu Glu Glu Cys Asp Arg Glu Asp Leu Val Glu
 20 25 30
 Leu Ala Leu Pro Glu Leu Ala Glu Val Val Thr Val Tyr Glu Phe Leu
 35 40 45
 Leu Met Lys Val Glu Lys Asp His Leu Ala Lys Pro Phe Phe Pro Ala
 50 55 60
 60 Ile Tyr Lys Glu Phe Glu Glu Leu His Lys Met Val Lys Lys Met Cys
 65 70 75 80
 Glu Asp Tyr Leu Ser Ser Ser Gly Leu Cys Ser Glu Glu Thr Leu Glu
 85 90 95
 65 Ile Asn Asn Asp Lys Val Ala Glu Ser Leu Gly Ile Thr Glu Phe Leu
 100 105 110
 Arg Lys Lys Glu Ile His Pro Asp Asn Leu Gly Pro Lys His Leu Ser
 115 120 125

Arg Asp Met Asp Gly Glu Gln Leu Glu Gly Ala Ser Ser Glu Lys Arg
 130 135 140
 Glu Arg Glu Ala Ala Gln Glu Gly Leu Ala Ser Val Lys Arg Pro Arg
 145 150 155 160
 5 Arg Glu Ala Leu Ser Asn Asp Thr Thr Glu Ser Leu Ala Ala Asn Ser
 165 170 175
 Arg Gly Arg Glu Lys Pro Arg Pro Leu His Ala Leu Pro Ala Gly Phe
 180 185 190
 10 Ser Pro Pro Val Asn Val Thr Val Ser Pro Arg Ser Glu Glu Ser His
 195 200 205
 Thr Thr Thr Val Ser Gly Gly Asn Gly Ser Val Phe Glu Ala Gly Pro
 210 215 220
 Gln Leu Gln Ala Leu Ala Asn Leu Glu Ala Arg Arg Gly Ser Ile Gly
 225 230 235 240
 15 Ala Ala Leu Ser Ser Arg Asp Val Ser Gly Leu Pro Val Tyr Ala Gln
 245 250 255
 Ser Gly Glu Pro Arg Arg Leu Thr Gln Ala Gln Val Ala Ala Phe Pro
 260 265 270
 20 Gly Glu Asn Ala Leu Glu His Ser Ser Asp Gln Asp Thr Trp Asp Ser
 275 280 285
 Leu Arg Ser Pro Gly Phe Cys Ser Pro Leu Ser Ser Gly Gly Gly Ala
 290 295 300
 Glu Ser Leu Pro Pro Gly Gly Pro Gly His Ala Glu Ala Gly His Leu
 305 310 315 320
 25 Gly Lys Val Cys Asp Phe His Leu Asn His Gln Gln Pro Ser Pro Thr
 325 330 335
 Ser Val Leu Pro Thr Glu Val Ala Ala Pro Pro Leu Glu Lys Ile Leu
 340 345 350
 30 Ser Val Asp Ser Val Ala Val Asp Cys Ala Tyr Arg Thr Val Pro Lys
 355 360 365
 Pro Gly Pro Gln Pro Gly Pro His Gly Ser Leu Leu Thr Glu Gly Cys
 370 375 380
 Leu Arg Ser Leu Ser Gly Asp Leu Asn Arg Phe Pro Cys Gly Met Glu
 385 390 395 400
 35 Val His Ser Gly Gln Arg Glu Leu Glu Ser Val Val Ala Val Gly Glu
 405 410 415
 Ala Met Ala Leu Lys Phe Pro Met Gly Ala Met Ser Tyr Cys Leu Arg
 420 425 430
 40 Asp Arg Ser Arg Phe Leu Phe Arg Leu Pro Met Gly Leu Ser Cys Pro
 435 440 445
 Leu Gln Val Gln
 450
 <210> 15
 <211> 321
 <212> PRT
 <213> Homo sapiens
 <400> 15
 50 Met Ala Glu Ala Glu Glu Asp Cys His Ser Asp Thr Val Arg Ala Asp
 1 5 10 15
 Asp Asp Glu Glu Asn Glu Ser Pro Ala Glu Thr Asp Leu Gln Ala Gln
 20 25 30
 55 Leu Gln Met Phe Arg Ala Gln Trp Met Phe Glu Leu Ala Pro Gly Val
 35 40 45
 Ser Ser Ser Asn Leu Glu Asn Arg Pro Cys Arg Ala Ala Arg Gly Ser
 50 55 60
 Leu Gln Lys Thr Ser Ala Asp Thr Lys Gly Lys Glu Glu Gln Ala Lys
 65 70 75 80
 60 Glu Glu Lys Ala Arg Glu Leu Phe Leu Lys Ala Val Glu Glu Glu Gln
 85 90 95
 Asn Gly Ala Leu Tyr Glu Ala Ile Lys Phe Tyr Arg Arg Ala Met Gln
 100 105 110
 65 Leu Val Pro Asp Ile Glu Phe Lys Ile Thr Tyr Thr Arg Ser Pro Asp
 115 120 125
 Gly Asp Gly Val Gly Asn Ser Tyr Il Glu Asp Asn Asp Asp Asp Ser
 130 135 140

145
 150
 155
 160
 165
 170
 175
 180
 185
 190
 195
 200
 205
 210
 215
 220
 225
 230
 235
 240
 245
 250
 255
 260
 265
 270
 275
 280
 285
 290
 295
 300
 305
 310
 315
 320

Lys Met Ala Asp Leu Leu Ser Tyr Phe Gln Gln Gln Leu Thr Phe Gln
 Glu Ser Val Leu Lys Leu Cys Gln Pro Gln Leu Glu Ser Ser Gln Ile
 His Ile Ser Val Leu Pro Met Glu Val Leu Met Tyr Ile Phe Arg Trp
 Val Val Ser Ser Asp Leu Asp Leu Arg Ser Leu Glu Gln Leu Ser Leu
 Val Cys Arg Gly Phe Tyr Ile Cys Ala Arg Asp Pro Glu Ile Trp Arg
 Leu Ala Cys Leu Lys Val Trp Gly Arg Ser Cys Ile Lys Leu Val Pro
 Tyr Thr Ser Trp Arg Glu Met Phe Leu Gln Arg Pro Arg Val Arg Phe
 Asp Gly Val Tyr Ile Ser Lys Thr Thr Tyr Ile Arg Gln Gly Glu Gln
 Ser Leu Asp Gly Phe Tyr Arg Ala Trp His Gln Val Glu Tyr Tyr Arg
 Tyr Ile Arg Phe Phe Pro Asp Gly His Val Met Met Leu Thr Thr Pro
 Glu Glu Pro Gln Ser Ile Val Pro Arg Leu Arg Thr Arg Glu Tyr Gln
 Asp

25
 30
 <210> 16
 <211> 172
 <212> PRT
 <213> Homo sapiens

35
 40
 45
 50
 55
 60
 65

<400> 16
 1
 5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55
 60
 65
 70
 75
 80
 85
 90
 95
 100
 105
 110
 115
 120
 125
 130
 135
 140
 145
 150
 155
 160
 165
 170

Ala Cys Pro Thr His Pro Pro Pro Pro Thr Ala Pro Arg Gly His Gln
 Ser Cys Arg Leu Gly Asp Ser Trp Ser Val Lys Ser Arg Trp Cys Pro
 Cys Pro Gln Glu Leu Gly Trp Ala Ser Cys Ala Arg Gly Val Cys Ala
 Trp Ser Phe Cys Ala Trp Ile Cys Ile Phe Ile Ala Leu Leu Val Glu
 Thr Pro Arg Pro Val His Pro Ala Lys Thr Pro Gln Ala Ala Cys Gly
 Ser Arg Thr Leu Pro Pro Phe Pro Arg Cys Pro Leu Arg Ala Arg Ala
 Ala Thr Gln Ala Cys Trp Leu Arg Pro Pro Leu Gly Gln Ala Leu Ala
 Gln Pro Ala Glu Trp Gly Val Val Gly Gln Ser Pro Arg Ser Trp Ala
 Pro Ala Gln Ala His Arg Ala Arg Pro His Pro Ala Ala Pro Arg Thr
 Ala Thr Arg Gly Val Leu Pro Leu Cys Pro Ala Pro Gly Thr Asn Ser
 Met Phe Gly Val Cys Leu Cys Leu Phe Phe Lys Lys

55
 60
 <210> 17
 <211> 472
 <212> PRT
 <213> Homo sapiens

60
 65
 70

<400> 17
 1
 5
 10
 15
 20
 25
 30
 35
 40
 45

Met Arg Glu Arg Phe Arg Asn Leu Asp Glu Glu Val Glu Lys Tyr Arg
 Ala Val Tyr Asn Lys Leu Arg Tyr Gly His Thr Phe Leu Lys Ser Glu
 Phe Glu His Gln Lys Glu Glu Tyr Ala Arg Ile Leu Asp Glu Gly Lys
 Ile Lys Tyr Glu Ser Glu Ile Ala Arg Leu Glu Glu Asp Lys Glu Glu

	50		55		60
	Leu Arg Asn Gln Leu	Leu Asn Val Asp Leu Thr	Lys Asp Ser Lys Arg		
	65	70	75	80	
5	Val Glu Gln Leu Ala Arg Glu Lys Val Tyr Leu Cys Gln Lys Leu Lys				
	85	90	95		
	Gly Leu Glu Ala Glu Val Ala Glu Leu Lys Ala Gln Lys Glu Asn Ser				
	100	105	110		
	Glu Ala Gln Val Glu Asn Ala Gln Arg Ile Gln Val Arg Gln Leu Ala				
	115	120	125		
10	Glu Met Glu Ala Thr Val Arg Ser Leu Gly Ala Glu Lys Gln Ser Ala				
	130	135	140		
	Asn Leu Arg Ala Glu Arg Leu Glu Lys Glu Leu Gln Ser Ser Ser Glu				
	145	150	155		160
15	Gln Asn Thr Phe Leu Ile Asn Lys Leu His Lys Ala Glu Arg Glu Ile				
	165	170	175		
	Asn Thr Leu Ser Ser Lys Val Lys Glu Leu Lys His Ser Asn Lys Leu				
	180	185	190		
	Glu Ile Thr Asp Ile Lys Leu Glu Thr Ala Arg Ala Lys Ser Gln Leu				
	195	200	205		
20	Glu Arg Gln Arg Asn Lys Leu Gln Ser Glu Leu Asp Gly Leu Gln Ser				
	210	215	220		
	Asp Asn Glu Ile Leu Lys Ala Ala Val Glu His His Lys Val Leu Leu				
	225	230	235		240
25	Val Glu Lys Asp Arg Glu Leu Ile Arg Lys Val Gln Ala Ala Lys Glu				
	245	250	255		
	Glu Gly Tyr Gln Lys Leu Val Val Leu Gln Asp Glu Lys Leu Gln Leu				
	260	265	270		
	Glu Asn Arg Leu Ala Asp Leu Glu Lys Met Lys Val Glu His Asp Val				
	275	280	285		
30	Trp Arg Gln Ser Glu Lys Asp Gln Tyr Glu Glu Lys Leu Arg Ala Ser				
	290	295	300		
	Gln Met Ala Glu Glu Ile Thr Arg Lys Glu Leu Gln Ser Val Arg Leu				
	305	310	315		320
35	Lys Leu Gln Gln Gln Ile Val Thr Ile Glu Asn Ala Glu Lys Glu Lys				
	325	330	335		
	Asn Glu Asn Ser Asp Leu Lys Gln Gln Ile Ser Ser Leu Gln Ile Gln				
	340	345	350		
	Val Thr Ser Leu Ala Gln Ser Glu Asn Asp Leu Leu Asn Ser Asn Gln				
	355	360	365		
40	Met Leu Lys Glu Met Val Glu Arg Leu Lys Gln Glu Cys Arg Asn Phe				
	370	375	380		
	Arg Ser Gln Ala Glu Lys Ala Glu Leu Glu Ala Glu Lys Thr Leu Glu				
	385	390	395		400
45	Glu Lys Gln Ile Gln Trp Leu Glu Glu Lys His Lys Leu His Asp Arg				
	405	410	415		
	Ile Thr Asp Arg Glu Glu Lys Tyr Asn Gln Ala Lys Glu Lys Leu Gln				
	420	425	430		
	Arg Ala Ala Ile Ala Gln Lys Lys Arg Lys Ser Leu His Glu Asn Lys				
	435	440	445		
50	Leu Lys Arg Leu Gln Glu Lys Val Glu Val Leu Glu Ala Lys Lys Glu				
	450	455	460		
	Glu Leu Gln Thr Glu Ile Arg Ser				
	465	470			
55	<210> 18				
	<211> 462				
	<212> PRT				
	<213> Homo sapiens				
60	<400> 18				
	Lys Ala Thr Ser Leu Thr Leu Glu Gly Gly Arg Leu Lys Arg Thr Pro				
	1	5	10	15	
	Gln Leu Ile His Gly Arg Asp Tyr Glu Met Val Pro Glu Pro Val Trp				
	20	25	30		
65	Arg Ala Leu Tyr His Trp Tyr Gly Ala Asn Leu Ala Leu Pro Arg Pro				
	35	40	45		
	Val Ile Lys Asn Ser Lys Thr Asp Ile Pro Glu Leu Glu Leu Phe Pro				

50
 Arg Tyr Leu Leu Phe Leu 55 Arg Gln Gln Pro Ala 60 Thr Arg Thr Gln Gln
 65 Ser Asn Ile Trp Val Asn Met Gly Asn Val 75 Pro Ser Pro Asn Ala Pro
 80
 85
 90
 95
 100
 105
 110
 115
 120
 125
 130
 135
 140
 145
 150
 155
 160
 165
 170
 175
 180
 185
 190
 195
 200
 205
 210
 215
 220
 225
 230
 235
 240
 245
 250
 255
 260
 265
 270
 275
 280
 285
 290
 295
 300
 305
 310
 315
 320
 325
 330
 335
 340
 345
 350
 355
 360
 365
 370
 375
 380
 385
 390
 395
 400
 405
 410
 415
 420
 425
 430
 435
 440
 445
 450
 455
 460

<210> 19

<211> 243

<212> PRT

<213> Homo sapiens

<400> 19

60 Pro Thr Trp Leu Glu Arg Gly Gly Gly Glu Pro Ala Ala Arg Pro Gln
 1 5 10 15
 Thr Pro Gln Pro Thr Ala Pro Glu Ser Arg Gly Pro Ser Gly Ala Ser
 20 25 30
 Ala Leu Arg Cys Arg Gly Pro Thr Ala Arg Ser Leu Pro Ala Ala Ser
 35 40 45
 65 Met Leu Gly Ala Pro Asp Glu Ser Ser Val Arg Val Ala Val Arg Il
 50 55 60
 Arg Pro Gln Leu Ala Lys Glu Lys Ile Glu Gly Cys His Ile Cys Thr

55
 Ser Val Thr Pro Gly Glu Pro Gln Val Phe Leu Gly Lys Asp Lys Ala
 85
 Phe Thr Phe Asp Tyr Val Phe Asp Ile Asp Ser Gln Gln Glu Gln Ile
 100
 Tyr Ile Gln Cys Ile Glu Lys Leu Ile Glu Gly Cys Phe Glu Gly Tyr
 115
 Asn Ala Thr Val Phe Ala Tyr Gly Gln Thr Gly Ala Gly Lys Thr Tyr
 130
 Thr Met Gly Thr Gly Phe Asp Val Asn Ile Val Glu Glu Glu Leu Gly
 145
 Ile Ile Ser Arg Ala Val Lys His Leu Phe Lys Ser Ile Gln Glu Lys
 165
 Lys His Ile Ala Ile Lys Asn Gly Leu Pro Ala Pro Asp Phe Lys Val
 180
 Asn Ala Gln Phe Leu Glu Leu Tyr Asn Glu Glu Val Leu Asp Leu Phe
 195
 Asp Thr Thr Arg Asp Ile Asp Ala Lys Ser Lys Lys Ser Asn Ile Arg
 210
 Ile His Glu Asp Ser Thr Gly Gly Asn Leu Tyr Cys Gly Arg Phe Gln
 225
 His Val Leu
 230
 235
 240

25
 <210> 20
 <211> 223
 <212> PRT
 <213> Homo sapiens

30
 Gly Asn Tyr Arg Pro Ser Lys Lys Arg Phe Arg Glu Gly Lys Glu Lys
 1
 Lys Arg Gly Lys Lys Val Trp Leu Val Lys Arg Ile Ile Gln Thr Leu
 20
 25
 30
 35
 Thr Lys Arg Arg Lys Lys Lys Arg Val Phe Arg Lys Glu Lys Pro Asn
 35
 40
 Glu Leu Glu Val Glu Glu Ser Gln Glu Val Ser Asp His Glu Asp Glu
 50
 Glu Glu Glu Glu Glu Glu Glu Asp Asp Ile Asp Gly Gly Glu Ser
 65
 Ser Asp Glu Ser Asp Ser Glu Ser Asp Glu Lys Ala Tyr Gln Ala Asp
 85
 90
 95
 100
 105
 110
 115
 120
 125
 130
 135
 140
 145
 150
 155
 160
 165
 170
 175
 180
 185
 190
 195
 200
 205
 210
 215
 220

60
 <210> 21
 <211> 206
 <212> PRT
 <213> Homo sapiens

65
 Met Asn Lys Pro Ile Thr Pro Ser Thr Tyr Val Arg Cys Leu Asn Val
 1
 5
 10
 15

	Gly	Leu	Ile	Arg	Lys	Leu	Ser	Asp	Phe	Ile	Asp	Pro	Gln	Glu	Gly	Trp	
			20						25					30			
	Lys	Lys	Leu	Ala	Val	Ala	Ile	Lys	Lys	Pro	Ser	Gly	Asp	Asp	Arg	Tyr	
			35					40					45				
5	Asn	Gln	Phe	His	Ile	Arg	Arg	Phe	Glu	Ala	Leu	Leu	Gln	Thr	Gly	Lys	
		50					55					60					
	Ser	Pro	Thr	Ser	Glu	Leu	Leu	Phe	Asp	Trp	Gly	Thr	Thr	Asn	Cys	Thr	
		65				70					75					80	
10	Val	Gly	Asp	Leu	Val	Asp	Leu	Leu	Ile	Gln	Asn	Glu	Phe	Phe	Ala	Pro	
					85					90					95		
	Ala	Ser	Leu	Leu	Leu	Pro	Asp	Ala	Val	Pro	Lys	Thr	Ala	Asn	Thr	Leu	
					100					105				110			
	Pro	Ser	Lys	Glu	Ala	Ile	Thr	Val	Gln	Gln	Lys	Gln	Met	Pro	Phe	Cys	
					115			120					125				
15	Asp	Lys	Asp	Arg	Thr	Leu	Met	Thr	Pro	Val	Gln	Asn	Leu	Glu	Gln	Ser	
		130					135					140					
	Tyr	Met	Pro	Pro	Asp	Ser	Ser	Ser	Pro	Glu	Asn	Lys	Ser	Leu	Glu	Val	
		145				150					155					160	
20	Ser	Asp	Thr	Arg	Phe	His	Ser	Phe	Ser	Phe	Tyr	Glu	Leu	Lys	Asn	Val	
					165					170					175		
	Thr	Asn	Asn	Phe	Asp	Glu	Arg	Pro	Ile	Ser	Val	Gly	Gly	Asn	Lys	Met	
					180				185					190			
	Gly	Glu	Gly	Gly	Phe	Gly	Val	Val	Tyr	Lys	Gly	Leu	Arg	Lys			
		195					200						205				
25	<210> 22																
	<211> 1260																
	<212> DNA																
	<213> Homo sapiens																
30	<400> 22																
	cttctccgca	cgactgttac	agaggtctcc	agagccttct	ctctctctgtg	cnnaatggca	60										
	actcttaag	annactcat	tgaccagll	gggannang	agqcaacagt	cccaaacat	120										
35	agatcaactg	tagtgggtgt	tgcccaagtt	ggtatggcgt	gtgctakag	cactctggga	180										
	aagtctctg	ctgatqaact	tgcctcttg	galgtlftgr	agataagct	tcaaggagaa	240										
	atgatggatc	tgacagcatg	gagcttattt	cttcagacac	claaatttqt	ggcagatasa	300										
	gallatctt	tgaccgcca	ttctaagall	ghggtntnn	ctgcaggagt	ccglcaggaa	360										
	gaaggggaga	gtgggtkna	tctggtgcag	agaaatgla	ahgtcttcaa	attcattatt	420										
40	actcagatcg	tcaagtacag	tcclgaktnc	ntcataattg	tggtttccaa	ccccgtggac	480										
	attcttaact	atgttacctg	gaaactaagl	gualkactna	nnccacgggt	gatttgaagl	540										
	ggatgtaate	tggattctgc	hagatttgc	tacctatgg	ctgaasaact	tggcattcat	600										
	ccacgagct	gacatggatg	gattttgggg	gacactggc	actcaagctg	ggclglglgy	660										
	agtgggtgta	atgtggcagg	tgtttctctc	caggaaclga	atccagaaat	gggaactgac	720										
	aatgatagtg	aaaattggaa	ggaggtccat	aagatgggtg	ttgaaglgc	ctatgaagtc	780										
45	atcagctna	aaggatatac	caactgggcl	atbgnattaa	gtgtggctga	tcltallgaa	840										
	tccatgttga	annatctatc	caggattcat	cccgtylwn	ccatgntaaa	ggggatgtat	900										
	ggcattgaga	atgaagctct	cccgagcctt	ccatgtatcc	tcaatgccc	gggttaacc	960										
	agcglkakra	accagaagct	aaaggatgal	gaggltyntc	agctcaagaa	aagtgcagal	1020										
	acccgtgtgg	acclpcagaa	gacctaata	gacctgtgac	taglmgctc	taggctgtag	1080										
50	aaatttaaaa	actacaatgt	gattaaclng	agcctttagt	tttcatccat	gtacatggal	1140										
	cacaglltgc	tttgatcttc	ttcaatatgt	gaallkqgg	tracagaaatc	aaagcctatg	1200										
	cttggtttaa	ctcttgcant	ctgagctctt	gaaccaataa	aallawctat	tgtagtgtga	1260										
55	<210> 23																
	<211> 3151																
	<212> DNA																
	<213> Homo sapiens																
60	<400> 23																
	taacacagtt	gtgaaaagag	atggatgtgg	gllmanatcc	tagccctgcc	tgtgtgcact	60										
	tatgcagaaa	cctaataaga	ctccactaca	ggactgtctg	agclgggtctg	gatgtgtcat	120										
	ctccatcag	ggtgggaaga	ggtgagtggc	tacgatgaga	acatgaacac	galccgcag	180										
	laccaggtgt	gcaacgtgtt	tgaatcaagc	cagannact	gactacggac	caagtttatc	240										
	cgccgcagly	ggcccccacg	catccacgtg	gagatgaagt	tttcggclnq	tgaatgcagc	300										
65	agcatcccca	gggtgactcg	ctcctgcaag	gagaccttca	acctctatla	clatgaggtcl	360										
	gactttgact	cgccacccaa	gaccllcccc	actggaatqn	agaatccatg	ggtgaagggtg	420										
	galaccaktg	cagccgagca	gagcttctcc	caggtggacc	tggtgacccg	cgtcatgaaa	480										

	atcmmnccg	ayytrccggag	ctkccgacot	glutcccgca	ggggcllnta	ccgggootto	540
	ngggactatn	gggggtgcmt	qtccctcabc	gggtyrntg	talctctaccg	caagtgcenr	600
	cggatcatcc	agmacgggc	catnccccag	gnacccctg	ggggggctga	gagmncatcg	660
5	ctggtygctg	ccgggggynag	ctgcalncc	aatgcggaag	ayntggatgk	acccatcaag	720
	ntctactqla	acgggggacgy	cnagtggclg	qtgcccalkg	gggntgcat	ghgcaagca	780
	ggcttcgagg	ccgttrgagaa	tggcnccgtc	tgnnagggtt	gtccatclgy	gaettlcnag	840
	qccaaccnag	gggatgaggg	ctgtaccnnc	tgtcccatca	acwgcgggac	cncttctgaa	900
	ggynccacca	actgtgtctg	cnccantggc	Laatcacagag	cnagccctgg	ccccctggac	960
10	atgccttqca	caacmctccc	ctccgcqccc	caggclntga	tl.tnccgtgt	cnatgagacc	1020
	toctctalnc	tggagtggan	ccctccccc	naetccggag	gcccgggynna	cccgctctac	1080
	ancatcatcl	gnnagagctg	tyntctgggc	cggtgtgect	gcaccccgclg	gggggacant	1140
	gtacagtacg	cancccgcca	gclaygcttg	acggagccac	gnatttacat	nantgacctg	1200
	ctggcccnca	cccagtaacc	cttcgagalc	caggctglga	acggcgltac	tgannagagc	1260
15	cccttctcgc	ctcagttcgc	ctctgtgaac	alraccacca	accaggcagc	tcnctggan	1320
	glgtccatca	tgnctcaggt	gagccgcacc	gtggamncca	ttamctgtc	glggtccag	1380
	ccagacnagc	ccaatgggnt	gatccctggc	batgagctgc	agtactatga	gaagcagyn	1440
	ctcagtgacl	ccnacgccac	ayccataaaa	agmccacca	acccggctcc	ntgtcagggc	1500
	clnnaagccg	ggccatctca	tgtcllcnag	gtgcgggnac	gcacccgtgc	agynlncgg	1560
20	cgctacccgc	gcaagatgla	cttcagacc	atgcacgaag	ccgattaccn	gaccaagcal	1620
	caggagaacl	tgcacatcat	calnagctcc	tggcnctgtg	gcctnntctt	cnctctgtct	1680
	gtggttgtca	tgcctctctt	gtgtaccaga	cnnggggttlg	agcgtgclga	ctcggagtae	1740
	acggacnncg	tgcacacclg	cccccagggc	canctgaccc	cnccgatgaa	gatctacatc	1800
	ytctctttca	ctnacaggga	gcaggtgala	ccagtgngng	agtl.lgcnca	ggaaahhgac	1860
25	atclctctgtg	tcaaaahhga	gcaggtgala	gnagcagggg	ngtttgccga	ngtctccagL	1920
	ggccaccllgn	agctgccagg	cnngnagag	atcl.ltgtgg	cnctccagac	gnctnngctg	1980
	ggctacacgy	ngnagccagc	ccgggncttc	ctgagccnng	cnctccatrat	gggcccagtle	2040
	gacatccca	acgclcntrca	ccctggaggg	gtctgtacca	ngagccacac	tgtgatgata	2100
	atcaccgaght	ctatggagaa	tggctccctg	gactcncttc	tcggcncaan	cgaLgggnng	2160
30	ttccagqtoa	tcnagchqnt	gggcattgcl	cgggccatcg	ngctcgccal	gnngtaoctg	2220
	gcagacalga	actatgttca	cnctgnccctg	gtgcccngca	acal.ctctgt	caacagcnnc	2280
	ctngtctgca	aggtntcgga	ctttgggclc	tcacgcttll	tnagggagca	tacctcagac	2340
	ccacactnca	ccagtgccll	gynccgnaag	atmccatcc	gclggacagc	ccccggancc	2400
	atccagtacc	gnaggttcc	ctcggclnng	natgtgtguc	gctacggcat	tgtcatgtgg	2460
35	gaggtgntgt	ccatgggyn	gcggccctac	tygganctga	ccanccagga	tgtlaahcant	2520
	gocattgagc	ngnactatcg	gctgcacnng	cccatggant	ccccagclgc	cnctgcaccaa	2580
	ctcalngctg	actgllgyn	gnaggacccg	aaanccgggc	ccaaqttcgg	ccaaal.lqtc	2640
	aaacagclng	acaagatgat	ccgcnctccc	aacagcccca	aagccalggc	gcccctctcc	2700
	ctnggcatca	actgtccctt	gttggaccgc	ncgatcccg	nttaacccag	cltcaacacg	2760
40	gtggacagnt	ggctgaaggg	cnlcaagatg	gggcnctaca	agggancttt	cgccaalggc	2820
	ggcttcaant	cccttgacgt	cllytctnng	atgatgalyn	aggaatllcl	ccgggttggg	2880
	gtcnctttgg	ctggcnacca	gaaaaaaate	clggacncta	lccnngtqat	gggggcnng	2940
	atgaaccaga	ttcagttctg	ggaggtttgn	catcaactn	ccctggclcn	cnctctctcc	3000
	cnagccccgc	cnctctctgc	ccaggtgcgc	gnctccctgg	lnctctatcc	anlycnnggc	3060
45	cagcnactcg	ccagggagyn	ccggggccag	gaggncccaa	gcyylgccc	ccagagagcy	3120
	tcaccaagyn	aaatgcac	tcaaaacnag	g			3180

<210> 24

<211> 1234

<212> DNA

50 <213> Homo sapiens

<400> 24

	tagltcaaga	canncagqan	aaagotaaga	tggggaggtt	ctglanantt	taggaatatag	60
55	aggtttlcan	agataatlcc	cnctnctgtg	aaactggant	cccaagcccl	gtaaccaaca	120
	tggncaacgc	cnctggccagc	gocacttgy	ngnctgcaa	ggggcgcttt	ggcccnctcg	180
	agaayntcgt	gaacnctaat	ggggagccgt	accatynna	gtgtttccgk	tnogctcagt	240
	gcttccagca	gttcccgaa	gganctttct	atnagtttga	ngnagaaag	tactghgaa	300
	atgaatttca	gatgtctott	gccccttgc	glnctcagt	tyglcncttc	atcattggcc	360
60	gagttatcaa	agccctnna	aaagctggc	atccggngtg	cttccgclgh	gacctctgoc	420
	aggaayttct	ggcagatall	gggtttgtca	agaaatgctg	gnnccacctg	lghngccct	480
	gtcataatcg	lgnagaagcc	agaggccctg	gganctacat	clgcnanana	tgcctgcta	540
	tcakcgatga	gcagcchtrn	atattcaaga	acgaccccl	cnatccagac	catttcaant	600
	ggcccaantg	cggaaggag	ctgac.lgccc	atgcacggga	gnlgnaaagg	gagctalac	660
65	gnctcccatg	cnctgataaa	atgggggtcc	ccatclgtgg	tgttgnngn	cgcccatcg	720
	aagggcgctg	ggtgaacgct	ntngncaagc	agtgccatgl	ggagcatlll	glttqtgcca	780
	agtgtgagaa	acccctttct	ggacalngcc	attatngag	gaanngnctg	gcataltgtg	840
	aaactcacta	taanagcta	cttgggtgatg	tttgettcca	ctgcaalngt	gttatagaa	900

5	gltgtgtgtgt ctctgtctctt aataaggcctt ngtgcgtgaa ctgccttgcct tglctctacct	960
	gcaacaccta attaaccttc aagaataagt tttgtgagtl tgacatgaag ccagttctyl	1020
	agaagtgtta htagatttcc attggagctg aagaatgac tlgaatgact agctgagac	1080
	ltaaggagga aaknagtctc tttttttttt cttttctatg caagatgagc gattacgac	1140
	attatctgtc ttgatctacc catahttaaa gclctatctc nngcagttg agagaagag	1200
	acctataalg atgtgtttat gtcatttttt taaa	1234
	<210> 25	
	<211> 4534	
10	<212> DNA	
	<213> Homo sapiens	
	<400> 25	
15	gtcagcagcc tgaagagcc aagcctgctt caggggggctt ggggggggctt ggggggggctt	60
	nggctcgttg gtcacccagc cngcggggag ggccttcagg ncccgccgctt ncccgccgctt	120
	gcttcccgcc cctccgacaa ggtccggggc gclcgctctt ccgtccctct ccttccgctt	180
	cggcagcttc cggggcactt cagctcggcc ggggggggag tctggccccc cgttcccttg	240
	cggttcgggt ccaagatgat tccgatgtll ctacccgttl atctcagtaa caatgagcag	300
20	cacttcacag aagtctcagt tttccagaa ttgcctattg gctgaagtgt ggtgctgtgc	360
	aaagaccccg gcgagagtga atgttcggcc ggtgctgtgc ggtgctgtgc ggtgctgtgc	420
	gagtttctat agtctggccc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	480
	ggtctcccaa agtctggccc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	540
	aaagaccccg cagttgcggt cttcctctgt cclgaccccg ggtgctgtgc ggtgctgtgc	600
25	cagaggaagc agtctcggga tccaaghtta aagagacatg ggtgctgtgc ggtgctgtgc	660
	agtgacccaa agtctcggga tccaaghtta aagagacatg ggtgctgtgc ggtgctgtgc	720
	tatcgaagca agtctcggga tccaaghtta aagagacatg ggtgctgtgc ggtgctgtgc	780
	cagaggaagc agtctcggga tccaaghtta aagagacatg ggtgctgtgc ggtgctgtgc	840
	aaagaccccg gcttaaatgt tttgaaacaa gclacacaaa aagatcagc atagctgaga	900
30	gagcagagga aacttaaaag gclacacaaa aagatcagc atagctgaga atagctgaga	960
	aaagaccccg caactaaagt cccagctggaa cagaagagac atagctgaga atagctgaga	1020
	gagcagagga caactaaagt cccagctggaa cagaagagac atagctgaga atagctgaga	1080
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	1140
	gagcagagga caactaaagt cccagctggaa cagaagagac atagctgaga atagctgaga	1200
35	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	1260
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	1320
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	1380
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	1440
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	1500
40	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	1560
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	1620
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	1680
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	1740
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	1800
45	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	1860
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	1920
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	1980
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	2040
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	2100
50	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	2160
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	2220
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	2280
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	2340
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	2400
55	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	2460
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	2520
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	2580
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	2640
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	2700
60	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	2760
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	2820
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	2880
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	2940
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	3000
65	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	3060
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	3120
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	3180
	aaagaccccg ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc ggtgctgtgc	3240

5	ccaagcctgc ccaatgatga aggcatacag gckcttcaca atgctgltgt tgcaggecnc 3300
	aaagaaatcg ttangtttct ggtacagttt ggtgtaaatg taatgctgc tgaatagtat 3360
	ggalgagctc cattaacalkt tgotgectca tjttaacaag tcaagltgt taagtlttttg 3420
	gtggagtcag gagccgctgt gltttccatg acciaacagt acatgcagac tqtgcagat 3480
	aaatggagga aggtacact cagtgcaccc aatllcttta tggaghtcag 3540
	gagaagtgg gcataatgaa lwaaggagtc gactgcctga caatcatcca cagggagagc 3600
	natgatgale agctgcccat gtagcgggtg cttaatgala agggaggala 3660
	gaaatgaaa tgcacgggtg aaqattaaa ccaagacaaa gggacttggc clqaaacttc 3720
10	aaattgtgtg gactgtaccc tttagtcaat gaagatttaa tctctgtlta atgacaatyl aggtgaaaj 3780
	lhtggcaaaa attlcccaag acttatttla alkcaccatt agaggacatt tanagtatg 3840
	tglttttoga agagaatgaa ggtttgaaga tgtgtlqgg ccaagtgtgc ccgtglagcu 3900
	aaataaagaa tctacgtcag caggctatcc tgtgtlqgg atootgtclt qtaaatagga 3960
	ctcagataag lctacngoga caatcclytt taatcagctc cagaaaggag 4020
15	tcatttattg ggcagttyy ttctctctgc agaaagagc ggggtccal gttngttgtc 4080
	tcctaaana agcagccct aagaacqla taagaattat acalattgtt ttgtaggcty 4140
	atltgtcagt atltcccaag ggtgtgtgtc ggtgtgtgtc agaggtctga aactttatta 4200
	tgtagcalkt taagaattat acalattgtt gaaatalcga aactaagcha cagtaccagt 4260
20	aatlagatgt agattcttct ttgtaggcty clacagactt acccglanta ttgtcagga 4320
	ctcagaaat tagaaacttg aactttttga tgcct 4380
	ctttaaaaac aqhttanta aactttttga tgcct 4440
	ctttttttga tgcct 4500
	ctttttttga tgcct 4534
25	<210> 26
	<211> 4660
	<212> DNA
	<213> Homo sapiens
	<400> 26
30	ggggtctaga aalctaaagc ttgtttatat aatlygctt aaalynggt agagtgaaga 60
	gactagagnc atctctggaa aacalcalkt tccatttccc cgggaagcta cctctkgaa 120
	ctcaagattt gacattatct gttttgagga ttccttatga acaaaagagt cctccaggtg 180
	tgaahtttt caacatgagt ggtctkqggg acagttcalr cagccctgct aaacccagct 240
35	ccataaagag gaaaggatcg ccattgtgaca caclggcttc agccacggaa agaggggcga 300
	gggagcaaga aataaatal lltgaaagac tagctgaglt actgtctgcc aannattagt 360
	acattgacag cttagtgtta aaaccagaca antgcagat atgcacac agaatgaa 420
	agatcacagc antgaaagga atgaaacaag agaaalcac aactgatga 480
	aalctagcat ctcatcaagt aglctagggg tgatagaaaa ggnatcttg ggaccccllc 540
40	ttttggagga tttggatgga tttttctttg lltgnaactg tgaaagggaa attgtatttg 600
	tgtagagaa lgtkacagc taactaggtt acaatcagga ggaattaaly 660
	telacagcat actgcactg ggggalcty cagaatttgt ggggaatctg ctaccaaaal 720
	cactagtann tgaatttct tggcctcaag aggnacac aggaalag cttacottta 780
	actgcaggat gctaattcau nttccagctg agccagggaa cagaaccaa gaaychhgc 840
	agcgttalcga ngtaatgag tgtttcactg tgcacagcc ttgcacggc attactcty 900
45	ggaagattt caaghtcat ctgatttcta aagatatac elygttggga agatctatag 960
	ttccnggtgt agaactlll algnacagc gctggcagaa ctgtttggga agaatgtg 1020
	atactagllc cctgagagct cggggcagag aaccatclt tgcagacag clghhrcag 1080
	tttatgottt tttccacct tctgtgcaat cctcctatag altcatattg aatgatggga 1140
50	aatgtatgac caatgcltar cggccacacc aagtgtaaac ttctgtaccc tcaagllc 1200
	ctttcatcat gggaattcat atcatcgaca gggagcagc ygtcaatcct 1260
	acantaatlc tggaaityta alhccccag taatccctc lgcacccatc caacayaac 1320
	cagctcatgg tgtggctcgt tcatccacal agctcagacc ttcalagcag cagtcatagt 1380
55	ccagaatcaa ccgccagcag aaghtthgyn tctcaccoc gaagtccag tytanccaat gttgocctaa 1440
	accagggcca agccagttca cagccagta alccctcttt aacctcaal aatttctcta 1500
	tggaaggtac ayraatctc ctgacacagt tcatgtctcc aaacctcaal aatttctcta 1560
	gatttggcaac aagggccagg algcacaaa attcctttcc tcatgtctcc aaacctcaal aatttctcta 1620
	gctclccngt tggcatgaca agtagtgcct gtaalaaah aaacctcaal aatttctcta 1680
60	tcocagtaac alcttttccag qhtatpatt gaggacccaa aagayahtgc ctaactttta 1740
	ccagttctcc agtctcag cagatgagct aagataaca ctaactttta aatgaaahga 1800
	accaghaaa agctgagtc caacagctct agagataaca ctaactttta aatgaaahga 1860
	ttcaatctga caacagctct agagataaca ctaactttta aatgaaahga 1920
	atgacagct ttcagatgga agtagtgcct gtagatgaga ctaactttta aatgaaahga 1980
65	ttttgacac aactgcogaa agtagtgcct gtagatgaga ctaactttta aatgaaahga 2040
	atgtctgtc ttgcacagc agtagtgcct gtagatgaga ctaactttta aatgaaahga 2100
	gtccctcttc tcatagclca agtagtgcct gtagatgaga ctaactttta aatgaaahga 2160
	gtccctcttc tcatagclca agtagtgcct gtagatgaga ctaactttta aatgaaahga 2220
	gtccctcttc tcatagclca agtagtgcct gtagatgaga ctaactttta aatgaaahga 2280

	agqatagccc	ctcagatato	acccctttgt	ctgkcgagcc	tgataaaaaq	gacngtgoat	2340
	ctacttctgt	gtcagtgcct	ggacagggtac	aaggaaactc	caqtataaaa	ctagaantng	2400
	atgcttcaaa	gnaaaagaa	ctaaaagacc	alraqtctct	acgtatcttt	tlagatasaq	2460
5	atqagaanga	tttaagtca	actcrnancc	tgagccctnn	tgatgtanng	gtgaaaqtgg	2520
	aaaagaaahq	acagatgyat	ccatgtanta	ccaaacccaa	cccaatgacc	nancccaclc	2580
	ctgaggaaal	aaaactggag	ccccagagcc	agttttacagc	tgaurttgac	cagkttigate	2640
	agttactgoc	cacgcctggg	aaggccagcc	agttgcctng	cttatgtgag	ccagacaggn	2700
	tggaatgknc	qgtccaccag	qtaaacclca	ccctggagat	cclgeccagct	tcacttcagt	2760
	ccgcactgic	ccncccaact	ctnaggctaa	atagcttccc	tgagctagga	ttggaaagaa	2820
10	ttgataacca	atttlygcaaa	ccaggnccag	ggatcaghl	tcocatggaca	mtaataacag	2880
	tgacagctat	aaatcagayt	aaatcagayt	ccagctgtat	tgaytccaaa	ttayntgagc	2940
	ttctctgtct	cccccaacca	glaqaaggga	gaatctgtga	gaaggctctt	cttgaanagc	3000
	tqgtatctct	ccllkgtngc	aaagakgaa	ctgagctagc	tgaaactagac	agagctctgg	3060
	gaakktgcaa	acttgttcay	gggggtgcal	taagtgtatt	atcagngnqa	tttcccccac	3120
15	aaacaagcaac	qccacctttg	alcatggag	aaagmccan	cccttacttc	cagccctant	3180
	cttctctctc	tcctactgoc	aatclmcta	gccttttcca	aygcctqgtc	agggcaaaac	3240
	cltccctngg	gaogatgccl	gtccaaagta	ccctctcccg	aggtgcclkt	ccactggcc	3300
	tgggcatgca	gcocaggcaa	actctanaca	gaactccggc	tgacactaac	cnqcttogac	3360
	ttccactaca	gcagmatta	cagggcaaac	ngcagttgat	acmccaaat	cgccanqeta	3420
20	tccttaacca	gtttgcagm	actgtctctg	llygcatcaa	tatgagahca	ggcatgcann	3480
	agcaaatlac	actccagcca	ccctgcaatg	ctcaaatytt	ggcacaacgt	cagccgggac	3540
	tttaccagta	acagmccnqa	cagagggcagc	taatacagca	gcaaaagmcc	atgcttctng	3600
	ggcagmcaag	ctttgggaac	ccctctctct	ctcccllknq	notaccagtt	nnatggggc	3660
	acccccgctct	lntccagggt	gtctmnancc	aattccctta	ctmcccaac	tatgclncaa	3720
25	atccaggaaac	ccacccclgct	tctaccagcc	ctllkthcaa	actagccagca	vatccctgaag	3780
	cactctllyg	ccacccgcaac	agmctngtga	gcagagggcal	gmnanqaaac	ataggnngac	3840
	agtttgccac	tggaalimct	ccctcagatgc	ngmngaatgt	cttccaglyl	ccaggagcay	3900
	gaatgkthcc	cccaagtgag	gcgaactttg	ctccactcll	ngccctggg	agclmccng	3960
	tgccgatgoc	aalccctctct	ccctcagagll	ctctnctcca	gcaactctm	ctgctctccg	4020
30	gylaknngtc	accagacatg	nggctctggc	agcaaggayt	ngataggaaac	aaamhctgt	4080
	tcagtcagcc	lgtccagaaac	cagccnccgc	ctgcacagcc	aggagclctac	aaacaactgc	4140
	gcctccagct	ttccatggca	ngtggaata	cgaaaghtca	gnccatgaac	nnatngatgg	4200
	ccagatgca	ctgagctctc	lctnngatgc	caggaatgaa	caatgntgtc	ctgagcagc	4260
	taaatgatcc	cgcactgaga	cacacagyn	lctactgcaa	ccagctctca	lccactgaac	4320
35	ttctncaaac	agaagcagcl	gganccnagg	tgcaacagcl	lccnggtttt	gctgacgllc	4380
	agtgtacagl	gactctggta	ggcgggggct	cttccctgaa	ccagcttytl	ccactgggaa	4440
	ctcaaaaagc	cagctnaggc	ccacagaccc	cccaaymcca	gcagaagagc	ctccclnngc	4500
	agctactgcn	tgaaataacca	ctllknggg	aatgtgaaat	ttaaalcaata	ngcatacaga	4560
	ggtatacaaa	tatalactat	atttttctga	galllkngat	atctcaatct	gcagccatct	4620
40	llknggttgt	agcatttgya	gcacacacaaa	aaaaaacaaa			4680

<210> 27

<211> 6773

<212> DNA

<213> Homo sapiens

<400> 27

	gggctggtt	gggggngngc	gggggctgg	gggagclyya	ngatcttgtt	caagatgggy	60
	lgggttccac	agctacccct	gggcccggga	aatctaagaa	tttyyagaaa	aanrtgaaga	120
50	actcagatca	aaactgtta	ctgaagggaac	lgytqwtatt	attaaggcat	taantgaaac	180
	tctqatgtct	cttcttclng	annagccaga	gactgagcaa	cnghtctctt	ctctgaaaaa	240
	ggaaatata	aaaatgaagc	aagaygktna	ngattctgta	acaaagatgy	ggcatgcaca	300
	taaggagttg	ggacnctcac	atataaacla	tytgaaagaa	attgaaaatt	tgaaanctga	360
	gttgatggca	gtacgllkca	aatncagtga	agacaaagcl	acclhctcaa	ngcagctgga	420
55	agaagmctg	nataccgaat	tagaacttcc	agaaacnctt	aaatttcaga	acaaactctn	480
	agataatgtt	aaanactcac	aagaagagat	tgaghaaaat	ngcccaagct	ttgaggagca	540
	aaattttatat	ctgcacnngc	acttngagcc	taccactgat	gaaaaagmgy	nancaattac	600
	tcnartccaa	aatatcattg	aggclanktc	tcagcatnac	caaaaaata	tlankgqttt	660
	gcaggagag	ctttttacagt	tgaaagctat	acaccanngn	ngngtgaana	agttgatgtg	720
60	ccagattgaa	gcclmngnta	aggaacatga	agcagagata	aalaaagllkq	ncngctaaa	780
	agmnaactta	gtaaacaaat	glgagggmcc	tgaaaagaaac	atccagaaga	aalnkgatn	840
	tgagttagaa	aattnagga	aagccacclc	aaalgcmnng	cnnngcaate	agatatgllc	900
	tattctcttg	caagaaacta	natttgtaga	acaaagttaga	aafgaaaaaq	tcanaacact	960
	agaagatccc	ttaaaagaaac	ttgaatclca	acnccgtatc	ttaaaagatg	agglmactta	1020
65	tatgaataat	cllkmngttn	acttgaaat	ggatgctcaa	catataaaag	atgagttttt	1080
	tcctgaacgg	gaagacttga	ngllknaaat	taatgaatta	ttactagcln	acgaangaaca	1140
	gggctctgca	attgaaaaat	taaaactctga	ngtanccgg	ttanataaac	agllkktgcln	1200

	tactgctgga	cagcataach	gmgagtaach	ggttcttaag	gacacacac	axxagagaa	1260
	atcagaacta	aatgagacat	tttltgtcaga	ttcagmnaa	gaaaxattan	catlaxkgtt	1320
	tgxatcacag	ggtctclamg	ncacgtgltg	aaacotacag	caagaaaagc	mgagagcaal	1380
5	tttaaahtet	gagagtttac	gmagattat	ggaantttta	camacagaac	tgghggaatc	1440
	tgcctggaaa	ataagtcacg	agltcgaatc	aalgmgacaa	cagcmngent	ctgalgttca	1500
	tgaactgcag	cagmngctca	gaactyrctt	tactgamaaa	natgccccll	tcgaaactyl	1560
	gaatcgccct	cagggagaaa	atgaaaagtt	mtatctocaa	camgnatttg	tacccagact	1620
	tgaataatcu	atonaqaaac	ttcamgaaaa	gaatgyngta	tacttaackla	gtctcagctc	1680
10	amgagatacc	atgllamng	nattagaagg	aaagataaat	letcttactg	agghmndaga	1740
	tgetttttta	aataaactga	amantccca	lgaggaantg	gataalttcc	ataagaahtg	1800
	tgaagggaag	qamngattga	ttcttgnnot	tgggaagaaa	ntagagcaaa	catccagta	1860
	caacngtgaa	ctagaaacaa	aggtaaatga	mttaacagga	gyactcagag	agacklltuno	1920
	agamngant	caaaatgacc	amantctaga	aaaacttatg	gttcaamhyn	aagttctctc	1980
15	tgaagacann	gaagttattgt	cagctgngnt	gaagttclct	tacgaggaaa	amntaaact	2040
	cngttcagaa	aaaaamngnt	tgaagtaggg	tttgagaggt	llllctgtctc	aaaaagaaag	2100
	tyttatccct	aaagaacata	ltctctcaatt	aghamngnaa	cttcagllaa	hngttgaaga	2160
	gcaagakaml	ctnaataaag	tgccllgaag	tgaagcaagll	cmgaagttat	ttgclmnaac	2220
	tcagttgtat	gylttcttta	aagaaatggg	mtcagaagtt	tcagmngaca	gtgaagagaa	2280
20	aggtgtttgt	aatgtctctac	aggtcagtg	tgaactcttg	gcaaaaataa	alagagaaaa	2340
	atgcannctg	gcttttccagc	gtgalkyaaa	agtatttagag	ltamnaaaag	agallamgtg	2400
	cottcaagaa	gagaglykhw	ttcagttgtg	agmcttaag	tctttatllg	gagactatga	2460
	gcmngqaaa	gttctcttaa	ggaamngntt	agaagaaall	caqtcagaaa	aagagggcct	2520
	gcagttgat	clltctagaa	tgaagaatgc	lmtngaaaa	acaagggcll	amntacagaa	2580
25	lcttttaatt	caagttgaag	aagltctctca	aacatgtatg	mnaqrgaaa	tccallmng	2640
	aaaagaaam	tytttttatna	aggaacalga	aaacttaag	ccaclmntng	acaaaaaaga	2700
	attacagagat	agygagngny	anttgatact	allamnggat	tcotttagcaa	ahcacccttc	2760
	lglnnaaat	gatccctctgt	cttcagttana	agagtttgaa	ghamngatng	aaactclgyn	2820
	aaaagaatgc	amngqaaag	aggaagaaat	amntaagata	aaattagllg	ccctgaaggg	2880
30	mgagaangaa	ctagattcca	gcmngnnga	gaocacagcl	ghyngngaa	aacttgaelr	2940
	tcttcagalc	gmaanggacc	agttatctgt	ttccttgaga	gatctcalll	mngagcaga	3000
	angctetaag	aatclllllll	hagantatga	aaagcaglyc	gaqcaactgg	atglygaaa	3060
	agmngctgt	aataaatttg	agcalngtat	tgaagacett	acmngmna	taagaaatte	3120
	gactttgcay	hgtgaanona	taaatctctga	lambgngnt	ctcctggctc	qlattgagac	3180
35	mtacagctct	aatgccaat	talhogaagt	acagatttta	ymghmngn	gaqccaaagc	3240
	aatgytagaa	mngaatlng	aagctgaaaa	achtcaqana	gaacagaaga	lamngyaaac	3300
	tgcactact	gtaaatgaac	ttgaagaact	tcaggtacaa	cltcmngng	aaaagaaaca	3360
	gttclmngaa	amctagcaag	aattagagcl	ggttaaaaag	gatgcccac	amccacatt	3420
	gatgaatatg	ganatagctg	attatgaacg	tttgalkmng	qacttaaatc	aaaagttaac	3480
40	tnatnaaaac	aacaagatag	aagntttngn	gcaagaataa	amallcmng	acagaaaca	3540
	agaaacccra	atcmngyact	tacttctgaa	amngtcttca	gtacaacaat	atymngmna	3600
	agmngaaact	gatcaactaa	haccllmng	aaacaaaaag	gaactggcag	attcaagaca	3660
	gcagcaagll	ngqctotata	aaatacagct	ntctttaaaa	gglyagylgg	mngnaagcca	3720
45	ccacgagcac	ctgamaampt	ctgcggaaca	gqntgnaatn	acatcagaga	agcmamab	3780
	gagmgtgaca	gcactacagg	aagaglycmg	gcaccagcyl	mngctuanrg	cataccagca	3840
	ctctgaatll	mgagctaca	aagtcagagt	tqctgcacag	gcagaacaa	ctactgttac	3900
	ntctatgtct	cagggclgaa	ntgngggcgc	tcalamtqkt	ctnaaacaa	agaaaaataa	3960
	galtgacccag	ctaaaaatca	aattacmng	taaacaaaga	mngmngctc	tgaagatgct	4020
50	tgaacttcas	mngttgcagt	ctgaacatga	taacaclycl	aaacttacaga	llaghtgctc	4080
	qmagaaact	gtgtccaaa	agmngnaact	cogggaaaaa	gmaamgaca	acaagatgct	4140
	gaacclmngt	atgaatctg	aacatacaaa	gamtngagt	ttgtgllcaa	taamgtong	4200
	ggtcctttng	aatngcttcc	gagatcaagt	gcmactltng	cagctaacat	cccagaacga	4260
	agtggagaca	llamngmng	agctctccaa	gatggaagca	ccgqamngac	acagaagagc	4320
55	tgaacogacc	acaagaagcc	caglllccctc	tcacacaaat	cagclntlcc	agcttaagaa	4380
	gagaaacmca	ngcctccogc	ttctagacat	gcacmngtga	ttgaagaacc	tlcmngamng	4440
	catggagaca	actgntmng	mtctgtgtc	ttccggccag	acccggqna	agggagaaag	4500
	gcagttgctt	aactctcccg	aaactaaac	lgmngctcca	acalacacac	mtctcttga	4560
	caagaagaa	ttgtttcagn	agctcagttc	caccacaaa	ttatggcatg	ctgaattttac	4620
60	ontgottcgg	gaacacagm	amamngatgc	aattcttatg	mtgcmngn	acttaaacgg	4680
	aaglymnaata	agaagattgg	aaaggaatca	agagccgagq	gagcaaatca	agcltclcm	4740
	atacttgaag	mngctcttgc	tgcagttcat	ttcttgaaga	amgtctgng	ctaactggga	4800
	actctctctc	gttalcaata	lyatlyktyca	gtctcagccct	mngghagty	aaagagagag	4860
	tgcggttngt	caaggtgag	aagaaatgc	ttcccgkctt	gaagaaaagg	gaaaactlyc	4920
65	tcatagttgg	hctggaectc	mtaggttga	tggaggaal	tctggatggg	catctatct	4980
	atctattttac	aaaaatgggt	namgtatatt	accccaatcc	allllllllll	accaaataga	5040
	akltgtttgc	atctacatat	atttlytact	cllaltgaga	ttttgtcaaa	aatgklykly	5100
	tcttgaaqle	amngtcaaac	agcttgaagt	gttgataga	gatgtatttt	aaaagtttca	5160
					ggmnaagcc	ctctaactca	5220

5	tgtgtatttcc ctctgggaac aattttggt tgggtgalkca gttagtgagc taaaantaa ttacagtgtg tgttggtann aatttaaaat atactatctc tatgagttag tgataggtg aatnaaaaac gggtgkktca nacacottag gllacttgcc tcaaatcaaa aatgtctctt tgtgttkhca tgtctgatac cttaqaagaa acatgaagag cgatgtaact ghctgtataa tcttgcalga tgagaggaag	catgextgct tcaggacccg ccalancanc tgootgaal kgttactccc agtaalaaa ttataaatlg aqtgacatgt acaghttagt aaaactcalh tgggcccacc kuntgcatg ctatcacccc gtgtkttttg aggkccgtgc tttgacaccl aatggataa aagcckhcag ctttggttac ktggttttgt cagacchanc tttagttttt aahctatntt acttgitttg taaaaaatta tqlaahggtt	gcacagaata ccattttctc tggaactctg nccactaact actgcactcc taaaaaatac ktqngaaatt taaggggcta tatttgctct atgtttgtac aclllgagtt caagccalga amgtatgtgt taccatgtta ntgcataatg tttglaahat tttataactc ataggaactt tctttaaaaa tagtgaatgt ttacllkhat aaatatatnt aatktatntc ctttgattac nttttaatac	aacacacagg ggcagkactg gttttaaaaa tgggghggtg agctcgggga glktttatgac tttglgctta tgaagtaash naataaaact agccclnngg aggtgattin atctgttttg tcaclcagca tccataagct aatgtccctc tttaalgact ttatgtgtta taallkactt ggtttccaal akagctcata attaalgmnn aactgtgaat cactllkctc totgtctacg aaagggcgta ttctatlann	natgaattca tgaaktttga toatgtttca aggctnngga ccagagcngg cttttattgc gaatntgaag atgctgcagl ctctcttttt ctggclngtn atgggtgtct agantccctc ttgyalctoa ttccatcaga gahtnccctc agatcccaan ahcacacagt ttctllchga tcagtttaac katntcatct atgcactclh ahggtatgc ttgactllan antgtcataa ttcllllntg tatgttttaac	ctccccactt agtcaantc nccgcagggt atlgctkqag nccctgtctc aaggtccagag gaaaaagctt toatttgtct tcllllann taacactgac lncagactct ccaktllkcc atataaaagt aggggtttta aggkglngt tgtgttgttc atgclctctg gttggaagac lghaatttgc ttctctclgl ttecagagctg cagctgcakn nccctttgaa caaaalann gtttctgcaa lgl	5280 5340 5400 5460 5520 5580 5640 5700 5760 5820 5880 5940 6000 6060 6120 6180 6240 6300 6360 6420 6480 6540 6600 6660 6720 6773
30	<210> 28 <211> 2619 <212> DNA <213> Homo sapiens						
35	<400> 28						
40	atgacacag atgaagcag tgttgaaalg gttaataatg gatenctate cccaacaact galgtgcttt gaggatcakt gtacagagct aaagalkang gaagaaganl ktagcaaaat accagattgc tcacctaaag ctgaatttgt atggctttgc ctgatcagac cagcaactta gatgatgntg gtgggagggg ktagcagagc cgagtgggac atcccttttg kaktactttt ttgankctg gaacgaagaa nccctcaaa gctatgngan ggagttgatg aatccagata tcttcttttg tacaataact	cttgtaaaag cagctgcaaa nagcctgcnc cagcagctat cctccaagaa nctgtctctg acttaacaga cccttttaac tccyyaaggl acaaagatga cagaagcctc taggcctkya totctaattg tngaatgtga tcattalccg cattattttg ktgtgtctaa ttactttata ccattgttgc nngtngncc tgacacttca ccctngnaac aagagllkhl tcaagtaga tcacaaagaa kactgtttct ttagactga atcctgcaga nnggagngtt ttgglatgtt aaactgaggg ghkactkng	akcagggagga gcactctaata gaatgagttt knaagccctc aggagcaagc nntaaaaatg agagaaggla ccgtgttatt knaaaanngc agatgaaaag ttcccaagg kagkghkht aaaaattgaa cttgacgtat aalggagaa caaagcgatg atcaaatgca agkcalaaag tgcttcgaag aantcccaat ggaacttttg tgnacttgtt kaktgnaann aacagagaa tttgggatta ctacagctta ccataltala cttgagaag ttccaaagaa cacalacgal tcagtttaact tgtacatttt	cctcagttctg ganngtact tgtctctcc gagctttata tcagcttaac aacaaagaa kctgaacttc ggaagagllh nccaaaggaag gaannngctg ataggtgala nctgagattg actgntttc cacactgtat nagaactctc agcaagclac gaccagatcc nctgaattta tgctllgann gaagaagatg ggagagaaa tgttaaaacc ctgnaatgag aaaltctctt tattatgann gttcaaggac gaktatgcac cagttgkhtg ttttttcagc gaktctacaa ctgactggga cccatggttg	aggaacttga aocacacgll nccaaacttt ayallkactg ttgagaactc gngctngaat ttgaattaly ttctotagtgc aaclganntr catgttctgc nctcacaggg atgccallng tcaatgcaact nctctcagga acagtcclya cccttgacgc ggagactnnc acagtcgaaa tggtttacta algaagngnc gaagaaacaa tggakhtctg ttctagaact ttatgacatg nctgaattcg agcaallgna ttgtccggct tngnatttga tgyllgtgna aattgttttg kagtactggg ctctacngaa	agctagccga nactlgnggc tcttcgtatg aaactctgt gannngkgr tgattttaaa tgaggaagga tgaggcaattg tcttcagca tgtctctalg agacaaact nnggtctac tgtataattg tcttaattat nctctcggan ccaagggaana ggagacttt lclagllgaal tgcaaatgta cctccctgan gaaaggtcct aanccactt ggtataagat tccctttata catgtncagt tccakhttg agagatgac aggagaacaa gggaactctc gtttaatcca tctgactatt nclaalgggg	60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620 1680 1740 1800 1860 1920

	aaaaaaggaa	cttttcogtyu	ottggggmgao	toteacnrag	tictatatoca	gagtttaaan	1980
	gatttatttg	agletgaag	uatgttgaa	uatgacatga	tgatcanctt	ccagatatoca	2040
	cagacagctc	tttttggtaa	cccaatgatg	talgatctaa	ngqaaatgg	tgataaant	2100
5	ccaattacaa	atqaaaacag	gaaggaalett	gtcaatcttt	attctqacta	ctttctcaat	2160
	aaatcagtag	aaaaacagtt	caaggctttt	cgagagaggtt	ttcatatggt	gaccaahtga	2220
	tetcccctaa	agtacltatt	cagaccagaa	gaanttgaa	lqcttataty	hrgaagccgg	2280
	aatctagatt	tccaagcct	agaagaaact	acagaalett	acggttqcta	tcnaggggac	2340
	tctgtttctga	ttggggagtt	acgggaaatc	gttcattcal	ttacagatga	acagaaahga	2400
10	ctctctcttg	agtttaccac	gygcnragac	agayaaactg	tgggnggact	agaaaaatta	2460
	nagatgatta	tggccaaaaa	tggccagaa	acagaaaggt	tacctacahr	tcatacltgc	2520
	tttactgtgc	tttacttcc	ggaaactoca	agcmagaaa	aacttaaga	gaaattgttg	2580
	aaggccatca	cgtatgucan	aggaatlbggc	atgctghaa			2619
	<210> 29						
15	<211> 4263						
	<212> DNA						
	<213> Homo sapiens						
	<400> 29						
20	ggcggttccc	cttccctcag	cagttagctct	atgyttttcag	ggcgguaacg	tgacaggtcc	60
	ttacuttgag	cctgtgcagt	tgccttucac	ccggaaatcua	tagtcaactyl	racagagggcg	120
	gaggacttgg	gcncaggtta	gcctcccagt	cccaagcagct	gugggtccgc	gcclggcccaa	180
	gcuaactcga	cctgtcaggt	tggggcggt	acccagcaat	tccccctgty	cagccggccgl	240
25	ttccaagggy	tcaggaaacg	ctgtgtttgt	tlcgtccggc	taycnaaggg	ggylrncrga	300
	glantgtgac	tgacccagac	gtggcaggtc	tgacggcgla	gcccagagacc	ggtgcccgyt	360
	gtaggaglcg	cagcctgggc	tgtnagcggc	tgctnngtag	acagacttgc	ttlclcttac	420
	agcatgtcat	ttccaaatg	catcgtnttg	ctctctgctt	aagtcctala	ngaagacant	480
	gcgcuaacta	gacgggtctc	tatggctcgc	actgttatcc	lgaactcaggt	cunrtgtcat	540
30	tgagcatatg	tatgaaaatg	ccttagggag	gaacactgga	gaaglatgtg	agactgcaga	600
	agattggaga	aggttccatt	ggaaaagctg	ttctgtttaa	ntcgacagag	gntngcagac	660
	atttatghat	caaggaaatt	aacatctcaa	gactgtctga	taagynnaag	caagantcca	720
	ggagagaagt	lactgtattg	gcaaacatga	agcatcnaa	tattgtccaa	tataaagaat	780
	actttgaaga	aaalggctct	ctctacatag	taatggatta	clgtgaagga	gghgcttct	840
35	ttaaacyaah	naatgctcag	aannggcctc	tgllhcnaga	agaccagatt	ttggactggl	900
	ttgtgcagat	algttttggc	ctgaagcctg	tacatgatay	aaaaattctt	cnngagaca	960
	taaaglnaca	gaacatatll	ctaaccaaag	algggccagt	gcagclhggg	gattttggaa	1020
	ttgtcaggt	lcttaatagt	actghaggg	tggtctgaa	ttncatagge	actccatact	1080
	acttgtccac	tgaactctgt	gaaacaaagc	cttatncaa	taaaugtgac	atttgggcll	1140
40	tgggtctgyl	cctttatgag	tlghctacac	ttaaacalgc	atttgaagct	gnaaacatga	1200
	aaaacotggc	ackgaagata	atctccagat	cctttctctc	agtgtctcca	callmctct	1260
	atgatctccg	cagcttgcct	cctcagttat	lcnngagaaa	tcclagggat	agaccatcag	1320
	tcaactccal	gtttctctag	gttctctatg	ctaaacgntt	cgaaaagttl	ctctccctcc	1380
	agottattgc	agynaaattt	tgtctaaan	cactttcaaa	glhggagcca	cagctctctc	1440
45	cauyhcaang	accagatcca	ggcaagggty	lcnngtcttt	tgctcnlqct	cagaaaatca	1500
	caaagcclyn	tgtataatac	ggagtgcctt	taacalalaa	gaagtatgga	gatonaaagt	1560
	tucttgagaa	aaacaccccc	ccaaaactta	aacaggccca	lcnnaatccc	gtganyann	1620
	tgaattctcg	agaagaaayq	aaagaaatgt	clgngnngc	agcaaaayuy	agaaggttgy	1680
	aattttattga	naagaaagay	aggttggayn	atcagatcny	gttctctgaag	yntnagcaga	1740
50	tgagcgggca	agaynagcag	cggctggayn	ggtataatag	gyccagggaa	caaggatcga	1800
	ggaatgtttt	aagggtcggl	ggagcggtg	aagtaagggc	ttccttttll	ggcattggag	1860
	gggtgtctc	lcnatcccg	tgttctcthc	ngggccagta	cyaaatttac	catgcacttt	1920
	ttgacaaant	gcagcggtct	agagcagaag	alaahtgaag	aagatygnny	gggggaatct	1980
	atggtcgaht	gctcccagaa	agccaaanaag	gacacttlay	tgtagagaga	gcccacnng	2040
55	tggaagaatt	actacagcgt	aaacyayayq	ctatgcagaa	lcnngccctga	gccgaagayn	2100
	actgtgttta	tttggcnaqn	ctgaggcaaa	lcnngactnca	aaattttant	nggcgccaac	2160
	agattcaagc	caaacttcgl	gylrnnnata	aagaagctlyu	tggtaccaaa	gganacagaa	2220
	caactgaaga	gactcnaay	agctcnaay	agctgnaagc	actlaagggc	caaacaaatg	2280
	caugtgcctg	tgtactlaay	gaacagctgg	cgagggtaay	aaaggaagcl	lchqnaagag	2340
60	aaaagaaant	atgggaagaa	clhctgtgtg	cgagggtaay	ayntcagat	gttctctctg	2400
	ctttggaact	acttgaacaa	ggtgttclcl	cttcaagcca	gcaglyayag	cctgtcattt	2460
	ctgtgacttc	agcllhaaaa	gaagtgggac	tyyhlqgnag	tetaactgal	ccccagggaag	2520
	aaagaactgyn	aaagagttaac	agtgtattt	caagtaagcg	aynaatcctg	cgttaggclay	2580
	atgaaaactct	lcnngctcaa	gaggtgaaay	aynaaagcca	gcataclnca	ggttctgtg	2640
	agaacncttg	tcacaaagnt	gaagagagat	atgagacayn	aatgcactt	tcclctgate	2700
65	gcaagaagly	ggagatggga	ggclagcttg	tgattctctc	cgalgagatg	acactggata	2760
	catccttctc	tgcaacccgaa	aaacatactg	tgqngngngt	tattaaahca	gattctaatg	2820
	gtctctccag	aaaagclctgg	gggaaaaacc	clcnagactc	tctgtcgaag	atunttggag	2880

	aagcttgaatt	acagctatbn	acagaactac	tagaaaacac	atcitttttaa	aglguygttt	2940
	atgctgaag	ggagaactac	aaacccctac	ltaactgaay	agagaattct	cagtgcaltt	3000
	nnnagaat	aaatccatca	gctantqttg	attctctctga	aaagaaaagt	ccaaagttta	3060
5	ctgaggtgtc	tcacaaantg	tcagaagayn	atgtggagga	acctgaltgt	ttggaaanng	3120
	aagtttctac	anagccaaagt	agccacacaca	anagtgggag	tttgccacct	gttcttaaty	3180
	atgtgtggac	laynngagag	gaagcnncta	aggaanctga	gttgagagat	aaggctnctg	3240
	tgcngongag	tgaagllhgt	gaagataynn	ttccagggna	cgtggacuna	tcctgtanng	3300
	atcagagayn	tcctgcagta	ganjattctc	cgcctctctg	clgtgatgta	ynagagtcag	3360
10	tcacagccaga	Atcgattttc	cagaangtng	ttcattctba	ggactltgaa	ttagtlcaag	3420
	cagttcattg	ctcaccaynn	gaaccaattc	cnnttogalc	tcactctgah	tctccacca	3480
	aaactaagng	caagaattcc	tlactgattg	gactttcaac	tggctctgtt	galgnaaaca	3540
	atccaaagat	gctnaggagc	tgtctacttc	cagatcttct	caagctgtlt	agaacctaa	3600
	tggagcttcc	cactglgggg	gacgttctac	aaagacagtc	lgaatctgat	gnctngag	3660
	atgaacnnt	taagaagggg	ctttctgatt	ccgnaagcac	tglctttgaa	gaactltgaa	3720
15	cagattttaca	agagcttccg	gctctnnctn	agcagclgt	tagggagcna	ccaggtgacy	3780
	aatnagtg	ggaggagng	tctgttttaa	naagcagoga	tytnagagag	anngcagag	3840
	ggacagatg	ncagagagag	gagggcnaac	ccagcagcga	agccctclg	acagagagag	3900
	gcactcagat	aataghgacn	ctgagaccac	hantgaatgt	gnatagaca	glgcttttaa	3960
	ccakttagag	gaactaagac	ltaacttgga	gcaggaantg	ggclcttgaa	agttcttlg	4020
20	ggtttatgag	naagtaagng	ctatctahga	ggatgaagat	gaatatttg	aatctgttc	4080
	aaactatagt	gagacttttt	tnggcaatga	gcacacagat	ctclctgcca	agattctnng	4140
	tttaglcntr	gcagatggag	ccctctcngga	agataalgct	gaataatcc	cngacattc	4200
	tttaatagtc	aaactgtaga	acacatttca	anttgctca	cnatcaagc	ttctlgggan	4260
25	ata						4263
	<210> 30						
	<211> 1756						
	<212> DNA						
	<213> Homo sapiens						
30	<400> 30						
	tggggcgag	ccgcgaagat	gacgttggan	ctgaagcaga	gnnngtga	gaagalctgg	60
	gtgcccgtgg	accacagggc	ctcgttgccc	agatctnttg	ggccaaagrt	gaaccaactc	120
35	cccannctca	togtcatggt	ggcctcctcc	gcccggggna	agacctacat	clccannag	180
	ctgactcgtl	acctcaactg	gattggcgla	cccaaaaag	tglctnncgt	cggggagtat	240
	nnccgggagg	ctgtgannng	ntccagctcc	tacaactct	tcggccccga	caatqaggaa	300
	gccalgaan	tcgggaagca	atgtgcnctt	gctgccttga	gnctgtctaa	aagctacclg	360
	gcgaagaag	ggggacaaat	tgcgttttct	galgcnaaca	ataclactag	agagagaga	420
40	ccatgatcc	ttcattttgc	nnanngnaat	gaatttaag	cncttttctat	cgaclcggtg	480
	tgcgaagacc	ctacagttgt	ggcctcnaat	ntcatggaag	tlannatctc	cagcccgat	540
	tacaagaccl	gnaactcggc	agaagccatg	gaugacttca	tgaagagynl	caattgctat	600
	gaagccagct	accagcccll	cgaccccgac	aatgggaca	gggaatttgc	gctgaltcay	660
	gtgattggag	tnggcgggag	gttctctgct	nnnngtgc	aggaacnaat	ccagagcccg	720
	atcgtgtact	acctgalynn	ctccacagtg	cagccgynln	ccctctacat	gtgcccgcna	780
45	ggcgaynnag	agcacaacct	ccaggcccg	atcgggggg	actcaggccct	gtccagccgg	840
	ggcaagaagt	ltyncaggtg	tctgagcaag	ttcglggag	agcagaacct	gnnggactg	900
	agntgttga	ccagccagcl	gaayngnacc	atccagagcg	nnnaggcgct	ggcgctgncc	960
	tacyagcngt	ggaaggcgct	caatgagalc	gaogccggcg	tclylgagga	gctgaactac	1020
	gaggagatca	ggacacacta	ccctgaggag	talgcnetgc	gggagcagga	caatctctat	1080
50	tcacgctacc	ccaccggggg	gtctatccng	gaactggtcc	ngcnetttga	gccagtgaic	1140
	atgganctbg	aggggcagga	gaatgtgclg	ntontctgcc	accagynnt	ccctgcctgc	1200
	ctgcttgcc	antctctgga	taagagtga	gagynntncc	ctacactgaa	algnactctt	1260
	naacccgtcc	tgaacttgc	gctgtctct	tatggctgac	gtgtggaatc	catctactct	1320
	aaactgnggt	cctgtctgac	acaccggggg	nggtcagagg	atgcaannng	gggaactaac	1380
55	ccgtctatga	gacncaatag	tgtcaacccg	ctagcnnngn	ccgaacccac	caaaaaycct	1440
	cgcctcaaca	gctttgagga	gnalghggcc	tcacactcgg	ccgcccctgc	cagctgcctg	1500
	cccccgaay	tgcacagca	gctgcctgga	caannctga	aaggctcccg	gagcayngct	1560
	gctctctcca	gggaannctg	anngcagngt	ctcgtttcca	ltaactttcc	atttctgag	1620
	cttagcttgt	gtctctgccc	ccgcccggag	caannctgat	ctgagynact	tcttcngag	1680
60	aggttgggt	ngagcaggg	gggagccttg	gcnngnagga	acctatgctg	gnanngctct	1740
	tgtccctnng	ncagct					1756
	<210> 31						
	<211> 1661						
	<212> DNA						
	<213> Homo sapiens						
65							

<400> 31

	tggtgcagcc	gclgcgrrcc	attcaggalc	tcattgcac	ggcncncnna	cgacgucnng	60
	acgtgcattc	cogatttcctt	ltggttccaa	gtccaaatnr	gcaactctaa	agcatcagct	120
5	gatttataat	attctaaagg	aagaaacnag	ccccagaa	nanattacag	tlgl.tggggt	180
	tggtgctgtt	ggcalggcct	gtgocatcag	katcttaatg	aaggaccttg	cagatgaact	240
	tgclctgttt	gatgtcatcg	anqncanatt	gaaggagag	atgatggatc	hccaaacatgg	300
	cagccttllr	cttagaacac	caanngtttq	ctctggcaaa	gactntaatg	caartnraaa	360
	ctccaaagctg	gkctttatca	cggtcggyu	ncrtongcaa	gagggggaaa	qccgtctttaa	420
10	lllqntccag	cgtaaagctga	ncotatttaa	attcafnatt	cctaagtgtg	l.mnntacag	480
	ccgaaagcgc	naagttgetta	ttgthtccaa	tcagttggat	alchtgacot	acglggrttg	540
	gaagataagt	gyltttccca	aaaacccgtg	hcttgqangt	ggttgcaacu	tcgattccagc	600
	cagattccgt	taactgatgg	grrnaaggct	gggagttca	ncnttaagct	gtcalggggtg	660
	ggtccttggg	qnnocatggag	attctagttt	qccgttatgg	agtggaaahq	atgttgctgg	720
	tgtctctctg	anpactctgc	acccagattt	agggactgat	aaagataagg	ncnagtgga	780
15	agaggttcac	aagcaggtgg	l.tgngagtgc	ttatgagglg	atcnaactca	aaggclacng	840
	atcctggguk	cttggaactct	ctgtaycnay	tttgccagag	agtataalg	agatcttag	900
	gcgggtgcac	ccaglttccc	ccatgattaa	ggttclllha	qqaataaagg	atgalgtctt	960
	ccctagtttt	ccctgcattt	tggyacnqna	tggaatctca	gaccllgtgn	aggtgactct	1020
	gacttctgag	ynagaaqccc	gtttgagaa	gngtgnngnt	acactttggg	ggal.mcnnaa	1080
20	ngagctgcaa	ttttaaglyc	ktctgatgtc	atatcacttu	actgtctang	ctaccaacag	1140
	atletagghq	gaggttgctc	atgllglkch	ttttatctga	totgtgalla	ncqcaqtaat	1200
	attttaagat	ggactggngn	naacatcaac	tcctgaaglt	anqaataaga	atggtllgtu	1260
	anctonacag	ctatatctctg	alyctggntg	gtatttaact	tgtgtaglll	taactgtgtt	1320
	agtgtgaaal	ayttctgcca	ccctgagcgc	acacclgccc	atnctgtacg	tactgcallt	1380
25	gccccctgag	ccaggtggat	gllkacnctg	tgttatataa	ctccclggcl	ncntcaactga	1440
	acatgcnlkg	tcnnaacttt	tttcccagtg	aglcacnctc	tgqgntccag	tgla.tcaahh	1500
	caatatcatg	tbllytgcak	natcttcca	aaggatctta	lllllylyanc	tatatcagta	1560
	glykacatta	ccatataatg	taaaaayatu	tanatccaaa	caatgcaacc	aculatccaa	1620
30	gtgttatacc	anctaaaaac	cccaataaac	cttgaacayll	g		1661

<210> 32

<211> 4169

<212> DNA

<213> Homo sapiens

<400> 32

	ggcggcttcc	aygtgaggrn	ncaggccgt	ggtcctgclt	lylyccclclg	acctgctgct	60
	gntgctncta	ctgtacccac	cgcclgggk	ctgcggcgcc	nanngctcgc	cggggagcgc	120
40	cgacaggtcl	cccccaactc	cccggaagaa	gaagaaggat	allcygath	ccaatgatgc	180
	agacatggcg	cgtcl.kclgy	ngnaatrrgn	gaagatgat	gacattgaag	aaygagakt	240
	l.cagagrac	aagagacctt	cagcacllgl	cyachctctc	aaqatngacc	caagcaagcc	300
	tgaaagcl.k	ttqnaactga	cgaaaaaagg	gaagactctc	algalylklg	tcantgtatc	360
	aggaagccot	actgyayaggy	ngnccnqngn	anttaocagc	ctctggcagg	gcagccllll	420
45	caatgcraac	tatgaocgtc	agaggttcat	lylyyyahcn	qacctgctca	tcttcatgct	480
	tcogcatggg	agclhcnccct	gggaqntcna	ggactttttg	gtcggkcaag	acaggtgkge	540
	tcactgaact	ctggaggggc	aggl.gll.kctc	cnqcnanngg	ggaggaagca	aagagaaaaa	600
	taaaacnnng	ccaaagcaag	gcaaaaaaa	gaaggaagya	gal.chqnnat	ctcgttcttc	660
	caaggaagaa	atcgaqctg	ggaataaaag	agaagacctg	tgatggggca	gcaglyagcc	720
50	gntgtcgggg	gacaggttga	cglggagng	l.ktttgncc	gtcctggggg	tgggagtggt	780
	ctcaggcaat	tncaacnccg	atgaacttct	agtgctctct	agaaaggglc	lyccnactgn	840
	ccagtttgtg	gtcaagaaal	laclgcllha	hcgacttcan	qtnagaagac	agatgttttc	900
	taatl.aatuc	tggaactga	caaattcatg	tttactctaa	aal.cl.cclha	catqgaantg	960
	tgactgtgll	gntttttccc	atttacaact	ggtgagtrct	caactctact	gagattccac	1020
	tccccccaaa	gcactlgctg	l.gal.kggglg	gctgctctg	atcagntage	caattctgat	1080
55	cayagangac	tttaaaactc	ttgaactaat	tgagtasacl	ctccalynca	katagctcat	1140
	tttcallakg	l.taaaggtaa	aatatgcttt	gtgaactcag	atgtctgtag	ccagggaagcc	1200
	aggggtgtga	aalccaaaal	ctahgcagg	natgcggcga	atnqaanata	tgtcaactga	1260
	aalccctnagt	agttttgaat	ttctttgact	tgaactctac	lcatcaghaa	gngaacltll	1320
	ggtgtctgk	aggttttatg	tggtctgtaa	agttaggggt	tctgctttgt	ttccttattt	1380
60	aggaagaggt	acthctgkly	tnaggggghl	atctgttccc	ttcaatrtgn	cagttttana	1440
	ggatttaagt	agggaaactg	agtcctttgc	agagtgkge	agagagarkca	alawccclnal	1500
	ttgtllctaa	ncattttctc	ttgataaagt	gctcaaatct	gtgclttcgt	atagagtaac	1560
	atgatgtgct	acthgtgkly	trtghklttg	ccgttccatg	tanqccctac	tgtgaatnag	1620
	agltatqancc	cttatataca	gatgtcattt	ctaagaacla	aatctctttg	ggnaaaaccc	1680
65	tcaattylga	l.tttaatana	tttaannrtag	ccacttacat	ggttagaaaa	tgtcagtggt	1740
	aaagaatggt	acaaagtgaa	aagtgatctc	clclclhgc	gonggtngka	gcttqctnca	1800
	gtggaagctg	ctgttaacaa	tttgtgcccc	caactcccc	ccccgccc	tnacccaaaa	1860

<400> 34

gagattgckg	gggtgcagc	gctgcctkccg	agaccgagayn	tgggtggagc	gggtcttcccl	60
ggaaggggtgc	gataagggccg	ggcgaggtgc	ctgggatget	tctcccttc	cgagaggaag	120
agalcctatt	gggtagggcg	gggtgcagact	agcclgccc	gocgcocgc	ngcacctgca	180
gctcctggtg	ggcctgggng	cccgccgaga	agttgttaa	ggggagcgag	gcytttnttc	240
ctggggctcg	agggcgccct	ctcagccct	gccccacaga	agccgagctc	ccgtgggghc	300
tgagagagca	gtttccttgt	taatacacaat	aaatcctgc	tccctctg	tcagacatct	360
acycagcgaa	atcgagcctg	gccttgaggg	tcacacctgc	ggggaagatg	cylgcgccc	420
ttccagagcc	taagcctggg	gacotgattg	agcttttctg	cccllctctac	agacactggy	480
ccatctatgt	tgccgatgga	tatgtggttc	atctggcctc	tcacagttag	gtcgcaggag	540
ctgggtgcag	caagtctctg	tcgcctctga	ctgacaaggc	ctcctggaag	aaggaaclkg	600
tgtatgatgt	ggcgggaggt	gacaggtacc	gggcccccaa	caaacalgh	gacaggtact	660
ggcggctgoc	ctgcacgaaa	atcaltccagc	ggcgccgagga	gctggtgggg	caggaggtgc	720
tctacaggt	ggccagctng	aactgcgagc	atctgtgaa	tgagctgctc	tatggagtcc	780
cccgccagtga	ccaggtcaga	gctgtcatca	tcgtgctgag	cgttgccagga	akggcttgg	840
cagccctgag	ccttatttga	gtcatgltct	caagaaacaa	ggcgcacaaq	caataactgc	900
aaaagactgt	ctgltcagcg	tcactttata	calcaagggg	gtcttgtlcl	gctagagagt	960
ttgggggtttg	gtttgtggat	ttcatlgtga	tttataataa	ggcttatttt	ccagaaclaa	1020
aataaagcaa	aaatgggag	gattttattg	ggggggtgca	gccccaaaa		1070

<210> 35

<211> 460

<212> DNA

<213> Homo sapiens

<400> 35

cttttctckc	catgtctgca	ccgaggtgoc	acggclgaga	cttctccgce	ggcctccgng	60
cagaagccgc	cgcgatgcgc	caagctgct	cctacctgct	gcttgcctca	gggggcaact	120
cctcccccag	cgcccaaggac	atcaagaaga	lcltggccag	cgtgggtalc	gagggccgag	180
ccgacccgct	caacaaggcl	atcagtgagc	tgaatggaaa	aaacttgaa	gacgtcattg	240
cccggtgtat	tgccagagct	ggcagtgtae	clgtctgtgg	ggctgtagcc	gltctgtctg	300
ccccaggtc	lgtggccct	gctgtgtgtt	ctgccccgc	hgcagcagag	gagaagaaag	360
atgagaagaa	ggaggagtct	gaaggtctca	nigatgacat	gggatcltgc	ctttttgatt	420
aatctctgc	tcccttgcaa	ataaagcctt	ctccacatcc			460

<210> 36

<211> 4416

<212> DNA

<213> Homo sapiens

<400> 36

ggcgcacagg	gttttatagg	atcacattga	caaaaglcac	atggagtttt	atgagtcagc	60
atattttatt	gltclctaklc	cttcaatagt	tattacagta	atttltctcl	tctctgtgct	120
tttcatgaaa	gaaacattat	atgatgaagc	lcltgcacaa	cagaaaagag	aaacaaagcl	180
tattctctgc	aaanccgata	aanngaaagc	agaaaagaa	aaagacnnaa	agaaagaaat	240
ccagaatgga	aacctccalc	aalgtgactc	tgngagtcta	cctcgagact	lhaatttctc	300
agatgctttg	gcagtagaag	atgatcaagt	tgcaatctt	ccattgaatg	tcgttgaaac	360
ttcaagltgt	gttagggaaa	gaaaaaagaa	ggaaaagaaa	caaaagctc	tgcttgaaga	420
gcaggtcatc	aaagaaagtg	ccgcctcaca	gattcctggc	aaaaaagtag	aaactgtccc	480
agttactaaa	cagcccccac	ctccctctga	agcagctgoc	tcgaagaaag	aaccagggca	540
gaagagctct	aaactgtgaa	gcgatgacca	ggataaaag	glggaaactc	tcctgtatcc	600
atcaaaaagg	caagaagcat	tgccctccca	ccaaagagct	aaacaagaaa	gtggatcagg	660
gaagagagaa	gcttcatcaa	agaaacaaaa	gacagaaact	gtlclhgtgc	atgaacccct	720
tattcatgca	atclactlata	lctctttgat	ggataatgct	gactcaagtc	clgtgghayc	780
taagagagag	gttatttgatt	tgcttaaaac	lgacaaagta	gaagggatcc	agaaatctgg	840
gaclaaaaaa	ctgagagccg	aaactgacaa	agaaaatgcl	gaggtgaggt	ttcaagattt	900
tcttctgtcc	tlgtagagcta	tgatgttttc	tgaaagttag	gctctttgtg	tlgttagactl	960
gctaaaggag	aggtctgtgt	taatacaaga	tgcllclhaag	aaqtcaagta	agggagaaat	1020
gactcccttt	atcacatcagc	ttcaagaaaa	ggacaagtta	ctcgtgltg	tgaaagagaa	1080
tgctgclgct	aaagaggtct	gltgtaaagc	gttaacccag	gaatgatga	cagagaaaga	1140
aaagaagcaat	gtggttatca	caaggatgaa	agcltcaact	ggancattag	aaaaggaaca	1200
taagtgtattt	caaaaacaaa	tacatgtcag	ttatcaagag	actgagagga	tgcatatgaa	1260
gtttccagca	gttccgtgagc	aaatggnggc	agagatagct	caettgagac	aggaactggy	1320
tatactgaga	gatgcaglca	gcacacclac	aaatcaactg	gaaagcaagc	agtctgcaga	1380
actaaataaa	ctacgccagg	attatgctag	gttggtgaat	gagctgactg	agaaaacagg	1440
aaagctccng	ccagaggaag	tcacaaagaa	aaatgctgag	caagaggtct	ctcagltgaa	1500
ggttcaacta	caagagagclg	agagaaagly	ggaaagagtt	cagagctaca	tcaggaagag	1560

5	aacagcggaa tgaagtacag gcnaagacta acaaabgnag gttccatttc agtatttga tgatgttta aaaagctga attgagagag gcaacta canagcattc ggahgttgtg ggagaaatg ataagaaca tgnatcagg tggaagatc ggagaaact tgacatgtt ottatta gaaagaccta aaaagcact gtttgaagaa catgctaaa agatgaaac ggcctctct aataaglygt gaaaaacaat cananaatta tggatltga gtttctagag tgaaactac tgttgagc acagattgag taaggahmt agagatggaa aacctcaca taaggtcaca tactgttatt gtctgtant acagctcaca tcatttgagg tttcaactt tagactactg agittttata aatctlltat gtanaattta aactgcctct taatggcgtc	catgagacag agtctgcata atccagttta gttccggata cagatagcag gaaagggata acaaagttaa gtgcagaaat atgcaacaaa catgaanttt aatcagaay gaacaaatgg ottgaaactg gaaatattca tcttttgcct aagtclttag gttcaggatt gaaaaggtct qnaaaagagg gcaatatacag gttcagggag cttgagattg gagagggaga anattgttta tttccctctc ctctggaaatg gaaagggcagc tttccnaagg cnaagattga aaatccctct gaagaaaaat lcatcattga gaaatctga aatcttga cagttacag gaaatctga aaacttga cagttacag gaaatctga ctaaatcaga aaggagaaag ataaanaagg tctactltgt atttaagaa taanaactgt cttatttgc aattttaat gaattcaat agcaataaaa	canagcaaga gtaaagctac tggaaatcga tlttgagaca cccagactc agcagatana aaagaggaact tacagagcct gtgtttatgt caannanaat ttcagahgt aanaatgcct gactlatta ctctgacaaa ctctagttya aagagcttct tgaacacagg aacgtttatc nacagalgaa gnaagtggtt tagcaacaa tgttgaaaga gtgaltcttc agtcccaaat atgnaanaat agttagalt naonggtgga tclctgtctc aagaatglt nagaagctga ttgcaanaac antggaaagi cactctcaga gaagagaaag atgttacaga ctgacanaaa agottatcca atgtttccoc ctgtaacana agcctacca callgtatta cagaacacat gnaaaaaaa ctgaanaatt tcaataaaa aclgntgttg caagaaacaa aggtatgctta	tttacagagt agatcccttg gcagaaaggg gnttgaggcl cgcthcagtt acagacagaa tanngatata ggcanatgag taaagalgat ggahgaattt acagaclett lunagaaaaa ggtyggcanct agaagtlcaa nnaacttaag ggagggcaga antaaggtcl talctctctc taccatgana acaggtctct taacttgana nnaagaaat tagcaanaaa tgaacagcti attaaagta tttgaaggah ayctgttgag ttctantttg qctgtgaant lgnatgcac agaaggaaht taaggtcgat acaaynqta agnacatttg aghtnagag tgaagagag gtcaaaata agaacaggag gttacagcag ggtglttagag tattttgaca gaacagagtt aagcgaactc agaccttlac tgttcagaa cacactyitt ctttttgtc ttattc	aaatlhgttg gtatcaaaa glyancaaa ttgaahgtc ctagcagaa gatlccttag cagaatatga caggtctgcl aaaalaaat nnaattctaa gtttctgac gatgagaagt aaagunagg gactlanaag nnaagtgala ctctcnaag ctaaaagang aaaagtcagg gctgtlltga cnaagagaaa gaggctctct gnaatgaaga cagclgttnc naaaacaaa atttcagaaa qagtttgaa llgnaagcta agttahgtg tcagggtcag actttgttac ttacagahgc gactcaca gagcynthaa gnaatggaac ttgnaagcag naggtagclg gtanaagctg tcttctgaga llgcttcagg tgaaahant nattaaag lgttctttc tgtagacac attctgag alanaagtg tacttaaat gclaatgtaa	unnaagaaa aaahgttgga aagagctctct aaattcagca aattacata naagtgaag atllcttatt ctgcacatga tgttggaaga atgacaaa agcctaata taaagantgt nctgaatgt ctahcaaaa atgaganaaa llqctaaca aatayyona agcttcagaa aagagaaaga atnaatctll ctgactaca gcttagaag agahgtaca actaccaaa gagagaaaga accagagga aaagattct aalgttga aggagllaa ayntagagtg tacagahgc agactattaa gaagagana tgaagagga aglttaatga gtgatttgc clggagacac aggagacant cgttaaaaa gggaahgtgt ttatttatgt laatccttgt ttcagagttt ataaacatgt taagagaaat tttgggaagi ctggtttttg	1620 1680 1740 1800 1860 1920 1980 2040 2100 2160 2220 2280 2340 2400 2460 2520 2580 2640 2700 2760 2820 2880 2940 3000 3060 3120 3180 3240 3300 3360 3420 3480 3540 3600 3660 3720 3780 3840 3900 3960 4020 4080 4140 4200 4260 4320 4380 4446
30	<210> 37 <211> 620 <212> DNA <213> Homo sapiens						
35	<220> <221> unsure <222> 284..284 <223> n = a, c, g or t						
60	<220> <221> unsure <222> 594..594 <223> n = a, c, g or t						
65	<220> <221> unsure <222> 597..597						

<223> n = a, c, g or t
 <220>
 <221> unsure
 <222> 607..607
 <223> n = a, c, g or t
 <400> 37
 10 100acgagagaa gaaqtctaaa aalggagagcg alqaccaggg ataaaaaggt qgaaactcgc 60
 atyghaccat caaaaaagga agaagcathq cccclrnacc aagngactaa acaaaqaaagt 120
 ggaacaggga aqagagaagc hcatcaaaq aaacaaaaay cagaaaatgt ctccglagat 180
 gaaacccotta ttcathcaac tactlwtatt cctllkgatgg alaatgctga chcaagtctt 240
 gtggctayata agagagaggg tntttattllg ottaaaccck accnaglkga agggakccag 300
 15 aaatctgggg ctaaaaaaact gaaqacccaa actgacaaag aaaatgctg agtgaaglll 360
 aaagattttc tltctgtcctt taagactatg atgltttctg aagatnaggc Ltcttggtgtt 420
 gtacatttgc taaaggagay qtctcgtgla atacaagatq ctttaagaa qtcagflaaq 480
 qgagaattga ctacgcttat acalcgqctt caaynaagg accaagttae lcgctgctgt 540
 gaayyagat gctgctgctv caaaggalce qtgtaaagaa ttaccctagg aatnalunon 600
 aagaaanana qagcaatttg gatatcaa 628
 <210> 38
 <211> 730
 <212> DNA
 <213> Homo sapiens
 25 <220>
 <221> unsure
 <222> 127..127
 <223> n = a, c, g or t
 30 <220>
 <221> unsure
 <222> 260..260
 <223> n = a, c, g or t
 35 <220>
 <221> unsure
 <222> 307..307
 <223> n = a, c, g or t
 40 <220>
 <221> unsure
 <222> 329..329
 <223> n = a, c, g or t
 45 <220>
 <221> unsure
 <222> 336..336
 <223> n = a, c, g or t
 50 <220>
 <221> unsure
 <222> 473..473
 <223> n = a, c, g or t
 55 <220>
 <221> unsure
 <222> 487..487
 <223> n = a, c, g or t
 60 <220>
 <221> unsure
 <222> 494..494
 <223> n = a, c, g or t
 65 <220>
 <221> unsure

<222> 563..563
 <223> n = a, c, g or t

 5 <220>
 <221> unsure
 <222> 640..640
 <223> n = a, c, g or t

 10 <220>
 <221> unsure
 <222> 680..681
 <223> n = a, c, g or t

 15 <220>
 <221> unsure
 <222> 689..689
 <223> n = a, c, g or t

 20 <220>
 <221> unsure
 <222> 708..708
 <223> n = a, c, g or t

 25 <220>
 <221> unsure
 <222> 714..714
 <223> n = a, c, g or t

 30 <220>
 <221> unsure
 <222> 728..728
 <223> n = a, c, g or t

 35 <220>
 <221> unsure
 <222> 730..730
 <223> n = a, c, g or t

 40 <400> 38
 Aaagaatttgg gcaaganttga agaccgaaac lgaacagaa aalyctgaa tgaagtttaa 60
 agattyyott ctgtcttga aaactatgat gttttclga gatgaggclc ttctgttgt 120
 agaactyncln aaggagaagt ctgglgknt accagatgct ttanagaagt caagtacgg 180
 ngatttgaact acgcttatac atcagcttca agaaaggac aaglyantog ctgtgtgaa 240
 ggaagntgct gctgcyaacn aggatcgggtg taagcaglta acccaggaa kgtgacaga 300
 45 gaaaganaga aqcnatgtgg ttataacnng qatqanagay cgaatyqaa cattagaaza 360
 ggracataat gtatyycaan acaaaataca tgcagtyat caagagacyt aacagntga 420
 gatgaagtlt cagcaagttc gtgagcagat gtaggcagay atagcyact tynagayg 480
 aatgggnata clngaqant gcagtcagca acatatacaa tcaaclgaa agcaagcagt 540
 ctgcagaaact aaataaacta agncaggatt atgctagglc qgtgaatgag cctgactgg 600
 50 aaacaggaaa gctacagcaa gaggaagtcn aagaagaatn clngagcago agctactcag 660
 tcgaaggttc caactanncg nacgctgng agaagglagg ggaggcgnlt cagngcctac 720
 atcagggngn

 55 <210> 39
 <211> 571
 <212> DNA
 <213> Homo sapiens

 60 <220>
 <221> unsure
 <222> 37..37
 <223> n = a, c, g or t

 65 <220>
 <221> unsure
 <222> 42..42
 <223> n = a, c, g or t

60
 120
 180
 240
 300
 360
 420
 480
 540
 600
 660
 720
 730

5 <220>
 <221> unsure
 <222> 64..64
 <223> n = a, c, g or t

10 <220>
 <221> unsure
 <222> 67..67
 <223> n = a, c, g or t

15 <220>
 <221> unsure
 <222> 73..73
 <223> n = a, c, g or t

20 <220>
 <221> unsure
 <222> 86..89
 <223> n = a, c, g or t

25 <220>
 <221> unsure
 <222> 106..107
 <223> n = a, c, g or t

30 <220>
 <221> unsure
 <222> 117..117
 <223> n = a, c, g or t

35 <220>
 <221> unsure
 <222> 139..139
 <223> n = a, c, g or t

40 <220>
 <221> unsure
 <222> 153..153
 <223> n = a, c, g or t

45 <220>
 <221> unsure
 <222> 243..243
 <223> n = a, c, g or t

50 <220>
 <221> unsure
 <222> 257..257
 <223> n = a, c, g or t

55 <220>
 <221> unsure
 <222> 264..264
 <223> n = a, c, g or t

60 <220>
 <221> unsure
 <222> 319..319
 <223> n = a, c, g or t

65 <220>
 <221> unsure
 <222> 337..337
 <223> n = a, c, g or t

 <220>

<221> unsure
<222> 341..341
<223> n = a, c, g or t

5 <220>
<221> unsure
<222> 353..353
<223> n = a, c, g or t

10 <220>
<221> unsure
<222> 362..362
<223> n = a, c, g or t

15 <220>
<221> unsure
<222> 373..373
<223> n = a, c, g or t

20 <220>
<221> unsure
<222> 379..379
<223> n = a, c, g or t

25 <220>
<221> unsure
<222> 384..385
<223> n = a, c, g or t

30 <220>
<221> unsure
<222> 419..419
<223> n = a, c, g or t

35 <220>
<221> unsure
<222> 421..421
<223> n = a, c, g or t

40 <220>
<221> unsure
<222> 427..427
<223> n = a, c, g or t

45 <220>
<221> unsure
<222> 433..433
<223> n = a, c, g or t

50 <220>
<221> unsure
<222> 440..442
<223> n = a, c, g or t

55 <220>
<221> unsure
<222> 444..444
<223> n = a, c, g or t

60 <220>
<221> unsure
<222> 448..448
<223> n = a, c, g or t

65 <220>
<221> unsure
<222> 450..450

<223> n = a, c, g or t
<220>
<221> unsure
5 <222> 455..455
<223> n = a, c, g or t
<220>
<221> unsure
10 <222> 486..486
<223> n = a, c, g or t
<220>
<221> unsure
15 <222> 488..489
<223> n = a, c, g or t
<220>
<221> unsure
20 <222> 493..493
<223> n = a, c, g or t
<220>
<221> unsure
25 <222> 496..497
<223> n = a, c, g or t
<220>
<221> unsure
30 <222> 500..500
<223> n = a, c, g or t
<220>
<221> unsure
35 <222> 504..504
<223> n = a, c, g or t
<220>
<221> unsure
40 <222> 506..507
<223> n = a, c, g or t
<220>
<221> unsure
45 <222> 515..515
<223> n = a, c, g or t
<220>
<221> unsure
50 <222> 520..520
<223> n = a, c, g or t
<220>
<221> unsure
55 <222> 523..523
<223> n = a, c, g or t
<220>
<221> unsure
60 <222> 525..526
<223> n = a, c, g or t
<220>
<221> unsure
65 <222> 538..538
<223> n = a, c, g or t

<400> 39

aaya	aatgc	ctttttt	ake	cccaaa	hag	rcagtt	hccc	antta	ctt	caacc	60
tgg	nagngel	ctntct	cott	lgtgr	nnnn	nnnn	nnnn	cccc	ynncg	aatggt	120
tact	gtgtt	acaghet	qnt	ttaggt	ttac	agnc	aktq	tccll	ckhag	gaggel	180
ttct	ggggg	acatca	ctll	ttca	ataa	agt	agtgt	ccgc	ageti	ttact	240
tgn	tgata	agttcc	ngt	ael	ttgag	ottal	gc	ta	acag	cttcl	300
ttca	hittgt	tcagtt	ctn	gtttt	gtgg	ctt	gc	ta	gtg	ccy	360
gn	ttctgla	acntag	ggng	ghnn	ttcc	ctt	gc	ta	gtg	ccy	420
ntct	gntct	ccn	ccag	nn	nn	nn	nn	cc	gnal	ctt	480
g	ctnn	gn	nn	nn	nn	nn	nn	cc	gnal	ctt	540
cat	ggc	ctll	tan	ctt	ctc	t					571

<210> 40

<211> 644

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> 415..435

<223> n - a, c, g or t

<220>

<221> unsure

<222> 525..526

<223> n - a, c, g or t

<400> 40

atall	ctmga	gcaga	atgag	gtttt	qaaa	ctca	aktca	gcagtt	ccat	lunc	agatag	60
cagcc	agat	ctcc	gctta	gttcl	agcag	aga	aattaca	lunc	gtgatt	gcaga	aaag	120
atn	gcagat	aaac	agact	gaag	attctt	lag	agatga	acgt	galcgt	ttan	caagta	180
aga	agaggg	aotta	aggat	alanc	agata	tga	attctll	att	aaaagot	gaag	tgag	240
aatt	acaggr	cel	ggc	aat	gagc	aggtc	ty	cl	gtcc	ta	gall	300
acag	gtttt	tg	ta	agat	g	at	aaata	gatt	gc	lga		360
ttt	caacaa	at	gga	agaa	ttta	agall		ta	nn	ta	cca	420
ag	ttccgaa	gt	acag	act	ctt	gtttctg	aa	ca	gntaa	ta	aggtg	480
tg	aaaaatg	cat	ta	agaa	aa	gthgagaa	gt	ta	aaagat	g	lyg	540
gga	cttat	ag	ttg	ccaa	ta	agagag	gg	ag	cl	gt	gag	600
ac	aaaggtt	ca	agact	tac	ag	thg	ccaa	tg	at	ccag	gll	644

<210> 41

<211> 566

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> 47..47

<223> n - a, c, g or t

<220>

<221> unsure

<222> 59..59

<223> n - a, c, g or t

<220>

<221> unsure

<222> 91..91

<223> n - a, c, g or t

<220>

<221> unsure

<222> 104..104

<223> n - a, c, g or t

<220>

<221> unsure

<222> 441..442
 <223> n = a, c, g or t

5 <220>
 <221> unsure
 <222> 448..448
 <223> n = a, c, g or t

10 <220>
 <221> unsure
 <222> 457..457
 <223> n = a, c, g or t

15 <220>
 <221> unsure
 <222> 525..525
 <223> n = a, c, g or t

20 <220>
 <221> unsure
 <222> 539..539
 <223> n = a, c, g or t

25 <220>
 <221> unsure
 <222> 564..564
 <223> n = a, c, g or t

30 <400> 41
 caacacacac tcaaggtctll caaacctggga tgcagagagag gccctctntca agtllctgtng 60
 tgtactlln tgaacaaggg ctlyaaaaga ntcaatggt tctngagag ccogtaacaa 120
 attcccgta ttggtatagg ctctctctll ctcttcaaaa caacaccttca lgggtattcat 180
 ctgltgctct ttctcttlla ataagttcgg aagcctctga actllggag tgatagata 240
 cygttgagcc ltttcaagct ggaractlln tttttctct ttttagagct ltttttcccg 300
 35 tllcaantoc cgaacaglll hctcttgtt agcaccattg agaaglgccg cctccagag 360
 ctctcttaca gacttgatct ttcaacchct tcatggalca ctctcttaag gtcttcaact 420
 agagaggcaa aagaacacga ncatttgnta gttttanget cgaactctt ttgtcagaga 480
 tgaattllct qttcttattg caktcaqct ctctctctta ggtgncacaa naataagyn 540
 40 agtqtcaaga aallcttcca cagnot 566

<210> 42
 <211> 878
 <212> DNA
 <213> Homo sapiens

45 <220>
 <221> unsure
 <222> 595..595
 <223> n = a, c, g or t

50 <220>
 <221> unsure
 <222> 756..756
 <223> n = a, c, g or t

55 <220>
 <221> unsure
 <222> 766..766
 <223> n = a, c, g or t

60 <220>
 <221> unsure
 <222> 815..815
 <223> n = a, c, g or t

65 <220>
 <221> unsure

<222> 818..818
 <223> n = a, c, g or t

 <220>
 <221> unsure
 <222> 827..827
 <223> n = a, c, g or t

 <220>
 <221> unsure
 <222> 831..831
 <223> n = a, c, g or t

 <220>
 <221> unsure
 <222> 853..853
 <223> n = a, c, g or t

 <220>
 <221> unsure
 <222> 866..866
 <223> n = a, c, g or t

 <400> 42
 accttaacct cctctgacck ggaqttccag ccataatctt ttttgccttt ktttcaatcc 60
 atgcaacuat taccataaac tcaahktagn agggacagac acrhktggaa ataaklkkt 120
 gagaacttct ttaycctcpa actcaacagc ctacpccgtt tgotgccllk cattgttttt 180
 ctactctctg tgttcaactg cctccttcaa agaatctaac tcaatccaga gaccacttat 240
 ttctttctcl cttcttgaaa ttactttllk taattcttca tgagggggaa aagaagatgc 300
 ctattgttag ttttgttggk taagctgctc aatttgggac ttaacaatt ttttttccat 360
 ttgtacacac tgtaacagct gtgtllkget agaaagatca clclmctct ctttttagcal 420
 ggcttctaac ctctlcaatt caatttccct tttlltcaa acatcttcaa gkttttcaaa 480
 clghgatgaa gaagaggcct clllcaatgt atgttgtget acttctgaa catgtgcllk 540
 taagaatttc attllttct tgaagatcct gtamucatt cctgtattg yctkngtctt 600
 tclclktctc ttccaaaaca gccllraagg tatccatctg ttctctttt ccttttaaaa 660
 agttctgaag cctctgaact ttggaagtga kagataactg ttgagccctt taaagcctgg 720
 acattcttaa ttctctcttt aaaagcctta attcngllk caaanccga aacagllklc 780
 ccccttgtaa gcaactttga yaaahkcggc tccaaancc ctcllanaga nttgatcttt 840
 caacctttcc aaaggtattac ttccnaaag ttccllka 878

 <210> 43
 <211> 620
 <212> DNA
 <213> Homo sapiens

 <220>
 <221> unsure
 <222> 391..391
 <223> n = a, c, g or t

 <220>
 <221> unsure
 <222> 400..400
 <223> n = a, c, g or t

 <220>
 <221> unsure
 <222> 411..411
 <223> n = a, c, g or t

 <220>
 <221> unsure
 <222> 414..414
 <223> n = a, c, g or t

 <220>
 <221> unsure

<222> 418..418
<223> n = a, c, g or t

5 <220>
 <221> unsure
 <222> 421..421
 <223> n = a, c, g or t

10 <220>
 <221> unsure
 <222> 427..428
 <223> n = a, c, g or t

15 <220>
 <221> unsure
 <222> 435..435
 <223> n = a, c, g or t

20 <220>
 <221> unsure
 <222> 446..446
 <223> n = a, c, g or t

25 <220>
 <221> unsure
 <222> 454..455
 <223> n = a, c, g or t

30 <220>
 <221> unsure
 <222> 463..463
 <223> n = a, c, g or t

35 <220>
 <221> unsure
 <222> 465..465
 <223> n = a, c, g or t

40 <220>
 <221> unsure
 <222> 471..471
 <223> n = a, c, g or t

45 <220>
 <221> unsure
 <222> 480..480
 <223> n = a, c, g or t

50 <220>
 <221> unsure
 <222> 484..484
 <223> n = a, c, g or t

55 <220>
 <221> unsure
 <222> 490..490
 <223> n = a, c, g or t

60 <220>
 <221> unsure
 <222> 493..493
 <223> n = a, c, g or t

65 <220>
 <221> unsure
 <222> 500..500
 <223> n = a, c, g or t

5 <220>
 <221> unsure
 <222> 514..515
 <223> n = a, c, g or t

 10 <220>
 <221> unsure
 <222> 524..524
 <223> n = a, c, g or t

 15 <220>
 <221> unsure
 <222> 539..539
 <223> n = a, c, g or t

 20 <220>
 <221> unsure
 <222> 568..568
 <223> n = a, c, g or t

 25 <220>
 <221> unsure
 <222> 573..574
 <223> n = a, c, g or t

 30 <220>
 <221> unsure
 <222> 581..581
 <223> n = a, c, g or t

 35 <220>
 <221> unsure
 <222> 600..600
 <223> n = a, c, g or t

 40 <220>
 <221> unsure
 <222> 604..604
 <223> n = a, c, g or t

 45 <220>
 <221> unsure
 <222> 608..608
 <223> n = a, c, g or t

 50 <220>
 <221> unsure
 <222> 616..616
 <223> n = a, c, g or t

 55 <220>
 <221> unsure
 <222> 619..619
 <223> n = a, c, g or t

60 <400> 43
 accttaacgt cctctgaccc tgaattccag ccacacatto ttttgccttt ttttcaaatc 60
 catgcaacaa ttccaccataa ctcaaattag aagggaacga caccotttga aataattttt 120
 tgagaacttc tttagcctcc aactcaacag ctccacclq ttgctgcctt tcattgtttt 180
 tottctcttg gtgttcaact gcacccctca aagaalclaa ctcatccag agaccactta 240
 ttctttctc: lctttctgaa attactttta ataattcll: atgaggggga aaagaagatg 300
 cctgtttggt qttttgttgt ttaagctgct caatttggga cttcaacaat ttgttttcal 360
 cctgtacatc ctgtaacaga tgtgttttgc naagaaaglu actcccccctt nccnttanca 420
 65 nggggtancca acctcettta atacanttec ttttucttla aannnaatct naggttctctn 480
 caangggtan lymaaanan gcccttttca agtnnggttg tgnacttcc tgaacatgng 540
 ctttaagatc atttclcltg aagatccngt acntttccag nattggtarg cttccctttn 600

ttcnaaaanag cttcavngqng

620

5 <210> 44
 <211> 623
 <212> DNA
 <213> Homo sapiens

10 <220>
 <221> unsure
 <222> 25..25
 <223> n = a, c, g or t

15 <220>
 <221> unsure
 <222> 409..409
 <223> n = a, c, g or t

20 <220>
 <221> unsure
 <222> 412..412
 <223> n = a, c, g or t

25 <220>
 <221> unsure
 <222> 414..414
 <223> n = a, c, g or t

30 <220>
 <221> unsure
 <222> 423..423
 <223> n = a, c, g or t

35 <220>
 <221> unsure
 <222> 426..426
 <223> n = a, c, g or t

40 <220>
 <221> unsure
 <222> 435..435
 <223> n = a, c, g or t

45 <220>
 <221> unsure
 <222> 444..444
 <223> n = a, c, g or t

50 <220>
 <221> unsure
 <222> 450..450
 <223> n = a, c, g or t

55 <220>
 <221> unsure
 <222> 454..454
 <223> n = a, c, g or t

60 <220>
 <221> unsure
 <222> 459..459
 <223> n = a, c, g or t

65 <220>
 <221> unsure
 <222> 490..490
 <223> n = a, c, g or t

<220>
 <221> unsure
 <222> 508..508
 <223> n = a, c, g or t
 5
 <220>
 <221> unsure
 <222> 511..511
 <223> n = a, c, g or t
 10
 <220>
 <221> unsure
 <222> 515..515
 <223> n = a, c, g or t
 15
 <220>
 <221> unsure
 <222> 524..524
 <223> n = a, c, g or t
 20
 <220>
 <221> unsure
 <222> 545..545
 <223> n = a, c, g or t
 25
 <220>
 <221> unsure
 <222> 555..555
 <223> n = a, c, g or t
 30
 <220>
 <221> unsure
 <222> 564..564
 <223> n = a, c, g or t
 35
 <220>
 <221> unsure
 <222> 600..600
 <223> n = a, c, g or t
 40
 <220>
 <221> unsure
 <222> 611..611
 <223> n = a, c, g or t
 45
 <400> 44
 accttaacct cctctgaccc tgaantctatg ccttacattc ttttggcttt ttttcaaaac 60
 catgcaacca ttcaacataa ctcaaattag aagggacaga cacttttggc ataatatttt 120
 tgagaacttc tttagcctcc aactcaactag ctccacactg ttgctgctt tccLLggaag 180
 50 tcttgttcac ttgtctctgc agcattttttt cagttgatgc caatgcttcc attgcttccc 240
 agttttttct ccgaaggtna ttgtttttct tctctgghg ttcaactgca tttttcaag 300
 aatctcaactc attccagaga ccaacttttt ttctgaaatt acttttcaat 360
 attcttctat aggggggaaaa gaagatgccc gctgggaatt tgglygttna anngggccaa 420
 ttnggnacct aaaaattttg gttncaactc gtanacccng taaaaactgt gttttgctaa 480
 55 aaagataaon cccctctctc ttaagpnnng nttonaaccl cttnattcat ttcttttctc 540
 tcaanaaaac tcaantctca aacngggatg uaaaagaggo tottcaayli aaggtgggcn 600
 atttccggaa natggncttt aan 623
 <210> 45
 <211> 625
 <212> DNA
 <213> Homo sapiens
 60
 <220>
 <221> unsur
 <222> 392..392
 <223> n = a, c, g or t
 65

5 <220>
 <221> unsure
 <222> 400..400
 <223> n = a, c, g or t

10 <220>
 <221> unsure
 <222> 417..417
 <223> n = a, c, g or t

15 <220>
 <221> unsure
 <222> 421..421
 <223> n = a, c, g or t

20 <220>
 <221> unsure
 <222> 424..425
 <223> n = a, c, g or t

25 <220>
 <221> unsure
 <222> 437..437
 <223> n = a, c, g or t

30 <220>
 <221> unsure
 <222> 439..439
 <223> n = a, c, g or t

35 <220>
 <221> unsure
 <222> 456..456
 <223> n = a, c, g or t

40 <220>
 <221> unsure
 <222> 467..467
 <223> n = a, c, g or t

45 <220>
 <221> unsure
 <222> 469..469
 <223> n = a, c, g or t

50 <220>
 <221> unsure
 <222> 473..473
 <223> n = a, c, g or t

55 <220>
 <221> unsure
 <222> 475..475
 <223> n = a, c, g or t

60 <220>
 <221> unsure
 <222> 496..496
 <223> n = a, c, g or t

65 <220>
 <221> unsure
 <222> 499..500
 <223> n = a, c, g or t

 <220>

<221> unsure
 <222> 516..516
 <223> n = a, c, g or t

5 <220>
 <221> unsure
 <222> 524..524
 <223> n = a, c, g or t

10 <220>
 <221> unsure
 <222> 535..535
 <223> n = a, c, g or t

15 <220>
 <221> unsure
 <222> 538..538
 <223> n = a, c, g or t

20 <220>
 <221> unsure
 <222> 560..560
 <223> n = a, c, g or t

25 <220>
 <221> unsure
 <222> 582..582
 <223> n = a, c, g or t

30 <220>
 <221> unsure
 <222> 592..592
 <223> n = a, c, g or t

35 <220>
 <221> unsure
 <222> 594..594
 <223> n = a, c, g or t

40 <220>
 <221> unsure
 <222> 604..604
 <223> n = a, c, g or t

45 <400> 45
 accttaacac cctctgaccc tggagtcacg ccatacattc ttttgccttc ttttcacac 60
 catgcaccca ttcaccataa ctcaaatag gagggacaga caccclltggg aataattttt 120
 tgagaaacttc tttagcctcc aactcaacag ctcccaactg ttgctgcctt tcatgtttt 180
 tottccctcg gtgttcaact gcattccttc aagaatctaa cttaattccag agaccactta 240
 50 tttctttctc tctttctgaa attactttta ataaktcttc atgagggggg aaggaagatg 300
 cctglttgta gttttgttgt ttacgctgct caatttgggg cttaaacaaat ttgtlctcat 360
 ctgtacatc ctggtaacag ctgtgtlctg cntagaaaag attactctcc ctctctntct 420
 neannnggtt caaccctna aattacattt cctctctctt aaacaanant cttaagtctt 480
 tcaaacctgt atgcacacac gctcttttca agttangtgc tgcnaactcc tgaacalctg 540
 55 ctttaacgat catttcttcn tgaacalctg aaccacttcc cnglclgggc angnottccc 600
 ttenottcaa aanngcctca aggtta 625

<210> 46
 <211> 4416
 60 <212> DNA
 <213> Homo sapiens

<400> 46
 65 gcgcacagg gttttatagg atcacattga ccaaaagtacc atggagtttt atgagtcagc 60
 atattttatt gttctctatc ctccaatagt tattacagtc atttctctct tcllclggct 120
 tttcatgaa gaaacattat atgaggaagt tottgcaaaa cagggagag aacaaaagct 180
 tattctctacc aaaaacagata aaaaagaaagc agggagaaa aagaatctaa agaaagaaat 240

	ccagaatgga	aacctccatg	ahccogactc	tgagagtqta	ctctnagact	ctnnattatc	300
	agntgecttg	gcagtaruag	atgati:agnt	tgcacctght	ccattgaatg	togttgaanc	360
	ttcaaghtagt	gttaggggaa	gcaaaaagaa	gganagaaa	caaaagcctg	tqcttgaaga	420
5	gcaggtcatc	anagaagtg	atgcatcana	gattccnhgc	aaaaagtag	aacctgtccc	480
	agttactaaa	cagcccaccc	ctccctctga	agcagctgcn	togaagaayn	aaccagggca	540
	gaaguantct	aaaaatggan	gcgatgacca	ggatcaaaa	gtgnaaactc	tcahgatacc	600
	atcaaaaaag	caagaagcat	tgcncctcca	ccaagagant	aaacaagann	gtggatcagg	660
	gangaagaaa	gctkcatcaa	agaaacaaaa	gncagaaaat	gtcttcgtag	ahgaacccct	720
	tattcctgca	actacttata	ttcctttgat	ggatantgct	gactcnaqtc	ctgtggttgn	780
10	taagagagay	gttcttqatt	tgcctaaaac	tgaaccaagta	gaagggatcc	anaaatctgg	840
	gaatnaaaaa	ctgaagagay	nnctgacaa	agaantgct	gaaglgcaat	ttaaagatct	900
	ccttctgccc	ctgaagacta	tgatgttttc	tgaagalyng	gotcttlgly	ttgtagactc	960
	gctaaaggag	anctctgggt	taatacnaqa	tgtctttaaag	auqtoaatga	agqngaat	1020
	gactaagctt	ataactcagg	ttcaagaaaa	gganagctta	clcgctgtgt	tgaagynaga	1080
15	tgnlqctgtt	acaaaaggac	ggtgttaagca	gttaaacccg	gaatgalyng	cagagaaaga	1140
	aagaagcaal	gtggttataa	caagynatga	agatcgaacl	ggaaacattag	aaanqnanca	1200
	taatgtattt	caaaacaaaa	tacatgtcag	ttahcangag	actcaacagn	tgcagatgyn	1260
	gtlctagcna	gttcgtgagc	agatggaggc	agagatagnt	caottgaayn	aggaacatgg	1320
	tatactgag	natgcagtoa	gcaacactac	naatcaacty	gungcaagc	agctctgcga	1380
20	actaaataaa	clacgcacng	attatgtctag	glttgtgaat	gagclgactg	agaaaacagg	1440
	aaagrtccag	caagaggag	trcaaaaagaa	gaatgctgag	caagcagcta	clcanttgaa	1500
	ggttcaacta	canqaagctg	agagaagylg	ggatgaagtt	cagngctaca	tcagggaagag	1560
	anagagcgaa	catgaggcng	caacngcaaga	tttacagagt	aaatttctgg	ccaaagaaaa	1620
	tgaagtaayg	ogtctgcata	gttaagctaac	agatnccctg	glatcnaaac	aaacgttlyng	1680
25	gcaaaagacta	atgcnattaa	tggaaatcaga	gcagynaggg	gtgaacaaay	agagctctct	1740
	acaaahgcag	gttcaggata	llhctgagcn	gaatgaggtc	ltgnaagctc	aaatlccngn	1800
	gttccattcc	cagctngcag	cccagacctc	cycttccagt	ctagcagang	nattacataa	1860
	agtgattgca	gaazaggyta	anagatana	acagactgyn	natctcttag	canghgcacg	1920
	tgatcgtlha	ccaagttaag	aagaggaacl	kanagatata	cagantatga	atttcttatt	1980
30	naagctgaa	gtgcagaaat	tncaggccct	ggcaaalng	cagctgtctg	clgncatga	2040
	attgynagag	atgcaacaaa	gtgllctatgt	taangatgat	aaahhagnt	tgtggaaaga	2100
	gcaactacaa	catgaatatt	caaacaaaaat	ggaagatatt	aagattctaa	ahgcnaaaa	2160
	caahgcatta	aaatcagaag	llhnaagnt	ccagactctt	glttctgnaa	agcctaataa	2220
35	ggatgttlyg	gaacaaatg	gaacttattca	tcaagyaann	gatgagaagt	haagactnt	2280
	ggaagaatta	cttgaactg	ctctgacaaa	ggtggcaac	anngagagg	agctgaatgc	2340
	aataagynca	gaanaattcat	ctctgacaaa	agaggttcaa	gacttaaaag	ctangcaaaa	2400
	tgatcaggtt	lcttttgcct	ctctagttga	agaactleay	naatgatcc	atgagaagaa	2460
	tgyanagatc	aagtctgtag	aagagclctt	ggaggcagaa	cttctcaang	ttgctaacaa	2520
	ggagaaaac	gttcaggtat	tgaacaggaa	aataaaggt	ctaaaagaag	aaataggaan	2580
40	tgtccagctt	gaazaggyta	anaggttate	tatcaactcc	aaagltcagg	agcttcagaa	2640
	cttacltcaan	ggaagagg	aacagatgaa	hccatgaag	gctgtttlyg	agaganaaga	2700
	gaagaccta	yncaatcang	ggaagtgtt	acaggalctt	caagaagaaa	atgaatcttl	2760
	aaahgcacat	gttcaggag	lagncaacaa	taacttgaaa	gaggcclctt	ctgcatacaa	2820
	gtttgagag	cttgagattg	tttgaaaga	aaagynnot	gaattgaaga	gylhagynag	2880
45	catgotaaaa	gagngggga	gtgatcttcc	tagcaaaan	canctgttac	aggtatgaca	2940
	agahgnaaac	aaattgttta	agtnccaat	tgaacagctt	aaacaacaaan	actnccaaan	3000
	ggcatclct	tttcccccct	atgaagaatt	attaanagtn	atttcagaaa	gagagaaaga	3060
	aataagtgtt	clctggaatg	agttagatto	tttgaaggal	ynagttnaac	accagaggaa	3120
	gaahcaaat	gaagggcagc	aaaggglyng	ynctgttag	ttggaggcta	caqaagtctt	3180
50	caaaaazett	tttccaaaag	tgtctgtccc	ttctaattlyg	agttatggtg	aatggttgca	3240
	tggatttgaa	aaaaaygna	aaqaatgtat	gnetggaact	tcaggttccg	aggaggttaa	3300
	ggttctagag	cacaaagtga	aagaagclga	lgnantgcac	acattgttac	agctnagatg	3360
	tgaaaaaat	aaatccgtcc	ttgcagaaac	agaagyaatt	ttccagaagc	tacagagaag	3420
	tgttgagcaa	gaagaaanta	aatggaagt	taaggtcgat	gaalcccaan	agactattaa	3480
55	acagatgcag	tcactcllha	natcttngg	ccagagcta	gagcgattaa	gaaagagaaa	3540
	taagynhatt	gaaaatctga	gaagagaacg	agaactttg	gnaatggaac	tagaaagggc	3600
	agagatggaa	cgatctaccc	atgttacaga	agtcagagag	tlgagggan	agttcaatga	3660
	aaactcaca	aaacttagaa	ctgaanaaaa	lgnagacag	aaggtagctg	gtgatttgca	3720
	taagctcaa	cagttactga	agttactcca	gtcaaaaah	gtanaagctg	ctggagacac	3780
60	tactgttatt	gaahatagtg	atgtttcccc	agaaacggag	tcttctgaga	agagagcaat	3840
	gttgttaagt	ctaaatcaga	ctgtaacaca	gttcaagcag	ttgttccagg	cggtaaacca	3900
	acagctcacc	agggagaag	agcactacca	ggtgttagag	tgaaagttaatt	gggaaactgt	3960
	tcatttgagg	aknaaaagq	cattgtatta	tattttgcca	aattaaagcc	lclatttathgt	4020
	ttlcccccct	tctactttgt	cagaacacta	gaacagagbt	ttgtcttttc	taactcttgt	4080
65	tagactactg	ctttaagaa	ggaacaaactc	aagccaactc	tgtagacacc	ttcagagttt	4140
	agttttataa	taaaaaclgt	ttgnatvath	agccctttac	attcttgaag	akaaacahgl	4200
	aactclttat	cttattttgc	tcaataaaat	tgtlcaagag	atcaagtggt	taaagacaat	4260

gtaaaattta	acattttaat	acigatgctg	tacactggtt	tactttaat	ttlgggagt	4320
aactgctct	gacttcaact	caagaaaaca	cltttttgtt	gclaatgtaa	tcgtttttg	4380
taatggcgt	agcaaataaa	aggatgctta	ttatt:			4416



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, A61K 31/70, 35/12, 38/17, C07K 16/18, G01N 33/574, C12Q 1/68	A3	(11) International Publication Number: WO 00/20587 (43) International Publication Date: 13 April 2000 (13.04.00)
(21) International Application Number: PCT/US99/22873 (22) International Filing Date: 4 October 1999 (04.10.99) (30) Priority Data: 09/166,300 5 October 1998 (05.10.98) US 09/166,350 5 October 1998 (05.10.98) US (71) Applicant: LUDWIG INSTITUTE FOR CANCER RE- SEARCH [CH/US]; 605 Third Avenue, New York, NY 10158 (US). (72) Inventors: OBATA, Yuichi; Chikusa-Ku, Nagoya 464 (JP). GOUT, Ivan; 91 Riding House Street, London W1P 8BT (GB). TURECI, Ozlem; Innere Medizin 1, D-66421 Hom- burg/Saar (DE). SAHIN, Ugar; Innere Medizin 1, D-66421 Homburg/Saar (DE). PFREUNDSCUHL, Michael; Innere Medizin 1, D-66421 Homburg/Saar (DE). SCANLAN, Matthew, J.; 1275 York Avenue, New York, NY 10021 (US). STOCKERT, Elisabeth; 1275 York Avenue, New York, NY 10021 (US). CHEN, Yao-Tseng; 525 East 68th Street, New York, NY 10021 (US). OLD, Lloyd, J.; 605 Third Avenue, New York, NY 10158 (US). JAGER, Elke; Hohl 2-28, D-60488 Frankfurt am Main (DE). KNUTH, Alex; Hohl 2-28, D-60488 Frankfurt am Main (DE).		(74) Agent: VAN AMSTERDAM, John, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US). (81) Designated States: AU, CA, CN, JP, KR, NZ, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> (88) Date of publication of the international search report: 12 October 2000 (12.10.00)
(54) Title: CANCER ASSOCIATED ANTIGENS AND USES THEREFOR		
(57) Abstract Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in renal cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with renal cancer. The invention provides, <i>inter alia</i> , isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

Inte. onal Application No

PCT/US 99/22873

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 A61K31/70 A61K35/12 A61K38/17
C07K16/18 G01N33/574 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database EMBL Entry AA858164; Accession number AA858164 13.03.1998 National Cancer Institute, Cancer Genome Anatomy Project; of66h01.s1 NCI_CGAP_Co8 Homo sapiens clone IMAGE:1435345; in relation to SEQ ID Nos. 1 and 12 XP002132221 see the abstract --- -/--	55,56, 60,68, 69,71, 72,75

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

23 June 2000

Date of mailing of the international search report

14.07.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alt, G

INTERNATIONAL SEARCH REPORT

Inte. onal Application No

PCT/US 99/22873

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database EMBL Entry HSAA10936; Accession number 188593 20.01.1997 The WashU-Merck EST Project zp75e04.r1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 626046; in relation to SEQ ID Nos. 1 and 12 XP002132222 see the abstract ---	55,56, 60,68, 69,71, 72,75
X	Database EMBL Entry AI139112; Accession number AI139112 25.09.1998 National Cancer Institute, Cancer Genome Anatomy Project; qc27h04.x1 Soares_pregnant_uterus_NbHPU Homo sapiens cDNA clone IMAGE:1710871; in relation to SEQ ID Nos. 1 and 12 XP002132223 see the abstract ---	55,56, 60,68, 69,71, 72,75
X	Database EMBL Entry MM1210701; Accession number AA415243 09.05.1997 The WashU-HHMI Mouse EST Project; vd25e08.s1 Knowles Solter mouse 2 cell Mus musculus cDNA clone 793574; in relation to SEQ ID Nos. 1 and 12 XP002132224 see the abstract ---	68,69
X	Database EMBL Entry HS437322, Accession number W00437 19.04.1996 The WashU-Merck EST Project yz99c04.r1 Homo sapiens cDNA clone 291174; in relation to SEQ ID Nos. 1 and 12 XP002132225 see the abstract ---	68,69
A	KAWAHARA, K. ET AL.: "Review: Potassium transport and potassium channels in the kidney tubules" JAPANESE JOURNAL OF PHYSIOLOGY, vol. 47, 1997, pages 1-10, XP000881680 see the whole document; in relation to SEQ ID Nos. 1 and 12 ---	1
A	WANG, W. ET AL.: "Renal K+ channels: Structure and function" ANNUAL REVIEW OF PHYSIOLOGY, vol. 59, 1997, pages 413-436, XP000881688 see the whole document; in relation to SEQ ID Nos. 1 and 12 ---	1
	--- -/--	

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/US 99/22873

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database EMBL Entry HSAA24402; Accession number AA211485 02.02.1997 zn55c06.s1 Stratagene muscle 937209 Homo sapiens cDNA clone IMAGE:562090 3' similar to TR:E245548 E245548 Chromosome XII Reading frame ORF YLR097C Hillier, L. et al.; in relation to SEQ ID No. 4 XP002140895 see the abstract	55,56, 60,68, 69,71, 72,75
X	SEMENKOVICH C F ET AL: "Human fatty acid synthase mRNA: tissue distribution, genetic mapping and kinetics of decay after glucose deprivation" JOURNAL OF LIPID RESEARCH,US,BETHESDA, MD, vol. 36, no. 7, July 1995 (1995-07), pages 1507-1521-1521, XP002105049 ISSN: 0022-2275 see Figure 1; in relation to SEQ ID No. 5	55,56, 60,68, 69,71, 72,75
X	US 5 665 874 A (KUHAJDA FRANCIS P ET AL) 9 September 1997 (1997-09-09) see cDNA and protein OA-519 (SEQ ID No. 9) corresponding to columns 43-60; in relation to SEQ ID Nos. 5 and 16	55,56, 60,68, 69,71, 72,75
A	GANSLER, T. S. ET AL.: "Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival" HUMAN PATHOLOGY, vol. 28, 1997, pages 686-692, XP000909948 related to SEQ ID No. 5	1
P,X	WO 99 18989 A (BAYLOR COLLEGE MEDICINE) 22 April 1999 (1999-04-22) see page 109, SEQ ID No. 41; in relation to SEQ ID No. 15	48,49
P,X	WO 98 48020 A (FIORE PIER PAOLO DI ;ISTITUTO EUROP DI ONCOLOGIA S (IT); CAPRA MAR) 29 October 1998 (1998-10-29) see pages 42-48 corresponding to SEQ ID Nos. 3 and 4; in relation to SEQ ID Nos. 7 and 18 --- -/--	55,56, 60,68, 69,71, 72,75

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/22873

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NAKAMURA, T. ET AL.: "A novel transcriptional unit of the tre oncogene widely expressed in human cancer cells" ONCOGENE, vol. 7, 1992, pages 733-741, XP000670282 see Figure 3; in relation to SEQ ID Nos. 7 and 18	55,56, 60,68, 69,71, 72,75
X	RICH, B.E. AND STEITZ, J.A. : "Human acidic ribosomal phosphoproteins P0, P1 and P2: Analysis of cDNA clones in vitro synthesis and assembly " MOLECULAR AND CELLULAR BIOLOGY, vol. 7, 1987, pages 4065-4074, XP000909977 see Figure 1C; phosphoprotein P2; in relation to SEQ ID No. 35	55,56, 60,68, 69,71, 72,75
X	SEKI, T. ET AL.: "Cloning of the cDNA encoding a novel importin alpha homologue, Qip1: Discrimination of Qip1 and Rchl from hSrp1 by their ability to interact with DNA helicase A1/RecQL" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 234, 1997, pages 48-53, XP000910159 see Figure 1 & Database EMBL; 10.04.1997; Entry HSAB2533; Accession number AB002533; in relation to SEQ ID No. 35	55,56, 60,68, 69,71, 72,75
A	JIANG, C. ET AL.: "Characterization of colorectal cancer related cDNA clones obtained by subtractive hybridization screening " JOURNAL OF CANCER RESEARCH AND ONCOLOGY, vol. 123, 1997, pages 447-451, XP000909986 see the whole document as far as related to phosphoprotein P2	1
A	WO 96 29409 A (UNIV LEIDEN ;LUDWIG INST CANCER RES (US)) 26 September 1996 (1996-09-26) the whole document	1
A	SAHIN ET AL: "Human neoplasms elicit multiple specific immune responses in the autologous host" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 92, 1 December 1995 (1995-12-01), pages 11810-11813, XP002091914 ISSN: 0027-8424 cited in the application the whole document	1

PCT/US 99/22873

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/22873

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 78, 79, 81-88, 90-107 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

B x II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

1-12, 14-17, 19-22, 24, 26-35, 37-44, 46-50, 52-69, 71-79, 81-88, 90-107, 109-116 (subject 1, 4, 6 and 22 of non-unity motivation)
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-4, 14-17, 20, 30-35, 39-41, 57-59, 75, 78, 79, 81, 83, 84, 98-101, 104, 109, 110, 112-114

1. The terms NA group 1, NA group 2, etc. and PP group 1, PP group 2, etc. are applicants own reference signs and have therefore no recognised meaning. Consequently, all claims in which these terms are used are unclear within the meaning of Article 6 PCT. For the purposes of the search the terms have been interpreted as shown in the description, pages 14 and 15.

2. Present claims 1, 2 (as far as points (g) - (i) are concerned), 3, 4, 14-17, 20, 30, 39-41, 57-59, 75, 78, 79, 81, 98-101, 104, 109, 110, 112-114 relate to an extremely large number of products and methods defined inter alia by reference to a desirable characteristic or property, namely in the case of

- 1) claims 1-4: "specifically binds to the nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof complexed with an HLA molecule"
- 2) claims 14-17 and 20, 78, 79, 81, 83, 84 and claims 98-101 as far as they relate to claims 14-17: "enriches selectively the presence of complexes of an HLA molecule and a human cancer associated antigen"
- 3) claims 30-35, 39-41: "binds selectively to a polypeptide"
- 4) claims 57-59 and 75: "of sufficient length to represent a sequence unique within the human genome"
- 5) claim 104: "inhibits the expression or activity of the protein"
- 6) claims 109, 110, 112-114: "bind to one or more MHC molecules presented on the surface of the cells which express an abnormal amount of the protein"

The above mentioned claims cover all products and methods having or using a compound having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a few or even none of these compounds or methods. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the complete claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound or method inter alia by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely:

- group 1) of claims: antibodies reacting with a peptide encoded by SEQ ID 1 and nucleic acids hybridizing to SEQ ID No. 1
- group 2) of claims: polypeptides encoded by SEQ ID No. 1, host cells expressing them, complexes of said polypeptide with HLA, nucleic acid having SEQ ID No. 1.
- group 3 of claims: antibodies and fragments thereof reacting with polypeptides encoded by SEQ ID No. 1
- group 4 of claims: complete SEQ ID No. 1
- group 5 of claims: antibodies reacting with a polypeptide encoded by SEQ

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

ID No. 1

group 6 of claims: no search

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-12,14-17,19-22, 24, 26-35, 37-44, 46-50, 52-69, 71-79, 81-88, 90-107, 109-116 all partially as far as they relate to SEQ ID Nos. 1 and 12

Pharmaceutical compositions or isolated molecules comprising a molecule having the sequence of SEQ ID No. 1 (cl. 42, 43, 55) or the corresponding protein (cl. 48, 68) and HLA binding fragments (cl. 56, 71, 72, 109), an expression vector comprising said DNA molecule (cl.61) and host cells comprising the expression vector (cl. 64) as well as related antibodies (cl. 115).

Fragments of SEQ ID No. 1 which are long enough to represent a sequence unique within the human genome (cl. 57, 75).

Kit for detecting the presence of a SEQ ID No. 1 molecule using nucleotide fragments of SEQ ID NO.1 (cl. 76)

Method of treatment consisting essentially of increasing the immune response to a molecule encoded by SEQ ID NO. 1 (cl. 78, 85, 88, 102) or in the administration of an antibody to such a molecule (cl. 95)

Methods for determining regression, progression or onset of a condition characterized by monitoring SEQ ID No. 1 or encoded molecules, fragments, etc. (cl.5)

Pharmaceutical compositions comprising an agent that enriches selectively the presence of complexes of HLA molecules with polypeptides encoded by SEQ ID No. 1 (cl. 14) and use in a method of treatment (cl. 98)

Composition comprising an agent binding to a polypeptide encoded by SEQ ID No. 1 molecule and fragments (cl. 30-34) or a conjugate thereof (cl. 39).

Method of treatment by inhibiting expression of a polypeptide encoded by SEQ ID No. 1 molecule (cl. 104).

Method of diagnosing using an agent binding to SEQ ID No. 1 or encoded molecule (cl.1)

2. Claims: 1-10,12,14-17,19-22, 24, 26-33, 35, 37-44, 46-50, 52-69, 71-79, 81-88, 90-107, 109-116 all partially as far as they relate to SEQ ID Nos. 2 and 13

essentially idem as for subject 1, but related to SEQ ID Nos. 2 and 13

3. Claims: 1-10,12,14-17,19-22, 24, 26-33, 35, 37-44, 46-50, 52-69, 71-79, 81-88, 90-107, 109-

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

116 all partially as far as they relate to SEQ ID N
os. 3 and 14

essentially idem as for subject 1, but related to SEQ ID
Nos. 3 and 14

4. Claims: 1-12,14-17,19-22, 24, 26-35, 37-44, 46-50, 52-69,
71-79, 81-88, 90-107,
109-
116 all partially as far as they relate to SEQ ID N
os. 4, 5, 15 and 16

essentially idem as for subject 1, but related to SEQ ID
Nos. 4, 5, 15 and 16

5. Claims: 1-10,12,14-17,19-22, 24, 26-33, 35, 37-44, 46-50,
52-69, 71-79, 81-88, 90-107,
109-
116 all partially as far as they relate to SEQ ID N
os. 6 and 17

essentially idem as for subject 1, but related to SEQ ID
Nos. 6 and 17

6. Claims: 1-12,14-17,19-22, 24, 26-35, 37-44, 46-50, 52-69,
71-79, 81-88, 90-107,
109-
116 all partially as far as they relate to SEQ ID N
o. 7 and 18

essentially idem as for subject 1, but related to SEQ ID
Nos. 7 and 18

7. Claims: 1-10,12,14-17,19-22, 24, 26-33, 35, 37-44, 46-50,
52-69, 71-79, 81-88, 90-107,
109-
116 all partially as far as they relate to SEQ ID N
os. 8, 9, 19, 20

essentially idem as for subject 1, but related to SEQ ID
Nos. 8, 9, 19 and 20

8. Claims: 1-10,12,14-17,19-22, 24, 26-33, 35, 37-44, 46-50,
52-69, 71-79, 81-88, 90-107,
109-

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

116 all partially as far as they relate to SEQ ID N
os. 10, 11, 21

essentially idem as for subject 1, but related to SEQ ID
Nos. 10, 11 and 21

9. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-
116 all partially as far as they relate to SEQ ID N
o. 22

essentially idem as for subject 1, but related to SEQ ID No.
22

10. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-
116 all partially as far as they relate to SEQ ID N
o. 23

essentially idem as for subject 1, but related to SEQ ID No.
23

11. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-
116 all partially as far as they relate to SEQ ID N
o. 24

essentially idem as for subject 1, but related to SEQ ID No.
24

12. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-
116 all partially as far as they relate to SEQ ID N
o. 25

essentially idem as for subject 1, but related to SEQ ID No.
25

13. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

116 all partially as far as they relate to SEQ ID N
o. 26

essentially idem as for subject 1, but related to SEQ ID No.
26

14. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-
116 all partially as far as they relate to SEQ ID N
o. 27

essentially idem as for subject 1, but related to SEQ ID No.
27

15. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-
116 all partially as far as they relate to SEQ ID N
o. 28

essentially idem as for subject 1, but related to SEQ ID No.
28

16. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-
116 all partially as far as they relate to SEQ ID N
o. 29

essentially idem as for subject 1, but related to SEQ ID No.
29

17. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-
116 all partially as far as they relate to SEQ ID N
o. 30

essentially idem as for subject 1, but related to SEQ ID No.
30

18. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

116 all partially as far as they relate to SEQ ID N
o. 31

essentially idem as for subject 1, but related to SEQ ID No.
31

19. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-
116 all partially as far as they relate to SEQ ID N
o. 32

essentially idem as for subject 1, but related to SEQ ID No.
32

20. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-
116 all partially as far as they relate to SEQ ID N
o. 33

essentially idem as for subject 1, but related to SEQ ID No.
33

21. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-
116 all partially as far as they relate to SEQ ID N
o. 34

essentially idem as for subject 1, but related to SEQ ID No.
34

22. Claims: 1-9,11,12,14-16,19-22, 24, 26, 28-31, 34, 35,
37-42, 44, 46-48, 50, 52-54, 69, 71-79, 81-88,
90-106,
109-
116 all partially as far as they relate to SEQ ID N
o. 35

essentially idem as for subject 1, but related to SEQ ID No.
35

23. Claims: 1-12,14-17,19-22, 24, 26-35, 37-44, 46-50, 52-69,
71-79, 81-88, 90-107,

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

109-
116 all partially as far as they relate to SEQ ID Nos. 36-46

Pharmaceutical compositions or isolated molecules comprising a molecule having the sequence of SEQ ID Nos. 36-46 (cl. 42) or the corresponding protein (cl. 48, 70) and HLA binding fragments (cl. 71, 72, 109), an expression vector comprising said DNA molecule (cl. 61) and host cells comprising the expression vector (cl. 64) as well as related antibodies (cl. 115).

Fragments of SEQ ID Nos. 36-46 which are long enough to represent a sequence unique within the human genome (cl. 57).

Kit for detecting the presence of a SEQ ID Nos. 36-46 molecule using nucleotide fragments of SEQ ID Nos. 36-46 (cl. 76)

Method of treatment consisting essentially in increasing the immune response to proteins encoded by SEQ ID Nos. 36-46 (cl. 78, 85, 88, 102) or in the administration of an antibody binding to the protein encoded by SEQ ID No. 36-46 (cl. 95)

Methods for determining regression, progression or onset of a condition characterized by monitoring SEQ ID Nos. 36-46 molecules or encoded fragments, etc. (cl. 5).

Pharmaceutical compositions comprising an agent that enriches selectively the presence of complexes of HLA molecules and molecules encoded by SEQ ID Nos. 36-46 (cl. 14) and use in a method of treatment (cl. 98)

Composition comprising an agent binding to proteins encoded by SEQ ID Nos. 36-46 (cl. 30, 32, 34) or a conjugate thereof (cl. 39)

Method of treatment by inhibiting expression of a protein encoded by SEQ ID Nos. 36-46 (cl. 104)

Method of diagnosing using an agent binding to SEQ ID Nos. 36-46 molecule or protein encoded (cl. 1)

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/US 99/22873

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5665874 A	09-09-1997	US 5759791 A	02-06-1998
		US 5872217 A	16-02-1999
		US 5864011 A	26-01-1999
		US 5759837 A	02-06-1998
		AU 682007 B	18-09-1997
		AU 4786493 A	14-02-1994
		CA 2140866 A	03-02-1994
		EP 0651636 A	10-05-1995
		JP 7509470 T	19-10-1995
		MX 9304501 A	29-04-1994
		WO 9402108 A	03-02-1994
		AT 151882 T	15-05-1997
		AU 632535 B	07-01-1993
		AU 5040690 A	13-08-1990
		CA 2045552 A	26-07-1990
		DE 69030494 D	22-05-1997
		DE 69030494 T	07-08-1997
		DK 454782 T	27-10-1997
		EP 0454782 A	06-11-1991
		ES 2101695 T	16-07-1997
		JP 2959837 B	06-10-1999
		JP 4504110 T	23-07-1992
		KR 174528 B	15-05-1999
		WO 9008324 A	26-07-1990
WO 9918989 A	22-04-1999	AU 1088399 A	03-05-1999
WO 9848020 A	29-10-1998	IT MI970905 A	19-10-1998
		AU 7077998 A	13-11-1998
WO 9629409 A	26-09-1996	US 5939526 A	17-08-1999
		AU 705768 B	03-06-1999
		AU 5429896 A	08-10-1996
		CA 2211448 A	26-09-1996
		EP 0815229 A	07-01-1998
		JP 11506904 T	22-06-1999
		NZ 306122 A	29-06-1999
		ZA 9602280 A	28-08-1996

THIS PAGE BLANK (USPTO)